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Riassunto 
 
L’Introduzione (Capitolo 1) riporta una descrizione generale dei coniugati metallici, 
in particolar modo quelli contenenti porfirine e delle loro applicazioni. Sono descritte 
le caratteristiche di un ideale precursore di Ru(II) per la formazione di coniugati. 
Inoltre viene presentato il legante utilizzato in questo lavoro di tesi per impartire 
solubilità in acqua, l’1,3,5-triaza-7-fosfoadamantano (PTA).  
I Capitoli dal 2 al 5 descrivono il progetto principale seguito durante la Tesi, ovvero 
la sintesi e caratterizzazione di diversi complessi di Ru(II) con PTA, quali precursori 
per la formazione di coniugati metallici. In particolar modo, il Capitolo 2 riprende 
quanto è noto in letteratura sui complessi neutri Ru(II)-PTA, ovvero trans- e cis-
RuCl2(PTA)4. Viene descritta la stabilità di questi complessi e la loro reattività nei 
confronti di leganti azotati bidentati, quali bpy, usata come modello per i linker di-
imminici chelanti, cppH e bpyAc. Inoltre viene descritto lo studio della reattività di 
noti precursori di Ru(II)-dmso, trans- e cis-RuCl2(dmso)4 nei confronti del PTA. 
Il Capitolo 3 indaga la reattività dei precursori neutri carbonilici di Ru(II) dalla 
formula generale RuCl2(CO)x(dmso)4-x (x = 1-3) nei confronti del PTA, visto che in 
letteratura non sono noti esempi di complessi carbonilici con PTA. Viene descritta 
la sintesi di sette nuovi composti, tra cui due dimeri. Tutti i complessi sono stati 
completamente caratterizzati sia spettroscopicamente che attraverso la struttura ai 
raggi X dei cristalli (eccezion fatta per i dimeri). Inoltre viene descritta anche la 
reattività dei complessi trans- e cis-RuCl2(PTA)4 nei confronti del CO. 
Nel Capitolo 4 è riportata la reattività dei composti descritti nel Capitolo 3 nei 
confronti del legante azotato bpy. Sono descritti e caratterizzati quattro nuovi derivati 
carbonilici di Rutenio-PTA con bpy. Inoltre viene anche indagato il comportamento 
 vi 
 
di questi complessi nei confronti della luce, indagine che ha portato all’isolamento 
di altri due isomeri dei complessi precedentemente descritti. 
Dal momento che in letteratura gli unici esempi di complessi Ru(II)-PTA con 
applicazione antitumorale sono composti organometallici contenenti areni, il 
Capitolo 5 descrive un’indagine preliminare dell’attività antitumorale dei complessi 
trans- e cis-RuX2(PTA)4 (con X = Cl o Br) e del complesso di Ru(III) tipo NAMI-A 
trans-RuCl4(PTA)2 (già descritti nel Capitolo 1).  
I Capitoli dal 6 all’8 sono invece focalizzati su tre diversi side projects seguiti 
durante il lavoro di Tesi.  
Il Capitolo 6 descrive la sintesi degli isomeri di legame di Ru(II) col linker cppH, 
trans,cis-RuCl2(CO)2(cppH-κNp) e trans,cis-RuCl2(CO)2(cppH-κNo). In particolar 
modo vengono utilizzati gli esperimenti 1H-15N HMBC per determinare il modo di 
coordinazione del cppH. Il metodo è stato validato usando due complessi isomeri di 
legame già noti in letteratura, [Ru([9]aneS3)(cppH-κNp)(PTA)](Cl)2 e 
[Ru([9]aneS3)(cppH-κNo)(PTA)](Cl)2. Inoltre viene studiata la reattività dei noti 
precursori neutri di Ru(II)-dmso trans- e cis-RuCl2(PTA)4 nei confronti del legante 
mpp. Anche in questo caso, il modo di coordinazione del legante è stato determinato, 
oltre che attraverso la struttura ai raggi X dei cristalli, registrando degli esperimenti 
1H-15N HMBC. 
Successivamente, i due complessi trans,cis-RuCl2(CO)2(cppH-κNp) e trans,cis-
RuCl2(CO)2(cppH-κNo) vengono utilizzati per la sintesi di bioconiugati col peptide 
neurotensina, nell’ambito di una mobilità Erasmus di sei mesi presso il gruppo del 
prof. Nils Metzler-Nolte a Bochum. La preparazione dei bioconiugati viene riportata 
nel Capitolo 7, insieme alla loro caratterizzazione NMR per determinare il modo di 
coordinazione del cppH e lo studio delle loro proprietà biologiche. 
Infine, il Capitolo 8 riporta la sintesi di cinque complessi del tipo 
[Ru([9]aneS3)(chel)(py)](Cl)2, dove chel è una di-immina chelante. È stata studiata 
la fotodissociazione della piridina di questi composti, nell’ambito di una 
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collaborazione col gruppo della dr. Anna Renfrew dell’Università di Sidney. Infatti, 
la nostra idea è di verificare se, in futuro, alcuni complessi di questa serie aventi delle 
molecole farmacologicamente attive al posto della piridina possano essere usati nella 
chemioterapia fotoattivata, un approccio terapeutico in cui un profarmaco viene 
attivato irreversibilmente attraverso irraggiamento con luce visibile che può indurre 
la rottura di un gruppo protettivo fotolabile o isomerizzazione. 
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Introduction 
1.1 Metal Conjugates 
Recent years have witnessed a growing interest in the use of metal conjugates in 
several fields. In general, a metal conjugate (Figure 1.1) is a complex molecule in 
which an organometallic or coordination compound is attached through a linker to 
an organic macromolecule, usually with a high molecular weight.  
 
Figure 1.1. Schematic structure of a metal conjugate. 
In the preparation of metal conjugates, the linker is a molecule that connects the 
metal compound to the organic macromolecule; in particular, the linker is often a 
bifunctional chelating agent, that is a molecule with two functional groups – which 
typically point in opposite directions – that binds both the organic molecule through 
an organic bond and coordinates the metal fragment (Figure 1.1). Since the metal 
coordination has to be stable in both kinetic and thermodynamic terms, chelating 
fragments are often used for this purpose.1,2 Between the linker and the functional 
groups appropriate spacers can be introduced. Typically, the coordination of the 
metal to the chelating part of the linker represents the last step in the sequence of 
reactions that lead to the construction of the conjugate. 
A typical example of linker is 4′-methyl-2,2′-bipyridine-4-carboxylic acid (bpyAc), 
a diimine chelating ligand that allows for the formation of a covalent bond through 
the carboxylic group in position 4, i.e. in the opposite direction compared to the metal 
coordination (Figure 1.2). 
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Figure 1.2. Structure of 4′-methyl-2,2′-bipyridine-4-carboxylic acid. 
In particular, in the group where I did my Ph D Thesis, there is a deep interest towards 
developing conjugates between porphyrins and metal complexes with potential 
applications in several fields: medicinal inorganic chemistry, supramolecular 
chemistry, and photo-catalysis. In general, porphyrins have several appealing 
features: a rigid and planar geometry; a large, flat and aromatic surface; inherent 
symmetry; intense electronic absorption bands in the visible region; a relatively long 
fluorescence decay time, and facile tunability of their optical and redox properties 
by metallation/functionalization.3 In particular, 4′-meso-pyridylphenylporphyrins 
(4′PyPs) are extensively used in the group as building blocks for the preparation of 
metal-conjugates. These macromolecules provide geometrically well-defined 
connections to as many as four metal centers by coordination of the pyridyl groups. 
Considering the number and relative geometry of the peripheral N(py) groups in the 
meso positions, 4'PyPs can be classified as terminal, 90° angular, linear, T-shaped 
and cruciform donor building blocks (Figure 1.3). 
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Figure 1.3. The 4′-meso-pyridylphenylporphyrins with their schematic building block labels. 
 
In medicinal inorganic chemistry porphyrins, both natural and synthetic, have been 
widely investigated – and used – as photosensitizers (PS) in photodynamic therapy 
(PTD),4,5,6 a clinically approved treatment for some skin diseases, age-related 
macular degeneration and some cancers. PDT uses a photosensitizer at non-toxic 
concentrations that, upon excitation with visible light, catalytically generates 
cytotoxic singlet oxygen (1O2).
7 In addition, porphyrins are studied as potential 
targeting molecules because, due to their preferential uptake and retention in tumor 
tissues, they might be capable of transporting cytotoxic metal fragments into cancer 
cells for synergistic affects. Functionalized porphyrins bearing from one to four 
peripheral bpyAc chelating moieties have been already synthesized in the group and 
used to prepare different metal-conjugates (an example is shown in Figure 1.4).8,9,10 
Also in the field of photo-catalysis metal conjugates with light-absorbing units are 
investigated for building molecular dyads and triads capable of accomplishing photo-
induced charge separation (i.e. for the photocatalytic conversion of water into H2 and 
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O2 or for the photo-reduction of CO2). There are many examples in which synthetic 
porphyrins are used as chromophores and the metal center is typically a Ru(II) or 
Re(I) complex. An example of a photo-catalyst for the reduction of CO2 prepared in 
the group is shown in Figure 1.4.11,12 
 
 
 
 
Figure 1.4. Example of a phototoxic Ru(II)-porphyrin conjugate (left) and of a Re(I)-porphyrin 
conjugate studied as photo-catalyst for CO2 reduction (right). 
 
Finally, in the field of supramolecular chemistry the group pursues the synthesis of 
metal-mediated multi-porphyrin assemblies. These synthetic multi-chromophore 
systems have the potential to behave as artificial light harvesting devices for the 
photoinduced energy transfer in artificial photosynthesis. In addition, cage structures 
are investigated for molecular recognition and supramolecular (photo)catalysis.13 
The metal-mediated self-assembly approach, which exploits the formation of 
coordination bonds between peripheral basic site(s) on the porphyrins and the metal 
centers, has recently allowed the design and preparation in reasonable yields of 
increasingly sophisticated supramolecular architectures.14,15 Depending on whether 
the metal centers of the acceptor building blocks belong to other porphyrins or to 
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coordination compounds, very different discrete ordered architectures can be 
constructed (Scheme 1.1).  
 
Scheme 1.1. Examples of a 2+2 molecular square of porphyrins (top) prepared from the reaction 
between trans,cis,cis-RuCl2(CO)2(dmso-O)2 and 4′-cis-dipyridilporphyrin, and a 2:2 sandwich 
structure (bottom) formed by two zincated molecular squares and two connecting 4′-trans-
dipyridilporphyrin.16 
 
In all the above mentioned applications, water solubility is of paramount importance. 
However, since synthetic porphyrins have essentially a hydrophobic nature, suitable 
strategies must be developed for attaining some solubility in water (or at least in 
compatible solvents such as DMSO or alcohols). A commonly adopted approach 
involves the functionalization of the porphyrins with water-solubilizing moieties, 
either neutral or charged. Since we are dealing with porphyrin-metal conjugates or 
metal-mediated supramolecular assemblies of porphyrins, we thought that it might 
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be possible to introduce water solubility by an appropriate choice of the supporting 
(or ancillary) ligands in the metal fragments. For this reason, we are particularly 
interested to the design and synthesis of suitable Ru(II) precursors for the preparation 
of water-soluble ruthenium-porphyrin conjugates. In this context, the leaving ligands 
in the ideal metal precursor need to match either the number and geometry of 4'PyPs 
used for the construction of the supramolecular assembly or the binding preferences 
of the bifunctional linker used for connecting the porphyrin(s) (Scheme 1.2).  
 
Scheme 1.2. Schematic representation of a Ru(II) precursor with leaving ligands in cis geometry that 
allows the coordination of a chelating linker.  
 
Our approach is that of using the residual coordination sites of the ruthenium 
precursors (those not used by the linker or by the 4'PyPs) for attaching inert ancillary 
ligands that give high water solubility to the complex and – as a consequence – also 
of the conjugates.  
Moreover it is highly desirable that the metal precursors generate highly symmetrical 
fragments in order to minimize the formation of stereoisomers when bound to the 
linker. 
In the past, my group has largely exploited Ru(II)-dmso, Ru(II)-dmso-CO,17,18,19 and 
Ru(II)-[9]aneS3 ([9]aneS3 = 1,4,7-trithiacyclononane) complexes as precursors for 
the preparation of ruthenium-porphyrin conjugates and supramolecular 
assemblies.8,10,20,21 Nevertheless, most of them – even though well behaved in terms 
of reactivity – did not provide sufficient solubility in water.  
To improve water solubility we decided to prepare new Ru(II) precursors introducing 
in the coordination sphere one or more highly water-soluble 1,3,5-triaza-7-
phosphoadamantane (PTA) supporting ligands.19,22 
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1.2 1,3,5-triaza-7-phosphaadamantane (PTA) 
The cage-like phosphine 1,3,5-triaza-7-phosphaadamantane (PTA, Figure 1.5), first 
reported in 1974 by Daigle and co-workers,23 is an amphiphilic, air-stable, neutral 
monodentate ligand that – besides dissolving in several organic solvents – is 
characterized by a high solubility in water (ca. 235 g/L) by virtue of H-bonding to 
the tertiary amine nitrogens.  
 
Figure 1.5. Schematic structure of PTA. 
 
The coordination chemistry of PTA has been thoroughly reviewed by Peruzzini and 
co-workers.24 It typically binds strongly to metal ions through the P atom in a 
monodentate fashion. It has moderate steric demand (cone angle 103°), good σ- and 
π-bonding abilities (comparable to those of P(OMe)3) and, above all, it typically 
imparts excellent water solubility to its complexes.  
This ligand is commercially available at moderate cost but it can be synthesized in 
two different ways: by the condensation of trishydroxymethylphosphine with 
formaldehyde and hexamethylenetetramine in ice-water (Scheme 1.3, route a) or by 
using a solution of ammonia and formaldehyde in place of hexamethylenetetraamine 
(Scheme 1.3, route b).23a 
 
Scheme 1.3. Synthesis of PTA. 
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Using H2N(CH2)nNH2 (n = 0, 2 and 6) instead of ammonia, various PTA-related 
compounds, bearing differently sized spacers between the nitrogen groups, have 
been prepared by Majoral and co-workers (Figure 1.6).25,26  
 
Figure 1.6. PTA-related compounds prepared using H2N(CH2)nNH2 (n = 0, 2 and 6) instead of 
formaldehyde. 
 
PTA can be N-alkylated rather easily at one nitrogen atom using MeI,27 EtI,28 
PhCH2Cl,
29,30 or I(CH2)4I
31 in refluxing acetone or methanol (Figure 1.7). The 
resulting alkyl salts PTA(R)+X- (R = alkyl, X = Cl, I) are air and water stable. 
However, consistent with their ionic character, they are less soluble in organic 
solvents than PTA.23b,27 Nevertheless, high solubility in water is maintained except 
when the anion is PF6
–. The N-alkylated PTA salts, similarly to PTA, bind to 
transition metal through the phosphorus donor atom.  
 
Figure 1.7. N-alkylated PTA. 
 
At moderately acidic pH (pKa = 5.89)
32 the regioselective protonation of one N atom 
– to generate PTAH+ – occurs. Experimental data and ab initio calculations show 
that a further protonation of PTAH+ is thermodynamically less favorite. The pKa 
decreases after the coordination of the ligand to a metal center (in Ru(II) complexes 
pKa has a value of ca 3).
33,34 Also the oxidation of the phosphorus atom decreases 
the basicity of nitrogen atoms: the pKa of PTA oxide, PTAO, is 2.52.
24a  
The 1H NMR spectrum of free PTA shows two resonances of 6H each. Usually, 
NCH2P protons have a chemical shift between 3.9 and 4.1 ppm, while NCH2N 
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protons are downfield shifted at 4.5 – 4.6 ppm. The chemical shift and multiplicity 
of signals are solvent-dependent: Figure 1.8 shows that in CDCl3 the resonance at 
higher frequency appears as a broad singlet at 4.61 ppm, whereas in D2O the same 
NCH2N protons give a well resolved quartet (typical of an AB spin system) centered 
at 4.52 ppm (ΔδAB = 0.04, JAB = 12.7 Hz). In both solvents the resonance of NCH2P 
protons appears as a doublet attributed to an AB spin system with a small JAB.  
 
 
Figure 1.8. 1H NMR spectra of PTA in D2O (top) e in CDCl3 (bottom). 
 
The 13C NMR spectrum of PTA in D2O shows two different resonances: a doublet 
centered at 47.7 ppm (1JCP = 20.1 Hz) that belongs to PCH2N carbons and a doublet 
at 70.8 (3JCP = 1.3 Hz) ppm for NCH2N carbons.
a The carbon resonances are not 
particularly affected by the nature of the solvent. Finally, the 31P NMR spectrum 
shows a singlet at ca. –100 ppm. Also in this case the chemical shift is solvent 
depending: in CD3OD the resonance is at –97.4 ppm, in D2O at –98.2 ppm, in CDCl3 
                                                          
a In all the Thesis it will use the abbreviation 13C NMR and 31P NMR instead of 13C{1H} and 
31P{1H} i.e. the 13C and 31P NMR experiments with decoupled proton signals. 
4.7 4.6 4.5 4.4 4.3 4.2 4.1 4.0 3.9 3.8
4.7 4.6 4.5 4.4 4.3 4.2 4.1 4.0 3.9 3.8
NCH2P NCH2N 
NCH2P 
NCH2N 
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at –102.3 ppm, in DMSO-d6 a –103.7 ppm.24a The coordination of PTA to 
diamagnetic metal centers affects strongly the 31P resonance, and much less the 1H 
and 13C resonances. Usually the resonances of the NCH2N and NCH2P methylene 
protons are well resolved also for metal-bound PTA.24 
By virtue of their solubility properties Ru-PTA complexes have been investigated as 
homogeneous catalysts, either directly in aqueous solution or in biphasic aqueous-
organic conditions (see Chapter 1).34,24,35,36,37 
Moreover, the solubility properties PTA-metal complexes were considered to be 
potentially very useful for the development of new metal anticancer drugs. In fact, 
metal complexes containing PTA as co-ligand are anticipated to have good solubility 
in water for ease of in vitro investigation and in vivo administration, whereas 
maintaining sufficient lipophilicity to cross cell membranes and hence enter cancer 
cells. Finally, PTA appears to be a quite safe molecule in terms of toxicity. Indeed, 
several Ru compounds containing PTA as supporting ligand have been  investigated 
as potential anticancer drugs.33,38,39,40,41,42,43 Among them, the most well-known are 
the organometallic RAPTA-type compounds RuCl2(η6-arene)(PTA) (RAPTA = 
Ruthenium-Arene-PTA) developed by the group of Dyson (Figure 1.9),39 but other 
Ru(II) compounds containing PTA have been also investigated for their 
anticancer33,40,41,44 or DNA-binding45 properties. 
 
Figure 1.9. A representative example of the RAPTA compounds (RAPTA-T). 
 
When this work started, only few Ru(II) complexes with PTA as main ligand were 
known, i.e. trans- and cis-RuCl2(PTA)4 (respectively 1 and 2).
35,46 Thus, we decided 
to perform a systematic investigation of the reactivity of this ligand with well-known 
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neutral Ru(II) complexes, such as Ru-dmso and Ru-dmso-CO compounds, with the 
aim of preparing novel water-soluble Ru(II) complexes that might behave as suitable 
precursors for the synthesis of metal conjugates (Figure 1.10).19,22,47 Chapters 2 and 
3 describe in detail the results of this study.  
 
Figure 1.10. Examples of Ru(II) complexes whose reactivity with PTA was investigated: Ru-dmso 
(left, Chapter 2) and Ru-dmso-CO (right, Chapter 3) complexes. 
 
Moreover, all the new compounds prepared were reacted with 2,2′-bipirydine, used 
as model for diimmine linkers. In some cases the reactivity with pyridine, used as 
model for 4'PyPs, was also investigated. These aspects are extensively described in 
Chapters 2 and 4 of this Thesis. 
Finally, since mainly organometallic Ru(II)-PTA complexes have been tested as 
potential anticancer agents, an explorative investigation of the in vitro anticancer 
properties, as well as protein and DNA binding ability of trans- and cis-RuX2(PTA)4 
(X = Cl, Br) and of the Ru(III)-PTA complex, trans-[RuCl4(PTAH)2]Cl, was 
performed. The results of this investigation are described in Chapter 5.  
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1.3 Side-Projects 
In addition to the above-described main project, during the three years of Ph D I was 
involved in other side-projects in the field of bioinorganic chemistry, whose results 
are included in this Thesis. The topics of these side-projects are briefly introduced 
here, whereas a more exhaustive introduction will be found in the corresponding 
Chapters. 
In particular, during a six-month stage in the group of Prof. Nils Metzler-Nolte at the 
University of Bochum (Germany), new Ru(II)-peptide bioconjugates with potential 
antitumor activity were prepared and characterized.18    
The group of Prof. Metzler-Nolte has a consolidate experience in the preparation, 
characterisation and utilisation of novel metal-bioconjugates with peptides or other 
biomolecules. Particularly interesting is the use of receptor-binding peptides, such 
as neurotensin and ocreotide, an analogue of somatostatin.48 Such peptides have a 
high affinity for receptors that are overexpressed in several tumors so they can be 
used positively to target cancer cells.49 We decided to prepare novel bioconjugates 
using Ru(II) precursors prepared in Trieste and the neurotensin synthesized in 
Bochum. In particular, we were interested to assess the individual properties of two 
stereoisomeric conjugates, obtained – in principle – by linking neurotensin to the two 
Ru(II) complexes of the cppH linker (cppH = 2-(2′-pyridyl)pyrimidine-4-carboxylic 
acid) that are linkage isomers: trans,cis-RuCl2(CO)2(cppH-κNp) and trans,cis-
RuCl2(CO)2(cppH-κNo) (Figure 1.11). Details of this project are reported in Chapter 
6 and 7. 
 
Figure 1.11. Schematic structure of cppH, and of trans,cis-RuCl2(CO)2(cppH-κNp) (left) and 
trans,cis-RuCl2(CO)2(cppH-κNo) (right). 
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As part of a collaborative project with the group of Dr. Anna Renfrew from the 
University of Sidney (Australia), we prepared a series of complexes of the type 
[Ru([9]aneS3)(chel)(py)](Cl)2, where chel is a chelating diimine (Figure 1.12).  
 
Figure 1.12. Schematic representation of complexes [Ru([9]aneS3)(chel)(py)](Cl)2 in the case of chel 
= bpy. 
 
These model compounds are inert in the dark but rapidly and quantitatively release 
the pyridine ligand in aqueous solution when illuminated with blue light (λ = 420 
nm).21b Since the photo-generated aqua species [Ru([9]aneS3)(bpy)(OH2)]
2+ showed 
a substantial lack of cytotoxicity (against the MDA-MB-231 human mammary 
carcinoma cell line) we suggested that Ru(II) compounds of this type might be 
suitable agents for the light-triggered release of coordinated drugs (photo-
uncaging).21c This strategy belongs to the so-called Photoactivated Chemotherapy 
(PACT), a phototherapy approach in which a kinetically inert and biologically non-
active prodrug is irreversibly activated by irradiation with visible light that – for 
example – induces the cleavage of a photolabile protecting group or an 
isomerization.50 
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Our aim was that of establishing if, in the future, complexes of this series, bearing a 
pharmacologically active molecule in the place of pyridine, can be realistically used 
within this strategy. Renfrew’s group, in fact, is studying the photo-triggered release 
of CHS-828 (Figure 1.13). This cyanoguanidine, which has shown interesting 
properties as a potential anticancer agent, behaves also as a ligand and binds to a 
metal center through the pyridine moiety.51 Chapter 8 describes the results of this 
project. 
 
Figure 1.13. Schematic structure of CHS-828. 
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Neutral Ru(II) complexes with PTA 
2.1 State of the art 
When we started this work, in the literature there were only few examples of Ru(II) 
complexes in which PTA is the main ligand and not simply a co-ligand. 
Darensbourg’s group was the first to report in 1992 the synthesis of the complex 
RuCl2(PTA)4, that precipitated in high yield when hydrate RuCl3 was treated with 
an excess of PTA in refluxing ethanol (Scheme 2.1).1 The complex, based on the X-
ray structure of crystals obtained by recrystallization of the raw product from water, 
had a cis geometry. However, in that paper there was an incongruence between the 
single-crystal X-ray structure of the complex and the NMR data in solution. In fact, 
the 31P NMR spectrum showed only a singlet, whereas for a cis compound an A2X2 
system, composed by two triplets of same intensity, is expected. The information if 
the 31P NMR spectrum had been recorded on the raw material or on the crystals was 
missing also in a subsequent 1994 publication from the same group. Afterwards 
(2007) Mebi and Frost reported that the synthesis proposed by Darensbourg’s group 
actually led to the formation of the trans isomer, trans-RuCl2(PTA)4 (1), in 
agreement with the spectroscopic data reported in both papers.2 The geometry of the 
complex was also confirmed by an X-ray structure performed on single crystals 
obtained by recrystallization of the raw product from a dichloromethane solution. 
The conflicting results of Darensbourg’s group were caused by the instability of 1 in 
water, that slowly isomerizes to the cis isomer, cis-RuCl2(PTA)4 (2) at room 
temperature. In conclusion, whereas 2 is the thermodynamically stable isomer, 1 is 
the kinetic product of the reduction of hydrate RuCl3 in the presence of PTA. 
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Scheme 2.1. Preparation of trans-RuCl2(PTA)4 (1). 
 
The X-ray structures of the two isomers show that the Ru–Cl bond lengths in 1 are 
equal (2.437(2) Å) and shorter than those in 2 (2.488(2) Å e 2.503(2) Å). The Ru–P 
bond distances in 1 are between 2.317(2) and 2.353(2) Å, i.e. shorter than that of the 
mutually trans PTAs in 2 (2.370(2) Å) and longer than that of PTA trans to Cl 
(2.260(2) Å). 
Finally, Darensbourg’s group reported also the single-crystal X-ray structure of the 
Ru(III) complex trans-[RuCl4(PTAH)2]Cl (3) (PTAH = protonated PTA), obtained 
in small amount upon recrystallization of 1 from 0.1M HCl (Figure 2.1).1b The 
structure shows that the two mutually trans PTAs have a protonated nitrogen: the 
protonation causes an elongation of the corresponding N–C distances. In fact, the 
average NH+–C bond length (1.520(8) Å) is slightly longer than that of the other six 
N–C bonds (1.462(8) Å). According to the Authors, compound 3 could derive from 
two processes: adventitious air oxidation of 1 during prolonged crystal growing 
experiments and incomplete reduction of Ru(III) in the initial preparation. 
 
Figure 2.1. X-ray molecular structure of trans-[RuCl4(PTAH)2]Cl (3).1b 
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According to Mebi and Frost, the partial isomerization from trans- to cis-
RuCl2(PTA)4 occurs (slowly) also in CDCl3 at room temperature and was followed 
by 31P NMR spectroscopy: in a few days the singlet of 1 decreased in intensity in 
favor of the two new triplets of 2. Equilibrium between the two isomers was reached 
in a week (cis/trans ratio ≈ 1.84).  Afterwards, Romerosa and coworkers found that 
1 is stable in CDCl3 if protected from light: its 
31P NMR spectrum remained 
unchanged for 25 days.3 The same group studied the effect of visible light on the 
interconversion of the two isomers.2 According to their findings, 1 (yellow) 
isomerizes rapidly and completely to 2 (pale yellow) by irradiation of a chloroform 
solution with visible light (λ > 416 nm), whereas the reverse isomerization occurs by 
irradiation of a chloroform solution of 2 with light at λ = 367 nm (Scheme 2.2). 
 
Scheme 2.2. Light-induced interconversion of trans-RuCl2(PTA)4 (1) and cis-RuCl2(PTA)4 (2). 
 
Conversely, the light-induced isomerization of 1 in water was found to be 
irreversible, no back-isomerization occurred when an aqueous solution of 2 was 
irradiated at λ = 367 nm. 
By virtue of their very good solubility in water, trans- and cis-RuCl2(PTA)4 have 
been used as catalyst precursors in several reactions in aqueous solution or in 
biphasic systems (very often without specifying which isomer was being 
employed).4,5,6,7 Compound 1 was used for hydrogenation of various aldehydes and 
substituted benzaldehydes into alcohols in aqueous-organic biphasic systems with 
conversions from 95% (for benzaldehyde) to 23.6% (for 2-
methoxybenzaldehyde).1b,4,8,9 Recently, this compound was also used for nitrile 
hydration to amides in water with high conversion (99% for different substrates).7 
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Laurency and coworkers found that 1 shows moderate activity in the reduction of 
CO2 and HCO3– to formic acid in water. More recently the same group found that 1 
catalyzes the direct hydrogenation of CO2 to HCOOH in DMSO without any 
additive, with a TON = 159 at 60°C (TON = Turnover Number).10 
 
Very recently the group of Romerosa reported the synthesis of other Ru(II) 
derivatives with PTA. The complex trans,mer-RuCl2(OH2)(PTA)3 (4) was obtained 
by the reaction between RuCl2(PPh3)3 and 3 eq of PTA.
11 The 31P NMR spectrum in 
D2O of 4 consists in an AX2 system with a triplet centered at –5.1 ppm for the PTA 
trans to OH2 and a doublet at –46.8 ppm (2JP-P = 34.6 Hz) for the two mutually trans 
PTAs.  
 
Scheme 2.3. Preparation of trans,mer-RuCl2(OH2)(PTA)3 (4).11  
 
When 4 is treated in aqueous solution with 1 eq of PTA the weakly bound water 
molecule is replaced yielding trans-RuCl2(PTA)4 (1), whereas when the solution is 
heated at reflux or irradiated with an halogen lamp the dinuclear species 
[{Ru(PTA)3}2(µCl)3]Cl (5) is obtained (Scheme 2.4).  The 
31P NMR spectrum of this 
complex in D2O shows a singlet at –14.6 ppm. The structure is confirmed by X-ray 
quality crystals obtained by layering 2-propanol on an aqueous solution of the 
complex. 
 
Scheme 2.4. Preparation of the dimer [{Ru(PTA)3}2(µCl)3]Cl (5). 
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Dissolution of trans,mer-RuCl2(OH2)(PTA)3 (4) in a 1M HCl solution results in 
protonation of all PTA ligands yielding mer-[RuCl3(PTAH)3](Cl)2 (6). The 
31P NMR 
in D2O shows the signals of mer-[RuCl3(PTAH)3]
2+
 in equilibrium with those of the 
aqua species trans,mer-[RuCl2(OH2)(PTAH)3]
3+ (6aq). In fact, the spectrum 
presents two AX2 systems in ca. 2/1 ratio. The main set (a triplet centrered at –4.6 
ppm for the PTAH trans to Cl, and a doublet at –40.6 ppm (2JP-P = 33.3 Hz) for the 
two mutually trans PTAHs) was attributed to mer-[RuCl3(PTAH)3]
2+, while the 
minor set (a triplet centered at –2.3 ppm for the PTAH trans to OH2, and a doublet 
at –36.3 ppm (2JP-P = 35.6 Hz) for the mutually trans PTAHs) was attributed to the 
aqua species trans,mer-[RuCl2(OH2)(PTAH)3]
3+. X-ray quality crystals, obtained by 
diffusion of 2-propanol to a 1M HCl solution of 6, confirmed the proposed structure, 
i. e. mer-[RuCl3(PTAH)3](Cl)2 (6). 
Romerosa’s group reported also that when irradiated with visible light in aqueous 
solution 6 isomerizes to fac-[RuCl3(PTAH)3](Cl)2 (7) that precipitates as X-ray 
quality crystals (Scheme 1.4).  
 
Scheme 2.5. Light-induced interconversion of mer-[RuCl3(PTAH)3](Cl)2 (6) to fac-
[RuCl3(PTAH)3](Cl)2 (7). 
 
Also the fac- isomer in D2O is in equilibrium with the aqua species; in fact the 
31P 
NMR spectrum presents a singlet at –12.8 ppm for the three equivalent PTAHs trans 
to Cl of 7 and an AX2 system consisting of a triplet at –4.6 ppm and a doublet at –
12.5 ppm (2JP-P = 36.5 Hz) for the aqua species, 7aq.  
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2.2 Aim of the Chapter 
The reactivity of 1 and 2 was largely unexplored. For this reason, we decided to 
investigate if they might be exploited as precursors for the preparation of water-
soluble conjugates.  
This Chapter reports a thorough investigation of the chemical behavior of the isomers 
1 and 2 in water and other coordinating solvents, as well as of their reactivity towards 
2,2'-bipyridine (bpy), used as a model for chelating diimine linkers (i.e. cppH and 
bpyAc – Figure 2.2). 
 
Figure 2.2. Diimine linkers bpyAc (left) and cppH (right) with proton numbering scheme. 
 
Such linkers might allow us to connect a {RuClx(PTA)y} fragment (x = 0-2, y = 2-4, 
x+y = 4) to an appropriately functionalized vector (e.g. a porphyrin) through the 
formation of an amidic or esteric bond.12,13 
In addition, the reactivity of the well-known Ru(II)-Cl-dmso isomers cis-
RuCl2(dmso)4 (8) and trans-RuCl2(dmso-S)4 (9) (Figure 2.3) towards PTA was also 
investigated. In fact, an ideal precursor for the preparation of conjugates might have 
one or more PTAs as co-ligands for solubility and one or more dmso ligands (with 
appropriate geometry) for facile replacement by the linker.  
 
Figure 2.3. Schematic structures of cis-RuCl2(dmso)4 (8) and trans-RuCl2(dmso-S)4 (9). 
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Complex 8 is an extremely versatile compound since, depending on the reaction 
conditions, it can replace the relatively labile dmso ligands or chlorides, or both – 
completely or partially – with neutral or anionic ligands. In addition, it is easily 
prepared with high yield and purity and has a good solubility in many solvents, from 
water to chloroform. For these reasons, it is widely used as precursor for the synthesis 
of Ru(II) complexes.14 The trans isomer 9 is similarly well-behaved, but has been 
much less explored. 
Usually, neutral nitrogen ligands (N) replace from one to four dmso’s of 8 depending 
on their nature and reaction conditions. The O-bonded dmso is the most labile ligand 
and can be selectively replaced by strong σ-donor ligands (i.e. NH3 or pyridine) in 
mild conditions, yielding mono-substituted complexes cis,fac-RuCl2(dmso-S)3(N). 
By increasing the reaction temperature and the stoichiometric ratio it is possible to 
obtain di-substituted derivatives, whose geometry can be either trans,cis,cis-
RuCl2(dmso-S)2(N)2 or cis,cis,cis-RuCl2(dmso-S)2(N)2, depending on the conditions. 
On the other hand, 9 selectively reacts with monodentate nitrogen ligands (N, i.e. 
NH3, pyridine, imidazole) in mild conditions (at room temperature) leading to di-
substituted trans,cis,cis-RuCl2(dmso-S)2(N)2 derivatives exclusively. 
In the literature there are not many examples of the reactivity of 8 and 9 with 
monodentate phosphines and usually they are quite dated.14 As better detailed below, 
only recently Kathó and coworkers studied the reactivity of 8 with 2 eq of PTA in 
chloroform affording cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10).
15 
We confirmed and expanded these results,15 and investigated the yet unexplored 
reactivity of 10 towards imine ligands and 4′-meso-pyridylphenylporphyrins since 
this complex, by virtue of the presence of two potentially labile ligands (the dmso’s), 
seems to be a promising precursor for the synthesis of water-soluble conjugates. 
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2.3 trans-RuCl2(PTA)4 (1) and cis-RuCl2(PTA)4 (2) 
The complex trans-RuCl2(PTA)4 (1) was prepared as described in the literature 
(Scheme 2.6).1  
 
Scheme 2.6. Preparation of isomers 1 and 2. 
 
In our hands, the best synthetic procedure for the preparation of 2 was irradiation of 
an aqueous solution of 1 with blue light (λ = 470 nm) for 1 h.3 Evaporation of the 
solvent afforded pure 2 quantitatively (according to NMR analysis). The 
isomerization of 1 could be performed also thermally, by heating to reflux the 
aqueous solution (1h). However, according to the 31P NMR spectrum, the thermal 
reaction was not as clean as the photochemical one, leading to the formation of by-
products, including PTA oxide (PTAO),16 characterized by a sharp singlet at δ = –
2.1 ppm in the 31P NMR spectrum.  
A complete, and yet missing, NMR characterization of 1 and 2 is reported in Table 
2.1 (in D2O) and Table 2.2 (in CHCl3). The 
1H and 31P NMR spectra of 1 in CDCl3 
are quite straightforward, due to the high symmetry of the complex. The 31P NMR 
spectrum of 2, consistent with the A2X2 spin system, presents two equally intense 
triplets at δ = –24.1 and –59.4 ppm (2JP-P = 28.6 Hz). Based on the spectrum of 1 
(Table 2.2) and literature data,4 the most shielded triplet was assigned to the pair of 
mutually trans PTA ligands. The 1H NMR spectrum of 2 in CDCl3 (that, contrary to 
what reported, is considerably less soluble than 1 in this solvent),3 never described 
before, is more complex and consists of two relatively broad singlets (12H each) at 
δ = 4.04 and 4.47 ppm, and of a multiplet (24H) centered at δ = 4.48 ppm (Appendix, 
A2.1). The singlets (or better, unresolved multiplets) belong to the NCH2P groups of 
the two pairs of equivalent PTA ligands: in fact, in the 1H-1H COSY spectrum they 
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are both coupled to the multiplet (generated by the NCH2N groups), whereas in the 
1H-13C HSQC spectrum (Appendix, A2.2) they have distinct crosspeaks with carbon 
atoms that resonate in the NCH2P region (Table 2.2). Thus, both the 
1H and 13C 
resonances of the NCH2P groups are sensitive to the PTA position in the complex. 
An 1H-31P HMBC spectrum (Figure 2.4) allowed us to assign unambiguously the 
two NCH2P singlets in the 
1H NMR spectrum, that are pairwise related to the two 
triplets in the 31P dimension. The shielded singlet – that has a crosspeak with the 31P 
triplet at δ = –24.1 ppm – was assigned to the PTAs trans to Cl, and the other to the 
mutually trans PTA ligands.  
Using hydrate RuBr3 as precursor and the same synthetic procedures described 
above, the corresponding – and unprecedented – bromo complexes trans-
RuBr2(PTA)4 (11) and cis-RuBr2(PTA)4 (12) were isolated in good yields and fully 
characterized. The 1H and 31P NMR features of 11 and 12 and their chemical 
behavior in aqueous solution are similar to those of the corresponding chloro 
compounds (Table 2 and 2 – D2O and CHCl3 respectively, see also Appendix, A2.7-
A2.10).1,2,3 
 
Figure 2.4. 1H-31P HMBC NMR spectrum in CDCl3 of cis-RuCl2(PTA)4 (2) with 2J = 5Hz. The peak 
marked with an asterisk belongs to a minor unidentified impurity. 
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Table 2.1. 1H, 13C, 31P NMR characterization (δ, ppm; J, Hz) of trans-RuCl2(PTA)4 (1), cis-
RuCl2(PTA)4 (2), cis-[RuCl(OH2)(PTA)4]+ (2aq), trans-RuBr2(PTA)4 (11), cis-RuBr2(PTA)4 (12) 
and cis-[RuBr(OH2)(PTA)4]+ (12aq),  in D2O. 
 1H (J) 13C{1H} 31P{1H} (J) Solvent 
trans-RuCl2(PTA)4 (1) 
4.63, br s, 24H, NCH2N 70.8 
NCH2N 
–49.6, s, 
mutually 
trans PTAs 
D2O 
 
4.35, br s, 24H, NCH2P 50.8 
NCH2P 
  
cis-RuCl2(PTA)4 (2) 
4.65, m, 24H, NCH2N  n.d. 
–21.6, t, 
(28.5) PTAs 
trans to Cl  
D2O* 
 
4.47, br s, 12H, NCH2P, 
mutually trans PTAs  
4.14 br s, 12H NCH2P, 
PTA trans to Cl 
 
–57.6, t, 
(28.5) 
mutually 
trans PTAs 
 
trans-RuBr2(PTA)4 (11) 
4.61, br s, 24H, NCH2N 
4.40, br s, 24H, NCH2P 
70.5 
NCH2N 
 
51.9 
NCH2P 
–54.5, s, 
mutually 
trans PTAs 
D2O 
cis-RuBr2(PTA)4 (12) 4.70, m, 24H, NCH2N 
4.56 br s, 12H, NCH2P  
4.23 br s, 12H, NCH2P 
n.d. –24.1, t, 
(28.2), PTA 
trans to Br 
–64.7 t, 
(28.2), 
mutually 
trans PTAs 
D2O** 
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 1H (J) 13C{1H} 31P{1H} (J) Solvent 
cis-[RuCl(OH2)(PTA)4]+ 
(2aq) 
4.59, m, 24H, NCH2N 70.3 
NCH2N 
–12.7, dt, 
(30.3,34.8) 
PTA trans to 
OH2 
D2O 
 
4.26, d, 12H, NCH2P 49.8 
NCH2P 
–22.7, dt, 
(26.1,34.8) 
PTA trans to 
Cl 
 
 
4.11, s, 6H, NCH2P 54.9 
NCH2P 
–52.6, dd, 
(26.1, 30.3) 
mutually 
trans PTAs 
 
 
3.97, s 6H NCH2P 54.6 
NCH2P 
 
 
cis-[RuBr(OH2)(PTA)4]+ 
(12aq) 
  –13.01, dt, 
(30.5, 33.9), 
PTA trans to 
OH2  
–23.24, dt, 
(33.9, 25.7), 
PTA trans to 
Br  
 –55.88, dd, 
(30.5, 25.7), 
mutually 
trans PTAs 
D2O 
* Recorded in the presence of ca. 1M NaCl, ** Recorded in the presence of ca. 1M NaBr. 
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Table 2.2. 1H, 13C, 31P NMR characterization (δ, ppm; J, Hz) of trans-RuCl2(PTA)4 (1), cis-
RuCl2(PTA)4 (2), trans-RuBr2(PTA)4 (11) and cis-RuBr2(PTA)4 (12) in CDCl3. 
  1H (J) 13C{1H} 31P{1H} (J) Solvent 
trans-RuCl2(PTA)4 
(1) 
4.61, 4.57 ABq, 
24H, NCH2N (13.7) 
73.3 NCH2N 
 
–50.6, s mutually 
trans PTAs 
CDCl3 
 
4.40, br s, 24H, 
NCH2P 
53.1 NCH2P   
cis-RuCl2(PTA)4 (2) 
4.48, m, 24H, 
NCH2N 
73.1 NCH2N  CDCl3 
 
4.47, br s, 12H, 
NCH2P, mutually 
trans PTAs 
54.0 NCH2P 
 
–59.4, t, (28.6) 
mutually trans 
PTAs 
 
 
4.04, br s, 12H, 
NCH2P, PTA trans 
to Cl 
58.7 NCH2P –24.1, t, (28.6) 
PTAs trans to Cl  
 
trans-RuBr2(PTA)4 
(11) 
4.60, 4.55 ABq 24H, 
NCH2N, (13.2) 
4.46, br s, 24H, 
NCH2P 
73.5 NCH2N 
 
54.0 NCH2P 
–56.5, s, mutually 
trans PTAs 
CDCl3 
cis-RuBr2(PTA)4 (12) 
4.54, br s,12H, 
NCH2P 
4.50, m, 24 H, 
NCH2N 
4.10, br s, 12H, 
NCH2P 
73.9 NCH2N 
 
59.6 NCH2P 
 
55.4 NCH2P 
–27.0 t, (27.4), 
PTA trans to Br  
–67.3 t, (27.4) 
mutually trans 
PTAs 
CDCl3 
 
The single-crystal X-ray structures of 11 and 12 (Figure 2.5) are closely comparable 
with those of the corresponding dichloro derivatives.1,2 To begin with, they show 
distortions from the perfect octahedral geometry around Ru(II) very similar to those 
found in 1 and 2. In complex 11 the two pairs of trans PTA ligands are vertically 
displaced in opposite directions from the average equatorial plane (163.46(2) and 
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164.05(2)°). In complex 12 the two trans PTA ligands make a P–Ru–P angle of 
164.639(18)° (164.8(1)° in 2) and are bent towards the Br atoms. A similar bending 
is found for the two cis PTAs (97.067(19)° vs 96.5(1)° in 2). Thus, in both isomers 
the PTA moieties move towards the less sterically encumbered region occupied by 
the two Br ligands. The two trans Ru–Br distances in 11 are nearly equal (2.5695(4) 
and 2.5582(4) Å) and slightly shorter than those found in the cis isomer 12 
(2.6142(14) and 2.6289(4) Å), consistent with the stronger trans influence of PTA. 
Similarly, the Ru–P distances in the trans isomer range between 2.3253(7) and 
2.3484(7) Å (cfr 2.316(2) – 2.353(2) Å in 1), whereas in 12 the two Ru–P distances 
trans to Br are considerably shorter (2.2805(13) and 2.2655(5) Å; cfr 2.260(2) Å 
trans to Cl in 2) than those of the two trans PTAs (2.4001(5) and 2.3562(5) Å; cfr 
2.370(2) Å in 2), which – in turn – are close to (but slightly longer than) those in the 
trans isomer.  
 
Figure 2.5. X-ray molecular structures (50% probability ellipsoids) of trans-
[RuBr2(PTA)4]·0.682(C4H10O) (11, left) and cis-[RuBr2(PTA)4]·0.37(H2O) (12, right). The 
crystallization water molecule with minor occupancy factor in the structure of 12 has been omitted 
for clarity. Coordination distances (Å): 11: Ru1–Br1 = 2.5695(4), Ru1–Br2 = 2.5582(4), Ru1–P1 = 
2.3461(7), Ru1–P2 = 2.3253(7), Ru1–P3 = 2.3484(7), Ru1–P4 = 2.3378(7). 12: Ru1–Br1 = 
2.6142(14), Ru1–Br2 = 2.6289(4), Ru1–P1 = 2.4001(5), Ru1–P2 = 2.2655(5), Ru1–P3 = 2.2805(13), 
Ru1–P4 = 2.3562(5). 
 
 Chapter 2: Neutral Ru(II) Complexes with PTA 
38 
 
The behavior of the two chloro isomers in aqueous solution was also reinvestigated. 
In agreement with published data,3 2 rapidly equilibrates with the mono-aqua species 
cis-[RuCl(OH2)(PTA)4]
+ (2aq), that was isolated as PF6
– salt following another 
synthetic route (see below). The 31P resonances of the mixture of 2 and 2aq were 
readily distinguished with a 31P-31P COSY spectrum (Appendix, A2.6). Integration 
of such resonances afforded an equilibrium constant K = 1.39×10–2 M. The 31P NMR 
spectrum of 2aq presents an AM2X spin system (Table 2.1), with multiplets centered 
at δ = –12.7 (PTA trans to OH2), –22.7 (PTA trans to Cl), and –52.6 ppm (mutually 
trans PTAs). The assignments are consistent with the multiplicity and intensity of 
each signal, as well as with the spectrum of 2 and literature data.3 The 1H NMR 
spectrum of the mixture 2 + 2aq is quite complex. Pure 2 – according to the 31P NMR 
spectrum – was obtained upon addition of an excess of NaCl (ca. 1M) to the D2O 
solution. The yet unreported 1H NMR spectrum of 2 in D2O (Table 2) is quite similar 
to that recorded in CDCl3. Release of the second chloride from 2aq and formation of 
the di-aqua species cis-[Ru(OH2)2(PTA)4]
2+, characterized by two equally intense 
triplets in the 31P NMR spectrum at δ = –16.0 (2JP-P = 27.1 Hz, PTA trans to OH2) 
and –45.9 ppm (mutually trans PTAs), became apparent for concentrations of 2 < 5 
mM. This species had been previously obtained upon addition of an excess of PTA 
to a solution of [Ru(OH2)6]
2+.17 Treatment of an aqueous solution of 2 with one eq 
of AgCF3SO3 for 48 h at room temperature afforded the triflate salt of 2aq, cis-
[RuCl(OH2)(PTA)4](CF3SO3), in moderate yield.
3 The chloride abstraction was 
accompanied by the formation of Ag and/or Ag2O (the AgCl precipitate was dark 
grey). Attempts to remove also the second chloride from 2 by increasing the Ag+/Ru 
ratio, and to isolate the corresponding dicationic salt cis-
[Ru(OH2)2(PTA)4](CF3SO3)2 were unsuccessful. Consistent with literature data on 
Ru(II)-halide complexes, the bromide ligands proved to be more easily released than 
the chlorides.18 An equilibrium constant of 2.42×10-2 M was measured between 12 
and its mono-aqua derivative cis-[RuBr(OH2)(PTA)4]
+ (12aq).  
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Contrary to what reported in the literature,3 we found that a light-protected D2O 
solution of 1 is perfectly stable at room temperature: the NMR spectra remained 
unchanged for days (Appendix, A2.3). On the contrary, exposure of the NMR tube 
to diffused indoor light induced the slow isomerization (days) of 1 to a mixture of 2 
and 2aq, as witnessed by the appearance of the corresponding resonances in the 31P 
NMR spectrum.  
The thermal stability of 1 in the coordinating solvents DMSO and CH3CN was also 
investigated. When a concentrated solution of 1 in DMSO (where the complex is 
only partially soluble) was heated to 150 °C for 4 h, complete thermal isomerization 
to the cis isomer 2 (that partially precipitates from the warm solution) was observed. 
When the reaction was performed at lower temperatures, a pale yellow solid was 
isolated upon addition of acetone. According to the 31P NMR spectrum, this 
precipitate is a mixture of 2 and of an intermediate characterized by an AX2 spin 
system: a triplet at δ = –25.6 ppm attributable to a PTA trans to Cl, and doublet at δ 
= –61.0 ppm (2JP-P = 27.9 Hz) in the region of mutually trans PTAs (Appendix, 
A2.11). The proton spectrum, besides several PTA peaks, shows a singlet at δ = 3.20 
ppm attributable to dmso-S in a symmetrical environment (equivalent methyl 
groups). Based on this spectral evidence, the intermediate species was identified as 
cis,mer-RuCl2(dmso-S)(PTA)3 (13, Figure 2.6). The intermediate 13 could not be 
isolated in pure form: the highest 13/2 ratio (40:60, without residual 1) was obtained 
by running the reaction at 70 °C for 1h.  
A similar behavior was observed when 1 was heated in acetonitrile. In this case the 
complex dissolves completely under reflux conditions and a pale yellow solid 
precipitates spontaneously from the solution. According to the 31P NMR spectrum 
(Appendix, A2.12-A2.13) it is a mixture of 2 (whose amount increases with the 
reflux time) and of two intermediates, 14 (major) and 15 (minor), both characterized 
by AX2 spin systems (Figure 2.6). According to the chemical shifts of the multiplets, 
the major intermediate 14 (triplet at δ = –16.1 ppm, doublet at δ = –53.3 ppm, 2JP-P 
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= 28.5 Hz) was identified as trans,mer-RuCl2(CH3CN)(PTA)3 whereas the minor 
one (triplet at δ = –24.0 ppm, doublet at δ = –54.3 ppm, 2JP-P = 37.2 Hz) as cis,mer-
RuCl2(CH3CN)(PTA)3 (i.e. 15 is the counterpart of 13 isolated in DMSO). 
Consistently, the corresponding 1H NMR spectrum shows, besides the overlapped 
PTA resonances, two singlets at δ = 2.30 and 2.46 ppm, in the same ratio as the 
resonances of 14 and 15 in the 31P NMR spectrum, attributed to coordinated CH3CN. 
 
Figure 2.6. Intermediates isolated (not in pure form) when the thermal isomerization of 1 to 2 was 
performed in DMSO (13), or in acetonitrile (14 and 15). 
 
In an unsuccessful attempt to prepare the presumed Ru(III) and Ru(II) intermediates 
trans-[RuCl4(PTAH)2]Cl (3) and trans-RuCl4(PTAH)2 (16), respectively, that had 
been occasionally isolated in the recrystallization of 1,1,19 we found that the reaction 
between hydrate RuCl3 and PTA in ethanol occurs also at room temperature, even 
though it is very slow (days) and affords low yields of 1. The Ru(III) compound 3 
was instead selectively prepared in high yield by a different route, i.e. by treatment 
of the Ru(III)-dmso precursor [(dmso)2H]trans-[RuCl4(dmso-S)2] with PTA in 
MeOH/HCl mixtures (Scheme 2.7). Due to the acidic conditions used in the 
preparation, both PTA ligands undergo protonation and the complex precipitates 
spontaneously in almost quantitative yield in its cationic form. 
 
Scheme 2.7. Selective preparation of trans-[RuCl4(PTAH)2]Cl (3) from the Ru(III)-dmso precursor 
[(dmso)2H]trans-[RuCl4(dmso-S)2]. 
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Dark crystals of trans-[RuCl4(PTAH)2]Cl·H2O (3·H2O) suitable for X-ray structure 
determination were obtained upon recrystallization of the raw product from water 
(Figure 2.7).  
 
Figure 2.7. Molecular structure of trans-[RuCl4(PTAH)2]Cl·H2O (3·H2O). Only the chloride in the 
position of maximum occupancy is shown. Coordination distances (Å): Ru1–P1 = 2.3427(5), Ru1–
Cl1 = 2.3565(12), Ru1–Cl2 = 2.3649(16). 
 
The molecular structure of complex 3 is in close agreement with that already 
published for this species.1b One N atom in each PTA ligand is fully protonated, as 
confirmed by lengthening of the corresponding C–N bonds from 1.456(4) Å to 
1.516(4) Å in the protonated form.4,15 The positive charge of the complex is balanced 
by an external chloride ion that is disordered over three different positions. 
The 1H NMR spectrum of 3 in D2O consists of two relatively broad peaks for bound 
PTA (one for the PCH2N and the other for the NCH2N protons) shifted upfield with 
respect to the typical PTA region (δ = 0.37 and –1.17 ppm, no assignment could be 
made, Appendix, A2.14). Consistent with the fact that P of PTA is directly bound to 
the paramagnetic Ru(III) nucleus, we were unable to observe any resonance in the 
31P NMR spectrum (most likely the expected singlet is too broad to be detected). 
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2.3.1 Reactivity of 1 and 2 towards diimine ligands 
The above reported results suggest that, even though PTA binds strongly to Ru(II), 
replacement of at least one chloride and one PTA from isomers 1 and 2 seems to be 
possible, depending on the solvent and reaction conditions. Thus, we investigated 
the reactivity of 1 and 2 towards 2,2'-bipyridine (bpy) as model for the diimine 
linkers 4′-methyl-2,2′-bipyridine-4-carboxylic acid (bpyAc, Figure 2.2) and 2-(2′-
pyridyl)pyrimidine-4-carboxylic acid (cppH, Figure 2.2). 
Both 1 and 2 were found to react with bpy in refluxing water (in light protected 
conditions), as evidenced by a progressive color change of the solution from pale to 
deep yellow. More specifically, treatment of 1 with 1 eq of bpy in refluxing water (1 
h), followed by evaporation of the solvent, afforded almost quantitatively the 
complex mer-[Ru(bpy)Cl(PTA)3]Cl (17, Scheme 2.8). 
 
Scheme 2.8. Preparation of mer-[Ru(bpy)Cl(PTA)3]Cl (17) upon treatment of 1 with bpy in water at 
reflux. 
 
Compound 17 was fully characterized by NMR and mass spectrometry (as PF6 salt, 
see the experimental section) and its single-crystal X-ray structure was also 
determined (Figure 2.8). The 1H NMR spectrum (Appendix, A2.15) shows eight 
aromatic resonances, typical of bpy in an unsymmetrical environment. In agreement 
with previous findings,20,21 the most deshielded doublet was assigned to H6, i.e. the 
proton with a partial positive charge that points towards the adjacent chloride 
(Scheme 2.8). The PTA region of the spectrum consists of two similar and partially 
overlapping sets of equally intense signals, an AB quartet and a broad singlet, in a 
1:2 ratio. The most intense and upfield shifted set was attributed to the two equivalent 
trans PTA ligands, whose protons fall in the shielding cone of the adjacent bpy. The 
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1H-13C HSQC spectrum established that, in each set, the deshielded quartet belongs 
to the NCH2N protons and the singlet to the NCH2P protons. The 
31P NMR spectrum 
(Appendix, A2.19) consists of an AX2 spin system: a triplet at δ = –30.2 ppm 
attributable to a PTA trans to N, and doublet at δ = –47.6 ppm (2JP-P = 32.8 Hz) for 
the mutually trans PTAs. The spectra did not change upon addition of NaCl, 
suggesting that they can be safely attributed to the intact mer-[Ru(bpy)Cl(PTA)3]
+ 
cation (see below). Interestingly, the crystals of 17 obtained upon recrystallization 
of the raw product from water/ethanol contain a network of water molecules 
distributed in parallel rows along the [001] direction, which arguably contribute to 
the cohesive energy of the crystal by means of hydrogen bonding to the N atoms of 
the PTA moieties. The coordination distances are in general agreement with the 
known trans influence of the ligands: thus, the Ru–P bond lengths of the two trans 
PTA ligands (2.3427(5) and 2.3275(5) Å) are slightly longer than the Ru–P distance 
trans to N (2.3018(5) Å) and the Ru–N bond length trans to P (2.1154(14) Å) is 
longer that trans to Cl (2.0770(13) Å). 
 
Figure 2.8. X-ray molecular structure (50% probability ellipsoids) of mer-
[Ru(bpy)Cl(PTA)3]Cl∙6H2O (17). Coordination distances (Å): Ru1–Cl1 = 2.4354(4), Ru1–N41 = 
2.1154(14), Ru1–N42 = 2.0770(13), Ru1–P1 = 2.3427(5), Ru1–P2 = 2.3018(5), Ru1–P3 = 2.3275(5). 
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The reaction between 2 and bpy is slower and less selective: when a slight excess of 
bpy was used (bpy/Ru = 1.5), full conversion required ca. 10 h of reflux. According 
to the NMR spectra, the final mixture contained – besides some unidentified minor 
species and PTAO – compound 17 as main product and another species identified as 
fac-[Ru(bpy)Cl(PTA)3]Cl (18) (17/18 = ca. 10). We found that an increase of the 
bpy/Ru ratio from 1.5 to 5, together with the addition of 1 eq of AgNO3, led to full 
conversion of 2 after 1h of reflux. In addition, in this case the main product was the 
fac isomer 18 (18/17 = ca. 7, Scheme 2.9), that was obtained in pure form for 
unambiguous characterization as PF6 salt (18PF6, see experimental section). An 
increase of the reaction time involved a progressive decrease of the 18/17 ratio, 
suggesting that 18 is the kinetic product of the reaction between 2 and bpy, whereas 
17 is thermodynamically more stable. 
 
Scheme 2.9. Preparation of a mixture of the cationic isomers mer-[Ru(bpy)Cl(PTA)3]Cl (17) and fac-
[Ru(bpy)Cl(PTA)3]Cl (18) upon reaction of 2 with bpy in water at reflux. 
 
Immediately after dissolution in D2O, the 
1H NMR spectrum of 18 has only four 
aromatic resonances, in agreement with a symmetrical coordination for bpy. 
However, a second set of four bpy resonances, each one slightly downfield shifted 
with respect to the parent one and attributed to the aqua species fac-
[Ru(bpy)(OH2)(PTA)3]
2+ (18aq) grows slowly with time at the expenses of the 
original one (Figure 2.9).  
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Figure 2.9. 1H NMR spectra of fac-[Ru(bpy)Cl(PTA)3](PF6) (18PF6) in D2O registered immediately 
after dissolution (a); after 1 hour in the dark (b); after 24 hours in the dark (c). 
 
Equilibrium (18/18aq = ca. 1.5) was reached within 24h at room temperature. 
Consistently, the 31P NMR spectrum shows two AX2 spin systems, attributed (based 
on their relative intensities and time evolution) to 18 (triplet at δ = –24.3 ppm, PTA 
trans to Cl) and to 18aq (triplet at δ = –17.7 ppm, PTA trans to OH2) (Figure 2.10). 
The two doublets overlap almost completely at δ = –44.2 ppm, i.e. in the typical 
region of PTA trans to N (2JP-P = 29.2 Hz).  
 
Figure 2.10. 31P NMR spectra of fac-[Ru(bpy)Cl(PTA)3](PF6) (18PF6) in D2O registered immediately 
after dissolution (top) and after 24 hours in the dark (bottom). 
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The PTA region of the 1H NMR spectrum is quite complicated due to the overlapping 
resonances of 18 and 18aq. It simplifies upon addition of an excess of NaCl (ca. 1M) 
that reverts completely the equilibrium towards 18. Under these conditions the 
spectrum is similar to that of 17, but in this case is the less intense set of signals, 
attributed to the PTA trans to Cl, to be shielded by bpy. Taken together, the NMR 
features are totally consistent with the proposed geometry. X-ray diffraction 
performed on single crystals of the protonated derivative fac-
[Ru(bpy)Cl(PTAH)2.5(PTA)0.5](ClO4)3.5·2.5H2O, obtained upon addition of HClO4 
to an aqueous solution of 18, allowed us to confirm the geometry of the complex 
(Appendix, A2.48). 
In conclusion, we found that the coordination of bpy to 1 and 2 in aqueous solution 
involves the replacement of one chloride and one PTA ligand, and affords – 
depending on the conditions – the two isomers 17 and 18. To be noted that formation 
of compound 18 was not observed in the reaction between 1 and bpy, indicating that 
the mechanisms of the two substitution reactions are different. 
Consistent with these findings, the reactivity of both isomers 1 and 2 with bpy in 
organic solvents in which chloride release is unfavorable (e.g. CH3CN, CHCl3) is 
much less pronounced, when not altogether negligible. For example, in refluxing 
chloroform no reaction was observed between 2 and bpy, whereas 1 reacted to a 
minor extent affording (after 5h) a complex mixture of products that – based on the 
31P NMR spectrum – contained 2, 18, PTAO and other minor uncharacterized 
species. 
 
Since trans-RuCl2(PTA)4 (1) reacts selectively with bpy forming only one of the 
possible stereoisomers, the reaction with the linker cppH was also investigated. This 
diimine ligand can originate linkage isomers; in fact, its pyrimidine ring can bind to 
the metal ion either through the nitrogen atom ortho (No) or para (Np) to the 
carboxylate linked to C4. Most of the cppH-Ru(II) conjugates reported so far were 
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prepared following a synthetic route that led selectively to the Np coordination mode 
(see also Chapter 6).22,23,24,25,26 
The reaction between 1 and cppH (actually obtained as cppH·HNO3) in refluxing 
water led to a main geometrical and linkage isomer, formulated as mer-
[RuCl(cppH-Np)(PTA)3]Cl (19), in a mixture with minor uncharacterized species 
(Scheme 2.10). In fact, the 1H NMR spectrum of the raw product in D2O presents 
one main set of aromatic resonances for coordinated cppH, whereas the PTA region 
of the spectrum present several multiplets, including those of free PTA 
(Appendix, A2.23). The 31P NMR spectrum of 19 consists of an AX2 system 
composed by a triplet centered at –39.9 ppm and a doublet centered at ppm –
51.9 (2JP-P = 35.5 Hz). Since the chemical shifts for the three bound PTA 
ligands are similar to the those of 17, also in this case the mer geometry was 
assigned to 19. Comparison of the chemical shifts of H6 and H6′ with those of other 
known Ru(II)-cppH complexes suggests that the cppH in 19 is bonded Np (see 
Chapter 5).21 However, we are unable to establish whether the pyridine or the 
pyrimidine ring of cppH is trans to PTA. Attempts to obtain 19 in pure form 
were unsuccessful. 
 
Scheme 2.10. Reactivity of trans-RuCl2(PTA)4 (1) towards cppH. 
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2.4 Reactions of Ru(II)-dmso complexes with PTA 
As mentioned above, the reactivity of the well-known Ru(II) precursors, cis- and 
trans-RuCl2(dmso)4 (8 and 9, respectively) towards PTA was investigated, with the 
aim to prepare new water-soluble precursors. 
After starting our work, we became aware that the reactivity of 8 towards PTA had 
been recently investigated by Kathó and coworkers.15 In good agreement with their 
results, we found that the treatment of 8 with PTA at room temperature leads 
selectively to the formation of cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10)  regardless 
of the nature of the solvent (e.g. in MeOH) and of the PTA/Ru ratio (Scheme 2.11). 
Even when less than two eq of PTA were used, compound 10 was obtained together 
with unreacted precursor. Replacement of all dmso-S ligands (with formation of a 
mixture of 1, 2 and 10) was observed when the reaction (PTA:Ru = 4) was performed 
in refluxing MeOH. Conversely, we found that treatment of trans-RuCl2(dmso-S)4 
(9, not investigated before) with PTA at room temperature leads exclusively to 1 
(Scheme 2.11). Also in this case the nature of the product does not depend on the 
PTA/Ru ratio employed. For example, when PTA/Ru = 2, a ca. 1:1 mixture of 1 and 
unreacted precursor was recovered at the end. In neither case any intermediate could 
be detected, suggesting that the replacement of two trans dmso ligands by two PTA 
ligands occurs rapidly and quantitatively. As already mentioned (see above), the 
same behavior, i.e. facile substitution of two trans dmso-S ligands, was observed 
also with the Ru(III)-dmso precursor [(dmso)2H]trans-[RuCl4(dmso-S)2] that 
afforded 3. 
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Scheme 2.11. Reactivity of cis-RuCl2(dmso)4 (8, top) and trans-RuCl2(dmso-S)4 (9, bottom) towards 
PTA at room temperature. 
 
The spectroscopic characterization of compound 10 (Appendix, A2.24) as well as its 
single-crystal X-ray structure (Figure 2.11) are in good agreement with what reported 
in the literature.15,27  
 
Figure 2.11. Molecular structure (50% probability ellipsoids) of the two crystallographically 
independent units of cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10). Disordered and under-occupied 
methanol and water crystallization molecules have been omitted for clarity. Coordination distances 
(Å): Ru1–Cl11 = 2.4482(7), Ru1–Cl12 = 2.4483(6), Ru1–S11 = 2.2488(6), Ru1–S12 = 2.2522(6), 
Ru1–P13 = 2.3764(7), Ru1–P14 = 2.3755(8). Ru2–Cl21 = 2.4583(6), Ru2–Cl22 = 2.4606(6), Ru2–
S21 = 2.2358(6), Ru2–S22 = 2.2578(6), Ru2–P23 = 2.3780(8), Ru2–P24 = 2.3304(8). 
 
Compound 10 is well soluble in water, DMSO, CHCl3, CH2Cl2 and, upon warming, 
also in MeOH and EtOH. We observed that the 1H NMR spectrum of a light-
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protected D2O solution of 6 changes very slowly (days) at room temperature 
(Appendix, A2.25). Since no signals for free DMSO or PTA were detected, the 
spectral changes were attributed to the progressive release of a chloride with 
formation of the mono-aqua species cis,cis,trans-[RuCl(OH2)(dmso-S)2(PTA)2]
+ 
(10aq). Consistent with this hypothesis, in the 31P NMR spectrum a new singlet at δ 
= –53.0 ppm grows slowly at the expenses of the original one at δ = –57.9 ppm 
(Appendix, A2.26). In the 1H spectrum, besides new signals in the PTA region, two 
new singlets for dmso-S grow at δ = 3.37 and 3.41 ppm (i.e. very close to the original 
singlet at δ = 3.38 ppm). In fact, in 10aq, whereas the two trans PTAs are still 
equivalent, the two sulfoxides are not.  
We also investigated the possibility of obtaining complexes with either five or six 
bound PTA moieties, using the cationic Ru(II)-dmso precursors cis,fac-[RuCl(dmso-
O)2(dmso-S)3](PF6) (20) and fac-[Ru(dmso-O)3(dmso-S)3](CF3SO3)2 (21), 
respectively. We found that treatment of 20 with 5 eq of PTA in methanol at room 
temperature afforded cis-[RuCl(OH2)(PTA)4](PF6) (2aq) in moderate yield. The 
1H 
NMR spectrum of the complex in D2O corresponds to that of 2aq observed in 
equilibrium with 2 (see above) with, in addition, a singlet for free MeOH 
(crystallization molecule). The nature of the compound was also confirmed by a low 
quality X-ray structural determination (Appendix, A2.49). Repeated attempts to 
obtain better crystals were unsuccessful. When the same reaction was performed at 
reflux temperature, precipitation of 2 occurred, whereas the resonances of 2aq, cis-
[Ru(OH2)2(PTA)4]
2+ and PTAO were found in the 31P NMR spectrum of the mother 
liquor (D2O). Since there is no external source of chloride, this finding suggests that 
the disproportionation of 2aq into di-chloro (2) and di-aqua {Ru(PTA)4} species 
occurs in these conditions. 
Conversely, treatment of 21 with 6 eq of PTA in methanol or acetone at room 
temperature afforded no product, but PTA was completely converted to PTAO 
within a few hours. When the reaction was performed in refluxing chloroform (no 
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reaction occurred at room temperature), precipitation of 2 was observed in moderate 
yield, implying chloride abstraction from the solvent. This finding suggests that 
cationic Ru(II)-PTA species have a very high affinity for chloride. 
 
Compound 10 was studied by Katho’s group as catalyst for the isomerization of 
allylic alcohol to the corresponding ketone; no further investigations about its 
reactivity were done.15 Only very recently Romerosa’s group studied the behavior of 
this compound with light. They reported that overnight irradiation of an aqueous 
solution of 10 with white light in presence of 3 eq of PTA affords the dimer 
[{Ru(PTA)3}2(µ-Cl)3]Cl·9H2O (5) (described above) (Scheme 2.12). Conversely, 
when the irradiation was done in the presence 4 eq of PTA, to trans-RuCl2(PTA)4 
(1) was obtained.11 
 
Scheme 2.12. Reactivity of cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10) with PTA under irradiation with 
white light in water.  
 
The complexes cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10), however, has the 
characteristics for being a good precursor for the preparation of Ru(II)-PTA 
derivatives, since it has the two dmso-S ligands that might be replaced with relative 
ease by a chelating ligand (e.g. a diimine) and – in principle – also by two 
monodentate ligands (e.g. pyridine). Indeed, we found that when 10 is treated with a 
slight excess of bpy in refluxing ethanol, the original pale-yellow solution becomes 
progressively ruby-red. A product of the same color, identified as cis,cis-
Ru(bpy)Cl2(PTA)2 (22), was isolated in moderate-to-good yield (Scheme 2.13). 
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Scheme 2.13. Preparation of cis,cis-Ru(bpy)Cl2(PTA)2 (22) upon treatment of cis,cis,trans-
RuCl2(dmso-S)2(PTA)2 (6) with bpy in refluxing ethanol. 
 
Thus, the selective replacement of the two sulfoxides by bpy is accompanied by the 
concomitant isomerization, yielding the less symmetrical all-cis product. Compound 
22, which is well soluble in water, in chloroform and DMSO, and moderately soluble 
in MeOH and EtOH, was fully characterized by NMR and mass spectrometry and its 
single-crystal X-ray structure was determined (Figure 2.12). 
 
Figure 2.12. Molecular structure (50% probability ellipsoids) of cis,cis-Ru(bpy)Cl2(PTA)2 (22). The 
three MeOH molecules of crystallization have been omitted for clarity. Coordination distances (Å): 
Ru1–Cl1 = 2.4789(4), Ru1–Cl2 = 2.4421(4), Ru1–N31 = 2.0540(14), Ru1–N32 = 2.1167(15), Ru1–
P1 = 2.2318(4), Ru1–P2 = 2.2849(4). 
 
In the 1H NMR spectrum of 22 in CDCl3, bpy presents eight well resolved resonances 
(1H each, Appendix, A2.27). As above, the most deshielded doublet was assigned to 
H6 (Scheme 2.12). The two inequivalent PTAs give four resolved resonances (6H 
each, Figure 2.13), pairwise coupled in the 1H-1H COSY spectrum (Appendix, 
A2.28). The two most upfield multiplets are attributed to the PTA trans to Cl that 
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falls into the shielding cone of the adjacent bpy. The assignments are confirmed by 
an 1H-31P HMBC spectrum. 
 
Figure 2.13. 1H NMR spectrum (PTA region) in CDCl3 of cis,cis-Ru(bpy)Cl2(PTA)2 (22). See the 
inset drawing for the peak labels. 
 
The 31P NMR spectrum of 22 in D2O (two doublets at δ = –7.0 and –31.9 ppm, 2JP-P 
= 37.7 Hz) is similar to that in CDCl3 (Appendix, A2.31). However, whereas the 
shielded resonance is compatible with a P trans to N, the other doublet falls in the 
region of PTA trans to O (see for example the spectra of 2aq and 18aq) rather than 
trans to Cl (expected at about –15 ppm). Thus, we hypothesized that, upon 
dissolution in water, complex 22 undergoes rapid, quantitative and selective release 
of the Cl trans to PTA affording cis,cis-[Ru(bpy)Cl(OH2)(PTA)2]
+ (22aq, Scheme 
24). This hypothesis is consistent with: i) what observed above with other complexes 
(e.g. 2 and 18) having Cl trans to PTA; ii) the larger trans-influence of PTA 
compared to bpy, which is reflected by the solid state data, according to which the 
Ru–Cl bond trans to PTA (2.4789(4) Å) is longer than that trans to bpy (2.4422(4) 
Å); iii) the downfield shifted resonance of H6 implies that the adjacent Cl remains 
bound to ruthenium. 
 
Scheme 2.14. Selective aquation of complex 22. 
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Indeed, we found that addition of aliquots of NaCl to the D2O solution leads to the 
progressive growth of a new set of resonances in the NMR spectra – attributed to 
intact 22 – at the expenses of the original ones thus unambiguously attributed to 22aq. 
Figure 2.14 shows an intermediate situation in the 31P NMR spectrum (see also 
Appendix, A2.32, for the 1H NMR spectrum). As expected, the chemical shift of the 
new deshielded doublet in the 31P NMR spectrum (δ = –12.7) is now in the region 
compatible with P trans to Cl. The complete transformation of 22aq to 22 upon 
addition of excess NaCl (ca. 1M) induces also a minor shift in the absorption 
maximum of the UV-vis absorption spectrum from 413 (22aq) to 418 nm (22) 
(Appendix, A2.45). 
 
Figure 2.14. 31P NMR spectrum in D2O of cis,cis-[Ru(bpy)Cl(OH2)(PTA)2]+ (22aq) after addition of 
an aliquot of NaCl (ca. 0.2M), affording a mixture of 22 and 22aq. 
 
Similarly, treatment of 10 with bpyAc in refluxing ethanol afforded cis,cis-
Ru(bpyAc)Cl2(PTA)2 (23) as a nearly 1:1 mixture of the two stereoisomers 23a (4-
carboxylic acid trans to PTA) and 23b (4-carboxylic acid trans to Cl) (Scheme 2.15). 
 
Scheme 2.15. Preparation of cis,cis-Ru(bpyAc)Cl2(PTA)2 (23) as a 50/50 mixture of the two 
stereoisomers 23a and 23b. 
 
The spectroscopic features of 23a and 23b (Appendix, A2.33) are quite similar, 
except for the bpyAc resonances in the 1H NMR spectrum, where twelve well-
resolved signals (1H each, six for each stereoisomer) were found in the aromatic 
22aq 22aq
22
22
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region, plus two methyl singlets (3H each). The most deshielded doublet (δ = 9.58 
ppm) was assigned to the H6 proton in 23a for the following reasons: i) in free bpyAc 
H6 gives the most deshielded resonance (8.87 ppm vs 8.57 ppm for H6′); ii) in the 
complex this proton is further deshielded – besides by coordination – by the adjacent 
chloride (see above). The second most downfield doublet was assigned to H6′ in 23b, 
where it points towards the adjacent Cl. All other bpyAc resonances were then 
unambiguously assigned by means of 2D 1H-1H COSY and NOESY spectra. 
Particularly relevant were the cross peaks between the CH3 (in position 4′) and the 
H3′ singlets in the COSY spectrum, and those between the singlets of H3 and H3′ in 
the NOESY spectrum. As in the case of 22, when dissolved in water also 23 releases 
the chloride trans to PTA, affording a mixture of 23aaq and 23baq, even though at a 
slower rate. 
 
The reactivity of 10 towards pyridine (py), used as a model for the 4′-meso-
pyridylphenylporphyrins, was also investigated. Treatment of 10 with an excess of 
py in refluxing ethanol led to an orange product that precipitates spontaneously upon 
concentration of the solution. The compound was identified as trans,cis,cis-
RuCl2(PTA)2(py)2 (24), and was isolated in moderate-to-good yield (Scheme 2.16). 
 
Scheme 2.16. Preparation of trans,cis,cis-RuCl2(PTA)2(py)2 (24) upon treatment of cis,cis,trans-
RuCl2(dmso-S)2(PTA)2 (10)  with py in refluxing ethanol. 
 
Compound 24, which is soluble in water, chloroform and DMSO, and moderately 
soluble in MeOH and EtOH, was fully characterized by NMR spectroscopy and mass 
spectrometry and its single-crystal X-ray structure was also determined (Figure 
2.15). 
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Figure 2.15. Molecular structure (50% probability ellipsoids) of trans,cis,cis-RuCl2(PTA)2(py)2 (24).  
Coordination distances (Å): Ru1–Cl1 = 2.4291(4), Ru1–N1 = 2.1933(8), Ru1–P3 = 2.2543(3). 
 
In the 1H NMR spectrum in CDCl3, the two equivalent py ligands show three well 
resolved resonances in the aromatic region. The two equivalent PTAs give two 
resolved resonances, a singlet and a multiplet (12H each, Figure 2.16), pairwise 
coupled in the 1H-1H COSY spectrum. As above, the singlet centered at 4.02 ppm 
belongs to the NCH2P protons while the multiplet at 4.25 ppm to the NCH2N protons. 
Integration of PTA and py signals is consistent with a 1:1 ratio. The 31P NMR 
spectrum consists of a singlet at –20.4 ppm for the two equivalent PTAs trans to 
pyridine. 
Thus, as with the diimine ligands, the selective replacement of the two sulfoxides by 
pyridine is accompanied by the isomerization of two PTAs from trans to cis. 
However, in this case, also the geometry of the two chlorides changes from cis to 
trans.  
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Figure 2.16. 1H (left) and 31P (right) NMR spectra in CDCl3 of trans,cis,cis-RuCl2(PTA)2(py)2 (24).  
 
The same reaction was also performed at reflux temperature in CHCl3. In this case a 
different – and unexpected – product, identified as trans,mer-RuCl2(py)(PTA)3 (25), 
precipitated in pure form as a yellow powder in moderate yield after the addition of 
diethyl ether to the solution (Scheme 2.17). In fact, the 31P NMR spectrum in CDCl3 
of the precipitate presents only an AX2 system with a doublet centered at –54.2 ppm, 
attributed to two mutually trans PTAs, and a triplet centered at –22.5 ppm (2JP-P = 
34.5 Hz) for a PTA trans to py (Appendix, A2.40). In the 1H NMR spectrum py 
presents three well resolved resonances; the PTA region shows two pairs of signals 
in 1 : 2 ratio: each pair is composed by an AB system (the most downfield shifted 
signal) and a broad singlet, pairwise coupled in the 1H-1H COSY spectrum 
(Appendix, A.38). The most intense pair of signal, respectively centered at 4.42 and 
3.92 ppm (12H each) were attributed to the two equivalent trans PTA ligands, while 
the other two signals, respectively centered at 4.59 ppm (partially overlapped with 
the water signal) and 4.27 ppm to the PTA trans to py. The 1H-13C HSQC spectrum 
established that, in each set, the deshielded quartet belongs to the NCH2N protons 
and the upfield singlet to the NCH2P protons. (Appendix, A2.39). Integration is 
consistent with a py/PTA ratio = 3. Since there is no external source of PTA, the 
formation of 25 implies a disproportionation.  
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Scheme 2.17. Preparation of trans,mer-RuCl2(py)(PTA)3 (25) upon treatment of cis,cis,trans-
RuCl2(dmso-S)2(PTA)2 (10) with py in a refluxing mixture of EtOH/CHCl3 (5/4 ratio). 
 
X-ray qualities crystals were obtained upon addition of diethyl ether to a chloroform 
solution of 25; the structure is in agreement with the NMR findings (Figure 2.17). 
The coordination distances are in general agreement with the known trans influence 
of the ligands: thus, the Ru–P bond lengths of the two trans PTA ligands (2.3439(5) 
and 2.3391(6) Å) are slightly longer than the Ru–P distance trans to N (2.251(1) Å). 
 
Figure 2.17. Molecular structure (50% probability ellipsoids) of trans,mer-RuCl2(py)(PTA)3 (25).  
Coordination distances (Å): Ru1–Cl1 = 2.4451(6), Ru1–Cl2 = 2.4546(6), Ru1–N4 = 2.224(2), Ru1–
P1 = 2.3439(5), Ru1–P2 = 2.3391(6), Ru1–P3 = 2.251(1). 
 
Compound 25 was isolated also when the reaction between 10 and pyridine was done 
in a 5/4 EtOH/CHCl3 mixture. This mixture of solvents was chosen because it allows 
the solubilization of pyridylporphyrins. 
Indeed, some test reactions between 10 and two eq of 5-(4′-pyridyl)-10,15,20-
(phenyl)-porphyrin (4′MPyP) were performed, at reflux temperature, either in a 5/4 
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EtOH/DCMb  mixture or in CHCl3. The reactions were monitored by TLC (silica gel, 
CHCl3/EtOH 98/2); in addition, samples were periodically withdrawn and, after 
evaporation of the solvent, analyzed by 1H and 31P NMR spectroscopy in CDCl3. 
The 31P NMR spectrum in CDCl3 of the crude reaction product after 8h showed only 
a low broad singlet centered at –20.0 ppm and no resonances for unreacted 10. On 
the contrary, in the 1H NMR spectrum the most intense signals corresponded to 
unreacted 4′MPyP (Appendix, A2.41), and very small signals for coordinated 
4′MPyP, belonging to different unidentified adducts, were observed in the aromatic 
region. Therefore, according to NMR spectroscopy, 10 underwent 
transformation/decomposition, but its reactivity towards 4′MPyP was only minimal. 
The crude reaction product was thus redissolved in a 5/4 EtOH/DCM mixture and, 
after addition of one equivalent of 10, it was heated to reflux for additional 8h. The 
final NMR spectra were very similar to the previous ones, again consistent with the 
decomposition of the complex. Attempts to increase the conversion by performing 
the reaction in a microwave reactor in CHCl3 at 75°C for 2.5 h were unsuccessful.  
Similarly unsuccessful were the attempts to purify the crude reaction product by 
column chromatography, using either silica gel or alumina as stationary phase. The 
1H NMR spectra performed on all the collected fractions suggested that the 
product(s) with coordinated 4′MPyP either decomposed during the elution or were 
retained on the stationary phase, since only the peaks of free 4′MPyP were observed.  
 
  
                                                          
b DCM was initially preferred to CHCl3 to avoid HCl traces that could be present in chloroform. The 
acid environment may cause the protonation of porphyrins, that could affect the reactivity. However, 
no difference in reactivity was observed when the reaction was performed in the refluxing 
EtOH/DCM mixture or in pure chloroform. 
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2.5 Conclusions 
In summary, this Chapter reports a thorough investigation of the neutral Ru(II)-
chloride-PTA isomers trans- and cis-RuCl2(PTA)4 (respectively 1 and 2), including 
their comprehensive NMR characterization (1H, 13C, and 31P) both in D2O and in 
CDCl3 (Table 2.1 and 1.2 respectively). The corresponding and unprecedented 
bromide derivatives, trans- and cis-RuBr2(PTA)4 (respectively 11 and 12), were also 
prepared and fully characterized. Next, the almost unexplored reactivity of 1 and 2 
was addressed: when warmed in a coordinating solvent, such as DMSO and 
acetonitrile, the kinetic complex 1 isomerizes to the thermodynamically stable cis 
isomer 2, as in water. The neutral intermediates cis,mer-RuCl2(dmso-S)(PTA)3 (13), 
trans,mer-RuCl2(CH3CN)(PTA)3 (14), and cis,mer-RuCl2(CH3CN)(PTA)3 (15) 
were isolated, even though not in pure form. Most interestingly, by virtue of these 
results, we found that both 1 and 2 can be used as precursors of the RuCl(PTA)3+ 
fragment. In fact, they react in refluxing water with chelating diimines such as bpy 
replacing selectively one chloride and one PTA ligand, and affording – depending 
on the conditions –  two unprecedented isomeric derivatives: the thermodynamic 
product mer-[Ru(bpy)Cl(PTA)3]Cl (17) and the kinetic product fac-
[Ru(bpy)Cl(PTA)3]Cl (18). 
The reactivity of the Ru(II)-dmso complexes cis-RuCl2(dmso)4 (8), trans-
RuCl2(dmso-S)4 (9), cis,fac-[RuCl(dmso-O)2(dmso-S)3](PF6) (20), and fac-
[Ru(dmso-O)3(dmso-S)3](CF3SO3)2 (21) towards PTA was also investigated. 
Expanding the results reported by Kathó and coworkers,15 we found that PTA reacts 
rapidly and under mild conditions with the neutral Ru-dmso precursors replacing 
with high selectivity pairs of mutually trans dmso ligands. Replacement of both 
dmso’s occurs also when PTA is in stoichiometric defect. Thus, 8 affords selectively 
cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10), whereas 9 gives 1. In both cases no 
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intermediates could be isolated or even detected. Conversely, no new cationic Ru(II)-
PTA complex was obtained from 20 and 21. 
In addition, we found that cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10) easily replaces 
the two molecules of dmso when treated with imine or diimine ligands in refluxing 
solvents (Scheme 2.18). The substitution of the dmso’s is accompanied by the 
isomerization of the geometry of the other ligands. In fact, the reaction with chelating 
diimines afforded the less symmetrical all-cis products cis,cis-Ru(bpy)Cl2(PTA)2 
(22) and cis,cis-Ru(bpyAc)Cl2(PTA)2 (23, as a 50/50 mixture of the two 
stereoisomers 23a and 23b), and that with pyridine yielded trans,cis,cis-
RuCl2(PTA)2(py)2 (24). 
Interestingly, when the reaction with pyridine was performed in a refluxing CHCl3 
and EtOH/CHCl3 mixture, an unusual disproportion was observed with formation of 
trans,mer-RuCl2(PTA)3(py) (25), in which one dmso is replaced by pyridine and the 
other by a PTA (coming from 10).  
In general, we observed that the trans-{Ru(PTA)2} and mer-{Ru(PTA)3} fragments 
are particularly stable (see also Chapter 3); only three among the new complexes do 
not have two mutually trans PTAs: cis,cis-Ru(chel)Cl2(PTA)2 (chel = bpy (22) or 
bpyAc (23)) and trans,cis,cis-RuCl2(PTA)2(py)2 (24).  
 
Scheme 2.18. Reactivity of cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10) towards mono and diimine 
ligands. 
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As anticipated, all the neutral Ru-PTA complexes acquire the amphiphilic nature of 
PTA and are typically quite soluble both in organic solvents (e.g. chloroform) and in 
water. Perhaps counterintuitively, the solubility in water decreases upon protonation 
of coordinated PTA, to such an extent that addition of a strong mineral acid to an 
aqueous solution of a neutral Ru-PTA complex is often a convenient approach for 
obtaining crystals of the corresponding charged PTAH derivative. The single-crystal 
X-ray structure of the following complexes was also determined: trans-
[RuCl4(PTAH)2]Cl·H2O (3·H2O), trans-[RuBr2(PTA)4]·0.682(C4H10O) (11), cis-
[RuBr2(PTA)4]·0.37(H2O) (12), mer-[Ru(bpy)Cl(PTA)3]Cl∙6H2O (17), cis,cis-
Ru(bpy)Cl2(PTA)2 (22), trans,cis,cis-RuCl2(PTA)2(py)2 (24) and trans,mer-
RuCl2(py)(PTA)3 (25). 
In aqueous solution all the above-reported complexes share common hydrolytic 
features, consistent with the rather high trans-influence of PTA: in both neutral and 
cationic species the selective dissociation of a chloride trans to PTA occurs (to 
different extents and with different rates, depending on the species), whereas 
mutually trans chlorides are stable and their dissociation is negligible.  
Furthermore, the color of the complex is affected by the chloride geometry: 
complexes with the {trans-RuCl2} fragment typically are yellow, whereas those with 
the {cis-RuCl2} fragment are colorless (or very pale yellow). 
Regarding the NMR characterization of octahedral Ru–PTA compounds, in general 
the 1H NMR spectra are not particularly informative about the ligand geometry. 
Coordinated PTA typically gives two resolved resonances (broad singlets or AB 
quartets) between 3.5 and 4.9 ppm. The one at higher frequency belongs to the 
NCH2N protons and the other to the NCH2P protons. In addition, they are coupled to 
well separated carbon resonances in the HSQC spectra: ca. 70-75 ppm for NCH2N 
carbons whereas 50-59 ppm for NCH2P. The 
31P NMR spectra are instead very 
informative about the number of coordinated PTAs and their geometry in the 
complex. In fact, the phosphorous chemical shift is strongly influenced by the nature 
 Chapter 2: Neutral Ru(II) Complexes with PTA 
63 
 
of the ligand in trans position and it can thus be used as a diagnostic tool to establish 
the PTA geometry in octahedral Ru–PTA complexes.28 The typical chemical-shift 
regions as well as the corresponding interval for the Ru(II)–P bond lengths are 
reported in Table 2.3. With the exception of the bis(hydride) complex cis-
RuH2(PTA)4,
2,22 there is a rough correlation between the two parameters: as the Ru–
P bond length increases, the 31P NMR resonance shifts progressively to lower 
frequencies. Moreover, we observed that when PTA is trans to an imine nitrogen 
(i.e. py, bpy), the 31P NMR chemical shift is affected by the nature of the ligand: 
when trans to py it falls in the range –20 ÷ –23 ppm, whereas when trans to bpy or 
bpyAc it falls in the range –34 ÷ –50 ppm. We argue that this behavior might be due 
to the different orientation of the aromatic rings containing the imine nitrogen: 
chelating diimine ligands (i.e. bpy, bpyAc) are in the plane containing PTA, whereas 
pyridine is typically almost orthogonal to such plane. The different orientation, and 
consequently different involvement of the π orbitals of these ligands, could explain 
the different 31P chemical shift intervals for PTA trans to pyridine and trans to 
diimine ligands. 
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Table 2.3. Typical 31P chemical shift intervals (Δ) and Ru–P distances for PTA bound to octahedral 
Ru(II) complexes as a function of the nature of the trans ligand. 
Ligand trans to 
PTA 
Δ 31P (ppm)[a] Δ Ru–P distance 
(Å) 
Ref. 
OH2/OH –5 ÷ –16 - this Chapter, 17, 11  
N[b] –20 ÷ –23 2.1933 ÷ 2.224 this Chapter 
Cl –14 ÷ –26 2.232 ÷ 2.283 this Chapter, 1b, 11  
Br –24 ÷ –27 2.266 ÷ 2.281 this Chapter 
S[c] –30 ÷ –45 2.280 ÷ 2.318  20, 29 
N[d] –34 ÷ –50 2.260 ÷ 2.344 
this Chapter, 30, 31, 32, 33, 34, 
35, 36, 37 
H –26.6[e] 2.299 ÷ 2.300 2 
P[f] –45 ÷ –60 2.290 ÷ 2.400 
this Chapter, 1b, 2, 11, 15, 17, 19, 
37, 38 
C[g] –68.4[e] 2.395(1) 39 
[a] For comparison, the singlet of free PTA falls at δ = –98.2 ppm in D2O and at –102.3 ppm in CDCl3. 
[b] From pyridine. [c] From [9]aneS3 = 1,4,7-trithiacyclononane. [d] From imine or azole. [e] Single hit. 
[f] From PTA. [g] From cyclometallated 2-phenylpyridine. 
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Ru(II)-PTA carbonyls 
3.1 State of the art 
In literature there are no clear examples of Ru(II) carbonyl complexes with 1,3,5-
triaza-7-phosphoadamantane (PTA). It was only reported that the reaction of trans-
RuCl2(PTA)4 (1) with CO (1 atm) leads to a complex of undefined geometry 
formulated as RuCl2(CO)(PTA)3, characterized only by elemental analysis and by 
the presence of an IR band for bound CO at 1987 cm–1.1 
In general, the literature about Ru(II)-CO phosphine compounds is quite dated, most 
of the studies were performed in the late 60’s – early 70’s of last century, and often 
important details are missing. Both mono- and dicarbonyl neutral complexes with 
phosphines, of general formula RuCl2(CO)(L)3 and RuCl2(CO)2(L)2, respectively, 
are known. Typically, the monocarbonyl compounds present the three phosphines 
(e.g. L = PPh3, PMe2Ph, PEt2Ph) in a mer geometry (i.e. trans,mer-RuCl2(CO)(L)3 
and cis,mer-RuCl2(CO)(L)3,), whereas the three stereoisomers cis,cis,trans-, all-
trans-, and all-cis-RuCl2(CO)2(L)2, have been identified for the dicarbonyl 
compounds.2 
Such Ru(II) compounds were mainly prepared by the addition of the phosphine to a 
carbonyl precursor: typically, hydrate RuCl3 was boiled in an organic solvent (i.e. 
ethanol or 2-methoxhyethanol) with bubbling CO, generating a poorly characterized 
“red carbonyl solution”, that most likely contains a mixture of the dinuclear species 
[RuCl2(CO)3]2 and of the less well characterized polymeric species [RuCl2(CO)2]n.
3 
Addition of two or three equivalents of the desired phosphine to this solution 
afforded the di- or monocarbonyl compounds, respectively.2,4 The monocarbonyl 
RuCl2(CO)(L)3 complexes were typically obtained with the cis,mer geometry, 
whereas the two cis,cis,trans- and all-trans- stereoisomers, either pure or in mixture, 
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were obtained for the dicarbonyl RuCl2(CO)2L2 compounds, depending on the 
reaction conditions after the addition of the phosphine. Column chromatography of 
the mixture afforded the pure isomers.5  
In another synthetic strategy, a mixture of the all-trans and cis,cis,trans-
RuCl2(CO)2(PPh3)2 isomers was obtained by bubbling CO in a warm acetone 
solution of  RuCl2(PPh3)4. The pure isomers were obtained by recrystallization.
2b 
The group of Mawby investigated the thermal- and light-induced interconversion of 
the dicarbonyl complexes.6 They reported that the cis,cis,trans-RuCl2(CO)2(L)2 
isomer can be converted by irradiation with a mercury lamp (125 W) to the all-trans 
isomer, that appears to be a kinetic product: by heating at 40°C it converts into the 
all-cis isomer, whereas at higher temperature it converts to the more stable 
cis,cis,trans isomer. Consistently, the all-cis isomer was fully converted to the 
cis,cis,trans-RuCl2(CO)2(L)2 compound upon heating (Scheme 3.1).  
 
Scheme 3.1. Thermal- and light-induced interconversion of the dicarbonyl Ru(II)-phosphine 
compounds (L = phospine). 
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3.2 Aim of the Chapter 
As stated in the Introduction, our aim is that of preparing new water-soluble 
complexes for the construction of supramolecular assemblies or metal-conjugates 
that maintain solubility in water.7 In this respect, Ru(II)-PTA carbonyls, in particular 
if possessing residual dmso ligands, might have suitable requisites. In addition, 
water-soluble Ru-PTA-CO complexes might be of interest also as catalysts in 
aqueous medium or in biphasic systems, in particular for reactions involving CO 
and/or CO2, where carbonyl species are likely intermediates. 
Finally, they might also be investigated as potential CO-releasing molecules 
(CORMs).8 This is an emerging field of medicinal chemistry in which several 
compounds, including metal carbonyls, are investigated for the release of CO in 
tissues or cells. In fact, controlled amounts of carbon monoxide show a positive role 
in cardiovascular and inflammatory impairment, in promoting wound healing, and 
have bactericidal action.9  Ideally, controlled CO-release should be triggered by an 
endogenous chemical or biochemical stimulus or by applying an external stimulus 
such as visible light (photo CO-releasing molecules or photo-CORMs). Up to date 
the most promising Ru(II) CORM is the water-soluble compound 
Ru(CO)3Cl(glycinate) (CORM-3) which has been extensively studied in the 
biological environment to understand the influence of CO inside the cells.10 
 
Here we reinvestigated the reactions of both trans- and cis-RuCl2(PTA)4 isomers 
with CO. Moreover, the investigation was extended to the complex cis,cis,trans-
RuCl2(dmso-S)2(PTA)2 (6).  
As the above compounds showed a rather poor reactivity towards CO, we decided to 
explore a different approach: instead of adding CO to Ru(II)-PTA complexes, the 
yet unexplored reactivity of a series of well-known neutral Ru(II)-CO-dmso 
compounds with PTA was investigated. These compounds, whose general formula 
is [RuCl2(CO)x(dmso)4-x] (x = 1-3, Figure 3.1), have from one to three carbonyls. 
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Besides the two chlorides – that can be either in cis or trans geometry –  the 
coordination sphere is completed by dmso ligands.3,11 In such complexes when a 
dmso is coordinated trans to CO it is always bonded through oxygen (dmso-O), is 
rather labile and easily replaced by monodentate N-donor ligands (e.g. py or NH3). 
However, also the more strongly bonded dmso-S ligands (if present) can be rather 
easily replaced by neutral ligands, e.g. by chelating diimines. 
 
Figure 3.1. Schematic structures of the Ru(II)-CO-dmso compounds used in this Chapter: the 
monocarbonyl fac-RuCl2(CO)(dmso)3 (26); the three dicarbonyl isomers cis,cis,trans-
RuCl2(CO)2(dmso-S)2 (27), cis,cis,cis-RuCl2(CO)2(dmso)2 (28), and trans,cis,cis-RuCl2(CO)2(dmso-
O)2 (29); the tricarbonyl fac-RuCl2(CO)3(dmso-O) (30). 
 
For the sake of clarity the reactivity of the neutral Ru(II)-CO-dmso compounds 
towards PTA will be reported first, followed by the reinvestigation of the behavior 
of neutral Ru(II)-PTA complexes with CO.    
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3.3 Reactions of neutral Ru(II)-CO-dmso compounds with 
1,3,5-triaza-7-phosphoadamantane  
Even though two meridional stereoisomers of the monocarbonyl compound fac-
RuCl2(CO)(dmso)3 (26) are also known,
10 only 26 has been investigated here.   
We found that treatment of 26 with two equivalents of PTA in methanol at room 
temperature afforded a pale yellow precipitate identified as cis,cis,trans-
RuCl2(CO)(dmso-S)(PTA)2 (31)  (Scheme 3.2). This complex is well soluble in 
water, chloroform and DMSO. The 31P NMR spectrum in CDCl3 shows a singlet at 
–55.2 ppm, the typical region of mutually trans PTAs.12 The 1H NMR spectrum of 
31 in CDCl3 shows three different resonances: a broad singlet at 4.53 ppm (12H), an 
AB system centered at 4.41 ppm (12H), and a sharp singlet at 3.26 ppm (6H) 
(Appendix, A3.2). The two downfield signals, that are coupled to one another in the 
1H-1H COSY spectrum, belong respectively to the NCH2N and to the NCH2P groups 
of the two equivalent PTA ligands (Appendix, A3.2) The upfield singlet belongs to 
the equivalent methyl groups of dmso-S (thus indicating that it has to be in a 
symmetrical environment and trans to a Cl rather than to CO).  
The NMR spectra in D2O are similar to those in chloroform, but the complex slowly 
(days) partially releases a chloride (presumably that trans to CO). In fact, 
immediately after dissolution in D2O the 
31P NMR spectrum of 31, presents 
exclusively a singlet at –52.8 ppm, but after three days in the dark a new singlet at –
47.7 ppm appears. This latter was found to disappear upon the addition of an excess 
of NaCl. (Appendix, A3.5). The corresponding 1H NMR spectrum in D2O after three 
days shows three new resonances downfield shifted compared those of 31. No signal 
for free DMSO was observed.  
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Scheme 3.2.  Preparation of cis,cis,trans-RuCl2(CO)(dmso-S)(PTA)2 (31) upon treatment of fac-
RuCl2(CO)(dmso)3 (26) with PTA in methanol. 
 
The presence of coordinated CO was supported by the solid state IR spectrum, that 
presents a carbonyl stretching band at 1950 cm-1 (Table 3.1). The geometry of the 
complex was confirmed by single-crystal X-ray diffraction (Figure 3.2).  
 
Figure 3.2. X-ray molecular structure (50% probability ellipsoids) of cis,cis,trans-RuCl2(CO)(dmso-
S)(PTA)2 (31). Crystals obtained by recrystallization of the raw product from chloroform/diethyl 
ether. Coordination distances in ångström (Å): Ru1–Cl1 = 2.432(2), Ru1–Cl2 = 2.40(1), Ru1–S1 = 
2.72(1), Ru1–C1 = 1.80(1), Ru1–P1 = 2.385(1), Ru1–P2 = 2.357(1). 
 
When the reaction was repeated using only one equivalent of PTA, a mixture of 31 
and unreacted 26 was obtained. Similar results were obtained performing the reaction 
at 4°C. Under all the conditions examined, 26 reacts with PTA forming always a 
complex with two mutually trans PTAs, even when a defect of the ligand is used. 
Moreover, the coordination of PTA causes the isomerization of CO from being trans 
to dmso to being trans to Cl. 
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The reaction of 26 with two equivalents of PTA in refluxing solvents led to a mixture 
of 31 and of a new complex in which three PTAs replaced all the dmso ligands. In 
fact the 31P NMR spectrum of the raw product shows, in addition to the singlet of 26, 
an AX2 system consisting of a doublet centered at –55.9 (2JP-P = 40.4 Hz) ppm and a 
triplet centered at –63.6 ppm. The chemical shift of the doublet is consistent with 
two mutually trans PTAs, while that of the triplet falls in an unusual region: since 
PTA trans Cl usually is between –21 and –26 ppm (see Chapter 2, Table 2.3), it was 
supposed that the triplet belongs to a PTA trans to CO, so the new species was 
formulated as trans,mer-RuCl2(CO)(PTA)3 (32). We found that this new complex 
can be isolated in pure form in two different ways (Scheme 3.3): i) by refluxing an 
ethanol solution of 26 and 4 eq of PTA for 15h or ii) by treating the same mixture in 
a microwave reactor at 140°C for 30 min. Both procedures afforded 32 as a yellow 
precipitate in good yield. Compound 32 is well soluble in water and DMSO and 
sufficiently soluble in CHCl3 (e.g. for NMR purposes). The 
1H NMR spectrum of 32 
in CDCl3 (Appendix, A3.6) shows resonances only in the region of coordinated PTA: 
two relatively broad singlets at δ = 4.32 (6H) and 4.37 ppm (12H), and a multiplet 
(18H) centered at δ = 4.57 ppm. The singlets belong to the NCH2P groups of the two 
types of PTA ligands: in fact, in the 1H-1H COSY spectrum they are both coupled to 
the multiplet (generated by the NCH2N groups), whereas in the 
1H-13C HSQC 
spectrum they have distinct cross-peaks with carbon atoms that resonate in the 
NCH2P region. The NMR spectra in D2O – in which 32 is more soluble –  are similar 
to those in CDCl3 and showed no change after one week in the dark. This finding is 
consistent with the trans geometry of the two chlorides, that is typically quite stable. 
Solid state IR spectrum confirmed the presence of coordinated CO with a band at 
1986 cm-1 (Table 3.1). To be noted that a different isomerization process occurs in 
this case (compared to 31): the two originally cis chlorides, have a trans geometry 
in the product, whereas CO is trans to a PTA. 
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Scheme 3.3. Preparation of trans,mer-RuCl2(CO)(PTA)3 (32) upon treatment of fac-
RuCl2(CO)(dmso)3 (26) with PTA in ethanol. 
 
The geometry of the complex was confirmed by single-crystal X-ray diffraction 
(Figure 3.3).  The Ru–PTA distance trans to CO (2.3821(7) Å) is slightly longer than 
those of the mutually trans PTAs (2.33458(6) and 2.3399(7) Å), suggesting that CO 
has a stronger trans-influence than PTA (Table 3.2). This is the first reported 
structure of a Ru(II) complex in which PTA is trans to CO. 
 
Figure 3.3. X-ray molecular structure (50% probability ellipsoids) of trans,mer-RuCl2(CO)(PTA)3 
(32). Crystals obtained by recrystallization of the raw product from chloroform/diethyl ether. 
Coordination distances in ångström (Å): Ru1–Cl1 = 2.4049(8), Ru1–Cl2 = 2.4253(7), Ru1–C1 = 
1.928(3), Ru1–P1 = 2.3399(7), Ru1–P2 = 2.3821(7), Ru1–P3 = 2.3458(5).  
 
When the reaction of 26 with three equivalents of PTA was performed in refluxing 
water, rather than in ethanol, the pale yellow cis isomer of 32, i.e. cis,mer-
RuCl2(CO)(PTA)3 (33), in which CO is trans to a Cl rather than to a PTA, was 
isolated  upon evaporation of the solvent. (Scheme 3.4).  
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Scheme 3.4. Preparation of cis,mer-RuCl2(CO)(PTA)3 (33) upon treatment of fac-RuCl2(CO)(dmso)3 
(26) with PTA in water. 
 
The presence of the coordinated CO was confirmed by the solid state IR spectrum 
that presents a CO stretching band at 1942 cm-1 (Table 3.1). Single-crystal X-ray 
analysis confirmed the geometry of the complex (Figure 3.4). The Ru–PTA bond 
length trans to Cl (2.2865(6) Å) is very short, whereas the Ru–P distances of the 
mutually trans PTAs (2.3811(5) and 2.3488(5) Å) are even longer than those found 
in 32. 
This complex is well soluble in water and DMSO, but – contrary to 32 – sparingly 
soluble in chloroform. Immediately after the dissolution in D2O, the 
31P NMR 
spectrum of 33 shows two AX2 systems in ca. 1/4 ratio, consisting of two triplets 
centered respectively at –16.4 (2JP-P = 26.8 Hz) and –20.9 ppm (2JP-P = 25.5 Hz) and 
two doublets centered respectively at –48.2 and –51.9 ppm. By addition of an excess 
of NaCl the downfield (and minor) AX2 system disappeared, in agreement with the 
presence of an equilibrium between 33 and the aqua species 33aq (Appendix, A3.10-
A3.12) (Scheme 3.5).  
 
Scheme 3.5. Chloride hydrolysis equilibrium of the complex cis,mer-RuCl2(CO)(PTA)3 (33) in 
aqueous solution. 
 
According to the chemical shifts, in 33 the triplet belongs to a PTA trans to Cl and 
the doublet to the mutually trans PTAs, whereas in the aqua species 33aq the triplet 
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belongs to a PTA trans to H2O. Therefore the selective dissociation of the chloride 
trans to PTA occurs. This hypothesis is supported also by the X-ray data (Table 3.2) 
in which the Ru–Cl bond length trans to PTA (2.4694(6) Å) is longer than that trans 
to CO (2.4419(7) Å). This behavior is also consistent with what observed in other 
Ru-PTA complexes featuring Cl trans to PTA (e.g. compound 17PF6 and 22 in 
Chapter 2). However, this finding is apparently in contradiction with the lower trans-
influence of PTA compared to CO found in 32, and suggests that not only the length 
of the Ru–PTA bond but also its trans-influence depend on the nature of the trans 
ligand: PTA prefers to be bound trans to σ-donors such as Cl (short Ru–P bond 
length) that, however, are remarkably destabilized (long Ru–Cl bond). The 1H NMR 
spectrum of 33 in D2O (registered with an excess of NaCl) shows three different 
resonances: two broad singlets and a multiplet centered respectively at 4.12, 4.33 and 
4.49 ppm. The upfield singlet (6H) belongs to the NCH2P groups of the PTA trans 
to Cl, while the other singlet (12H) belongs to the NCH2P group of the mutually 
trans PTAs. Both singlets are coupled in the 1H-1H COSY spectrum with the 
multiplet (generated by the NCH2N groups) (Appendix, A3.10-A3.12).  
 
Figure 3.4. Molecular structure (50% probability ellipsoids) of cis,mer-RuCl2(CO)(PTA)3 (33). 
Crystals formed spontaneously from a DMSO solution. Coordination distances in ångström (Å): Ru1–
Cl1 = 2.4419(7), Ru1–Cl2 = 2.4694(6), Ru1–C1 = 1.926(3), Ru1–P1 = 2.3811(5), Ru1–P2 = 
2.2865(6), Ru1–P3 = 2.3488(5). 
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We found that, when heated in refluxing water, 32 isomerizes completely to 33 in 5 
h (Scheme 3.6), thus indicating that 33 is the thermodynamic isomer.  
 
Scheme 3.6. Isomerization of trans,mer-RuCl2(CO)(PTA)3 (32) to cis,mer-RuCl2(CO)(PTA)3 (33) in 
refluxing water. 
 
Moreover, since other Ru(II)-PTA complexes undergo light-induced isomerization 
(see Chapter 2),13 and 32 has an absorption band at 431 nm, we monitored by NMR 
spectroscopy the behavior of a water solution of 32 irradiated with blue light (λ = 
470 nm, 40 mW) (Scheme 3.7). After 1h of irradiation the 31P NMR spectrum shows 
the presence of a new main AX2 system (in 2.5 : 1 ratio with 32) formed by a doublet 
centered at –27.9 ppm and a triplet centered at –64.3 ppm (2JP-P = 32.1 Hz) (Figure 
3.5). According to the position of the signals, this spectrum belongs to a new 
monocarbonyl complex that has two equivalent PTAs trans to Cl and a PTA trans to 
CO, i.e. to fac-RuCl2(CO)(PTA)3 (34), a stereoisomer of 32 and 33. For longer 
irradiation times, 32 disappeared completely and the resonances of 33 and 33aq 
appeared besides those of 34 (Figure 3.5). Unfortunately it was not possible to isolate 
34 in pure form and register the IR spectrum.  
 
Scheme 3.7. Light-induced isomerization (λ = 470 nm) of trans,mer-RuCl2(CO)(PTA)3 (32) to 
cis,mer-RuCl2(CO)(PTA)3 (33) and fac-RuCl2(CO)(PTA)3 (34). 
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Figure 3.5. 31P NMR spectra of trans,mer-RuCl2(CO)(PTA)3 (32, black dots) registered immediately 
after dissolution in D2O (top), after 1 hour of irradiation with blue light (middle) and after 7 hours of 
irradiation (bottom). The signals of fac-RuCl2(CO)(PTA)3 (34) are labeled with red dots, while those 
of cis,mer-RuCl2(CO)(PTA)3 (33) and cis,mer-RuCl(OH2)(CO)(PTA)3 (33aq) with green and blue 
dots, respectively. 
 
The reactivity of fac-RuCl2(CO)(dmso)3 (26) towards PTA is summarized in Scheme 
3.8. From this precursor we were unable to prepare monocarbonyl Ru(II) complexes 
with a single PTA ligand. Even sub-stoichiometric amounts of PTA replaced at least 
two dmso ligands in 26; in addition, we notice that all the three isolated isomers 31 
– 33 have two mutually trans PTAs, suggesting that this geometry is particularly 
stable.  
Even though the Ru–CO bond lengths in the isomers 32 and 33 are similar (1.928(3), 
1.926(3) Å respectively), i.e. are not significantly affected by the nature of the ligand 
in trans position, we notice that the CO stretching frequency in 32 (1986 cm–1, CO 
trans to PTA) is significantly higher than in 33 (1942 cm–1, CO trans to Cl). This 
finding is consistent with the presence of a π back-bonding component in the Ru–
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PTA bond, that in 32 is in competition with the trans CO ligand. Conversely, Cl is a 
good π-donor and therefore reinforces the π-back donation onto the trans carbonyl. 
Indeed, as seen above, 33 is more thermodynamically stable than 32. The CO 
stretching frequency in 31, that corresponds to 33 with a dmso-S in the place of the 
PTA trans to Cl, is indeed similar to that of 33 (1950 vs 1942 cm–1. This finding is 
consistent with the fact that dmso-S is a moderately good π-acceptor and suggests 
that the CO stretching frequency is mainly affected by the nature of the trans ligand 
rather than by those in the other coordination positions.  
 
Scheme 3.8. Reactivity of fac-RuCl2(CO)(dmso)3 (26) with PTA. 
 
We found that both di-carbonyl isomers cis,cis,trans-RuCl2(CO)2(dmso-S)2 (27) and 
cis,cis,cis-RuCl2(CO)2(dmso)2 (28), as well as a mixture of them, when treated with 
2 equivalents of PTA in methanol at room temperature afforded the mono-carbonyl 
compound 31 in good yield (Scheme 3.9). The observed reactivity is consistent with 
the established preference of the two PTA ligands for being mutually trans. 
Nevertheless, it is quite remarkable that in both cases the phosphine easily replaces 
a molecule of CO rather than the second dmso ligand. In the case of 27, the 
coordination is also accompanied by isomerization.  
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Scheme 3.9.  Preparation of cis,cis,trans-RuCl2(CO)(dmso-S)(PTA)2 (31) upon treatment of either 
cis,cis,trans-RuCl2(CO)2(dmso-S)2 (27) or cis,cis,cis-RuCl2(CO)2(dmso)2 (28) with PTA in methanol. 
 
A different reactivity was found when the isomer trans,cis,cis-RuCl2(CO)2(dmso-
O)2 (29) was treated with two equivalents of PTA in methanol at room temperature 
(Scheme 3.10). The reaction afforded a precipitate that, according to the 31P NMR 
spectrum, is a mixture of 32 and a new species (35) characterized by a singlet at –
47.6 ppm, consistent with two mutually trans PTAs. Complex 35 was isolated in 
pure form and good yield, upon evaporation of the solvent, when the reaction was 
performed in water rather than in methanol. The 1H NMR spectrum of 35 in D2O 
consists of a multiplet and a broad singlet centered respectively at 4.57 and 4.27 ppm 
(12H each) (Appendix, A3.13); no signal for coordinated dmso is present. The 
upfield resonance belongs to NCH2N groups while the other to NCH2P groups, in 
fact in the 1H-13C HSQC spectrum the multiplet has a crosspeak with a carbon 
resonance at 70.7 ppm while the singlet with a carbon resonance at 47.3 ppm. Solid 
state IR shows a band at 1941 cm–1, attributed to a coordinated CO. The yellow color 
of the complex is consistent with the presence of trans chlorides. The ESI-MS 
spectrum (positive mode) shows a main peak at 479.1 m/z, compatible with the 
fragment [RuCl(CO)(PTA)2]
+. Overall, the experimental data suggest that complex 
35 has two mutually trans PTAs, two trans chlorides, one CO and one “vacant 
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position”. Thus, as in the case of 27 and 28, also with the third isomer 29 PTA easily 
replaces a molecule of CO. The elemental analysis is consistent either with a 
monomeric species formulated as trans,trans,trans-RuCl2(CO)(OH2)(PTA)2·3H2O 
or with a dimeric species with two bridging chlorides formulated as 
[RuCl2(CO)(PTA)2]2·8H2O. The X-ray structure of complex 32 shows that 
crystallization with multiple water molecules is not unusual for PTA complexes, and 
the presence in the ESI-MS spectrum (negative mode) of a main peak at 548.9 m/z, 
consistent with the anion [RuCl3(CO)(PTA)2]
–
, is in better agreement with the 
hypothesis of a dinuclear species. Organometallic Ru(II) dimers with bridging 
chlorides, such as [RuCl2(CO)3]2 and [RuCl2(η6-p-cymene)]2 (Figure 3.6), are very-
well known Ru(II) precursors, whose reactivity is characterized by the facile 
cleavage of the chloride bridges. Therefore, it is quite likely that 35, even though 
dimeric in the solid state, in solution will undergo a similar cleavage and behave as 
a monomer with a formally vacant position occupied by a labile solvent molecule.  
 
Figure 3.6. Schematic structure of the chloro-bridged dimers [Ru(CO)3Cl2]2 (left) and [RuCl2(η6-p-
cymene)]2. 
 
Scheme 3.10. Reactivity of trans,cis,cis-RuCl2(CO)2(dmso-O)2 (29) with PTA. 
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In fact, when 35 was treated with a slight excess of pyridine (py, 1.2 eq with respect 
to Ru) in water at room temperature, the trans,trans,trans-RuCl2(CO)(py)(PTA)2 
(36) complex was selectively obtained as a yellow precipitate upon evaporation of 
the solvent (Scheme 3.11). The 1H NMR spectrum of 36 (Appendix, A3.16) shows 
three resonances for coordinated py in the aromatic region, plus an AB quartet and a 
singlet in the PTA region. Integration is consistent with a PTA:py ratio = 2. The 31P 
NMR spectrum consists of a singlet at –50.0 ppm, in the typical region of mutually 
trans PTAs. The solid state IR spectrum confirmed the presence of CO (carbonyl 
stretching band at 2010 cm–1) and the ESI-MS (positive mode) presents a peak at 
594.0 m/z consistent with [RuCl2(CO)(py)(PTAH)(PTA)]
+. 
 
Scheme 3.11. Preparation of trans,trans,trans-RuCl2(CO)(py)(PTA)2 (36) upon treatment of 
[RuCl2(CO)(PTA)2]2·8H2O (35) with py in water. 
 
Finally, the reactivity with PTA of the neutral complex with three facial CO ligands 
and one dmso-O, fac-RuCl2(CO)3(dmso-O) (30), was investigated. Only in methanol 
it was possible to isolate pure products that precipitated spontaneously during the 
reaction. When 30 was treated with one equivalent of PTA, a white solid (37), that 
is well soluble only in DMSO and water, was collected in good yield (Scheme 3.12). 
The 31P NMR spectrum of 37 in DMSO-d6 consists of a singlet at –28.8 ppm, in 
agreement with PTA trans to Cl (Appendix, A3.19), while the 1H NMR spectrum 
shows only the resonances of coordinated PTA. The solid state IR spectrum shows 
two intense bands at 2060 and 1989 cm–1 respectively, consistent with the presence 
of two cis CO ligands. The ESI-MS spectrum (positive mode) presents a peak at 
409.3 m/z in agreement with the species [RuCl2(CO)2(PTA)Na]
+, while the negative 
mode has two peaks at 421.2 and 393.2 m/z, attributable to [RuCl3(CO)2(PTA)]
–
 and 
[RuCl3(CO)(PTA)]
–, respectively. The elemental analysis is consistent with a 
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dinuclear species similar to 35, formulated as [RuCl2(CO)2(PTA)]2·H2O (37), in 
which each Ru(II) – besides one terminal and two bridging chlorides – has two cis 
CO ligands, and a single PTA trans to Cl. The reaction of 30 with PTA performed 
in chloroform or dichloromethane led to the same product in a mixture with 
unreacted precursor. 
The formulation of 37 with PTA trans to a bridging, rather than to the terminal, 
chloride is consistent with the presumed reaction mechanism: PTA rapidly replaces 
the dmso-O of 30, thus inducing the release of the trans CO molecule. The vacant 
coordination site is then filled through the formation of the chloride bridges, leading 
to the precipitation of 37 (Scheme 3.12).  
 
Scheme 3.12.  Mechanistic hypothesis for the formation of the dimer [RuCl2(CO)2(PTA)]2 (37) upon 
treatment of fac-RuCl2(CO)3(dmso-O) (30) with 1 eq of PTA in methanol. 
 
In addition, also the behavior of the complex in water is consistent with PTA being 
trans to a bridging chloride. In fact, the 31P NMR spectrum of 37 recorded in D2O 
presents a singlet at –14.6 ppm, attributed to PTA trans to H2O. This could be 
explained with the rapid cleavage of the chloride bridges and the formation of the 
neutral species cis,cis,trans-RuCl2(CO)2(OH2)(PTA). (Scheme 3.13).  
 
Scheme 3.13. Behavior of the dimer [RuCl2(CO)2(PTA)]2 (37) in water. 
 
Consistent with this hypothesis, treatment of 37 with a slight excess of py in D2O 
afforded crystals of cis,cis,trans-RuCl2(CO)2(py)(PTA) (38). Even though the 
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crystals were of low quality, the X-ray structure (Appendix, A3.28) unambiguously 
established the geometry of the complex, with the pyridine trans to PTA, i.e. in the 
place of the bridging chloride (Scheme 3.14). 
 
Scheme 3.14. Reactivity of the dimer [RuCl2(CO)2(PTA)]2·H2O (37) with pyridine in D2O. 
 
The 1H NMR spectrum of the crystals in CDCl3 (their solubility was much higher in 
chloroform than in water) shows three peaks for the coordinated pyridine in the 
aromatic region. The aliphatic region presents two singlets for PTA. Integration 
confirms the 1:1 ratio between PTA and py. The 31P NMR spectrum shows a singlet 
at –28.7 ppm, in the region of a PTA trans to an imine (see Chapter 2). 
The ESI-MS (positive mode) shows a main peak at 464.9, m/z in agreement with the 
species [RuCl2(CO)2(py)(PTAH)]
+. The IR spectrum presents two bands at 2058 and 
1994 cm-1 in agreement with the presence of two CO ligands in cis geometry. 
 
The reaction of 30 with 2 (or more) eq of PTA in methanol at room temperature 
afforded the mononuclear complex cis,cis,trans-RuCl2(CO)2(PTA)2 (39) as a white 
powder in good yield (Scheme 3.15). Compound 39 was fully characterized by NMR 
and IR spectroscopy, mass spectrometry, and its single-crystal X-ray structure was 
also determined (Figure 3.7).  The geometry of 39 is in agreement with the 
mechanistic hypothesis advanced before for the formation of 37 (Scheme 3.15): in 
this case, the vacant site trans to the first PTA ligand is rapidly occupied by the 
second PTA molecule. 
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Figure 3.7. X-ray molecular structure (50% probability ellipsoids) of cis,cis,trans-RuCl2(CO)2(PTA)2 
(39). Crystals formed spontaneously from a methanol solution. Coordination distances in ångström 
(Å): Ru1–Cl1 = 2.4370(4), Ru1–C1 = 1.877(2), Ru1–P1 = 2.3397(5). 
 
The solid state IR spectrum shows two intense bands at 2053 and 1988 cm–1, in 
agreement with the presence of two cis CO ligands. Complex 39 is well soluble in 
water, CHCl3 and DMSO. The 
1H NMR spectrum in CDCl3 consists of two relatively 
broad singlets in the region of coordinated PTA at 4.58 and 4.42 ppm (Appendix, 
A3.22). The 31P NMR presents only a singlet at –51.0 ppm, the region of mutually 
trans PTAs. The NMR spectra in D2O are similar to those in CDCl3 (Appendix, 
A3.23).  The complex slowly and partially releases a Cl. In fact, the 31P NMR 
spectrum in D2O after the dissolution presents a singlet at –48.8 ppm, whereas after 
one day (in the dark) another singlet appears at –45.7, in addition to the first one. 
The new resonance disappears upon addition of an aliquot of NaCl. 
 
Chapter 3: Ru(II)-PTA Carbonyls  
90 
 
 
Scheme 3.15. Mechanistic hypothesis for the formation of cis,cis,trans-RuCl2(CO)2(PTA)2 (39) upon 
treatment of fac-RuCl2(CO)3(dmso-O) (30) with two eq of PTA in methanol. 
 
The literature reports that complexes of the type cis,cis,trans-RuX2(CO)2L2 (where 
X = Cl or Br and L = PMe2Ph, PMePh2, P(CH2Ph)Ph2, P(OMe)2Ph) isomerize to the 
all-trans geometry when irradiated with visible light.6 In our case, irradiation of a 
CDCl3 solution of 39 with white light (150 W) induced no changes in the NMR 
spectra of the complex.  
When precursor 30 was reacted with 2 eq of PTA in water (room temperature), rather 
than in methanol, a mixture of 39 and of the tri-substituted species cis,mer-
RuCl2(CO)(PTA)3 (33) (ca. 2/1 ratio) was obtained upon removal of the solvent 
(Scheme 3.16). This finding suggests that, unless the dicarbonyl product precipitates 
from the solution as in methanol, PTA can easily replace also a second CO ligand 
from 30. When three equivalents of PTA were used, the relative amount of 33 in the 
product mixture increased (39/33 = 1/2.75).  
 
Scheme 3.16. Reactivity of fac-RuCl2(CO)3(dmso-O) (30) with PTA in water. 
 
When 30 was treated in water with 1 equivalent of PTA at room temperature, a quite 
surprising behavior was observed (Scheme 3.17): the addition of the phosphine to a 
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colorless solution of 30 was immediately accompanied by the development of CO2 
bubbles and the color of the solution turned to yellow. After 20 minutes of stirring, 
the precipitation of a small amount of an orange powder was observed that, according 
to the IR spectrum in CHCl3, is mainly composed by the well-known Ru(0) cluster 
Ru3CO12 (40), with minor impurities (Figure 3.8).   
  
Scheme 3.17. Formation of Ru3CO12 (40) upon treatment of fac-RuCl2(CO)3(dmso-O) (30) with 1 eq 
of PTA in water. 
 
 
Figure 3.8. IR spectra in CHCl3 of a commercial sample of the Ru3CO12 cluster (blue line) and of the 
orange powder obtained from the reaction of fac-RuCl2(CO)3(dmso-O) (30) with one equivalent of 
PTA in water (orange line). 
 
From the literature it is known that the Ru(0) cluster 40 can be obtained from the 
Ru(II) dimer [Ru(CO)3Cl2]2 in the presence of KOH and a stream of CO at 75°C in 
an organic solvent.14 Briefly, each Ru(II) center in the dimer has three coordinated 
CO ligands in fac geometry that are very electrophilic because of the competition for 
the π back-donation. One of them undergoes nucleophilic attack by OH–. This step 
is followed by decarboxylation of the hydroxycarbonyl adduct 
{Ru(CO)2Cl2(COOH)}
– with the formation of a hydride that, after a reductive 
elimination of HCl and coordination of another CO, leads to the formation of the 
cluster. We found that the same reaction occurs also using 30 instead of the dimer 
[Ru(CO)3Cl2]2 (indeed, 30 can be considered as an activated monomeric form of 
0
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[Ru(CO)3Cl2]2).
15 It is surprising that 30 yields the Ru(0) cluster in the absence of 
added KOH and CO. However, it has to be considered that PTA, besides being a 
ligand, is also a base (pKa = 5.89)
16 and generates OH– ions. We argue that when the 
phosphine is ca. stoichiometric with ruthenium, the nucleophilic attack of OH– onto 
one of the CO ligands competes with PTA coordination. Nevertheless, for explaining 
the formation of the cluster without using a source of CO, the double role of PTA 
has to be invoked: as seen above, coordination of PTA induces the rapid release of 
the CO in trans position, that can thus bind to another ruthenium fragment leading 
to the cluster. In fact, when the reaction was performed by addition of a 
stoichiometric amount of KOH or NEt3 instead of PTA, uncharacterized red-brown 
ruthenium-carbonyl precipitates were obtained that – according to their IR spectra – 
do not contain Ru3(CO)12. In summary, in this reaction also 30, similarly to PTA, 
has a double role: part of it undergoes nucleophilic attack on a carbonyl by OH– and 
part is the source of CO, thus explaining the very low yield of cluster. When the 
reaction is performed with two or more equivalents of ligand, PTA binding prevails 
over the nucleophilic attack of OH– onto the coordinated carbonyls and formation of 
the cluster was not observed (Scheme 3.18).  
 
Scheme 3.18. Reactivity of fac-RuCl2(CO)3(dmso-O) (30) with PTA in water. 
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The 31P NMR spectrum of the orange precipitate in DMSO-d6 does not present any 
peak for PTA (either free or bound). We observed the slow formation of red-orange 
crystals after the addition of an excess of PTA to the DMSO solution. Even though 
the crystals were of low quality, the X-ray structure unambiguously established that 
they were made of the known cluster Ru3(CO)9(PTA)3, that usually is prepared by 
treating Ru3(CO)12 with a slight excess of PTA in refluxing methanol.
17,18  
 
Figure 3.9. X-ray structure (thermal ellipsoids drawn at the 50% probability level) of the cluster 
Ru3(CO)9(PTA)3 reported by Darensbourg’s group.18  
 
In summary, the reactivity of fac-RuCl2(CO)3(dmso-O) (30) towards PTA confirms 
what seen with the previous Ru-CO-dmso precursors (Scheme 3.19): the phosphorus 
ligand is able to replace easily one or two CO ligands at room temperature, besides 
the dmso-O. In methanol we managed to isolate, for the first time, two dicarbonyl 
complexes, 37 and 39, that have either one or two PTA ligands, respectively. In fact, 
only monocarbonyl PTA species were isolated from the reactions of the dicarbonyl 
precursors with PTA (see above). In water, where 37 and 39 remain in solution, 
substitution of an additional CO ligand occurs, even when sub-stoichiometric 
amounts of PTA are used. Moreover, only with 30 the unexpected formation of the 
cluster Ru3CO12 (40) was observed from the reaction with one equivalent of PTA in 
aqueous solution. 
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Scheme 3.19. Reactivity of fac-RuCl2(CO)3(dmso-O) (30) with PTA. 
3.4 Reactions of neutral Ru(II)-PTA complexes with CO 
As mentioned already, Darensbourg and coworkers reported that the complex trans-
RuCl2(PTA)4 (1) reacts with a CO atmosphere in ethanol forming the complex of 
undefined geometry RuCl2(CO)(PTA)3 in which CO has replaced one PTA.
1 We 
decided to study more carefully the reactivity of both isomers cis- and trans-
RuCl2(PTA)4 towards CO. In our hands, the afore-mentioned preparation could not 
be reproduced: only unreacted 1 was found after one night treatment with a CO 
atmosphere. This is not surprising, since 1 is basically insoluble in ethanol (in fact it 
is prepared from RuCl3·3H2O and an excess of PTA in refluxing ethanol, from which 
it precipitates). The reaction was then repeated in CHCl3, where the precursor 1 is 
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well-soluble. Overnight treatment with CO (1 atm) followed by solvent removal 
afforded the monocarbonyl complex 32 (Scheme 3.20). 
 
Scheme 3.20. Reactivity of trans-RuCl2(PTA)4 (1) with CO. 
 
The monocarbonyl compound 32 was obtained also when 1 was treated with 30 atm 
of CO in an autoclave for 24h. Upon increasing the reaction temperature to 40 °C 
two additional singlets were found in the 31P NMR spectrum of the raw product: one 
corresponding to the dicarbonyl species cis,cis,trans-RuCl2(CO)2(PTA)2 (39) and a 
new one at –49.3 ppm, region of mutually trans PTAs. Slow diffusion of diethyl 
ether into a chloroform solution of the raw material afforded a small number of 
yellow crystals that, according to single crystal X-ray analysis, belonged to the new 
dicarbonyl species trans,trans,trans-RuCl2(CO)2(PTA)2 (41) (Figure 3.10). The Ru–
CO bond length in 40 (1.9691(12) Å) is significantly longer than that found in the 
stereoisomer 39 for the two CO’s trans to Cl (1.877(2) Å), in agreement with the 
expected competition between the two mutually trans carbonyls. The Ru–P distance 
in 41 (2.3432(3) Å) is also longer than that distance in 39 (2.3397(5) Å). 
Unfortunately, the amount of crystals was not sufficient for performing a detailed 
NMR analysis, and additional crystallization attempts to obtain other batches of pure 
compound were unsuccessful. 
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Figure 3.10. X-ray molecular structure (50% probability ellipsoids) of trans,trans,trans-
RuCl2(CO)2(PTA)2 (41) with a crystallization molecule of chloroform. Coordination distances in 
ångström (Å): Ru1–Cl1 = 2.4151(3), Ru1–C1 = 1.9691(12), Ru1–P1 = 2.3432(3). 
 
Compound 32 could be removed from the raw reaction product through a rapid 
washing with water, as witnessed by the 31P NMR spectrum (in CDCl3) of the 
remaining solid (Figure 3.11).  
 
Figure 3.11. 31P NMR spectrum in CDCl3 of a mixture of trans,trans,trans-RuCl2(CO)2(PTA)2 (41) 
and cis,cis,trans-RuCl2(CO)2(PTA)2 (39). 
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The IR spectrum of this solution presents three different signals in the CO stretching 
region: two equally intense bands at 2055 and 1995 cm–1 that belong to 39 and an 
additional one at 2018 cm–1 attributed to the antisymmetric carbonyl stretching mode 
in 41. Consistent with this hypothesis, the CO stretching band for the structurally 
similar trans,trans,trans-RuCl2(CO)2L2 compounds reported in literature (L = 
PMe2Ph, PMePh2, PPh3) falls between 1997 and 2023 cm
–1 in chloroform.6 Finally, 
the ESI-MS spectrum of the same solution shows a main peak at m/z = 479 attributed 
to a [Ru(PTA)2(CO)Cl]
+ fragment. All these data suggest that the singlet at –49.3 
ppm in D2O ppm (or –52.2 ppm in CHCl3) can be safely attributed to 41.  
Attempts to improve the yield of 41 by increasing the reaction time (from 1 to 4 d), 
and/or the CO pressure (from 30 to 50 atm) and/or the temperature (from 40 to 60 
°C) were unsuccessful and, conversely, led to an increase of the relative amount of 
39, suggesting that the monocarbonyl species 32 is an intermediate in the formation 
of the two dicarbonyls, and that 41 is a kinetic product (Scheme 3.21). 
 
Scheme 3.21. Reactivity of trans-RuCl2(PTA)4 with CO (P = 30 - 50 atm, T = 40 - 60°C) in 
chloroform. 
 
The use of 32, rather than 1, as starting material led to no significant improvement 
in the attempt to isolate the elusive all trans isomer 39. On the contrary, treatment of 
32 with CO under different reaction conditions (T = 50 -  70 °C, P = 30 or 50 atm, t 
= 13 – 72 h) afforded a raw product containing (according to the 31P NMR spectrum) 
also different amounts of the cis isomer 33, besides residual 32 and a mixture of 39 
and 41. This finding was not surprising, since complex 32 was found to isomerize to 
33 when refluxed in water (see above).  
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The behavior of the isomer cis-RuCl2(PTA)4 (2) towards CO was somehow different. 
Similarly to the trans isomer, 2 did not react with CO in ethanol (where it is 
insoluble), whereas in chloroform it very slowly afforded fac-RuCl2(CO)(PTA)3 (34) 
in low amount (10%, according to the 31P NMR spectrum, after overnight treatment, 
Scheme 3.22). An increase of the reaction time to 72h did not improve the yield of 
34 significantly (20% of 34). Full conversion of 2 was not achieved even when the 
reaction was performed in an autoclave, in different reaction conditions (T: 30 – 
50°C, P = 30 – 50 atm, 24 – 48 h).  
 
Scheme 3.22. Reactivity of cis-RuCl2(PTA)4 (2) with CO in chloroform. 
 
When the reaction between 2 and CO was performed in autoclave for a longer time 
(110h, r.T., 30 atm), a mixture of products was obtained after evaporation of the 
solvent. According to the 31P NMR spectrum (performed in D2O) this mixture 
contained the signals of unreacted 2 together with 33, 34 and a new complex (42), 
characterized by an AM2X system, in 1.5:1:4:7 ratio, respectively. The AM2X 
system of 42 consists of two double triplets centered respectively at –31.4 (2JA-M = 
20.5 Hz, 2JA-X = 32.8 Hz) and –61.9 ppm (2JX-M = 35.8 Hz) (one PTA each) and one 
double doublet centered at –59.8 ppm (two equivalent PTAs). Washing of the raw 
solid with chloroform afforded a white residue that, according to the 31P NMR 
spectrum, is an 8:1 mixture of 42 and 34 (Appendix, A3.26). The ESI-MS spectrum 
of the solid shows a peak at m/z = 793.1 attributable to the cationic species 
[RuCl(CO)(PTA)4]
+. Based on these data, the complex was unambiguously 
formulated as cis-[RuCl(CO)(PTA)4]Cl (42Cl), which is the first cationic Ru(II) 
carbonyl complex with PTA. Single crystals of 42Cl were obtained upon 
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recrystallization and X-ray analysis confirmed the nature and geometry of the 
complex (Figure 3.12). The Ru–P bond length of the PTA trans to CO (2.3828(6) Å) 
is similar to those of the two mutually trans PTAs (2.3898(6) and 2.3892(6) Å) and 
all three are longer than the Ru–P distance trans to Cl (2.3107(5) Å). The Ru–CO 
distance (1.913(2) Å) is similar to that found in 32 (1.928(3) Å), where the CO ligand 
is also trans to PTA. This complex was selectively obtained in good yield, as nitrate 
salt (42NO3), by treatment of 2 with 1 eq of AgNO3 in CHCl3 in atmosphere of CO 
for 24h (Scheme 3.23).  
 
Scheme 3.23. Preparation of cis-[RuCl(CO)(PTA)4](NO3) (42NO3). 
 
The 31P NMR and ESI-MS spectra of 42NO3, that is well soluble in water and 
DMSO, are coincident with those of 42Cl (Appendix, A3.27). The CO stretching 
band occurs at 2020 cm–1 in the solid state IR spectrum (nujol), i.e. at remarkably 
higher wavenumbers compared to the neutral mono-carbonyl complexes 31-33, in 
agreement with a higher competition for π back-donation and lower electronic 
density on Ru(II) because of the positive charge of 42. 
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Figure 3.12. X-ray molecular structure (50% probability ellipsoids) of the cationic part of cis-
[RuCl(CO)(PTA)4](Cl) (42Cl). Crystals obtained by recrystallization of the raw product from 
water/acetone. Coordination distances in ångström (Å): Ru1–Cl1 = 2.4855(5), Ru1–C1 = 1.913(2), 
Ru1–P1 = 2.3828(6), Ru1–P2 = 2.3898(6), Ru1–P3 = 2.3892(6), Ru1–P4 = 2.3107(5). 
 
Finally, the reactivity of the complex cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10) 
towards CO was also tested. Even if this compound has two relatively labile dmso 
ligands it reacted with CO only under pressure in autoclave (P = 30 atm, T = 60°C). 
Under these conditions, a chloroform solution of 10 was completely converted to 39 
after 24h. Thus, two CO molecules selective replaced both dmso ligands, with 
retention of the geometry (Scheme 3.24). At lower temperature 10 did not show any 
reactivity with CO. 
 
Scheme 3.24. Reactivity of cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10) with CO. 
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Table 3.1. Selected CO stretching bands for compounds 31-33, 35-37, 39, 41 (cm–1). 
complex ν cm–1 CO trans to 
cis,cis,trans-RuCl2(CO)(dmso-S)(PTA)2 (31) 1950[a] Cl 
trans,mer-RuCl2(CO)(PTA)3 (32) 1986[a] PTA 
cis,mer-RuCl2(CO)(PTA)3 (33) 1942[a] Cl 
[RuCl2(CO)(PTA)2]2·8H2O (35) 1941[a] Cl 
[RuCl2(CO)2(PTA)]2·H2O (37) 2060, 1989[a] Cl 
cis,cis,trans-RuCl2(CO)2(PTA)2 (39) 2053, 1988[a] Cl 
trans,trans,trans-RuCl2(CO)2(PTA)2 (41) 2018[b] CO 
[a] Solid state (Nujol mulls), [b] Chloroform solution. 
 
Table 3.2. Selected coordination bond lengths (Å) in complexes cis,cis,trans-RuCl2(CO)(dmso-
S)(PTA)2 (31), trans,mer-RuCl2(CO)(PTA)3 (32), cis,mer-RuCl2(CO)(PTA)3 (33), cis,cis,trans-
RuCl2(CO)2(PTA)2 (39), all-trans-RuCl2(CO)2(PTA)2 (41). 
 31 32 33 39 41 
Ru–P (mutually 
trans) 
2.385(1), 
2.357(1) 
2.3399(7), 
2.3458(6) 
2.3811(5), 
2.3488(5) 
2.3397(5) 2.3432(3) 
Ru–P (trans to Cl)   2.2865   
Ru–P (trans to CO)  2.3821(7)    
Ru–CO (trans to 
PTA) 
 1.928(3)    
Ru–CO (trans to Cl) 1.80(1)  1.926(3) 1.877(2)  
Ru–CO (trans to 
CO) 
    1.9691(12) 
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3.5 Conclusions 
In summary, the well-known neutral Ru(II)-CO-dmso complexes fac-
RuCl2(CO)(dmso)3 (26), cis,cis,trans-RuCl2(CO)2(dmso-S)2 (27), cis,cis,cis-
RuCl2(CO)2(dmso)2 (28), trans,cis,cis-RuCl2(CO)2(dmso-O)2 (29), and fac-
RuCl2(CO)3(dmso-O) (30) demonstrated to be good precursors for the synthesis of 
new carbonyl derivatives with PTA. In fact, we could isolate and completely 
characterize a series of Ru(II)-CO complexes with PTA, which show a good 
solubility in water and, most often, also in chloroform: cis,cis,trans-
RuCl2(CO)(dmso-S)(PTA)2 (31) trans,mer-RuCl2(CO)(PTA)3 (32), cis,mer-
RuCl2(CO)(PTA)3 (33), [RuCl2(CO)(PTA)2]2·8H2O (35), [RuCl2(CO)2(PTA)]2·H2O 
(37) and cis,cis,trans-RuCl2(CO)2(PTA)2 (39) (Figure 3.13). It was also determined 
the single X-ray structure of all of them, with the exception of the two dimers. 
 
Figure 3.13. Ru(II)-PTA carbonyls complexes synthesized using the well-known neutral Ru(II)-CO-
dmso precursors. 
 
The common behavior when a Ru(II)-CO-dmso complex is reacted with PTA is the 
coordination of two mutually trans phosphine ligands even when PTA is in defect, 
suggesting that this geometry is particularly stable. We were unable to isolate a 
carbonyl compound with only one bound PTA. Furthermore, in the di- and tri-
carbonyl precursors PTA easily replace at least one CO at room temperature, even 
when there is a residual dmso ligand available in the coordination sphere. As a 
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consequence, Ru(II)-PTA dicarbonyls could be obtained only from the precursor 
with 3 CO ligands, and we were unable to isolate Ru(II)-PTA compounds with more 
than 2 CO ligands. In addition, PTA prefers to avoid binding trans to CO. In fact, 
the only monocarbonyl compound with one PTA trans to CO that we managed to 
isolate trans,mer-RuCl2(CO)(PTA)3 (32) is a kinetic isomer.  
 
Using the opposite strategy, that is the reaction of Ru(II)-PTA precursors with CO, 
we found that both trans-RuCl2(PTA)4 (1) and cis-RuCl2(PTA)4 (2) can replace a 
single PTA (originally trans to another PTA) with CO at ambient pressure, affording 
respectively trans,mer-RuCl2(PTA)3(CO) (32) and fac-RuCl2(CO)(PTA)3 (34, in 
low yield): i.e. the substitutions do not imply isomerization (Scheme 3.25). In the 
case of 2, owing to the trans-influence of PTA, it was possible for a CO to replace 
(partially) one of the two chlorides trans to PTA. Assisted removal of the chloride 
by addition of a soluble silver salt led to the isolation of the unprecedented cationic 
species cis-[RuCl(CO)(PTA)4](NO3) (42NO3).   
Moreover, when treated with CO in more forcing conditions (T = 40 - 60°C, P = 30 
- 50 atm) compound 1 could partially replace two PTAs, affording mixtures of 31 
together with the two dicarbonyl stereoisomers: cis,cis,trans-RuCl2(CO)2(PTA)2 
(39) and all-trans-RuCl2(CO)2(PTA)2 (41). Compound 41, which is a kinetic 
intermediate in the transformation of 32 to 39, was not observed when the Ru(II)-
CO-dmso precursors were treated with PTA.  
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Scheme 3.25. Reactivity of trans- (1, top) and cis-RuCl2(PTA)4 (2, bottom) with CO. 
 
Finally, the compound cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10), that was shown to 
be a good precursor with N-donor ligands (see Chapter 2), reacts with CO only in 
relatively forcing condition (P = 30 atm, T = 60°C), substituting both dmso ligands 
and forming cis,cis,trans-RuCl2(CO)2(PTA)2 (39) thus leaving unchanged the 
geometry of the complex. 
To conclude, here is reported the preparation of a series of unprecedented water-
soluble Ru(II)-carbonyl complexes with PTA. We found that, as reported in the 
literature with other phosphines, the Ru(II)-CO-PTA compounds are better prepared 
by treatment of Ru(II)-carbonyl precursors with PTA rather than the other way 
around, i.e. treatment of Ru(II)-PTA precursors with CO. However, the two synthetic 
approaches not necessarily lead to the same products, and compounds 41 and 42 
were obtained exclusively by the second route.  
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Ru(II)-CO-PTA derivatives with 2,2'-
bipyridine 
 
4.1 Aim of the Chapter 
As mentioned in the Introduction, one of the aims of this investigation is that of 
obtaining novel water-soluble precursors to be exploited as building blocks in the 
construction of metal-conjugates and metal-mediated supramolecular assemblies. 
For this reason, we started a preliminary investigation of the reactivity of the new 
Ru-CO-PTA complexes described in Chapter 3 towards 2,2'-bipyridine (bpy), used 
as a model for chelating diimine linkers (e.g. bpyAc and cppH, Figure 4.1). All the 
reactions were performed in water and the NMR spectra were recorded on the raw 
products obtained by rotary evaporation of the solvent (except when written 
differently). 
 
Figure 4.1. 2,2'-bipyridine (bpy) and the chelating diimine linkers bpyAc and cppH. 
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4.2 Reactions with 2,2′-bipyiridine 
The complex cis,cis,trans-RuCl2(CO)(dmso-S)(PTA)2 (31), with a residual 
potentially labile ligand (dmso-S), seemed to be a good starting point for this 
investigation. Complex 31 reacts with bpy in water (either 16h at reflux or 30 min at 
150°C in a microwave reactor) by replacing the molecule of dmso and the adjacent 
chloride yielding cis,trans-[Ru(bpy)Cl(CO)(PTA)2]Cl (43) (Scheme 4.1).  
 
Scheme 4.1. Preparation of cis,trans-[Ru(bpy)Cl(CO)(PTA)2]Cl (43) upon treatment of cis,cis,trans-
RuCl2(CO)(dmso-S)(PTA)2 (27) with bpy in water at reflux. 
 
Compound 43 was fully characterized by NMR spectroscopy and mass spectrometry. 
The 1H NMR spectrum shows in the aromatic region eight different resonances, one 
for each proton of bpy, consistent with the asymmetric environment of the diimine 
ligand (Appendix, A4.1). In agreement with previous findings,1,2 the most deshielded 
doublet was assigned to H6, i.e. the proton with a partial positive charge that points 
towards the adjacent chloride (Scheme 4.1). The PTA region of the spectrum consists 
of two AB quartets centered respectively at 4.21 and 3.65 ppm; the 1H-13C HSQC 
spectrum established that the most downfield one belongs to NCH2N protons and the 
other to NCH2P protons. The 
31P NMR spectrum presents a singlet at –50.6 ppm, i.e. 
in the typical region of mutually trans PTAs.  
The presence of CO was supported by the IR spectrum in EtOH that shows a band 
at 1984 cm–1 (see also Table 4.1 for a comparison of the carbonyl stretching 
frequencies of all the derivatives isolated); the stretching frequency is shifted to 
higher wavenumbers compared to the precursor 31 (1950 cm–1), in agreement with 
a lower π back-bonding contribution from ruthenium because of the positive charge. 
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The same product 43 was obtained also by treatment of [RuCl2(CO)(PTA)2]2·8H2O 
(35) with bpy after 2h at reflux (Scheme 4.2). In this case bpy replaces the two 
bridging chlorides, i.e. the weakest ligands. This reactivity, together with that 
observed with pyridine and reported earlier, is consistent with the proposed nature 
of 35. 
 
Scheme 4.2. Preparation of cis,trans-[Ru(bpy)Cl(CO)(PTA)2]Cl (43) upon treatment of 
[RuCl2(CO)(PTA)2]2·8H2O (35) with bpy in water at reflux. 
 
A very small amount of colorless crystals very slowly grew out of this solution. The 
single-crystal X-ray structure shows that they are composed by the neutral Ru(II) 
complex trans-RuCl2(bpy)(CO)(PTA) (44) (Figure 4.2).  
 
Figure 4.2 X-ray molecular structure (50% probability ellipsoids) of trans-RuCl2(bpy)(CO)(PTA) 
(44) Coordination distances (Å): Ru1–C1 = 1.842(2), Ru1–Cl11 = 2.417(2), Ru1–Cl12 = 2.402(1), 
Ru1–N31 = 2.134(2), Ru1–N32 = 2.154(1), Ru1–P2 = 2.305(1). 
 
This compound might be a side product of the reaction, formed upon substitution of 
a bridging chloride and the adjacent PTA of 35 by bpy (Scheme 4.3); as shown in 
Chapter 2, there are previous examples in which bpy replaced a PTA.  As an 
alternative, 44 might derive from 43: the driving force of the unprecedented 
replacement of a PTA by Cl–, accompanied by isomerization, might be the low 
solubility of the complex in aqueous solution. A low solubility in water was also 
observed with the neutral py derivative, cis,cis,trans-RuCl2(CO)2(py)(PTA) (38) 
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described in Chapter 3, whose crystals spontaneously formed in D2O, and that was 
much more soluble in CDCl3. 
 
Scheme 4.3. Hypothesis of formation of the side product trans-RuCl2(bpy)(CO)(PTA) (44). 
 
The crystals of 44 were dissolved in DMSO-d6. The 
1H NMR spectrum presents eight 
different resonances in the aromatic region, one for each proton of bpy, consistent 
with the asymmetric environment of the diimine ligand (Appendix, A4.7). The PTA 
region of the spectrum presents a multiplet and a broad singlet centered at 4.52 ppm 
and 4.32 ppm, belonging respectively (according to the 1H-13C HSQC spectrum) to 
the NCH2N and to the NCH2P protons. The 1D NOESY spectrum allowed us to 
assign the aromatic protons: saturation of the multiplet at 9.12 ppm gave an NOE 
effect with the resonance of the NCH2P protons of the PTA, thus implying that it 
belongs to proton H6′, i.e. the one closest to the adjacent PTA. In fact, no NOE effect 
was observed when the doublet at 9.16 ppm was saturated. The other bpy resonances 
were then assigned through an 1H-1H COSY spectrum. The 31P NMR spectrum 
presents a singlet at –38.4 ppm, i.e. in the typical region PTA trans to bpy. Thus, all 
the NMR data are consistent with the structure. Unfortunately the solution was too 
diluted for recording an IR spectrum.  
 
The reaction of cis,mer-RuCl2(CO)(PTA)3 (33) with bpy in refluxing water led to 
the replacement of both chlorides by bpy, affording the dicationic complex mer-
[Ru(bpy)(CO)(PTA)3](Cl)2 (45) (Scheme 4.4).  
Chapter 4: Ru(II)-CO-PTA derivatives with 2,2’-bipyridine  
113 
 
 
Scheme 4.4. Preparation of mer-[Ru(bpy)(CO)(PTA)3](Cl)2 (45) upon treatment of cis,mer-
RuCl2(CO)(PTA)3 (33) with bpy in water at reflux. 
 
Compound 45, that is soluble in water, methanol, ethanol and DMSO, was fully 
characterized by NMR and IR spectroscopy, mass spectrometry, and its single-
crystal X-ray structure was also determined (Figure 4.2).  
The PTA region of the 1H NMR spectrum consists of two pairs of signals, in a 1:2 
ratio. The most intense and upfield shifted multiplets, respectively centered at 4.41 
and 3.83 ppm (12H each) were attributed to the two equivalent trans PTA ligands, 
whose protons fall in the shielding cone of the adjacent bpy, while the other two 
signals, respectively centered at 4.81 ppm (partially overlapped with the water 
signal) and 4.65 ppm to the PTA trans to N. The 1H-13C HSQC spectrum established 
that, in each set, the deshielded quartet belongs to the NCH2N protons and the upfield 
signal to the NCH2P protons. The downfield region of the spectrum shows six 
resonances in which, according to integration, the unresolved multiplet centered at 
8.42 ppm accounts for three protons (indeed, the 1H-13C HSQC spectrum it shows 
correlations with the resonances of three different carbon atoms of bpy). The 1D 
NOESY spectrum allowed us to assign the aromatic protons: saturation of the singlet 
of the NCH2P protons of the PTA trans to bpy gave an NOE effect with the multiplet 
at 8.42 ppm (Appendix, A4.13 - 4.14), thus implying that it contains the resonance 
of proton H6′, i.e. the one closest to the adjacent PTA. The other bpy resonances 
were then assigned through an 1H-1H COSY spectrum. The 31P NMR spectrum of 
45 shows an AX2 system in which the triplet is centered at –49.6 (2JP-P = 25.2 Hz) 
ppm and the doublet at –55.6 ppm (Appendix, A4.15). The chemical shift of the 
triplet, that belongs to the PTA trans to bpy is upfield shifted of ca. 10 ppm compared 
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to the known monocationic Ru(II)-PTA-bpy compounds with PTA trans to bpy (i.e. 
mer-[Ru(bpy)Cl(PTA)3](PF6) (17PF6) and fac-[Ru(bpy)Cl(PTA)3](PF6) (18), 
Chapter 2). The difference might be attributed to the presence of the CO ligand and 
also to the different net charge of the complexes.  
The IR spectrum shows a carbonyl stretching band at 2010 cm–1, i.e. at higher 
wavenumbers than in the precursor (1942 cm–1), in agreement with the 2+ charge of 
45. For comparison, the CO stretching band in the dicationic monocarbonyl Ru(II) 
complex fac-[Ru(CO)(dmso-O)3(dmso-S)2](PF6)2 falls at 2012 cm
-1, suggesting that 
this parameter is not particularly affected by the nature of the ligands, but rather by 
the net charge of the complex.3 
X-ray quality crystals of 45 were obtained upon recrystallization of the raw product 
from water/acetone (Figure 4.3). The coordination distances are in general agreement 
with the known trans influence of the ligands: thus, the Ru–P bond lengths of the 
two trans PTA ligands (2.3650(5) and 2.3631(4) Å) are slightly longer than the Ru–
P distance trans to N (2.3391(4) Å). Similarly, the Ru–N bond length trans to CO 
(2.139(1) Å) is longer than that trans to P (2.119(1) Å), consistent with the previous 
finding that CO has a stronger trans influence than PTA. Compared with the 
structure of trans-Ru(bpy)Cl2(CO)(PTA) (44), the Ru–C bond in 45 is longer 
(1.8746(14) Å in 45 vs 1.842(2) Å in 44), consistent with a lower -back donation 
from Ru(II) because of the 2+ charge. 
 
Figure 4.3. X-ray molecular structure (50% probability ellipsoids) of mer-[Ru(bpy)(CO)(PTA)3](Cl)2 
(45) obtained by recrystallization of the raw product from water/acetone. Coordination distances (Å): 
Ru1–C1 = 1.8746(14), Ru1–N51 = 2.119(1), Ru1–N52 = 2.139(1), Ru1–P2 = 2.3650(4), Ru1–P3 = 
2.3391(4), Ru1–P4 = 2.3631(4). 
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The reaction of trans,mer-RuCl2(CO)(PTA)3 (32) with bpy led to a mixture of 
compounds (Scheme 4.5): the 31P NMR spectrum of the raw product shows a singlet 
at –50.6 ppm for 43 and two AX2 systems in 1:1.5 ratio, belonging respectively  to 
45, and to mer-[Ru(bpy)Cl(PTA)3]Cl (17) – already described in Chapter 2 – in 
which bpy has replaced a chloride and a molecule of CO. 
 
Scheme 4.5. Reactivity of trans,mer-RuCl2(CO)(PTA)3 (32) towards bpy in refluxing water. 
 
Treatment of [RuCl2(CO)2(PTA)]2·H2O (37) with bpy led to the isolation of the new 
cationic dicarbonyl compound cis,trans-[Ru(bpy)(CO)2Cl(PTA)]Cl (46) (Scheme 
4.6). In fact the 31P NMR spectrum presents a singlet at –25.4 ppm as main signal, 
i.e. in the typical region of PTA trans to Cl. Unlike in the other Ru(II)-PTA 
complexes in which a PTA is trans to Cl (i.e. in the neutral species cis-RuCl2(PTA)4 
(2), cis,cis-Ru(bpy)Cl2(PTA)2 (22), and cis,mer-RuCl2(CO)(PTA)3 (33)), in this case 
the hydrolysis of the chloride was not observed. In fact, no changes were observed 
in the NMR spectrum after the addition of an excess of NaCl to the D2O solution. 
Probably, since 46 is a monocationic dicarbonyl compound, the formation of a 
dicationic product is unfavorable. This behavior was also observed with the 
monocataionic monocarbonyl complexes cis-[RuCl(CO)(PTA)4](NO3) (42NO3) 
described in Chapter 3. The 1H NMR spectrum shows in the aromatic region four 
equally intense signals (2H each), in agreement with bpy coordinated in a 
symmetrical environment (Scheme 4.6). The PTA region of the spectrum presents a 
broad singlet at 4.09 ppm for the NCH2P protons and a multiplet centered at 4.47 
ppm for the NCH2N protons. The integration ratio of bpy and PTA resonances is 
consistent with the stoichiometry of the complex. (Appendix, A4.16-A4.18). 
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Scheme 4.6. Reactivity of [RuCl2(CO)2(PTA)]2·H2O (37) towards bpy. 
 
The IR spectrum of 46 in MeOH presents two carbonyl stretching bands at 2085 and 
2034 cm-1, in agreement with the presence of two cis CO ligands. For comparison, 
the CO stretching bands in the cationic dicarbonyl Ru(II) complex cis,fac-
[Ru(CO)2Cl(dmso)3](PF6) fall at 2092 and 2030 cm
-1.3 
 
The reaction between cis,cis,trans-RuCl2(CO)2(PTA)2 (39) and bpy afforded a 
mixture of 46 with a new product 47 in ca. 1 / 2 ratio (Scheme 4.7). The PTA region 
of the 1H NMR spectrum presents three different signals, two broad singlets and a 
multiplet, and is scarcely useful for determining the nature of the new species. 
However, the downfield region of the spectrum shows a new set of four equally 
intense bpy signals, indicating that also in 47 bpy is coordinated in a symmetrical 
environment. The 31P spectrum shows a new singlet in the region of mutually trans 
PTAs (–50.9 ppm) attributed to 47. Based in this spectroscopic evidence, 47 could 
be formulated as the dicationic species with two mutually trans PTAs cis,trans-
[Ru(bpy)(CO)2(PTA)2](Cl)2 (47), derived from 39 upon replacement of both 
chlorides. To be noted that the formation of 46 from 39 involves isomerization: Cl, 
that was trans to CO in the precursor, is trans to PTA in 46. 
 
Scheme 4.7. Reactivity of cis,cis,trans-RuCl2(CO)2(PTA)2 (39) towards bpy. 
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Compound 47 was selectively obtained, as nitrate salt (47NO3), when 39 was reacted 
with bpy in refluxing water after the addition of 2.1 eq of AgNO3 (Scheme 4.8). The 
1H (aromatic region), 31P NMR and ESI-MS spectra of 47NO3, that is well soluble 
in water and DMSO, are coincident with those of 47. The PTA region of the 1H NMR 
spectrum (previously not discussed because of the overlaps with the signals of 46) 
presents a broad singlet at 3.91 ppm for the NCH2P protons and a multiplet centered 
at 4.30 ppm of NCH2N protons. The bpy/PTA integration ratio is in agreement with 
the proposed stoichiometry (Appendix, A4.19-A4.21). Consistent with the cis 
geometry of the two CO ligands, complex 47 presents two CO stretching bands at 
2086 and 2038 cm–1. Compared with the precursor, the IR absorption bands of both 
46 and 47 are shifted to higher wavenumbers, in accordance with the positive charge 
of the two products; it is remarkable that the CO stretching frequencies in 47 are very 
similar to those found in 46, despite the higher positive charge. Compound 47 is the 
first dicationic dicarbonyl Ru(II) compound that we have isolated thus far; the 
previously prepared dicationic species have a single CO (e.g. fac-[Ru(CO)(dmso-
O)3(dmso-S)2](PF6)2), and the dicarbonyl compounds were monocationic (e.g. 45). 
 
Scheme 4.8. Preparation of cis,trans-[Ru(bpy)(CO)2(PTA)2](NO3)2 (47NO3). 
 
4.3 Light-induced rearrangements in water-soluble Ru(II)-
CO-bpy complexes 
Ru(II)-PTA complexes have shown to be photoreactive: cis-RuCl2(PTA)4 is 
prepared from the trans- isomer in water upon irradiation with blue light (see Chapter 
2). Moreover, as mentioned in Chapter 2, the group of Romerosa has recently 
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reported a study of the effects of visible light on a series of water-soluble Ru(II) 
complexes with PTA.4 They reported the synthesis of mer-[RuCl3(PTAH)3](Cl)2 (6) 
and its conversion to the fac- isomer (7) promoted by irradiation with an halogen 
lamp (Scheme 4.9).  
 
Scheme 4.9. Light-induced interconversion of mer-[RuCl3(PTAH)3](Cl)2 (6) to fac-
[RuCl3(PTAH)3](Cl)2 (7). 
 
For this reason we decided to investigate the effect of visible light on the previously 
described Ru(II)-CO-bpy complexes since all of them are from deep yellow to 
orange. In general, D2O solutions of the complexes were directly irradiated in the 
NMR tube, without isolating the products. 
We found that 24 h irradiation with blue light (470 nm) of a D2O solution of cis,trans-
[Ru(bpy)Cl(CO)(PTA)2]Cl (43) induces its complete transformation to the 
unprecedented cis- isomer cis,cis-[Ru(bpy)Cl(CO)(PTA)2]Cl (48) (Scheme 4.10). In 
fact, the 31P NMR spectrum of the product presents an AX system of two doublets 
centered respectively at –25.1 ppm (2JP-P = 24.7 Hz) and –42.3 ppm. The first doublet 
is in the region of PTA trans to Cl, while the second in that of PTA trans to bpy. The 
PTA region of the 1H NMR spectrum shows a broad singlet at 3.93 ppm and three 
partially overlapped AB systems centered respectively at 4.41, 4.58, and 4.71 ppm. 
According to the 1H-13C HSQC spectrum, the singlet and the multiplet at 4.58 ppm 
belong to NCH2P protons, while the other two multiplets to NCH2N protons. The 
1H-1H COSY shows correlation peaks between the two most upfield signals, 
attributed to the PTA trans to Cl that falls into the shielding cone of the adjacent bpy, 
as well as between the two most downfield signals (Appendix, A4.22-A4.26). The 
aromatic region of the spectrum presents eight equally intense signals for bpy 
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coordinated in an asymmetric environment. The 1D NOESY spectrum allowed us to 
assign the aromatic resonances: saturation of the singlet of the NCH2P protons of the 
PTA trans to bpy gave an NOE effect with the multiplet at 9.09 ppm, thus implying 
that it contains the resonance of proton H6, i.e. the one closest to the adjacent PTA. 
An IR spectrum of 48 recorded in EtOH solution shows a carbonyl stretching band 
at 1992 cm–1, i.e. a frequency similar to that of the trans-isomer 43 (1984 cm–1). 
 
Scheme 4.10. Light-induced isomerization (λ = 470 nm, 24 h) of cis,trans-
[Ru(bpy)Cl(CO)(PTA)2]Cl (43) to cis,cis-[Ru(bpy)Cl(CO)(PTA)2]Cl (48).  
 
A similar behavior, i.e. a light-induced isomerization, was observed for cis,trans-
[Ru(bpy)(CO)2Cl(PTA)]Cl (46) (Scheme 4.11). In this case the process was slower 
(and less selective) and complete transformation required the irradiation with blue 
light of an aqueous solution of 46 for 3 days. The 31P NMR spectrum of the product 
shows a singlet at –39.6 ppm, i.e. in the region of PTA trans to bpy together with 
other less intense signals. The 1H NMR spectrum shows eight major resonances in 
the aromatic region for asymmetrically bound bpy. The PTA region of the spectrum 
presents a singlet at 3.21 ppm for the NCH2P protons and a multiplet centered at 4.23 
ppm for the NCH2N protons. According to the NMR spectra the new compound 
could be formulated as cis,cis-[Ru(bpy)(CO)2Cl(PTA)]Cl (49). The IR spectrum in 
EtOH presents two carbonyl stretching bands at 2006 and 1979 cm–1 in agreement 
with the presence of two CO ligands in cis geometry. Compared to the trans isomer 
(2085 and 2034 cm–1), the two bands are shifted to lower wavenumbers, possibly 
because one CO is trans to the good -donor Cl.  
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Scheme 4.11. Light-induced isomerization (λ = 470 nm, 72 h) of cis,trans-
[Ru(bpy)(CO)2Cl(PTA)]Cl (46) to cis,cis-[Ru(bpy)(CO)2Cl(PTA)]Cl (49). 
 
Conversely, compound cis,trans-[Ru(bpy)(CO)2(PTA)2](NO3)2 (47NO3) was light-
stable. The 31P NMR spectrum of a D2O solution of 47NO3 remained unchanged 
even after one week of irradiation either with blue or visible light. 
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4.4 Conclusions 
In this Chapter the reactivity of the water-soluble Ru(II)-PTA-CO complexes 31-33, 
35, 37, and 39 with the diimine ligand bpy was investigated. Typically bpy reacts 
with these compounds by replacing the two weakest ligands (i.e. dmso and/or Cl), 
affording one main mono- (Scheme 4.12) or dicationic product (Scheme 4.13).  
 
 
Scheme 4.12. Preparation of the monocationic derivatives 43 and 46. 
 
 
Scheme 4.13. Preparation of the dicationic derivative 45 from 33. 
 
The reaction of trans,mer-RuCl2CO(PTA)3 (32) with bpy led to a mixture of the three 
species cis,trans-[Ru(bpy)Cl(CO)(PTA)2]Cl (43), mer-[Ru(bpy)Cl(PTA)3]Cl (17), 
and mer-[Ru(bpy)(CO)(PTA)3](Cl)2 (45),  obtained respectively by the replacement 
of a chloride and a PTA (43), of a chloride and a CO (17), or of the two chlorides 
(45)) (Scheme 4.14).  
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Scheme 4.14. Reactivity of complex trans,mer-RuCl2(CO)(PTA)3 (32) with bpy. 
 
Also in cis,cis,trans-RuCl2(CO)2(PTA)2 (39) bpy replaced either both chlorides 
(forming cis,trans-[Ru(bpy)(CO)2(PTA)2](Cl)2 (47)) or one chloride and one PTA 
(forming cis,trans-[Ru(bpy)(CO)2Cl(PTA)]Cl (46)). In this case, however, the 
dicationic species 47 could be selectively obtained (as nitrate salt) by removing the 
chlorides of 39 with AgNO3 (Scheme 4.15). 
 
Scheme 4.15. Reactivity of complex cis,cis,trans-RuCl2(CO)2(PTA)2 (39) with bpy. 
 
Finally we found that the unexpected neutral compound trans-
Ru(bpy)Cl2(CO)(PTA) (44) spontaneously crystallized in small amount out of the 
aqueous mother liquor of the reaction that transformed [RuCl2(CO)(PTA)2]2·8H2O 
(35) into 43.  
In these reactions the geometry of the PTA ligands remained unchanged, except 
when one PTA was replaced by bpy (in 43, 44 and 46); conversely, in some cases 
selective isomerization was induced by irradiating the bpy complexes with blue light. 
Thus, irradiation with blue or visible light transformed cis,trans-
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[Ru(bpy)Cl(CO)(PTA)2]Cl (43) into cis-[Ru(PTA)2(bpy)Cl(CO)]Cl (48), and 
cis,trans-[Ru(CO)2Cl(PTA)(bpy)]Cl (46) into cis,cis-[Ru(CO)2Cl(PTA)(bpy)]Cl 
(49) (Scheme 4.16). 
 
 
Scheme 4.16. Light-induced isomerization (λ = 470 nm, 72 h) of cis,trans-
[Ru(bpy)Cl(CO)(PTA)2]Cl (43) and cis,trans-[Ru(bpy)(CO)2Cl(PTA)]Cl (46)).  
 
All new compounds were fully characterized through NMR and IR spectroscopy, 
mass spectrometry and the single-crystal X-ray structures of trans-
Ru(bpy)Cl2(CO)(PTA) (44) and mer-[Ru(bpy)(CO)(PTA)3](Cl)2 (45) were 
determined. 
Table 4.1 reports the carbonyl stretching bands of complexes 43, 45-49, that are 
always higher than in the corresponding neutral precursor, due to the positive 
charge(s). With the exception of 49, in all the new compounds the COs (either one 
or two) are always trans to bpy. Only 49, besides a CO trans to bpy, presents a CO 
trans to a chloride. In this case the two carbonyl stretching frequencies are shifted to 
lower wavenumbers compared to the isomer 46 with the same charge, possibly 
because the chloride is a good -donor.  
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Table 4.1. Carbonyl stretching bands of compounds 43, 45-49 (cm–1). 
 
complex ν cm–1 CO trans to 
cis,trans-[Ru(bpy)Cl(CO)(PTA)2]Cl (43) 1984[a] N 
mer-[Ru(bpy)(CO)(PTA)3](Cl)2 (45) 2010[b] N 
cis,trans-[Ru(bpy)(CO)2Cl(PTA)]Cl (46) 2085, 2034[c] N 
cis,trans-[Ru(bpy)(CO)2(PTA)2](NO3)2 (47) 2086, 2038[c] N 
cis,cis-[Ru(bpy)Cl(CO)(PTA)2]Cl (48) 1992[a] N 
cis,cis-[Ru(bpy)(CO)2Cl(PTA)]Cl (49) 2006, 1979[a] Cl 
[a] EtOH solution, [b] Solid state (Nujol mulls), [c] MeOH solution. 
 
The new Ru(II)-CO-PTA complexes and their derivatives with bpy allowed us to 
expand the diagnostic Table 2.2 of Chapter 2, that reports the typical 31P NMR 
chemical shift intervals (Δ) for PTA bound to Ru(II) as a function of the nature of 
the trans ligand. In fact, since the phosphorous chemical shift is strongly influenced 
by the nature of the ligand in trans position, Table 4.2 can be used as a diagnostic 
tool for establishing the geometry of octahedral Ru–PTA complexes. We observed 
that when PTA is trans to an imine nitrogen (i.e. py, bpy), the 31P NMR chemical 
shift is affected by the nature of the ligand: when trans to py it falls in the range –20 
÷ –23 ppm, whereas when trans to bpy or bpyAc it falls in the range –34 ÷ –50 ppm. 
We argue that this behavior might be due to the different orientation of the aromatic 
rings containing the imine nitrogen: chelating diimine ligands (i.e. bpy, bpyAc) are 
in the plane containing PTA, whereas pyridine is typically almost orthogonal to such 
plane. The different orientation, and consequently different involvement of the π 
orbitals of these ligands, could explain the different 31P chemical shift intervals for 
PTA trans to pyridine and trans to diimine ligands. 
Finally, as noted already, there is a rough correlation between the Ru–P bond length 
and the chemical shift of the 31P NMR resonance: as the Ru–P distance increases, 
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the phosphorous resonance shifts progressively to lower frequencies; this trend is 
confirmed also with the two complexes bearing PTA trans to CO (trans,mer-
RuCl2(CO)(PTA)3 (32) and cis-[RuCl(CO)(PTA)4](NO3) (42NO3).  
 
Table 4.2. Typical 31P NMR chemical shift intervals (Δ) and Ru–P distances for PTA bound to 
octahedral Ru(II) complexes as a function of the nature of the trans ligand. 
Ligand trans to 
PTA 
Δ 31P (ppm)[a] Δ Ru–P distance (Å) Ref. 
OH2/OH –5 ÷ –16 - Chapter 2, 4, 5 
N[b] –20 ÷ –23 2.1933 ÷ 2.224 Chapter 2 
Cl –14 ÷ –26 2.232 ÷ 2.283 Chapter 2, 4, 6 
Br –24 ÷ –27 2.266 ÷ 2.281 Chapter 2 
S[c] –30 ÷ –45 2.280 ÷ 2.318 1, 7 
N[d] –34 ÷ –50 2.260 ÷ 2.344 
Chapter 2, this Chapter, 8, 9, 
10, 11, 12, 13, 14, 15,  
H –26.6[e] 2.299 ÷ 2.300 16  
P[f] 
–45 ÷ –60 
2.290 ÷ 2.400 
Chapter 2 and 3, this 
Chapter, 4, 5, 6, 15, 16, 17, 
18, 19 
CO –60 ÷ –70 2.3821 ÷ 2.3828 Chapter 3, this Chapter 
C[g] –68.4[e] 2.395(1) 20 
[a] For comparison, the singlet of free PTA falls at δ = –98.2 ppm in D2O and at –102.3 ppm in CDCl3. 
[b] From pyridine. [c] From [9]aneS3 = 1,4,7-trithiacyclononane. [d] From imine or azole. [e] Single hit. 
[f] From PTA. [g] From cyclometallated 2-phenylpyridine. 
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Biological properties of Ru(II)- and Ru(III)-
PTA complexes 
 
5.1 State of the Art  
As written in the Introduction, since several years the cage-like monodentate 
phosphine 1,3,5-triaza-7-phosphaadamantane (PTA) has been widely used as a co-
ligand in the design of organometallic Ru(II) anticancer compounds. The half-
sandwich RAPTA-type compounds [RuCl2(η6-arene)(PTA)] (RAPTA = Ruthenium-
Arene PTA, Figure 5.1) developed  by the group of Dyson are the most well-known,1 
but other Ru(II) compounds containing PTA have been investigated for their 
anticancer2 or DNA-binding3 properties.  
 
Figure 5.1. A representative example of the RAPTA compounds (RAPTA-T). 
 
Given these premises, we were surprised at realizing that even though PTA has been 
extensively used as co-ligand in many Ru half-sandwich anticancer compounds, no 
investigation has been yet performed on the ruthenium-halide complexes of PTA, 
i.e. on complexes in which PTA is the main ligand. Only very recently the group of 
Pettinari reported a cytotoxic study of Ru(II) complexes of general formula cis,trans-
RuCl2(PTA)2(chel) and mer-Ru[Cl(PTA)3(chel)]Cl (chel = 2,2’-bipyridine (bpy – 17 
described in Chapter 2) or 1,10-phenanthroline (phen)).4 These compounds were 
prepared by treatment of [RuCl2(COD)]n (COD = 1,5-cyclooctadiene) with 
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stoichiometric amount of bpy or phen, in EtOH solution at reflux conditions; addition 
2 eq of PTA led to cis,trans-RuCl2(PTA)2(chel), while addition of 3 eq of PTA led 
to mer-Ru[Cl(PTA)3(chel)]Cl. All compounds showed to be moderate active in 
reducing necrotic cell death in multiple myeloma cell lines (IC50 values from 65.8 to 
197.6 µM).4 
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5.2 Aim of the Chapter 
This chapter is focused on a preliminary investigation of the biologic activity of the 
already described Ru(II)-PTA complexes of general formula trans- or cis-
Ru(PTA)4X2 (X = Cl (1, 2), Br (11, 12)), and on the Ru(III)-PTA compound trans-
[RuCl4(PTAH)2]Cl (3) (Figure 5.2, see also Chapter 2).  
 
Figure 5.2. Schematic structures of compounds 1 - 3, 11, 12. 
 
In particular we investigated the chemical behavior of the above compounds in water 
and in physiological buffer, their interactions with two model proteins – cytochrome 
c (cyt c) and ribonuclease A (RNase A) – as well as with a single strand reference 
oligonucleotide (5'-CGCGCG-3', ODN4). Their in vitro cytotoxicities against a 
human colon cancer cell line (HCT-116) and a myeloid leukemia (FLG 29.1) are 
also reported. 
Complex 3 is particularly interesting since it is structurally similar to the two best 
known Ru(III) anticancer complexes, namely NAMI-A (i.e. [imH]trans-
[RuCl4(dmso-S)(im)], im = imidazole) and NKP1339 (i.e. [Na]trans-[RuCl4(ind)2], 
ind = indazole) (Figure 5.3).5,6 
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Figure 5.3. Comparison of the structurally related Ru(III) complexes NAMI-A (left), NKP1339 
(center) and 3 (represented in its anionic form with unprotonated PTA). 
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5.3 Spectrophotometric analysis 
The studied compounds display a remarkable solubility and a sufficient stability in 
water (see Chapter 2), thus being well amenable for biological studies. UV-vis 
absorption spectroscopy was chosen as the election method to monitor the behavior 
of the five complexes. 
The electronic absorption spectra of 1 and 11 in chloroform (Appendix, A5.1) show 
a single band of low intensity in the visible region (max = 452 nm for 1 and 475 nm 
for 11), whereas those of the less symmetric cis isomers (Appendix, A5.2) are 
characterized by a broad band, probably the overlap of two bands, at higher 
frequencies (max = 348 nm for 2 and 368 nm for 12). They are attributed to MLCT 
transitions from Ru(II) to the -acceptor PTA, as in the corresponding Ru(II)-
CH3CN
7 and Ru(II)-dmso8 compounds. Consistent with this assignment, the main 
absorption band of each Br isomer is red-shifted of ca. 20 nm compared to that of 
the corresponding Cl species (bromide, being a better -donor than chloride, leads 
to an increase in the energy of the filled t2g orbitals).
7 The electronic absorption 
spectra of 2 and 12 in pure water and after addition of excess NaCl or NaBr are 
consistent with the NMR findings in D2O (see Chapter 2): both complexes release 
the halide trans to PTA when dissolved in water, forming the aqua species cis-
[RuCl(OH2)(PTA)4]
+ (2aq) and cis-[RuBr(OH2)(PTA)4]
+ (12aq). (Appendix, A5.3-
A5.6; see below the results in phosphate buffer).  
The visible region of the absorption spectrum of 3 in water has the typical halide-to-
Ru(III) charge-transfer manifold typical of all Ru(III) complexes with a similar 
structure 7,8,9,10 a main broad band centered 383 nm and a weaker band at 444 nm 
(Appendix, A5.7). The spectrum shows a very slow decrease of the band intensities 
(ca. –15 % in 72h at room temperature) without significant shifts in the absorption 
maxima (Appendix, A5.7). Such spectral changes are not consistent with slow 
chloride release (in fact, addition of excess NaCl after 72h induces no significant 
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change in the spectrum),7,8,9,10 but rather suggest a progressive aggregation (and 
consequent decrease of the complex concentration), perhaps involving species with 
different charge derived from the deprotonation equilibria of coordinated PTAH+. 
Next, the behavior of the five complexes in a reference buffer at physiological pH 
was monitored over a time period of 24h. Time-dependent spectral profiles for each 
compound are reported in Figure 5.4 (1, 2, 11, 12) and Figure 5.5 (3).  
 
Figure 5.4. Time course UV-vis spectra of compounds 1 (A), 2 (B), 11 (C), and 12 (D) dissolved in 
10 mM phosphate buffer, pH 7.4, over 1 hour. Figures show spectra recorded at t = 0 (black solid 
line), 10 min (red dashed line), 30 min (blue dotted line), and 1h (green dashed-dot line).  
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Figure 5.5. Time course UV-vis spectra of compound 3 dissolved in 10 mM phosphate buffer, pH 
7.4, over 24 hours. Figures show spectra recorded at t = 0 (black solid line), 1h (red dashed line), 6h 
(blue dotted line), 12h (green dashed-dot line), and 24h (brown dashed-dot-dot line).  
 
For the trans isomers 1 and 11, contrary to what observed by NMR spectroscopy in 
D2O, where they are stable, spectral changes occurred within one hour for each 
complex (Figure 5.4A and C): the absorption band in the visible region (456 nm for 
1 and 475 nm for 11) progressively disappeared, whereas the band in the near UV 
region shifted to lower frequencies (325 nm for 1 and 344 nm for 11). These spectral 
changes are ascribed to the progressive release of the halide ligands, even though 
concomitant partial release of PTA cannot be excluded. Conversely, the cis isomers 
2 and 12 displayed a different behavior, similar to that found in pure water (Figure 
5.4B and D): after dissolution of 2 and 12 in the buffer, both complexes showed a 
similar spectrum, with a band at 340 nm, whereas in chloroform solution compound 
12 has a band which is red-shifted of ca. 20 nm compared to that of compound 2 (see 
above). In addition, the spectra in phosphate buffer showed no significant change 
with time, consistent with the NMR findings (in D2O) that evidenced rapid 
equilibration of the cis isomers with the mono- and diaqua species upon release of 
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the halide ligands. The aquation process, that is expected to be more pronounced at 
the concentration used in the UV-vis spectra (compared to NMR), apparently leads 
to the common cis-[Ru(OH2)2(PTA)4]
2+ species.  
The spectrum of compound 3 changed with time in a manner similar (but faster) to 
that observed in pure water (see above) (Figure 5.5). 
 
5.4 Reactions with model proteins 
The interactions of compounds 1 - 3, 11, 12 with the model proteins RNAse and cyt 
c were subsequently monitored by ESI-MS analysis. Results are summarized in 
Figure 5.6 (interaction with cyt c) and in the Appendix (A5.8 - with RNase A). In 
general, as can be judged from the amount of the metallodrug-protein adducts that 
are formed, the reactivity is very limited, in particular with compound 3. 
Nevertheless, careful analysis of ESI mass spectra allowed us to identify the metallic 
fragments that are bound to the proteins. In most cases mono-metallated derivatives 
are formed, in which the metallic fragment consists of the ruthenium center plus a 
variable number of PTA ligands. In particular, Figure 5.6 shows that in the case of 
cyt c the main peaks can be assigned to adducts bearing the fragments [Ru(PTA)]2+, 
[Ru(PTA)2]
2+ and [Ru(PTA)3]
2+, respectively. In some cases fragments containing 
Cl– or Br– were also detected: [RuCl(PTA)2]
+ for compound 1, [RuBr(PTA)4]
+ for 
compound 11, [RuBr(PTA)3]
+ for compound 12, [RuCl3(PTAH)]
+ and 
[RuCl4(PTAH)2]
+ for compound 3. The interactions with RNase A lead to adducts 
that are similar to those obtained with cyt c. Moreover, adducts with [RuCl]+ (for 
compounds 1 and 2) and [RuBr]+ (for compound 11 and 12) were also detected.   
Overall, the interactions detected between the model proteins and the five ruthenium 
complexes are rather modest, suggesting that proteins might not be primary and/or 
relevant targets. 
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Figure. 5.6. LTQ Orbitrap ESI mass spectra of compound 1 (A), 2 (B), 11 (C), 12 (D) and 3 (E) 
dissolved in 20 mM ammonium acetate buffer, pH 7.4, in the presence of cyt c after 24h incubation 
at 37°C. The spectra in the back are the amplification of a region of the front spectra. 
 
5.5 Reactions with a single strand oligonucleotide 
The lack of relevant adduct formation with the selected model proteins, together with 
the evidence in literature that several Pt and Ru-based complexes may exert their 
biological effects through a direct interaction with DNA,11 prompted us to study the 
reactivity of the five ruthenium complexes with a DNA model system.  
Investigations were performed on a single strand oligonucleotide, ODN4, (5'-
CGCGCG-3'), chosen as reference, and the interactions were monitored through 
ESI-MS. In this case adduct formation was far more evident than with model 
proteins, with the exception of compound 3 (Figure 5.7). Adducts between the 
oligonucleotide and ruthenium fragments containing more than one PTA ligand were 
identified. Specifically, the main adduct between ODN4 and the trans isomers 1 and 
11 (Figure 5.7A and C) contains the fragment [Ru(PTA)2]
2+, whereas that with the 
cis isomers 2 and 12 (Figure 5.7B and D) bears [Ru(PTA)3]
2+. Notably, even though 
compound 2 was reacted with ODN4 under the same conditions as the other 
ruthenium complexes, a drastic decay in the intensity of ESI-MS peaks was detected 
A B C
D E
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in this case, which might be tentatively ascribed to the occurrence of 
aggregation/precipitation processes. Nonetheless, a low intensity spectrum could be 
obtained (Figure 5.7B) and peak assignment was performed. It is worth mentioning 
that in this case the peak relative to the free oligonucleotide was not detected after 
24h incubation at 37°C, revealing that all the ODN4 has reacted. The only adduct 
that could be identified was that with the metallic fragment [Ru(PTA)3]
2+.  
In addition to the main adduct, ESI mass spectra of compounds 1 and 11 show peaks 
corresponding to derivatives: 2[Ru(PTA)2]
2+ and [Ru(PTA)2]
2++[RuCl(PTA)3]
+ for 
compound 1, [Ru(PTA)2]
2++[RuBr(PTA)3]
+ and 2[RuBr(PTA)3]
+ for compound 11. 
In the case of compound 12, other mono- and bis-metallated adducts were also 
detected (i.e.  [Ru(PTA)4]
2+ and 2[RuBr(PTA)3]
+).  
The interaction between more inert compound 3 and ODN4 is less evident and only 
small amounts of adducts could be detected. In fact, Figure 5.7E shows two peaks 
corresponding to the adducts between ODN4 and the fragments [Ru(PTA)]3+ and 
[Ru(PTA)2]
3+, while most of the free compound in solution is in the form 
[RuCl4(PTA)]
- or [RuCl4(PTA)2]
- (Appendix, A5.9). 
It is evident that, in agreement with the NMR and UV-vis findings reported above, 
the two cis complexes (2 and 12) are more reactive than the respective trans species 
(1 and 11), and that the adduct formation is more evident with the chloride than with 
the bromide. 
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Figure 5.7. LTQ Orbitrap ESI mass spectra of compound 1 (A), 2 (B), 11 (C), 12 (D) and 3 (E) 
dissolved in milliQ water, in the presence of ODN4 after 24h incubation at 37°C.   
 
5.6 Antiproliferative properties 
The antiproliferative properties of compounds 1 - 3, 11, 12 were assessed against 
two cell lines: HCT-116 (human colon cancer) and FLG 29.1 (human acute myeloid 
leukemia) according to the method described in the experimental section. Both cell 
lines were treated for 24 hours with increasing concentrations of the drug and IC50 
values determined (calculated through the Trypan blue exclusion test). The findings 
are summarized in Table 5.1. In general, the antiproliferative effects are quite 
moderate, yet the two cis isomers 2 and 12 were found to be significantly more 
effective than the trans congeners 1 and 11 in the leukemia cell line, whereas the 
cytotoxicity of compound 3 is far lower. It is also remarkable that the cytotoxic 
profile of 1 is virtually identical to that of 11, and the same similarity was found for 
the two cis isomers 2 and 12. This finding suggests that – in both cases – similar 
halide-free species are ultimately responsible for the biological effects. Such species 
are presumably different for the two stereoisomers because the activity clearly 
depends on the geometry of the complex. These results, together with the reactivity 
A B C
D E
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profiles toward the oligonucleotide, point out that the biological effects may be 
related to the direct interaction of these ruthenium compounds with DNA. 
 
Table 5.1. IC50 values (μM) for compounds 1 - 3, 11, 12 on a solid tumor cell line, HCT 116, and a 
myeloid leukemia cell lines, FLG 29.1. 
Compound FLG 29.1 HCT 116 
trans-RuCl2(PTA)4 (1) >200 >100 
cis-RuCl2(PTA)4 (2) 60.83±0.59 >100 
trans-RuBr2(PTA)4 (11) >200 >100 
cis-RuBr2(PTA)4 (12) 59.33±0.41 >100 
trans-[RuCl4(PTAH)2]Cl·2H2O (3) 84.91±0.39 >100 
Cisplatin 24.33±0.75
12 7.65 ± 0.6313 
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5.7 Conclusions 
In conclusion we found that the chemical behavior of the Ru(II) compounds in 
aqueous solution depends on their structure and on the pH. In pure water, whereas 
the trans isomers 1 and 3 are very stable (in the dark), the cis analogues 2 and 12 
readily equilibrate with the aqua species cis-[RuX(OH2)(PTA)4]
+ and cis-
[Ru(OH2)2(PTA)4]
2+.  However, when dissolved in phosphate buffer at physiological 
pH, also the trans isomers undergo aquation processes that can be mainly ascribed 
to halide replacement.  
In general, compounds 1, 2, 11, 12 showed a pairwise different – structure-related – 
behavior, clearly indicating that the four isomers do not converge to a common 
species but rather to two main halide-free stereoisomeric Ru-PTA fragments. Their 
reactivity towards cyt c and RNase A was found to be quite limited and minimal 
amounts of protein adducts were formed. Compounds 1, 2, 11, 12 exhibited a far 
higher reactivity toward the reference oligonucleotide than toward model proteins 
and substantial amounts of adducts – mainly mono-ruthenated – are indeed formed 
in which ruthenium fragments are coordinated to DNA nucleobases. The two cis 
isomers (2 and 12) turned out to be more reactive than the respective trans species 
(1 and 11). Finally, the four Ru(II) compounds manifested rather moderate 
antiproliferative properties against the two investigated cell lines: HCT-116 (human 
colon cancer) and FLG 29.1 (human acute myeloid leukemia). Consistent with the 
results described above, the cis isomers 2 and 12 were found to be significantly more 
effective than the trans congeners 1 and 11 in the leukemia cell line FLG 29.1. 
The only investigated Ru(III) complex, 3, deserves a separate comment. It was found 
to be very inert, both in pure water and in buffer, and basically unreactive towards 
the investigated biomolecules and devoid of any relevant cytotoxic activity towards 
the investigated cancer cell lines. Given the structural similarity between 3 and well 
known anticancer compounds KP1019/NKP1339 and NAMI-A, these findings were 
particularly disappointing. Nevertheless, they might suggest that for this type of 
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anionic Ru(III) complexes, cytotoxicity is strictly related to the activation kinetics. 
Whereas the lack of cytotoxic activity of NAMI-A has been attributed to the fast 
kinetics that lead to aquated Ru(III) metabolites unable to cross the cell 
membrane,14,15 the scarce activity of 3 might be attributed to exceedingly slow 
kinetics and to the consequential paucity of reactive aqua species. The intermediate 
activation kinetics (i.e. chloride release) of the cytotoxic KP1019/NKP1339 
complexes are apparently in the optimal range for observing in vitro activity. 
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Ru(II) complexes with cppH 
 
6.1 State of the art 
As already described in the Introduction, a metal conjugate is a complex molecule in 
which an organometallic or coordination compound is attached through a linker to 
an organic macromolecule usually with a high molecular weight. The linker is a 
molecule that connects the metal compound to the organic macromolecule; in 
particular, the linker is often a bifunctional chelating agent, that is a molecule with 
two functional groups – which typically point in opposite directions – that binds both 
the organic molecule through an organic bond and coordinates the metal fragment, 
often through a chelating mojety.  
A typical example of linker is 4′-methyl-2,2′-bipyridine-4-carboxylic acid (bpyAc, 
Scheme 6.1), a bidentate diimine that allows for the formation of a covalent bond 
through the carboxylic group in position 4′, i.e. in the opposite direction compared 
to the metal chelation.  
Most examples of bpyAc involve the attachment of redox and/or luminescent metal 
fragments (e.g. polypyridyl Ru(II) complexes1) to the macromolecular component 
(e.g. polymers and peptides,2 PNA sequences,3 porphyrins,4,5 biotin pendants6). 
Even if bpyAc was extensively used as linker, its synthesis is tedious and long. In 
short, bpyAc is made from direct oxidation of 4,4'-dimethyl-2,2'-bipyridine with 
SeO2 followed by treatment of the crude with Ag2O, that further oxidizes the 
intermediates with aldehyde groups (Scheme 6.1); finally bpyAc is separated from 
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the product mixture by Soxhlet extraction. The overall process requires several 
days.7 
 
Scheme 6.1. Synthesis of bpyAc, in red. 
 
With the aim of bypassing the difficulties that affect the preparation and purification 
of bpyAc, in 2009 Spiccia and coworkers introduced an alternative asymmetric 
diimine ligand bearing a single carboxylate functionality, 2-(2′-pyridyl)pyrimidine-
4-carboxylic acid (cppH, Scheme 6.2).8 The synthesis of cppH is a three steps 
reaction (Scheme 6.2): in the first step 2-cianopyridine reacts with ammonia to form 
the intermediate 2-picolinimidamide hydrochloride , that is reacted with 
acetaldehyde dimethylacetal to give 4-methyl-2-(2′-pyridyl)pyrimidine (mpp). The 
final product (actually isolated as cppH·HNO3) is obtained by the oxidation of the 
methyl to carboxylic group with concentrated nitric acid. This preparation is much 
faster than that of bpyAc.8 Moreover, cppH is soluble in a wider range of solvents 
compared to bpyAc. 
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Scheme 6.2. Synthesis of 2-(2′-pyridyl)pyrimidine-4-carboxylic acid (cppH): a) NaOMe, NH4Cl, 
MeOH b) NaOEt, reflux c) HNO3 conc./HCl (1:1 v/v), reflux.   
 
The cppH linker has been used in the preparation of electrochemiluminescent Ru(II)-
bioconjugates with PNA and peptides for biosensing and biomedical applications.9,10 
In addition, the coordinatively saturated and substitutionally inert Ru(II) complex 
[Ru(dppz)2(cppH)](PF6)2 (dppz = dipyrido[3,2-a:2′,3′-c]phenazine) was found to be 
remarkably cytotoxic against different cancer cell lines inducing mitochondria-
mediated apoptosis.10,11 Interestingly, the carboxylic function of cppH was exploited 
for controlling the cytotoxicity of the complex through a light-triggered mechanism 
(“photocaging”):12 conjugation to an appropriate photo-labile protecting group 
(PLGP) through an esteric bond made the complex inactive. The cytotoxic action 
was restored in living cells upon light illumination (λ = 350 nm) that photo-cleaved 
the protecting moiety (Scheme 6.3).   
 
Scheme 6.3. Chemical structure of the photolabile protected (left) and active Ru(II) complex with 
cppH. The caging group is released upon irradiation at 350 nm.12 
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However, unlike bpyAc, cppH can originate linkage isomers. In fact, its pyrimidine 
ring can bind to the metal ion either through the nitrogen atom ortho (No) or para 
(Np) to the carboxylic group linked to C4. Most of the cppH-Ru(II) conjugates 
reported so far were prepared following a synthetic route that led selectively to the 
Np coordination mode.8-12 Nevertheless, an example of the No coordination mode of 
cppH on a Ru(II) fragment had been described in the first report on this linker,8 and 
the group were I did my Thesis recently demonstrated that the two linkage isomers 
[Ru([9]aneS3)(cppH-κNp)(PTA)](Cl)2 and [Ru([9]aneS3)(cppH-κNo)(PTA)](Cl)2 
(50Np and 50No, respectively) are formed in comparable amounts when the Ru(II) 
precursor fac-Ru([9]aneS3)Cl2(PTA) ([9]aneS3 = 1,4,7-trithiacyclononane) is treated 
with cppH in refluxing water (Scheme 6.4).13 For this reason cppH was defined an 
“irresolute linker”. The two isomers were fully characterized individually, both in 
the solid state and in solution.  
 
Scheme 6.4. The formation of the two linkage isomers 50Np and 50No. 
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6.2 Aim of the Chapter 
Since from the relatively few examples of Ru(II)-cppH complexes reported so far it 
was unclear if this linker has any preference for one of the two possible coordination 
modes, we decided to extend our investigation to other Ru(II) precursors and, above 
all, to establish a spectroscopic fingerprint that might allow us to distinguish the 
coordination mode of cppH also in the absence of an X-ray structural 
characterization. 
In this Chapter we investigated the reactivity of three Ru(II) precursors – cis-
RuCl2(dmso)4 (8), trans-RuCl2(dmso-S)4 (9) (see Chapter 1), and trans,cis,cis-
RuCl2(CO)2(dmso-O)2 (29) (see Chapter 2) (Figure 6.1) – towards cppH or, when 
appropriate, its parent compound and (presumed) model 4-methyl-2-(2′-
pyridyl)pyrimidine (mpp) (Figure 6.1) in which a methyl group replaces the 
carboxylic group on the pyrimidine ring.  
The binding mode of cppH and mpp – either through No or Np – was unambiguously 
established through the {1H,15N}- HMBC NMR spectra at natural abundance of 15N 
isotope (see below). 
 
Figure 6.1. The Ru(II) precursors cis-RuCl2(dmso-S)4 (8), trans-RuCl2(dmso-S)4 (9), trans,cis,cis-
RuCl2(CO)2(dmso-O)2 (29), (top) and diimmine linkers with numbering schemes and labels (bottom) 
used in this work. 
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6.3 Reactions with cppH 
Compound trans,cis,cis-RuCl2(CO)2(dmso-O)2 (29) reacts with the model diimine 
bpy, under different reaction conditions, replacing the two dmso-O ligands and 
affording with high selectivity trans,cis-RuCl2(bpy)(CO)2.
14 We found that cppH 
behaves similarly to bpy. Treatment of 29 with cppH in water at room temperature 
affords a small amount of a crystalline colorless product identified from mass and 
NMR spectroscopy as trans,cis-RuCl2(CO)2(cppH) (51) (Scheme 6.5). The single 
crystal X-ray analysis (Figure 6.2) established that cppH is bound via Np, i.e. 51 is 
trans,cis-RuCl2(CO)2(cppH-κNp). Similar results were obtained performing the 
reaction in refluxing water or chloroform (see below). Compound 51 had been 
previously prepared by Spiccia and coworkers upon treatment of the oligomeric 
Ru(II)-carbonyl precursor [Ru(CO)2(Cl)2]n with cppH in refluxing methanol.
8 Our 
X-ray results for compound 51 (space group, unit cell dimensions and atomic 
coordinates) closely agree with those already published,8 including the H-bonding 
scheme of the crystallization water molecule, which is found to interact with the 
carboxylic hydrogen, the carboxylate oxygen and one chlorido ligand belonging to 
three distinct neighboring complex moieties. To be noted that, as in the other 
structurally characterized Ru-(cppH-κNp) complexes,8,13 the carboxylate group is 
basically coplanar with the pyrimidine ring. 
 
Figure 6.2. X-ray molecular structure (50% probability ellipsoids) of trans,cis-RuCl2(CO)2(cppH-
κNp)∙H2O (51). Coordination distances (Å): Ru1–N1 = 2.112(2), Ru1–N2 = 2.103(1), Ru1–Cl1 = 
2.3819(7), Ru1–Cl2 = 2.4010(7), Ru1–C1 = 1.891(3), Ru1–C2 = 1.900(3). 
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Interestingly, when the reaction was performed in methanol (either at room 
temperature or in refluxing conditions) we found that partial esterification of the 
carboxylic group occurs and compound 51 co-crystallizes with its methyl ester 
trans,cis-RuCl2(CO)2(cppCH3-κNp) (51Me).15  
In the X-ray structure (Appendix, A6.21) the asymmetric unit gives an averaged 
composition of the whole crystal, and it shows the presence of both a methanol 
molecule (linked through hydrogen bonds to neighboring complexes) and a methyl 
moiety with reasonable bond lengths. The fraction of complexes with esterified cppH 
was estimated at 55%, refining the occupancy of the associated methoxy carbon atom 
(OCOO–Cmethyl bond length 1.460(5) Å) and of the methanol molecule that occupies 
the same site (OCOOH–Omethanol bond length 2.44(1) Å). In the 1H NMR spectrum a 
new set of six aromatic signals, each one falling very close to – when not altogether 
overlapped with – those of 51, was observed (ESI). A singlet at δ = 4.02, that 
integrates for three protons with respect to the aromatic resonances of 51Me, was 
attributed to the methoxy group.  
In the original preparation by Spiccia and coworkers – performed in methanol –  the 
formation of 51Me was not observed.8  
 
Scheme 6.5. The reaction between 29 and cppH, yielding the two linkage isomers trans,cis-
RuCl2(CO)2(cppH-κNp) (51) and trans,cis-RuCl2(CO)2(cppH-κNo) (52). The nature of compound 52 
was established on the basis of the 15N NMR spectra. 
 
We also found that, regardless of the reaction conditions, a second product (52) is 
always recovered from the mother liquor upon concentration (Scheme 6.5). 
According to elemental analysis, NMR, IR and mass spectroscopy evidence, this 
product is an isomer of 51. The fact that in the 1H NMR spectrum (Figure 6.3) the 
resonances of the pyridyl protons of 52 are basically coincident with those of 51, 
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whereas the two doublets of the pyrimidine protons are shifted upfield (∆δ = –0.36 
ppm for H6 and –0.11 ppm for H5) suggested that 52 is the linkage isomer of 51 in 
which cppH is bound via No, i.e. it is trans,cis-RuCl2(CO)2(cppH-κNo). To be noted 
that in each compound the 1H NMR assignments of H5 and H6 were fully 
confirmed by the 1H-13C HSQC spectra, in which H5 and H6 are coupled to carbon 
resonances that fall at ca. 120 and ca. 160 ppm, respectively (Appendix, A6.5 for 51 
and A6.7 for 52). 
Compound 52, that had not been previously detected, was best obtained in pure form 
when the reaction was performed in water at room temperature. Under these 
conditions, the reaction is basically quantitative and the ratio between 51 and 52 is 
ca. 1:9. A larger amount of 51 was obtained as first precipitate when the reaction was 
performed at higher temperature, however the second fraction was a mixture of 51 
and 52 (refluxing methanol or chloroform), with additional unidentified minor 
species in the case of refluxing water.  
 
Figure 6.3. The 1H NMR spectra (DMSO-d6) of trans,cis-RuCl2(CO)2(cppH-κNp) (51, top) and 
trans,cis-RuCl2(CO)2(cppH-κNo) (52, bottom), obtained as first and second fraction, respectively, by 
treatment of 29 with cppH in water at room temperature (details in experimental section). See Figure 
6.1 for the labeling scheme of cppH. Some minor unidentified peaks in the spectrum of 52 are labeled 
with x. To be noted that 52 was recovered from the mother liquor upon complete removal of the 
aqueous solvent. 
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Nevertheless, even though quite unlikely according to the known reactivity 
between 29 and bpy,14 the spectroscopic data might also be consistent with the 
hypothesis that 52 is the stereoisomer of 51, cis,cis-RuCl2(CO)2(cppH-κNp): in 
fact, in both hypotheses two carbonyl resonances in the 13C NMR spectrum and two 
CO stretching bands in the IR spectrum would be expected. In the absence of crystals 
suitable for X-ray investigation, the nature of 52 was eventually determined through 
15N NMR spectroscopy (see below).  
Our investigation was then extended to the two isomeric Ru(II)-dmso precursors cis-
RuCl2(dmso-S)4 (8) and trans-RuCl2(dmso-S)4 (9). In recent years, the reactivity of 
8 and 9 towards the model diimine bpy was thoroughly investigated by Toyama and 
coworkers.16 They found that bpy selectively replaces two dmso ligands and – by a 
careful choice of the reaction conditions – all the three possible stereoisomeric 
products, namely trans,cis-Ru(bpy)Cl2(dmso-S)2, cis,cis-Ru(bpy)Cl2(dmso-S)2, and 
cis,trans-Ru(bpy)Cl2(dmso-S)2 (Figure 6.4), were individually isolated and fully 
characterized. The all-cis complex was found to be the thermodynamically most 
stable isomer.17   
 
Figure 6.4. The three stereoisomers of Ru(bpy)Cl2(dmso-S)2. 
 
We found that treatment of both 8 and 9 with cppH under different reaction 
conditions afforded only small amounts of products, whose NMR spectra had 
exclusively very broad – almost undetectable – signals. These unexpected findings 
suggested that cppH reacts with 8 and 9 as a bridging ligand, both through the 
diimine unit and the carboxylic group, replacing more than two ligands in the 
precursors and thus leading to oligomeric species (that typically give broad NMR 
resonances). For this reason, we decided to investigate 4-methyl-2-(2′-
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pyridyl)pyrimidine ligand (mpp) instead of cppH. The presence of a methyl in 
position 4 instead of the –COOH group was anticipated to eliminate the undesired 
reactivity and – given the similarity between the two diimines – mpp might be 
considered as a good model for cppH. 
 
6.4 Reactions with mpp 
In principle, assuming that mpp reacts with 8 and 9 similarly to bpy,16 four 
stereoisomeric products can be expected (being mpp unsymmetrical, two all-cis 
isomers are possible), each of them potentially as a pair of linkage isomers depending 
on the binding preference of the pyrimidine ring. The dmso resonances in the 1H 
NMR spectra are anticipated to be essential for determining the geometry of the 
products.18,19  
Treatment of cis-RuCl2(dmso-S)4 (8) with mpp in refluxing ethanol afforded a deep-
red solution, from which two types of crystals of the same color, in comparable 
amounts, were obtained. They were manually separated under the microscope and 
characterized individually by NMR spectroscopy as the two isomers cis,trans-
RuCl2(dmso-S)2(mpp) (53, Figure 6.5) and cis,cis-RuCl2(dmso-S)2(mpp) (54, Figure 
6.5). Some crystals suitable for X-ray analysis turned out to be of compound 54. The 
X-ray analysis established that in both cases (X-ray quality crystals of 53 were 
obtained by a different route, see below) mpp is bound via Np, and that in 
compound 54 the pyridyl ring of mpp is bound trans to dmso-S. 
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Figure 6.5. The X-ray molecular structures (50% probability ellipsoids) of cis,trans-RuCl2(dmso-
S)2(mpp-κNp) (53, left) and cis,cis-RuCl2(dmso-S)2(mpp-κNp) (54, right). Coordination distances (Å): 
53: Ru1–N11 = 2.057(2), Ru1–N12 = 2.056(3), Ru1–Cl1 = 2.426(1), Ru1–Cl2 = 2.427(1), Ru1–S1 = 
2.1981(9), Ru1–S2 = 2.2977(9). 54: Ru1–N11 = 2.0525(12), Ru1–N12 = 2.1025(12), Ru1–Cl1 = 
2.4396(4), Ru1–Cl2 = 2.4193(4), Ru1–S1 = 2.2742(4), Ru1–S2 = 2.2441(4). 
 
The structure of 53 can be compared with that of the equivalent complex cis,trans-
RuCl2(dmso-S)2(bpy) (determined at 298K).
16 Replacement of the pyridyl ring of 
bpy with the 4-methyl-pirimidine ring of mpp leads to no significant difference in 
the corresponding Ru–N bond length (an overall bond contraction, from 2.083(5) to 
2.056(3) Å in 53, can be fully ascribed to the lower temperature used for data 
collection in this work). The same is valid for the Ru–S bond lengths. It is worth 
mentioning that the dmso-S ligands (observed along the S–Ru–S direction) are 
eclipsed in 53, whereas they are staggered in the bpy complex, most likely due to a 
packing effect. Also the single-crystal X-ray structure of 54 is tightly correlated to 
that of the equivalent bpy complex cis,cis-RuCl2(dmso-S)2(bpy) (determined at 
296K).16 Both molecules are chiral and both crystallize as racemic mixtures in 
centrosymmetric space groups. No significant difference in the coordination sphere 
was found between the two compounds. 
The 1H NMR spectra of both products contain a single set of mpp resonances (Table 
6.1). Consistent with the geometries found in the solid state, the spectrum of 53 has 
two singlets (6H each) in the dmso-S region (the two equivalent dmso ligands 
have diastereotopic methyls) at δ = 3.18 and 2.98, whereas the spectrum of 54 
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has four singlets (3H each) in the same region at δ = 3.53, 3.51, 3.30, and 2.59 
(Figure 6.6). The very upfield shifted resonance at δ = 2.59 ppm (correlated in 
the 1H-1H COSY spectrum to that at 3.30 ppm, Appendix A6.12) is attributed 
to the methyl group of the dmso-S trans to Cl, that sits on top of mpp and feels 
its shielding cone. A similar effect had been found in the spectrum of the 
corresponding bpy complex.16 The singlet of the methyl group of mpp (δ = 2.71) 
was unambiguously attributed through the 1H-13C HSQC spectrum (Appendix, 
A6.13), as it correlates with a carbon resonance at ca. 25 ppm, whereas the dmso 
carbon resonances fall at ca. 45 ppm. The proton NMR spectrum of 54 contained 
also a minor set, with the same number of resonances, attributable to another isomer 
with all-cis geometry, cis,cis-RuCl2(dmso-S)2(mpp) (55). This species – that was 
more abundant in the second batch of precipitate obtained from the concentrated 
mother liquor of the reaction – might be either the stereoisomer of 54, in which the 
pyridyl ring of mpp is bound trans to Cl, or one of the two possible all-cis linkage 
isomers in which mpp is bound via No. The nature of 55 was established by 15N 
NMR spectroscopy (see below). 
We found that when the reaction between 8 and mpp was repeated under milder 
conditions (e.g. shorter reaction time and/or lower temperature), the amount of 
compound 54 in the isolated mixture decreased. For example, operating in refluxing 
methanol or chloroform, the product is a ca. 4:1 mixture of 54 and 55, thus allowing 
us to assign the NMR resonances of 55. Viceversa, when the reaction was performed 
for longer reaction times and/or at higher temperature (e.g. refluxing toluene) 
compound 53 was the prevailing product, suggesting that it is the thermodynamic 
most stable isomer. This issue, however, was not investigated in detail since it was 
not the main scope of our work. 
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Figure 6.6. The region of the methyl resonances in the 1H NMR spectra (CDCl3) of cis,trans-
RuCl2(dmso-S)2(mpp-κNp) (53, bottom, with minor amounts of 54 and 55), a mixture of the two 
cis,cis-RuCl2(dmso-S)2(mpp-κNp) isomers (54 + 55, middle), and trans,cis-RuCl2(dmso-S)2(mpp-
κNp) (56, top). In the central spectrum, the eight dmso-S resonances are labeled with the number of 
the corresponding complex. The peak of residual free DMSO is labeled with x. 
 
Consistent with the known reactivity of 9,16,19 treatment of this precursor with mpp 
at room temperature (90 min) afforded, upon concentration, crystals of trans,cis-
RuCl2(dmso-S)2(mpp) (56). The X-ray structure established the geometry of the 
complex and that, also in this case, mpp is bound via Np (Figure 6.7). Comparison 
with the X-ray structure of the analogous bpy derivative trans,cis-Ru(bpy)Cl2(dmso-
S)2 shows that the orientation of the two dmso-S ligands is the same in both 
compounds:16 one dmso points its O atom towards the N–N ligand, whereas the other 
is oriented such that the ring plane of the diimine bisects its S–CH3 bonds. As already 
noted for the bpy derivative, we also find a considerable distortion of the N–N–S–S 
equatorial plane. These observations add support to the hypothesis, put forward by 
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Toyama and coworkers,16 of a high level of steric hindrance on the equatorial plane, 
with the observed conformation of the dmso ligands being the only one energetically 
allowed in the solid state. Additional evidence comes from the comparison of the 
coordination distances. Even though the diffraction measurements were done at 
296K for the bpy complex and at 100K in our case, only the Ru–Cl bond distances 
show a significant contraction (2.416(1), 2.400(1)16 vs. 2.3825(6), 2.3927(6)), 
whereas the bond distances in the equatorial plane are almost unchanged (Ru–S: 
2.273(1), 2.309(1)16 vs 2.2647(6), 2.3002(5); Ru–N: 2.124(3), 2.127(3)16 vs. 
2.1258(17),2.1343(17)). The steric encumbrance in the equatorial plane might 
explain the instability of this species towards isomerization (see below). 
 
Figure 6.7. The X-ray molecular structure (50% probability ellipsoids) of trans,cis-RuCl2(dmso-
S)2(mpp-κNp) (56). A disordered CH3OH crystallization molecule is also shown. Coordination 
distances (Å): Ru1–N31 = 2.1343(17), Ru1–N32 = 2.1258(17), Ru1–Cl1 = 2.3825(6), Ru1–Cl2 = 
2.3927(6), Ru1–S1 = 2.3002(5), Ru1–S2 = 2.2647(6). 
 
In accord with this geometry (the two dmso-S ligands are inequivalent but have 
equivalent methyls), two partially overlapped and equally intense singlets are 
found in the dmso-S region of the 1H NMR spectrum (δ = 3.56, Figure 6.6). 
Compound 56 turned out to be an intermediate in the formation of the three 
isomers 53-55. In fact, if the rapid precipitation of 56 was not induced and the 
mother liquor was slowly saturated with diethyl ether over a period of hours, 
a mixture of 54 (crystals suitable for X-ray analysis) and 55, with 55 prevailing 
(ca. 2:3) was obtained. A mixture of 53-55 remained in the mother liquor. 
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Similarly, if the crystals of 56 were not removed from the mother liquor they 
slowly redissolved (days), eventually affording a mixture of 53-55 upon 
addition of diethyl ether. The NMR spectra of mixtures of 53-55 in CDCl3 did 
not change with time, indicating that these three isomers are not in equilibrium 
at room temperature. Attempts to obtain crystals of 55 suitable for X-ray 
analysis were unsuccessful.  
The reactivity of the Ru(II)-dmso precursors 8 and 9 towards mpp is 
summarized in Scheme 6.6, and basically is consistent with the findings by 
Toyama and coworkers on the corresponding bpy complexes.16 
 
Scheme 6.6. The reactivity of precursors 8 and 9 towards mpp. The nature of compound 55 was 
established on the basis of the 15N NMR spectra. 
 
Table 6.1 summarizes the 1H NMR resonances of mpp in the four isolated 
products. It is quite obvious that some resonances (in particular those of H6 
and H6') are remarkably affected by the geometry of the complex. 
Nevertheless, even though the X-ray structures establish that in 53, 54 and 56 
mpp binds to ruthenium via Np, we were unable to find a clear-cut trend in the 
proton resonances that might be used to determine unambiguously (in the 
absence of a crystal structure) the nature of compound 55 (in particular with 
regard to the binding mode of mpp). 
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Table 6.1. 1H NMR chemical shifts (δ, ppm) of the mpp ligand in compounds 53 – 56.a 
 53 54 55 56 
H6' 9.58 9.79 9.51 8.96 
H6 9.58 9.62 9.79 10.30 
H3' 8.54 8.69 8.69 8.78 
H4' 7.97 8.08 7.97 8.02 
H5' 7.60 7.70 7.54 7.57 
H5 7.29 7.32 7.42 7.33 
Me 2.69 2.71 2.76 2.71 
a See Figure 6.1 for labeling scheme. 
 
6.5 {1H,15N}- HMBC NMR experiments 
Given the above mentioned limits of 1H NMR spectroscopy, we decided to 
investigate if the 15N NMR resonances can provide a spectroscopic fingerprint 
for determining the binding mode of cppH and mpp unambiguously. For this 
purpose we performed {1H,15N}- HMBC NMR experiments at natural abundance 
of the 15N isotope to measure the 15N chemical shifts, both in the free ligands 
and in the complexes. In these experiments, the careful choice of the coupling 
constants nJ(15N, 1H) (n = 2, 3) is of paramount importance. Each 15N 
resonance was assigned on the basis of the cross peak(s) with the proton(s) 
closest to the N atom in the molecule, namely H6 for Np, H5 (and –CH3 in 
mpp) for No and H6' for Npy. A first series of experiments was performed on 
cppH∙HNO3 and mpp, testing several values of the scalar coupling constants 
in the range from 1.2 to 12 Hz (with increments ranging from 0.1 to 2 Hz). The 
value of 11 Hz was established as the most suitable for 2J(15N, 1H), i.e. for 
observing the coupling between H6 and Np, as well as between H6' and the 
pyridyl N atom Npy. A value of 1.8 Hz was instead found to be optimal for 
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3J(15N, 1H), i.e. for observing the coupling between H5 and both Np and No 
(Appendix, A6.2). Both coupling constants were subsequently used for the 
experiments on each complex (a value of 1.7 Hz for 3J, instead of 1.8 Hz, was 
found to give better results), producing sets of complementary data that 
allowed us to distinguish between coordinated and unbound nitrogen atoms. 
In other words, the experiments performed with the smallest coupling constant 
afforded the chemical shift of No, whereas those performed with the larger 
value of J afforded the chemical shifts of Np and Npy. The spectra of 51 and 52 
are shown in Figure 6.8. In order to validate the method of analysis on a larger 
set of compounds, the measurements were performed also on the two cppH 
linkage isomers [Ru([9]aneS3)(cppH-κNp)(PTA)](Cl)2 and [Ru([9]aneS3)(cppH-
κNo)(PTA)](Cl)2 (50Np and 50No, respectively, Appendix A6.3) that we had fully 
characterized previously.13 The 15N resonances for free ligands and for the 
complexes, together with the coordination induced shift (CIS) values, are 
reported in Table 6.2 (cppH) and 6.3 (mpp).  
 
Table 6.2. 15N NMR chemical shifts (δ, ppm vs CH3NO2, DMSO-d6) for cppH·HNO3 and for 
the cppH ligand in compounds 50Np, 50No, 51, and 52. Numbers in parentheses are the CIS 
values calculated as δcomplex– δligand. 
 cppH·HNO3 50Np 50No 51 52 
Npy –136.6 –150.4 (–13.8) –150.6 (–14.0) –126.5 (10.1) –126.5 (10.1) 
Np –84.1 –150.1 (–66.0) –95.1 (–11.0) –130.2 (–46.1) –86.2 (–2.1) 
No –95.5 –92.0 (3.5) –170.6 (–75.1) –108.9 (13.4) –143.6 (–48.1) 
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Figure 6.8. {1H,15N}-HMBC spectra of trans,cis-RuCl2(CO)2(cppH-κNp) (51, top) and trans,cis-
RuCl2(CO)2(cppH-κNo) (47, bottom) in DMSO-d6 with J = 11 Hz (left) and J = 1.7 Hz (right). 
 
The 15N resonances of free cppH show that in DMSO the pyridyl nitrogen – 
i.e. the most basic site of the ligand – is protonated by HNO3. For this reason 
its chemical shift is so remarkably upfield shifted compared to those of the N 
atoms on the pyrimidine ring as well as to the typical values expected for a 
free nitrogen atom in a pyridyl ring (cfr also the chemical shift of the 
corresponding unprotonated N atom in free mpp, Table 6.3).20,21 The results 
obtained with 50Np, 50No and 51 clearly showed that coordination to Ru(II) 
induces a remarkable upfield shift for the 15N resonance (except for that of Npy, 
see above), with CIS values ranging from ca. –45 to  –75 ppm, whereas the 
unbound N atom resonates at a frequency similar to that of the free ligand (CIS 
values from –11.0 to +13.4 ppm). Our results are consistent with the literature 
data indicating that the binding of imine nitrogen atoms to Ru(II) involves significant 
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15N shielding effects, thus resulting in negative CIS values.20 The differences in the 
chemical shifts of the bound Np atoms observed between 51 and 50 are 
attributable to the different ligand environment and charge of the species. 
Finally, the 15N chemical shifts measured for 52 clearly indicate that in this 
complex cppH is indeed bound via No, and 52 is therefore the linkage isomer 
of 51, i.e. trans,cis-RuCl2(CO)2(cppH-κNo) (Figure 6.8).  
Similar experiments were performed on mpp and on its four complexes. The 
results are reported in Table 6.3 (see also Appendix, A6.8 for the {1H,15N}-
HMBC spectrum of mpp, A6.14-A6.16 for {1H,15N}-HMBC spectra of 53-55 and 
A6.19, A6.20 for the {1H,15N}-HMBC spectrum of 56). From the values of 15N 
chemical shifts of the pyrimidine N atoms it can be concluded that also in 55 
mpp is bound via Np and therefore this complex is the missing all-cis 
stereoisomer rather than the linkage isomer of 54. 
 
Table 6.3. 15N NMR chemical shifts (δ, ppm vs CH3NO2, CDCl3) for the mpp ligand free and 
in compounds 53-56. Numbers in parentheses are the CIS values calculated as δcomplex–δligand. 
 mpp 53 54 55 56 
Npy –71.2 –145.0 (–73.8) –130.7 (–59.5) –135.9 (–64.7) –124.6 (–53.4) 
Np –101.2 –160.4 (–59.2) –153.4 (–52.2) –147.6 (–46.4) –143.3 (–42.1) 
No –92.5 –90.2 (2.3) –87.7 (4.8) –88.7 (3.8) –89.5 (3.0) 
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6.6 Conclusions 
First of all, we demonstrated that the 15N NMR chemical shifts of the diimine linker 
2-(2′-pyridyl)pyrimidine-4-carboxylic acid (cppH), obtained through {1H,15N}-
HMBC NMR spectra at natural abundance of the 15N isotope, unambiguously 
establish the coordination mode of the pyrimidine ring (either via No or Np). In fact, 
coordination of cppH to Ru(II) induces a marked upfield shift for the resonance 
of the N atoms directly bound to the metal, with coordination induced shifts 
(CIS) ranging from ca. –45 to –75 ppm, depending on the complex, whereas 
the unbound N atom resonates at a frequency similar to that of the free ligand. 
Similar results were found for the complexes of the parent diimmine ligand 4-
methyl-2-(2′-pyridyl)pyrimidine (mpp). This ligand, having a methyl instead of 
the –COOH group in position 4 of the pyrimidine ring, cannot be exploited as 
a linker but, given the strict similarity with cppH, was considered as a good 
model thereof. When the 15N chemical shifts of the pyrimidine N atoms in the 
free ligands are compared (Table 6.2 and 6.3), it is clear that Np is affected 
much more than No by the nature of the substituent on position 4. The 
replacement of the electron-donor group –CH3 (mpp) with the electron-
withdrawing group –COOH (cppH) induces a remarkable shift to higher 
frequency of the Np resonance (–101.2 vs –84.1 ppm). 
Our method was first validated on a number of Ru(II) complexes with either 
cppH or mpp in which the coordination mode of the diimine was known from 
X-ray structure determinations, and then it was used to determine the ligand 
binding mode in two complexes, namely 52 and 55, for which the X-ray 
structure was not available. More specifically, we investigated the reactivity 
of the Ru(II) carbonyl complex trans,cis,cis-RuCl2(CO)2(dmso-O)2 (29) towards 
cppH. Compound 29 proved once more to be an excellent precursor for the selective 
preparation of trans,cis-RuCl2(CO)2(N-N) complexes when treated with diimines (N-
N), including cppH. Most importantly, cppH confirmed to be an “irresolute linker”, 
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as we had previously found in its reaction with the Ru(II) precursor fac-
Ru([9]aneS3)Cl2(PTA) that afforded comparable amounts of the two linkage 
isomers [Ru([9]aneS3)(cppH-κNp)(PTA)](Cl)2 and [Ru([9]aneS3)(cppH-
κNo)(PTA)](Cl)2 (50Np and 50No, respectively).13 In fact, we found that treatment 
of 29 with cppH affords both linkage isomers trans,cis-RuCl2(CO)2(cppH-κNp) (51) 
and trans,cis-RuCl2(CO)2(cppH-κNo) (52), with 52 largely prevailing when the 
reaction is performed in water at room temperature. The binding mode of cppH in 
compound 52 was established through the 15N NMR experiments. Typically, in all 
solvents investigated (i.e. water, chloroform, methanol) 51 precipitates 
spontaneously whereas 52, more soluble, is found only when the mother liquor is 
analyzed. Most likely for this reason compound 51 had been already prepared – even 
though from a different Ru(II)-carbonyl precursor – and fully characterized, whereas 
its linkage isomer 52 had escaped detection. It is quite remarkable that in this case, 
unlike in that of 50Np and 50No, each linkage isomer can be easily obtained in 
pure form by exploiting their different solubility properties. Thus, using 
compounds 51 and 52 as precursors, the preparation of isomeric Ru-conjugates 
that differ only in the orientation of the organic macromolecule (e.g. a peptide 
or a porphyrin) and the assessment of their individual properties might eventually 
become possible. 
We also found that when the reaction between 29 and cppH is performed in 
methanol, partial esterification of the carboxylic group occurs and a mixture of 51 
and of trans,cis-RuCl2(CO)2(cppMe-κNp) (51Me) cocrystallizes. The single crystal 
X-ray structures of both pure 51 and of this mixture were determined. 
The Ru(II)-dmso precursors cis-RuCl2(dmso-S)4 (8) and trans-RuCl2(dmso-S)4 (9) 
turned out to be unsuitable for the preparation of cppH complexes, since they 
originate oligomers. Conversely, their reactivity with mpp is similar to that observed 
with bpy.24 All the four possible stereoisomers – namely cis,trans-RuCl2(dmso-
S)2(mpp-κNp) (53), the two cis,cis-RuCl2(dmso-S)2(mpp-κNp) isomers (54 + 55), and 
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trans,cis-RuCl2(dmso-S)2(mpp-κNp) (56) – were obtained and individually 
characterized through NMR spectroscopy. The X-ray structures of three of them, 53, 
54, and 56, were also determined. According to 15N NMR spectroscopy, and in 
agreement with the X-ray structures, in all cases mpp is always bound via Np. No 
trace of No linkage isomers was found for the mpp complexes. When this behavior 
is compared with that of cppH, it can be concluded that mpp is not such a good model 
for cppH. As suggested by the comparison of the 15N chemical shift values of Np in 
the free ligands the methyl group in position 4 makes the trans N atom a better 
nucleophile compared to cppH and the Np coordination mode becomes largely 
preferred over the alternative No.  
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Novel Ru(II) bioconjugates with neurotensin 
 
7.1 State of the art 
As mentioned in the Introduction, the synthesis and biological evaluation of metal-
bioconjugates is an active field of the bioinorganic field, with applications in 
radiolabeling, biosensing, as well as anticancer and antimicrobial drug 
development.1  
Among the investigated biomolecules, particularly interesting are the receptor-
binding peptides, such as neurotensin (NT) and ocreotide, an analogue of 
somatostatin. Such peptides have a high affinity for receptors that are overexpressed 
in several tumors so they can be used to selectively internalize the bound metal into 
target cancer cells in the so-called “trojan horse approach”.2,3  
Neurotensin (NT) is a tridecapeptide hormone with primary structure pGlu-Leu-Tyr-
Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu that is recognized by three NT receptors 
(NTR1–3). All three receptors recognize the C-terminal hexapeptide sequence 
NT(8–13), which is thus sufficient for recognition and binding (Figure 7.1).  
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Figure 7.1. Schematic representation of Neurotensin; the red box indicates the fragment 8-13. 
 
Since both NTR1 and NTR3 are upregulated in several human cancers such as colon, 
pancreatic, prostate, and lung cancer,4 bioconjugates with this peptide, in particular 
the fragment NT(8-13), are interesting candidates for antiproliferative applications. 
In the literature there are some examples of bioconjugates with the NT, in which the 
peptide is bound – through a peptidic bond – either to a functionalized arene of a 
ferrocene or ruthenocene derivative,5 or to a platinum(IV) moiety through its 
succinate axial ligands (Figure 7.2).6  
 
Figure 7.2. Schematic representation of Platinum(IV) precursor (R = R′ = OH) and two derivatives 
with neurotensin: the mono-conjugate (R = OH, R′ = NT(8-13)) and the bis-conjugate (R = R′ = NT(8-
13). 
 
NT(8-13) 
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7.2 Aim of the Chapter 
This Chapter describes the synthesis and characterization of novel Ru(II) 
bioconjugates with potential antitumor activity. The bioconjugates were prepared 
during a six-month stage in the group of Prof. Nils Metzler-Nolte at the University 
of Bochum (Germany), who has a consolidate experience in the preparation, 
characterisation and utilisation of novel metal-bioconjugates with peptides and other 
biomolecules.  
In Chapter 6 we described the synthesis of two Ru(II) complexes with the diimine 
linker cppH that are linkage isomers: trans,cis-RuCl2(CO)2(cppH-κNp) (51) and 
trans,cis-RuCl2(CO)2(cppH-κNo) (52) (Figure 7.3). Previously, cppH has been used 
in the preparation of Ru(II)-bioconjugates with PNA and peptides for biosensing and 
biomedical applications; in all the reported examples the ligand was always bonded 
through the para nitrogen atom of the pyrimidine ring.7,8 
 
Figure 7.3. Schematic representation of the precursors trans,cis-RuCl2(CO)2(cppH-κNp) (51) and 
trans,cis-RuCl2(CO)2(cppH-κNo) (52). 
 
We argued that the two linkage isomers 51 and 52 might offer – in principle – the 
unique opportunity to prepare unprecedented stereoisomeric Ru-bioconjugates that 
differ only in the orientation of the organic macromolecule with respect to the metal 
fragment, and to investigate if they behave differently in terms of activity/selectivity 
in biological experiments. Thus, the cppH carboxylic group of both isomers was 
exploited for linking the C-terminal hexapeptide sequence of neurotensin, NT(8–13) 
(Arg-Arg-Pro-Tyr-Ile-Leu or RRPYIL), which is sufficient for recognition and 
binding. Cytotoxicity assays against three different cell lines: colon adenocarcinoma 
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(HT-29), breast cancer (MCF-7) and pancreatic cancer (PT-45), were selected as 
biological tests to be performed both on the precursors and bioconjugates. 
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7.3 Synthesis of bioconjugates 
 NT(8-13) was synthesized by Solid Phase Peptide Synthesis (SPPS, see the 
Experimental Part for details), then the same procedure was used for preparing the 
desired bioconjugates by forming a peptide bond between the terminal arginine of 
the peptide and the carboxylic group of cppH in both linkage isomer 51 and 52. 
For the complex 52 (No isomer) it was possible to isolate the bioconjugate 57 
adapting a previously established peptide coupling procedure.10 After purification of 
the reaction product with preparative HPLC (in general, every bioconjugate was 
purified using preparative HPLC), analytical HPLC showed a single peak 
(performed with a linear gradient of A (H2O/CH3CN/TFA 95:5:0.1, v/v/v) and B 
(CH3CN/H2O/TFA 95:5:0.1, v/v/v) (TFA = Trifluoroacetic Acid), retention time 
(Rt) 18.2 min), suggesting that the product 57 was in pure form. In the ESI MS 
spectrum the molecular peak [M+H]+ at 1227.3 m/z was consistent with the expected 
product (1226.6 m/z) (Scheme 7.1). At this stage, however, it was impossible to 
establish the binding mode of the cppH linker in 57. In addition, given that the HPLC 
elution time of the conjugate is mainly dictated by the peptide fragment (51, 52, 
NT(8-13) and cppH-NT have Rt of 12.2, 10.5, 15.9 and 16.4 min respectively),  it 
cannot be excluded that compound 57 is actually a mixture of the two possible 
linkage isomers, provided that they have undistinguishable retention times. 
Scheme 7.1. The last step of the synthesis of 57 using SPPS. (a) Fmoc deprotection, (b) washing the 
resin with 4×DMF and 3×DCM, (c) coupling for 1h (coupling mixture: PyBOP/DIPEA 5/10), (d) 
washing the resin with 4×DMF and 3×DCM. (PyBOP = benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate, DIPEA = N,N-Diisopropylethylamine). R is the 
peptide sequence: Arg-Arg-Pro-Tyr-Ile-Leu. 
 
The behavior of the Np isomer 51 was different: it was not possible to isolate a 
bioconjugate, because none of the mixtures of coupling agents tried for different 
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reaction times (from 1 to 7 days), either at room temperature or using a microwave 
(60°C or 80°C), led to a product in acceptable yield.  
Given these results, a different synthetic strategy for obtaining the bioconjugates was 
explored. NT(8-13) was first linked to cppH through a peptidic bond between the 
carboxylic group of cppH and the amino group of the terminal arginine using SPPS. 
The cppH-NT moiety was deprotected and cleaved from the resin, and then it was 
reacted with the Ru(II) precursor trans,cis,cis-RuCl2(CO)2(dmso-O)2 (29) in 
aqueous solution at room temperature, i.e. under the conditions that, with cppH, lead 
to a mixture of the two linkage isomers 51 and 52 (see Chapter 6).  
Treatment of 29 with cppH-NT at room temperature for 60h, during which time the 
solution color changed from pale yellow to orange, afforded a bioconjugate whose 
ESI MS and analytical HPLC signatures were equal to those of the bioconjugate 57 
described above. Thus, the two synthetic pathways described in Schemes 7.1 and 7.2 
led to the same product 57, within the above mentioned limits. NMR characterization 
was planned to define the coordination mode of cppH to the ruthenium center (see 
below).  
 
Scheme 7.2. The alternative synthesis of 57. R is the peptide sequence: Arg-Arg-Pro-Tyr-Ile-Leu. 
 
Given its good reactivity, the peptide-functionalized cppH was reacted also with two 
additional Ru(II) precursors, Ru([9]aneS3)Cl2(dmso) (58), and 
Ru([9]aneS3)Cl2(PTA) (59) (PTA = 1,3,5-triaza-7-phosphaadamantane). These 
complexes, whose reactivity towards chelating diimines is known, were chosen 
because the face-capping tridentate ligand [9]aneS3 gives a geometrical restrain that 
reduces the number of possible stereoisomers with asymmetric ligands such as cppH.  
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It is known from the literature that treatment of 58 with a chelating diimine such as 
2,2′-bipyridine (bpy) in refluxing ethanol for 1 hour leads selectively to 
[Ru([9]aneS3)Cl(bpy)]Cl.
9  
Similarly, we found that [Ru([9]aneS3)Cl(cppH)]Cl (60) precipitates spontaneously 
when 58 is reacted with unmodified cppH in refluxing water. X-ray quality crystals 
of 60 were obtained upon slow evaporation of the mother liquor after removal of the 
precipitate (Scheme 7.3). Ethanol was avoided as solvent in order to prevent the 
esterification of the carboxylic group, as observed in Chapter 6. The model 
compound 60 was fully characterized by NMR spectroscopy, mass spectrometry, 
and its single-crystal X-ray structure was also determined (Figure 7.4).  
 
Scheme 7.3. Synthesis of [Ru([9]aneS3)Cl(cppH)]Cl (60). 
 
The single crystal X-ray analysis established that cppH is bound via Np, i.e. 60 is 
[Ru([9]aneS3)Cl(cppH-κNp)]Cl. The 1H NMR spectrum in D2O shows two pairs of 
six resonances for cppH, due to the chloride hydrolysis equilibrium of compound 60 
with the corresponding aqua species 60aq. In 60aq the aromatic resonances are 
slightly downfield shifted (ca 0.1 ppm) compared to those of the parent complex, and 
their relative intensity decreases upon adding an excess of NaCl (Appendix, A7.1).  
Compound 60 was obtained also when the reaction between 58 and cppH was 
performed at room temperature, i.e. in the conditions that in the case of 29 led to the 
isolation of the No isomer 52. In this case, the formation of the No isomer of 60 was 
not observed. 
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Figure 7.4. X-ray molecular structures (50% probability ellipsoids) of [Ru([9]aneS3)Cl(cppH-
κNp)]Cl (60). The chloride is omitted for clarity. Coordination distances in ångström (Å): 60: Ru1–
Cl1 = 2.4319(7), Ru1–N31 = 2.094(3), Ru1–N32 = 1.092(3), Ru1–S21 = 2.304(1), Ru1–S22 = 
2.2936(9), Ru1–S23 = 2.2785(9).  
 
The conjugate 61 was obtained in pure form, according to the analytical HPLC, from 
the reaction between 58 and cppH-NT in water at 80°C for 5h (Scheme 7.4); in this 
case the color of the solution changed from yellow to deep red during the reaction. 
The molecular peak found in the ESI MS spectrum (1394.4 m/z) is in agreement with 
that expected for the cationic species [Ru([9]aneS3)Cl(cppH-NT)]
+ (1394.2 m/z).  
 
Scheme 7.4. Synthesis of bioconjugate 61. R is the peptide sequence: Arg-Arg-Pro-Tyr-Ile-Leu. 
 
As already stated in Chapter 6, the complex Ru([9]aneS3)Cl2(PTA) (59) reacts in 
refluxing water with cppH forming both linkage isomers [Ru([9]aneS3)(cppH-
κNp)(PTA)](Cl)2 and [Ru([9]aneS3)(cppH-κNo)(PTA)](Cl)2 in ca 3/2 ratio (they 
could be separated after recrystallization by manual separation of the different types 
of crystals).10 
The reaction between 59 and cppH-NT was performed at 80°C in water for 8h and 
afforded the bioconjugate 62 (Scheme 7.5). The reaction was accompanied by a color 
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change from yellow to red. According to the analytical HPLC, the bioconjugate was 
pure and the value of the molecular peak in the ESI MS spectrum (1438.6 m/z) was 
consistent with the expected product ([M–H]+ 1438.4 m/z). 
 
Scheme 7.5. Synthesis of bioconjugate 62. R is the peptide sequence: Arg-Arg-Pro-Tyr-Ile-Leu. 
 
As before with 57, also with 61 and 62 it was not possible, at this stage, to assess the 
binding mode of cppH or even if each product was actually pure or a mixture of the 
two possible linkage isomers (assuming that they have equal retention times at HPLC 
analysis). 
 
7.4 NMR characterization 
All the prepared bioconjugates were characterized by NMR spectroscopy for 
determining the coordination mode of the cppH-NT unit to the ruthenium center. 
Resonances were assigned through conventional 1H-1H COSY and 1H-13C HSQC 
NMR spectra. 
The 1H NMR spectrum in DMSO-d6 of bioconjugate 57 obtained using SPPS from 
trans,cis-RuCl2(CO)2(cppH-κNo) and NT(8-13) presents six well resolved signals for 
coordinated cppH in the aromatic region. The comparison with the NMR spectra of 
the two linkage isomers trans,cis-RuCl2(CO)2(cppH-κNp) (51) and trans,cis-
RuCl2(CO)2(cppH-κNo) (52) suggests that in this bioconjugate the cppH-NT is 
bonded through the Np (Figure 7.5, see also Table 7.1). In fact, all the signals of 57 
have chemical shifts very similar to those of 51 except for H3′ on the pyridyl ring, 
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probably due to some interaction with the peptide. Accordingly, 57 was formulated 
as trans,cis-RuCl2(CO)2(cppH-NT-κNp). This finding was rather surprising, 
considering that in the starting complex 52 cppH was bound through No, and 
suggested that, during the SPPS synthesis, the cppH isomerized to the Np isomer. 
 
Figure 7.5. 1H NMR spectra in DMSO-d6 in the aromatic region of trans,cis-RuCl2(CO)2(cppH-κNo) 
(52) (top), trans,cis-RuCl2(CO)2(cppH-κNp) (51) (middle) and trans,cis-RuCl2(CO)2(cppH-NT) (57) 
(bottom). R is the peptide sequence: Arg-Arg-Pro-Tyr-Ile-Leu. 
 
The aromatic region shows also four resonances for the amidic protons of the 
peptide. In fact, in the 1H-13C HSQC spectrum these peaks have no correlation 
crosspeaks with carbon resonances (Appendix, A7.3) and in the 1H-1H COSY 
spectrum they correlate with the protons on the respective Cα, whose resonances fall 
between 4.0 and 4.6 ppm (Figure 7.6). Moreover, the resonance at ca. 9.17 ppm, that 
has no correlation peak in the 1H-1H COSY and 1H-13C HSQC spectra, was assigned 
to the proton of the hydroxyl group of the Tyrosine. Finally, at ca. 7 ppm it is possible 
to distinguish two doublets, correlated in the 1H-1H COSY spectrum, for the ortho 
and meta protons of the phenyl ring of the Tyrosine, and two broad singlets for the 
two guanidinium NH protons of the two Arginines. All the remaining signals belong 
to the peptide chain and were not analyzed in detail (Appendix, A7.4) 
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Figure 7.6. 1H-1H COSY in DMSO-d6 of the selected regions of 57. R is the peptide sequence: Arg-
Arg-Pro-Tyr-Ile-Leu. NH indicates the amidic protons of the peptide. 
 
The 1H NMR spectrum of the same compound dissolved in D2O presents twice the 
number of cppH-NT resonances in the aromatic region (Figure 7.7). The two sets of 
four resonances for the protons on the pyridine ring of cppH-NT are well resolved 
(the attributions of 3′ and 6′ are consistent with the 13C NMR chemical shifts, 
obtained through an 1H-13C HSQC spectrum), while the signals for protons 5 and 6 
of the pyrimidine ring are partially or completely overlapped. Each of them 
integrates as the sum of the two resonances of each proton of the pyridine ring. Thus, 
there are two species in ca. 3/2 ratio (blue/red) that presumably have the pyrimidine 
rings in very similar environments (overlapping resonances) and the pyridine rings 
in relatively different environments. It is worth nothing that typically the opposite 
occurs in case of linkage isomers of cppH, i.e. the resonances of the pyrimidine 
protons are affected much more than those of the pyridine protons by the different 
binding mode. The region of the peptide resonances is obviously more complicated. 
 Chapter 7: Novel Ru(II) Bioconjugates with Neurotensin 
 
 
188 
 
However, it is possible to distinguish two sets of resonances (two doublets each) for 
the aromatic protons of Tyr that are basically in the same 3/2 intensity ratio as the 
cppH protons (Figure 7.8). They are pairwise connected in the 1H-1H COSY 
spectrum according to their relative intensity. The upfield part of the spectrum, with 
the other peptide resonances, is shown in the Appendix (A7.4). 
 
 Figure 7.7. 1H-1H COSY in D2O of the aromatic region of 57. R is the peptide sequence: Arg-Arg-
Pro-Tyr-Ile-Leu. 
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Figure 7.8. 1H NMR spectra in D2O (region of the aromatic protons of Tyr) of bioconjugate 57 
obtained from the reaction (using SPPS) between trans,cis-RuCl2(CO)2(cppH-κNo) and NT(8-13) 
(top), and from the reaction in solution between trans,cis,cis-RuCl2(CO)2(dmso-O)2 and cppH-NT 
(bottom). 
 
An increase in the temperature (up to 65°C) induced no significant change in the 
aromatic region of the 1H NMR spectrum, thus suggesting that the two species are not 
in a conformational equilibrium. 
Then the effect of pH on the NMR spectrum was investigated. The pD of the original 
D2O solution (ca. 3.5) was gradually increased to 8 by stepwise addition of small 
volumes of a NaOD solution, and spectra were recorded after each step. Also in this 
case no significant change was observed in the aromatic region of the spectrum. 
Similarly unchanged was the spectrum of the final pD 8 solution when recorded at 
higher temperature (up to 65°C). 
The bioconjugate 57 obtained through the other synthetic procedure, i.e. by treating 
trans,cis,cis-RuCl2(CO)2(dmso-O)2 with cppH-NT in aqueous solution at room 
temperature, has the same NMR spectral features (Figure 7.8 and 7.9). The 1H 
resonances are the same, also in terms of relative intensities; the only difference 
between the two NMR spectra is the presence of different amounts of minor 
impurities.  
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Figure 7.9. 1H NMR spectra in D2O of the bioconjugate 57 obtained from the reaction (using SPPS) 
between trans,cis-RuCl2(CO)2(cppH-κNo) and NT(8-13) (top), and from the reaction in solution 
between trans,cis,cis-RuCl2(CO)2(dmso)2 and cppH-NT (bottom). 
 
In conclusion, the NMR spectra in DMSO-d6 show that both synthetic procedures 
afford the same bioconjugate trans,cis-RuCl2(CO)2(cppH-NT) (57) in pure form and 
that the cppH-NT is bonded through the Np.  
On the contrary, the NMR spectra in D2O show that in this solvent 57 originates two 
very similar bioconjugates. The spectra were not affected by an increase in 
temperature and by changing the pH of the solution. For the moment we have no 
clear explanation for this finding. Typically, in trans-{RuCl2} fragments chloride 
hydrolysis is unlikely to occur, and was not observed in the corresponding cppH 
complexes. Since the NMR spectra of the two species differ mainly in the resonances 
of the pyridine ring of cppH-NT, we argue that they might derive from some intra- 
or inter-molecular interaction between the peptide and the pyridine ring of cppH. 
This hypothesis is also in agreement with the results of 61 and 62 shown below. 
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In fact, the 1H NMR spectrum in DMSO-d6 of [Ru([9]aneS3)Cl(cppH-NT)]
+ (61) is 
similar to that of 57. The downfield region presents six signals for the bonded cppH 
and other four signals for the amidic protons, partially overlapped with the cppH 
resonances, that in the 1H-1H COSY spectrum have crosspeaks with protons in the 
peptide zone (Appendix, A7.6).  
The comparison with the resonances of the corresponding complex with unmodified 
cppH 60 suggests that in 61 the cppH-NT is bonded through Np (see also Table 7.1). 
Accordingly, 60 was formulated as [Ru([9]aneS3)Cl(cppH-NT-κNp). Only the 
resonance of proton 3′ on the pyridine ring of 61 is downfield shifted compared to 
60, so that it falls at higher frequency than that of 6′. The two resonances are easily 
distinguished in the 1H-13C HSQC spectrum since 3′ has a correlation peak with a 
carbon at ca 127 ppm, while 6′ with a carbon at 155 ppm (Appendix, A7.7). Typically 
in Ru(II)-cppH complexes the resonances of protons 6 and 6′, that are adjacent to the 
bonded nitrogen atoms, are the most downfield signals. In this case some interaction 
between the peptide and the pyridine ring might be invoked to explain the variation 
of chemical shift for the signal of proton 3′.  
The 1H spectrum of 61 in D2O, however, presents more resonances compared to that 
in DMSO-d6, as in case of 57. The spectrum is additionally complicated by the partial 
hydrolysis of the chloride. In fact, the addition of excess NaCl simplifies the 
spectrum since it reverts the aquation equilibrium, leaving only the resonances of 
non-hydrolyzed species (Figure 7.10). The behavior is similar to that found for the 
model complex 60 with unmodified cppH (Appendix, A7.1). 
 Chapter 7: Novel Ru(II) Bioconjugates with Neurotensin 
 
 
192 
 
 
Figure 7.10. Downfield region of 1H NMR spectrum of [Ru([9]aneS3)Cl(cppH-NT)]+ after 
dissolution in D2O (top) and after addition of an excess of NaCl (bottom). 
 
Figure 7.11 shows the 1H-1H COSY spectrum of the cppH-NT region in 61: it is 
possible to distinguish at least three different sets of signals for three different major 
species in ca. 1/1/3 ratio (red/green/blue). The three species have very similar 
(overlapping) resonances for the pyrimidine protons 5 and 6 (thus suggesting that 
they are not linkage isomers), whereas several resonances of the pyridine protons are 
well resolved. In more detail, the two minor species (red and green) have very similar 
resonances for the pyridine protons, which are rather different from those of the main 
species (blue). In particular, the resonances of the pyridyl protons 3′ and 4′ of the 
minor species are upfield shifted compared to those of the main species. The region 
of the tyrosine resonances is rather complex (see below) but it is consistent with the 
presence of at least three species. Integration established that in each species the 
peptide chain is still attached to cppH.  
The upfield part of the spectrum, with the other peptide resonances, is shown in the 
Appendix (A7.9). 
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Figure 7.11. Downfield region of the 1H-1H COSY in D2O + NaCl of [Ru([9]aneS3)Cl(cppH-NT)]+ 
(61). R is the peptide sequence: Arg-Arg-Pro-Tyr-Ile-Leu. 
 
Thus, according to NMR data, when dissolved in D2O compound 61 consists of at 
least three different species; all of them have the bonded cppH-NT moiety and differ 
mainly for the chemical shifts of the pyridine ring protons. As above for 57, the NMR 
data are not consistent with the presence of linkage isomers or conformers. 
Conversely, the spectrum of the same compound 61 recorded in DMSO-d6 presents 
peaks for only one species, in agreement with HPLC and ESI MS data. 
Also in case of [Ru([9]aneS3)(cppH-NT)(PTA)]
2+ (62), the 1H NMR spectrum in 
DMSO-d6 presents six signals for cppH-NT, partially overlapped with those of amide 
protons of the peptide. The comparison of the resonances with the two linkage 
isomers of the corresponding complex with unmodified cppH, 50Np and 50No, 
suggests that in the bioconjugate 62 the cppH-NT in bonded through Np, (see also 
Table 7.1). Also in this case, as for 61, the resonance of the pyridine ring proton 3′ 
is downfield shifted compared to 50Np and falls at higher frequency than 6′ 
(Appendix, A7.10 and A7.11). The 31P NMR spectrum of 62 shows a broad singlet 
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centered at –39.1 ppm that is similar to that for the corresponding model complex 50 
with unmodified cppH (–34.9 for the Np isomer and –35.0 for the No isomer, recorded 
in D2O instead of DMSO-d6). 
The 1H NMR spectrum of 62 in D2O is similar to those of the other bioconjugates 
(Figure 7.12). As above for compound 61, it is possible to distinguish at least three 
different sets in ca 1/1.5/2.5 ratio (green/red/blue) that differ mainly in the 
resonances of the pyridine ring protons. Two sets (red and green) are almost 
completely overlapped: only the resonances of proton 4′ are resolved. Moreover, 
each signal of the blue set also seems to be the sum of two very similar, almost 
completely overlapped resonances (e.g. see the signal of H6′ in Figure 7.12). The 
region of tyrosine resonances (Figure 7.13) is consistent with the presence of four 
species. In conclusion, compound 62 in aqueous solution is most likely a mixture of 
four very similar species. When the integration of the cppH protons is compared with 
those of PTA and aromatic protons of Tyr, it established that in each species PTA is 
still bonded to the ruthenium center and the peptide chain is connected to cppH. The 
upfield part of the spectrum, with the other peptide resonances, is shown in Appendix 
(A7.13). 
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Figure 7.12.  Downfield region of the 1H-1H COSY in D2O of [Ru([9]aneS3)(cppH-NT)(PTA)]++ 
(62). R is the peptide sequence: Arg-Arg-Pro-Tyr-Ile-Leu. 
 
Also in this case an increase in temperature (up to 65°C) and an increase in pD (from 
ca. 3 to ca. 8) left the 1H NMR spectrum substantially unchanged.  
 
As above mentioned, in the 1H NMR spectra in D2O the complexity of the cppH 
region is mirrored in that of the aromatic protons of Tyr (Figure 7.13): this region in 
the spectrum of 57 (top) is much simpler than those of the bioconjugates with 
[9]aneS3, 61 (middle) and 62 (bottom). The spectra of 61 and 62 are consistent with 
the presence of three or more species, as indicated by the cppH region. 
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Figure 7.13. 1H NMR spectra in D2O (region of the aromatic Tyr protons) of trans,cis-
RuCl2(CO)2(cppH-NT) (top), [Ru([9]aneS3)Cl(cppH-NT)+ (middle – D2O + NaCl) and 
[Ru([9]aneS3)(cppH-NT)(PTA)]2+ (bottom). 
 
7.5 Antiproliferative properties 
The antiproliferative properties of compounds 29, 51, 52, 57 - 59, 61, 62 were 
assessed against three different cell lines: colon adenocarcinoma (HT-29), breast 
cancer (MCF-7) and pancreatic cancer (PT-45) according to the method described in 
the Experimental Section. All the cell lines were treated for 48 hours with increasing 
concentrations of each comopund. None of the precursors and bioconjugates showed 
antiproliferative activity, even at the concentration of 200 µM.  
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7.6 Conclusions 
In this Chapter we described the preparation of three novel Ru(II)–NT(8-13) 
bioconjugates with two different approaches and their characterization (Figure 7.14).  
The original aim of the work was that of preparing two stereoisomeric bioconjugates 
starting from the two linkage isomers trans,cis-RuCl2(CO)2(cppH-κNp) (51) and 
trans,cis-RuCl2(CO)2(cppH-κNo) (52). The SPPS approach applied to complex 52 
and NT(8-13) afforded the bioconjugate trans,cis-RuCl2(CO)2(cppH-NT-κNp) (57), 
whereas it was ineffective with the Np isomer 51. The second synthetic approach, i. 
e. the preparation of cppH-NT using SPPS followed by its reaction with the precursor 
of 51 and 52, trans,cis,cis-RuCl2(CO)2(dmso-O)2 (29), afforded again 57. Two 
additional bioconjugates, [Ru([9]aneS3)Cl(cppH-NT)]Cl (61) and 
[Ru([9]aneS3)(cppH-NT)(PTA)]
2+ (62), were prepared by reaction of cppH-NT with 
the appropriate Ru(II) precursors.  
 
Figure 7.14. Schematic representation of the bioconjugates synthesized: trans,cis-RuCl2(CO)2(cppH-
NT) (57), [Ru([9]aneS3)Cl(cppH-NT)]+ (61) and [Ru([9]aneS3)(cppH-NT)(PTA)]2+ (62). R is the 
peptide sequence: Arg-Arg-Pro-Tyr-Ile-Leu. 
 
The NMR characterization in DMSO-d6 revealed that, in accordance with HPLC and 
ESI-MS data, each bioconjugate is a single compound and of quite good purity. The 
cppH chemical shifts are in accordance with the presence of a single stereoisomer, 
in which the linker is bound to Ru(II) through Np: Table 7.1 shows the ∆δH between 
the diagnostic chemical shits of the pyrimidine protons in the model complexes with 
cppH (both isomers when possible) and their corresponding bioconjugates, in D2O 
(where in all species these resonances are overlapped). It results that the ∆δH 
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between trans,cis-RuCl2(CO)2(cppH-NT) (57) and 51 (N
p isomer) is 0.15 whereas it 
is 0.64 with respect to 52 (No isomer). This finding implies that, during the SPPS 
between 52 and NT, the cppH isomerizes from No to Np. The behavior is similar also 
for the bionconjugate [Ru([9]aneS3)(cppH-NT)(PTA)]
2+ (62) In the case of the 
model complex [Ru([9]aneS3)Cl(cppH-κNp)]+ (60), where only the Np isomer was 
isolated, the ∆δH with respect to 61 is 0.04, suggesting also in this bioconjugate cppH 
is bonded through the para nitrogen atom. 
 
Table 7.1. 1H NMR chemical shifts of pyrimidine ring protons in D2O for model complexes with 
cppH (both Np and No linkage isomers when possible) and their corresponding bioconjugates with 
cppH-NT. In green there are the values of ∆H(bioconjugate  ̶  complex). 
 
Complexes 
 
H6 H5 
trans,cis-RuCl2(CO)2(cppH-κNp) (51) 9.64 8.22 
trans,cis-RuCl2(CO)2(cppH-NT) (57) 9.79 8.38 
   0.15 0.15 
trans,cis-RuCl2(CO)2(cppH-κNo) (52) 9.17 7.72 
trans,cis-RuCl2(CO)2(cppH-NT) (57) 9.79 8.38 
   0.62 0.66 
[Ru([9]aneS3)Cl(cppH-κNp)]+ (60) 9.52 8.11 
[Ru([9]aneS3)Cl(cppH-NT)]+ (61) 9.55 8.16 
   0.03 0.05 
[Ru([9]aneS3)(cppH-κNp)(PTA)]2+ (50Np) 9.28 8.16 
[Ru([9]aneS3)(cppH-NT)(PTA)]2+ (62) 9.42 8.26 
   0.14 0.10 
[Ru([9]aneS3)(cppH-κNo)(PTA)]2+ (50No) 9.13 7.64 
[Ru([9]aneS3)(cppH-NT)(PTA)]2+ (62) 9.42 8.26 
   0.29 0.62  
 
However, when dissolved in D2O each bioconjugate generates a mixture of two (57) 
or even three or four species (61 and 62), each one containing the cppH-NT fragment 
(and the PTA ligand in 62). This finding is in contrast with the single peak observed 
in analytical HPLC. Each species is characterized by a set of very similar proton 
resonances in the cppH region, always consistent with cppH bound through Np, thus 
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they are not linkage isomers. The NMR spectra were unaffected by an increase of 
the temperature up to 65°C, thus suggesting that the species are not in dynamic 
equilibrium, as well as by increasing the pD from ca. 3 to ca. 8. The presence of 
many species is observed only when the bioconjugates are dissolved in D2O; this 
could be tentatively explained with some kind of strong intra- or inter-molecular 
interaction involving the Ru center and the peptide chain. Since mainly the 
resonances of the pyridine protons of cppH are affected, it is reasonable to 
hypothesize that this ring is involved in the above mentioned interactions.  We notice 
that, contrary to 57, in 61 and 62 Ru is a stereogenic center, thus – given the presence 
of chiral atoms on the peptide chain – diastereoisomeric derivatives may form. 
However, this observation does not explain the difference observed between DMSO-
d6  and D2O, and why two species are observed in D2O also for 57. Unfortunately, 
the metal-bioconjugates are not typically characterized through NMR spectroscopy, 
and thus our data can be hardly compared with the literature.  
 
Unluckily, none of the tested compounds – both precursors bioconjugates – showed 
any antiproliferative properties. Thus, the presence of the NT peptide proved to be 
ineffective for promoting cytotoxicity. Due to the lack of activity, no experiments 
for evaluating the ruthenium uptake by the cells were performed.  
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Photolabile complexes for light-triggered drug 
release 
 
8.1 State of the art 
In therapy, light-triggered treatments are appealing since – in principle – they can 
generate a drug with high spatial and temporal selectivity, resulting in a greater 
specificity of action. Such treatments require light-activated prodrugs that – ideally 
– are inactive and non-toxic in the dark, whereas they are locally activated in vivo 
upon irradiation with visible light. In this context, photodynamic therapy (PDT), a 
clinically approved treatment for some skin diseases, age-related macular 
degeneration and some cancers, is the most well-known application. PDT uses a 
photosensitizer (PS) at non-toxic concentrations that, in the most common type II 
mechanism, upon light-excitation catalytically generates singlet oxygen (1O2) or 
other highly cytotoxic ROS such as superoxide radical anions.1 Another 
phototherapy approach is the so-called photoactivated chemotherapy (PACT) in 
which a kinetically inert and biologically non-active prodrug is irreversibly activated 
by irradiation with visible light that induces the cleavage of a photolabile protecting 
group.2 The photoactivation process is also called photo-uncaging. Compared to 
PDT, PACT is a stoichiometric rather than catalytic process, but has the advantage 
of not depending on the presence of molecular oxygen. Thus, in principle, PACT 
agents are active also in hypoxic tumor tissues. In general, ideal PDT or PACT agents 
are water-soluble and resistant to photobleaching. In addition, they should be 
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activated within the phototherapeutic window (λ > 600 nm), where light is more 
penetrating into the tissues and less harmful. 
By virtue of their peculiar light absorption properties and rich photoreactivity, d-
block metal compounds are attracting rapidly increasing interest as potential PDT 
and PACT agents.3,4,5,6,7 Among them, Ru(II) compounds are extensively 
investigated due to their superior photophysical and photochemical properties.8,9,10 
For example, even though most PDT photosensitizers used in clinic are based on 
porphyrin derivatives,11 a Ru(II)-polypyridyl complex (TLD-1433) is undergoing a 
phase I clinical trial in Canada as PDT agent in patients with bladder cancer.12,13  
A typical reaction that can occur in inorganic PACT agents is the photo-induced 
release of ligands from coordinatively-saturated and inert prodrugs. The most 
extensively investigated class of ruthenium PACT agents is that of polypyridyl 
complexes of the [Ru(bpy)3]
2+ family that contain (at least) one sterically hindering 
diimine such as 6,6′-dimethyl-2,2′-bipyridine (dmbpy).14 The strain induced by such 
a ligand in the coordination sphere promotes the light-induced population of low-
lying dissociative metal-centered triplet excited states (3MC) and consequently its 
release. Coordination and organometallic Ru(II) compounds in which visible light 
triggers the release of a single monodentate ligand have also been investigated.15,16 
A careful design of the metal prodrug can lead to metal complexes with dual activity, 
i.e. photo-triggered ligand release (PACT) and singlet oxygen production (PDT).17 
The activation of coordinatively-saturated cytotoxic Ru complexes through the 
photo-deprotection of a ligand has been also been reported.18 
In photo-labile metal complexes the focus can be on the activated metal fragment, 
that may bind to biomolecules such as DNA through its newly generated 
coordination sites,14,19 or on the released ligand if itself a pharmacologically-active 
molecule,20 or on the combined action of both.21 In polypyridyl Ru(II) complexes the 
increased cytotoxicity is generally attributed to the intracellular formation of the bis-
aqua complex cis-[Ru(bpy)2(OH2)2]
2+ species. However, a very recent paper by 
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Bonnet and coworkers demonstrated that in the case of [Ru(bpy)2(dmbpy)]
2+ the 
photo-released dmbpy ligand, rather than the ruthenium bis-aqua fragment, is 
responsible for the observed phototoxicity.22 
In the recent past, the group where I did my Thesis reported that dicationic Ru(II) 
complexes, such as [Ru([9]aneS3)(bpy)(py)](PF6)2 ([9]aneS3  = 1,4,7-
trithiacyclononane, bpy = 2,2′-bipyridine), are inert in the dark but rapidly and 
quantitatively release the pyridine ligand in aqueous solution when illuminated with 
blue light (λ = 420 nm).23,24 Since the photo-generated aqua species 
[Ru([9]aneS3)(bpy)(OH2)]
2+ showed a substantial lack of cytotoxicity (against the 
MDA-MB-231 human mammary carcinoma cell line) we suggested that Ru(II) 
compounds of this type might be suitable PACT agents for the light-triggered release 
of coordinated drugs (photo-uncaging).25  
 
  
Chapter 8: Photolabile Complexes for Light-Triggered Drug Release  
 
 
208 
 
8.2 Aim of the Chapter 
This Chapter reports the work on the model complexes of the type 
[Ru([9]aneS3)(chel)(py)](Cl)2, where chel is a chelating diimine. The aim was that 
of establishing if complexes of this series, bearing a pharmacologically active 
molecule in the place of pyridine, can be realistically used within the photo-uncaging 
strategy. First, it was investigated if the absorption maxima in the visible spectrum 
and the photoinduced release of pyridine can be tuned by changing the nature of the 
diimine ligand. For this purpose, the model complexes with chel = 1,10-
phenanthroline (phen), 4,7-diphenil-1,10-phenanthroline (4,7-Ph2phen), dipyrido-
[3,2-a:2′,3′-c]phenazine (dppz), 2,2′-biquinoline (bq) were prepared, fully 
characterized and investigated. The photo-induced release of py was qualitatively 
investigated by 1H NMR and UV-vis spectroscopy. A particularly detailed 
experimental and theoretical investigation was performed on the bq derivative, for 
explaining its peculiar spectral features and photochemical behavior.  
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8.3 Diimine Ligands 
The series of chelating diimines used in this Chapter, with different size and 
aromaticity, are shown in Figure 8.1. The 2,2′-biquinoline ligand, owing to its steric 
demand, is known to induce deformation in the pseudo-octahedral coordination 
sphere of Ru(II) complexes that can improve the photo-induced dissociation of 
ligands.14b,15 In addition, its low-lying acceptor orbitals are expected to red-shift the 
1MLCT absorption maximum typical of diimine-Ru(II) complexes closer to the PDT 
window.26,27 
 
Figure 8.1. The diimine ligands used in this Chapter with proton labelling scheme for NMR purposes: 
2,2′-bipyridine (bpy), 1,10-phenanthroline (phen), 4,7-diphenil-1,10-phenanthroline (4,7-Ph2phen), 
dipyrido-[3,2-a:2′,3′-c]phenazine (dppz), 2,2′-biquinoline (bq). 
 
8.4 Synthesis of the complexes 
The Ru(II) compounds were prepared as chloride salts, rather than as PF6 salts, for 
improving aqueous solubility. A two-step procedure was followed (Scheme 8.1).  
 
Scheme 8.1. Synthetic procedure for the [Ru([9]aneS3)(chel)(py)](Cl)2 compounds 68 – 72, 
exemplified in the case of chel = bpy. 
Chapter 8: Photolabile Complexes for Light-Triggered Drug Release  
 
 
210 
 
In the first step, modified from the literature,28 treatment of the [Ru([9]aneS3)(dmso-
S)Cl2] precursor with a two-fold excess of chel in refluxing ethanol (3h) afforded the 
known mono-cationic intermediates of formula [Ru([9]aneS3)(chel)Cl]Cl(chel = bpy 
(63), phen (64), 4,7-Ph2phen (65), dppz (66)) in good isolated yields (65 – 85%). The 
insertion of bq was more difficult, possibly due also to the low solubility of the ligand 
in ethanol. A microwave assisted reaction in ethanol (140°C, 90 min) was preferred 
to prolonged reflux for obtaining [Ru([9]aneS3)(bq)Cl]Cl (67) in good yield. All 
complexes, already reported in the literature either as Cl or PF6 salts,
28,29 were 
characterized by NMR and UV-vis spectroscopy (Appendix, A8.8), and mass 
spectrometry. They are well soluble in ethanol, chloroform, DMSO, and – with the 
exception of 65 and 66 – also in water.  
As clearly shown by 1H NMR spectroscopy (Appendix, A8.1), in D2O compounds 
63 – 67 are in equilibrium – to different extents – with the corresponding aqua species 
[Ru([9]aneS3)(chel)(OH2)]
2+ (63aq – 67aq). In 63aq – 66aq the aromatic resonances 
are slightly downfield shifted (ca. 0.1 pm or less) compared to those of the parent 
complex, and their relative intensity increases upon diluting the solution and 
decreases (or disappears altogether) upon adding an excess of NaCl. In the case of 
67 a single set of resonances is observed in D2O, suggesting that no significant 
equilibration with the aqua species 67aq occurs at typical NMR concentrations. The 
resonances of 67aq appear upon dilution, and in this case some of them are shifted 
upfield compared to those of 67 (e.g. the doublet of H8,8′ falls at 9.26 ppm in 67 and 
at 9.09 ppm in 67aq). The resonances of [Ru([9]aneS3)(dppz)Cl]
+ (66), that are sharp 
in CDCl3, are rather broad and have concentration-dependent shifts in D2O, most 
likely due to stacking interactions occurring in solution. Consistent with this 
hypothesis, they (and those of 66aq as well) become sharper upon diluting the 
solution.  
Treatment of intermediates 63 – 67 with a slight excess of pyridine in refluxing water 
afforded the corresponding dicationic complexes [Ru([9]aneS3)(chel)(py)](Cl)2 
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(chel = bpy (68), phen (69), 4,7-Ph2phen (70), dppz (71), bq (72)) that, with the 
exception of 68 previously reported by us as PF6 salt,
23 are described here for the 
first time. They were fully characterized as 63 – 67 above, and the single-crystal X-
ray structures of 69 (Appendix, A8.10) and 72 (Figure 8.2) were also determined. In 
72, as in its precursor 67 and other bq octahedral complexes,14b,15,28,29,30 the distortion 
in the geometry induced by the sterically demanding diimine is evident. In particular, 
the average plane of bq is remarkably tilted relative to the equatorial coordination 
plane (37.43 (4)°, with the “front” of the ligand pointing towards the axial py), 
whereas the twist about the C–C bond between the two quinolines (3.9(2)°) is 
negligible. The geometrical features of coordinated bq are similar also in the trans-
RuCl2(bq)(CO)2 (73) complex (Figure 8.2), in which the other ligands are sterically 
undemanding and that we expressly prepared for the sake of comparison. Another 
major structural difference in 72 concerns the rotation of the py ligand about the Ru–
N bond: in 72 py is ca. orthogonal compared to the other similar complexes (e.g. ca. 
76° with respect to complex 68), most likely for avoiding steric clashes between the 
oH atoms of py and H8,8′ of bq.  
 
Figure 8.2. X-ray molecular structures (50% probability ellipsoids) of [Ru([9]aneS3)(bq)(py)](Cl)2 
(72) (left) and of trans-RuCl2(bq)(CO)2 (73) (right). The two chlorides and an ethanol crystallization 
molecule in 72 omitted for clarity. Only one of the two independent molecules of 73 present in the 
unit cell is shown. Coordination distances in ångström (Å): 72: Ru1–N11 = 2.121(1), Ru1–N31 = 
2.116(1), Ru1–N32 = 2.107(1), Ru1–S21 = 2.3221(3), Ru1–S22 = 2.3113(3), Ru1–S23 = 2.3178(5); 
73: Ru2–C21 = 1.899(2), Ru2–C22 = 1.897(2), Ru2–Cl21 = 2.3858(5), Ru2–Cl22 = 2.4179(5), Ru2–
N21 = 2.139(2), Ru2–N22 = 2.136(2). 
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All dicationic complexes are fairly soluble in water. The 1H NMR spectra of 
compounds 68 – 71 (Appendix, A8.2-A8.5) are unexceptional and, as for the 
corresponding precursors, consistent with the CS symmetry of each complex cation. 
The most downfield resonance is that of the protons adjacent to the N atoms of the 
diimine ligand. The 1H NMR spectrum of the bq compound 72 is treated in more 
detail below.  
The electronic absorption spectra of 68 – 71 in the visible region are characterized 
by two bands of roughly comparable intensities (ε in the range 3000 - 6000 M-1 cm-
1), partially or completely overlapped, at 350 - 430 nm. The spectrum of 72, instead, 
shows two rather sharp and more intense bands at 359 and 378 nm, whereas the 
lowest energy MLCT band – in good agreement with the expectations – is red-
shifted, with an absorption maximum at nearly 500 nm (Figure 8.3).  
 
Figure 8.3. UV-vis spectra of compounds 68 – 72 (ca. in 0.1 mM H2O) in the visible region. 
 
8.4.1 The 2,2′-biquinoline complexes  
In the 1H NMR spectrum of 2,2′-biquinoline the most downfield resonance is that of 
H3,3′, followed by that of H4,4′. The anti conformation assumed by the two 
quinolines in the free ligand brings N′ close to H3 (and N to H3′), and the deshielding 
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of H3,3′ was attributed mainly to the electrostatic effect of the lone pairs (Figure 
8.4).31 When symmetrically bound to diamagnetic octahedral metal centers, such as 
in Re(CO)3(bq)Br,
32 the proton NMR spectrum of bq undergoes remarkable changes: 
the doublet of H8,8′ becomes the most downfield signal (∆δ = 0.71 ppm), whereas 
that of H3,3′ is shifted to lower frequencies (∆δ = –0.50 ppm). Such variations are 
attributable to the conformational change of the ligand (from anti to syn) and to its 
coordination. Regretfully, in the other symmetrical Ru-bq compounds such as 
[Ru(phen)2(bq)](PF6)2,
14b [Ru(η6-p-cymene)(bq)Cl](PF6),33 and [Ru(bq)3][(PF6)2,34 
the proton NMR spectra  were not assigned. 
We found that, whereas the 1H NMR spectrum of 67 is consistent with such features, 
the spectrum of 72 is quite different and more similar to that of the free ligand: the 
resonance of H8,8′ falls to lower frequencies than those of H3,3′ and H4,4′ (Figure 
8.4).  
 
Figure 8.4. 1H NMR spectrum (aromatic region) of, from top to bottom: 2,2′-biquinoline, 
[Ru([9]aneS3)(bq)Cl]Cl (67), [Ru([9]aneS3)(bq)(py)](Cl)2 (72), and [Ru([9]aneS3)(bq)(NH3)](Cl)2 
(74). The spectrum of bq is in DMSO-d6, the others in D2O. In the spectrum of 74 the asterisk indicates 
residual chloroform. 
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Since these changes in the chemical shifts of the bq protons between 67 and 72 could 
not be attributed to different conformational strains in the bq frame (see above), we 
came to the conclusion that the H8,8′ doublet in 72 is shifted upfield by the shielding 
cone of the adjacent axial pyridine. In order to confirm this hypothesis, that is 
consistent also with the orientation of py evidenced by the X-ray structure shown in 
Figure 8.2, we prepared the complex with NH3 in the place of pyridine, i.e. 
[Ru([9]aneS3)(bq)(NH3)](Cl)2 (74). Indeed, even though the structural features in 74 
(Figure 8.5) are again similar to those of 67 and 72 (e.g. the tilt angle of bq is 
38.89(3)°), the NMR spectral pattern of coordinated bq follows the “normal” order, 
and the H8,8′ doublet is again the most downfield resonance.35 
 
Figure 8.5. X-ray molecular structure (50% probability ellipsoids) of [Ru([9]aneS3)(bq)(NH3)](Cl)2 
(74). The two chlorides and a methanol crystallization molecule omitted for clarity. Coordination 
distances in ångström (Å): Ru1–N1 = 2.164(1), Ru1–N21 = 2.135(1), Ru1–N22 = 2.100(1), Ru1–S31 
= 2.3121(4), Ru1–S32 = 2.3341(4), Ru1–S33 = 2.3277(3). 
 
8.5 Photo-induced release of ligands 
In the dark, compounds 68 – 72 are stable in D2O (3 mM solutions) for at least 24h 
at ambient temperature, no changes in the NMR spectra were observed.  
The group where I did my Thesis recently demonstrated that, when irradiated with 
blue light at 420 nm, [Ru([9]aneS3)(bpy)(py)](PF6)2 rapidly and quantitatively 
releases the coordinated pyridine.23 
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Compounds 68 – 71 have a similar behavior: when irradiated with blue light (LED, 
λ = 470 nm, 40 mW) they release the coordinated pyridine at comparable rates and 
extents, generating selectively the corresponding aqua species (63aq – 66aq) in 
equilibrium with the chlorido species (63 – 66) (Scheme 8.2). No other reaction 
occurs. 
 
 
Scheme 8.2. Photo-dissociation of pyridine from compounds 68 – 71, exemplified in the case of chel 
= bpy.   
 
The photo-reactions were performed in D2O and quantitatively monitored by 
1H 
NMR spectroscopy. An example is reported in Figure 8.6. In the case of the dppz 
complex 71, the resonances of the photo-generated aqua and chlorido species – as 
mentioned above – are rather broad; the sharp pyridine signals allowed reliable 
integration to be performed. Table 8.1 reports the percentage amount of photo-
released pyridine as a function of the irradiation time. 
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Figure 8.6. Photo-induced dissociation of pyridine from [Ru([9]aneS3)(phen)(py)](Cl)2 (69) 
monitored as a function of the irradiation time (λ = 470 nm, 40 mW) by 1H NMR spectroscopy in 
D2O. The positive charges of the complexes are omitted. 
 
Table 8.1. Extent of photo-released pyridine as a function of the irradiation time (LED, λ = 470 nm, 
40 mW). 
complex diimine ligand 5 min 10 min 15 min 30 min 
68 bpy 80,0% 92,8% 93,3% 98,8% 
69 phen 60,0% 78,2% 87,8% 96,6% 
70 4,7- Ph2phen 75,0% 78,8% 81,4% 95,4% 
71 dppz 50,0% 75,0% 85,0% 97,7% 
 
In summary, the photo-dissociation of py is almost complete after 30 min of 
illumination and the bpy complex 68 is the fastest one, even though it has the smallest 
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absorption coefficient at 470 nm. We found that the dppz complex 71, that has a very 
weak absorption at ca. 540 nm (Appendix, A8.9), is still photoactive when irradiated 
with green light at 530 nm, even though the photo-release of pyridine is slower: 33% 
after 15 min (λ = 530 nm, 30 mW) compared to 78% when irradiation was performed 
at 470 nm with the same power.  
The behavior of the bq complex 72 upon illumination is quite different and photo-
dissociation of both py and bq in ca. equal amounts occurs. In general, contrary to 
the expectations, the complex is more photo-stable compared to 68 – 71: after 2h of 
illumination at 470 nm (40 mW) in D2O ca. 25% of 72 is still present in solution. 
The interpretation of the NMR spectra (Figure 8.7) was made more difficult by the 
following facts: i) 2,2′-biquinoline is insoluble in water, thus the resonances of 
photo-released bq cannot be seen; ii) the chemical shifts of the bq resonances in both 
67 and 67aq, i.e. the Ru complexes obtained upon photo-release of py, as well as the 
ratio between the two species, are concentration-dependent; iii) (most of) the 
released py binds to the {Ru([9]aneS3)(py)}
2+ fragment (thus the resonances of free 
py are not clearly seen), affording the [Ru([9]aneS3)(py)2(OH2)]
2+ complex cation 
that, in addition, is in equilibrium with [Ru([9]aneS3)(py)2Cl]
+. The resonances of 
these latter species were unambiguously identified: for this purpose we made 
[Ru([9]aneS3)(py)2Cl]Cl (75), that in aqueous solution equilibrates with 
[Ru([9]aneS3)(py)2(OH2)]
2+ (75aq). When a D2O solution of 72 was irradiated with 
green light (30 mW) at 530 nm a similar behavior was observed, but the photo-
release of both bq and py is slower. A similar photochemistry was observed when 
the irradiation of 72 was performed in DMSO-d6 where the resonances of free bq 
(that is soluble) could be observed: in this medium the photo-induced dissociation of 
bq prevails over that of py (Appendix, A8.7).  
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Figure 8.7. 1H NMR spectrum of the reaction mixture obtained upon irradiation (λ = 470 nm, 40 mW, 
180 min) of a D2O solution of [Ru([9]aneS3)(bq)(py)](Cl)2 (72). The positive charges of the 
complexes are omitted. 
 
Although parallel photo-release of two different ligands has not been often described, 
it has been observed recently in the complex [Ru(bpy)(dmbpy)(L-proline)]PF6, in 
which substitution of both dmbpy and L-proline occurred upon illumination.36 
8.6 Theoretical calculationsc 
Intrigued by the remarkably different photochemical behavior of the biquinoline 
complex 72, we performed a series of theoretical calculations on it and on the 
corresponding bpy complex 68, taken as model for the other diimine compounds 69–
71. Structure-wise, complex 10 has two main geometrical differences compared to 
the canonical features of 68, that are likely to be related to its different 
photochemistry: the tilted geometry of bq and the orientation of py (see above). 
                                                          
c Calculations were done by Dr. Gabriele Balducci. 
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First of all, our computational protocol (DFT with plane wave basis set, 
pseudopotentials and periodic boundary conditions) was tested on compound 68 that 
had been previously investigated using a different computational approach (DFT 
with localized basis functions).23 The results obtained in terms of optimized 
geometry, calculated MOs, and electronic transitions were in excellent agreement 
with those reported in the literature, thus confirming the reliability of our protocol. 
Next, the calculations were extended to 72.  
Figure 8.8 shows the density of states and its projection onto selected atomic orbitals 
of the Ru, py and bq or bpy ligands for complexes 72 and 68 in the ground state 
configuration.  
 
Figure 8.8. Density of states (DOS) and its projection onto selected atomic orbitals for complexes 72 
(top) and 68 (bottom). Vertical lines indicate the energy of the molecular orbitals in the range from 
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HOMO–2 to LUMO+6. Plots have been aligned so that the energy of the HOMO’s for the two 
complexes is 0.0 eV. 
 
Consistent with the red-shifted absorption band in the UV-vis spectrum, and with the 
general features expected for bq complexes (i.e. stabilized bq π* orbitals relative to 
those of bpy),14b,15 the HOMO−LUMO energy gap in 72 is smaller than in 68 (2.01 
vs 2.32 eV). TDDFT calculations well reproduced the experimental absorption 
spectrum of both complexes (Figure 8.9 and Appendix, A8.11) and allowed us to 
assign also the character of each band (Appendix, Table A8.1),37 thus confirming 
that the lowest energy transition has a ca. 85 – 90% HOMO → LUMO component.23 
In both complexes the LUMO is almost coincident with a π* MO of the diimine 
ligand (Appendix, A8.12). However, we notice that whereas in the bpy complex the 
three frontier occupied orbitals – HOMO, HOMO−1 and HOMO−2 (Appendix, 
A8.12) – have an almost exclusive metal-centered character, i.e. are coincident with 
the filled d orbitals of Ru(II), in 10 the HOMO and HOMO−1 get an appreciable 
contribution from the atomic orbitals of C and N atoms of the biquinoline ligand (see 
also Figure 8.8). We argue that the tilted orientation of bq in 10 is responsible for the 
mixing of diimine π orbitals with the filled d orbitals of Ru(II). Therefore, the lowest 
energy electronic transition can be safely labeled as a pure MLCT in 68, whereas it 
has a π − π*component in 72.  
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Figure 8.9. Experimental (top) and calculated (with the “turbo_lanczos” program, bottom) absorption 
spectra for complex 72. The vertical bars in the simulated spectrum are the calculated transitions (with 
the “turbo_davidson” code), with height equal to the oscillator strength.  
 
Consistent with what previously observed, in 68 the LUMO+4 and LUMO+5 MOs 
have a strong metal d-antibonding component; in addition, they have a significant σ-
antibonding character towards the bpy and – above all – the pyridine ligands (Figure 
8.10). Thus, the light-induced population of such orbitals is presumably responsible 
for the photo-dissociation of py. Conversely, in 72 the orbitals with the most relevant 
d* component are the LUMO+3 and LUMO+4, and they have a relevant bq – rather 
than py – contribution (Figure 8.10). This finding is consistent with what established 
for Ru(II)-polypyridyl complexes that contain bq, in which distortion is known to 
lower the energy of a dissociative metal-centred state.14b,15 In addition, whereas 
LUMO+4 has a significant σ-antibonding character towards bq, in both the 
LUMO+3 and LUMO+4 the antibonding character towards py is mainly of π 
symmetry (i.e. involving p atomic orbitals normal to the py plane). This finding, i.e. 
Chapter 8: Photolabile Complexes for Light-Triggered Drug Release  
 
 
222 
 
the increase of π back-bonding from the filled metal orbital to the π* orbitals of py, 
is most likely attributable to the different orientation of py in the bq complex and 
might account for the less-pronounced light-induced dissociation of pyridine in 72.  
 
Figure 8.10. Selected virtual molecular orbitals for 68 (right) and 72 (left) in the singlet ground state. 
 
The other significant photochemical difference between the two complexes concerns 
the photo-induced dissociation of the chelating diimine, that occurs in 72 (bq) but 
not in 68 (bpy). We observe that the binding of bq is arguably weaker compared to 
that of bpy because of its tilted coordination geometry that leads to a smaller overlap 
in the bonding orbitals. 
In conclusion, contrary to what has been found by Turro and coworkers for mer-
[Ru(tpy)(chel)(py)]2+ species (chel = bpy or bq), where the distortions induced by 
the bulky bq led to an increased photo-induced release of py compared to bpy,15 in 
this case – mainly because of the facial, rather than meridional, geometry of the 
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complex – the distortions led to the preferential photo-dissociation of biquinoline 
itself.38 
Although triplet states are generally thought to be responsible for the photochemistry 
of ruthenium complexes via facile intersystem crossing, we are confident that our 
analysis based on singlet ground and excited states captures the essential features of 
complex 72. In fact, the already reported study on complex 68 has shown that triplet 
excited states trace the character and ground state orbital composition of the singlet 
counterparts.23 
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8.7 Conclusions 
The photo-triggered release of pyridine from the series of water-soluble model 
complexes [Ru([9]aneS3)(chel)(py)](Cl)2 was thoroughly investigated as a function 
of the nature of thechelating diimine (chel = 2,2′-bipyridine (bpy, 68) 1,10-
phenanthroline (phen, 69), 4,7-diphenil-1,10-phenanthroline (Ph2phen, 70), 
dipyrido-[3,2-a:2′,3′-c]phenazine (dppz, 71), 2,2′-biquinoline (bq, 72)) (Figure 
8.11). In 68 – 72, owing to the face-capping 1,4,7-trithiacyclononane ligand 
([9]aneS3), the leaving ligand (py) and the diimine have a facial arrangement. Our 
aim is that of establishing if this type of complexes in the future might be realistically 
used in photoactivated chemotherapy (PACT). 
 
Figure 8.11. Schematic representation of complexes studied for the photo-triggered release of 
pyridine. 
 
We found that compounds 68 – 71 behave quite homogeneously and their 
photochemical behavior is not particularly affected by the nature of the diimine: 
when irradiated with light at 470 nm, they rapidly and quantitatively release the 
coordinated pyridine, generating selectively the corresponding aqua species 
[Ru([9]aneS3)(chel)(OH2)]
2+ (63aq – 66aq). Even though 68 was found to be non-
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phototoxic against the MDA-MB-231 human mammary carcinoma cells,25 in the 
future we plan to investigate the phototoxicity also of 69 – 71, as well as the 1O2 
production on selected compounds. The more lipophilic compounds in the series 
might be expected to have better accumulation in cancer cells and potentially show 
higher phototoxicity. We also argue that upon illumination the extended aromatic 
dppz ligand could generate singlet oxygen, thus giving to complex 71 two 
mechanisms of phototoxicity.  
In addition, we plan to bind the anticancer drug CHS-828 (Figure 8.12) in the place 
of pyridine on the {Ru([9]aneS3)(chel)} scaffold,
39 and investigate its photo-
triggered release also in terms of in vitro phototoxicity against cancer cell lines. The 
photo-uncaging of anticancer drugs is a PACT strategy that does not require the 
concomitant formation of a cytotoxic metal fragment.  
 
Figure 8.12. Schematic structure of the anticancer drug CHS-828. 
 
Complex 72 turned out to behave quite differently from to the others in the series. 
As expected, the low-lying acceptor orbitals of bq induce a red-shift in the MLCT 
absorption maximum of the complex from ca. 430 to ca. 500 nm. However, contrary 
to the expectations, complex 10 turned out to be more photo-stable compared to 68 
– 71 and – upon prolonged illumination with blue light – photo-dissociation of both 
py and bq, in ca. equal amounts, occurs. The single crystal X-ray structure of 72 
showed that in this complex, besides the expected distortion of coordinated bq due 
to its steric demand (a >35° tilt relative to the equatorial coordination plane), the 
orientation of py is ca. orthogonal compared to that found in 68 and 69. A detailed 
theoretical investigation performed on 72 (and on 68 for comparison), showed that 
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the biquinoline-induced geometrical distortions lead to differences in the nature of 
the excited states that might account for the different  photochemical behavior of this 
complex.  
In view of the potential investigation of these complexes as PACT agents, we 
observe that – unlike the rest of the series – upon irradiation with visible light 
complex 72 could generate in vivo a Ru(II)-aqua species with two or even three 
coordination sites that is expected to be more reactive, and thus more cytotoxic, 
compared to the mono-aqua species generated from 68 – 71 (e.g. it might be capable 
of cross linking DNA). Consistent with this hypothesis, we found that the 
[Ru([9]aneS3)(py)(OH2)2]
2+ species binds rapidly the small amount of photo-
released pyridine.  
Finally, in the future it would be interesting to make the 6,6′-dimethyl-2,2′-bipyridine 
(dmbpy) analogue of these complexes. It might be expected to behave similarly to 
the bq complex and the photo-released dmbpy could induce cell death according to 
what shown by Bonnet and coworkers.22 
 
 
Chapter 8: Photolabile Complexes for Light-Triggered Drug Release  
 
 
227 
 
8.8 Bibliography
1 a) D. E. J. G. J. Dolmans, D. Fukumura, R. K. Jain, Nat. Rev. Cancer, 2003, 3, 380 
- 387; b) A. Juzeniene, Q. Peng, J. Moan, Photochem. Photobiol. Sci., 2007, 6, 1234 
- 1245; c) T. Debele, S. Peng, H.-C. Tsai, Int. J. Mol. Sci., 2015, 16, 22094 - 22136. 
2 G. Mayer, A. Heckel, Angew. Chem. Int. Ed., 2006, 45, 4900 - 4921. 
3 K. Szaciłowski, W. Macyk, A. Drzewiecka-Matuszek, M. Brindell, G. Stochel, 
Chem. Rev., 2005, 105, 2647 - 2694. 
4 a) N. J. Farrer, L. Salassa, P. J. Sadler, Dalton Trans., 2009, 10690 - 10701; b) N. 
A. Smith, P. J. Sadler, Phil. Trans. R. Soc. A, 2013, 371, 20120519. 
5 U. Schatzschneider, Eur. J. Inorg. Chem., 2010, 1451 - 1467. 
6 E. Ruggiero, S. Alonso-de Castro, A. Habtemariam, L. Salassa, Struct. Bond., 2015, 
165, 69 - 108. 
7 J. D. Knoll, C. Turro, Coord. Chem. Rev., 2015, 282-283, 110 - 126. 
8 H. Yin, M. Stephenson, J. Gibson, E. Sampson, G. Shi, T. Sainuddin, S. Monro, S. 
A. McFarland, Inorg. Chem., 2014, 53, 4548 - 4559. 
9 C. Mari, V. Pierroz, S. Ferrari, G. Gasser, Chem. Sci., 2015, 6, 2660 - 2686. 
10 V. H. S. van Rixel, B. Siewert, S. L. Hopkins, S. H. C. Askes, A. Busemann, M. 
A. Sieglerb, S. Bonnet, Chem. Sci., 2016, 7, 4922 - 4929. 
11 a) M. Ethirajan, Y. Chen, P. Joshi, R. K. Pandey, Chem. Soc. Rev., 2011, 40, 340 
- 362; b) A. B. Ormond, H. S. Freeman, Materials, 2013, 6, 817 - 840. 
12 http://theralase.com/pressrelease/health-canada-approves-clinical-trial-
application-anti-cancer-drug/. http://theralase.com/pressrelease/theralase-research-
published-international-peer-reviewed-journal/. 
13 a) G. Shi, S. Monro, R. Hennigar, J. Colpitts, J. Fong, K. Kasimova, H. Yin, R. 
DeCoste, C. Spencer, L. Chamberlain, A. Mandel, L. Lilge and S. A. McFarland, 
Coord. Chem. Rev., 2015, 282 - 283, 127 - 138; b) J. Fong, K. Kasimova, Y. Arenas, 
P. Kaspler, S. Lazic, A. Mandel, L. Lilge, Photochem. Photobiol. Sci., 2015, 14, 
 
Chapter 8: Photolabile Complexes for Light-Triggered Drug Release  
 
 
228 
 
 
2014 - 2023; c) P. Kaspler, S. Lazic, S. Forward, Y. Arenas, A. Mandela, L. Lilge, 
Photochem. Photobiol. Sci., 2016, 15, 481 - 495. 
14 a) B. S. Howerton, D. K. Heidary, E. C. Glazer, J. Am. Chem. Soc., 2012, 134, 
8324 - 8327; b) E. Wachter, D. K. Heidary, B. S. Howerton, S. Parkin, E. C. Glazer, 
Chem. Commun., 2012, 48, 9649 - 9651; c) D. Havrylyuk, D. K. Heidary, L. Nease, 
S. Parkin, E. C. Glazer, Eur. J. Inorg. Chem., 2017, 1687 - 1694.  
15 J. D. Knoll, B. A. Albani, C. B. Durr, C. Turro, J. Phys. Chem. A, 2014, 118, 10603 
- 10610. 
16 a) S. Betanzos-Lara, L. Salassa, A. Habtemariam, P. J. Sadler, Chem. Commun., 
2009, 6622 - 6624; b) S. Betanzos-Lara, L. Salassa, A. Habtemariam, O. Novakova, 
A. M. Pizarro, G. J. Clarkson, B. Liskova, V. Brabec, P. J. Sadler, Organometallics, 
2012, 31, 3466 - 3479. 
17 a) M. A. Sgambellone, A. David, R. N. Garner, K. R. Dunbar, C. Turro, J. Am. 
Chem. Soc., 2013, 135, 11274 - 11282; b) Y. Chen, W. Lei, G. Jiang, Y. Hou, C. Li, 
B. Zhang, Q. Zhou, X. Wang, Dalton Trans., 2014, 43, 15375 - 15384; c) J. D. Knoll, 
B. A. Albani, C. Turro, Acc. Chem. Res., 2015, 48, 2280 - 2287; d) T. Sainuddin, M. 
Pinto, H. Yin, M. Hetu, J. Colpitts, S. A. McFarland, J. Inorg. Biochem., 2016, 158, 
45 - 54. 
18 T. Joshi, V. Pierroz, C. Mari, L. Gemperle, S. Ferrari, G. Gasser, Angew. Chem. 
Int. Ed., 2014, 53, 2960 - 2963; b) C. Mari, V. Pierroz, A. Leonidova, S. Ferrari, G. 
Gasser, Eur. J. Inorg. Chem., 2015, 3879 - 3891. 
19 a) A. N. Hidayatullah, E. Wachter, D. K. Heidary, S. Parkin, E. C. Glazer, Inorg. 
Chem., 2014, 53, 10030 - 10032; b) K. T. Hufziger, F. S. Thowfeik, D. J. 
Charboneau, I. Nieto, W. G. Dougherty, W. S. Kassel, T. J. Dudley, E. J. Merino, E. 
T. Papish, J. J. Paul, J. Inorg. Biochem., 2014, 130, 103 - 111. 
20 a) T. Respondek, R. N. Garner, M. K. Herroon, I. Podgorski, C. Turro, J. J. 
Kodanko, J. Am. Chem. Soc., 2011, 133, 17164 - 17167; b) R. Sharma, J. D. Knoll, 
P. D. Martin, I. Podgorski, C. Turro, J. J. Kodanko, Inorg. Chem., 2014, 53, 3272 -
3274; c) N. Karaoun, A. K. Renfrew, Chem. Commun., 2015, 51, 14038 - 14041; H. 
Chan, J. B. Ghrayche, J. Wei, A. Renfrew, Eur. J. Inorg. Chem., 2017, 1679 - 1686. 
21 A. Zamora, C. A. Denning, D. K. Heidary, E. Wachter, L. A. Nease, J. Ruiz, E. C. 
Glazer, Dalton Trans., 2017, 46, 2165 - 2173. 
Chapter 8: Photolabile Complexes for Light-Triggered Drug Release  
 
 
229 
 
 
22 J. A. Cuello-Garibo, M. S. Meijer, S. Bonnet, Chem. Commun., 2017, 53, 6768 -
6771. 
23 G. Ragazzon, I. Bratsos, E. Alessio, L. Salassa, A. Habtemariam, R. J. McQuitty, 
G. J. Clarkson, P. J. Sadler, Inorg. Chim. Acta, 2012, 393, 230 - 238. 
24 The photo-triggered ligand release is more efficient compared to the corresponding 
photoactivable organometallic compounds of the type [Ru(η6-arene)(N-
N)(py)](PF6)2 previously developed by Sadler and co-workers (ref 16). 
25 I. Finazzi, I. Bratsos, T. Gianferrara, A. Bergamo, N. Demitri, G. Balducci, E. 
Alessio, Eur. J. Inorg. Chem., 2013, 4743 - 4753. 
26 F. Barigelletti, A. Juris, V. Balzani, P. Belser, A. von Zelewsky, Inorg. Chem., 
1983, 22, 3335 - 3339. 
27 E. Baranoff, J.-P. Collin, J. Furusho, Y. Furusho, A.-C. Laemmel, J.-P. Sauvage, 
Inorg. Chem., 2002, 41, 1215 - 1222. 
28 B. J. Goodfellow, V. Félix, S. M. D. Pacheco, J. P. de Jesus, M. G. B. Drew, 
Polyhedron, 1997, 16, 393 - 401.  
29 J. Madureira, T. M. Santos, B. J. Goodfellow, M. Lucena, J. P. de Jesus, M. G. 
Santana-Marques, M. G. B. Drew, V. Félix, J. Chem. Soc., Dalton Trans., 2000, 
4422 - 4431. 
30 B. Machura, R. Kruszynski, Polyhedron 2007, 26, 3336 - 3342. 
31 a) J. A. G. Drake, D. W. Jones, Org. Magn. Res., 1982, 18, 42 - 44; b) A. G. 
Osborne, R. Green, I. H. Sadler, D. Reed, Magn. Res. Chem., 1989, 27, 4 - 12. 
32 S. A. Moya, J. Guerrero, R. Pastene, R. Schmidt, R. Sariego, R. Sartori, J. Sanz-
Aparicio, I. Fonseca, M. Martinez-Ripoll, Inorg. Chem., 1994, 33, 2341 - 2346. 
33 R. Lalrempuia, M. R. Kollipara, Polyhedron, 2003, 22, 3155 - 3160. 
34 P. Belser, A. von Zelewsky, Helv. Chim. Acta, 1980, 63, 1675 - 1702. 
35 We found that in the 1H NMR spectra of complexes 67, 72, and 74, the chemical 
shifts of the bq protons are remarkably affected by the nature of the solvent (e.g. 
DMSO-d6 vs D2O), even though the sequence order is maintained (Appendix, A8.6). 
Chapter 8: Photolabile Complexes for Light-Triggered Drug Release  
 
 
230 
 
 
36 J. A. Cuello-Garibo, E. Perez-Gallent, L. van der Boon, M. A. Siegler, S. Bonnet, 
Inorg. Chem., 2017, 56, 4818 - 4828. 
37 The calculated UV-vis spectra of complexes 67 and 72 reproduce quite well the 
general spectral features, even though the absorption bands are red-shifted of ca. 60 
nm compared to experimental spectra. Calculations were performed in the vacuo and 
this might be one of the reasons for this general shift. To be noted that in ref. 23 the 
singlet excited state transitions for complex 67, calculated with a different approach, 
had a numerically similar shift – but in the opposite direction – with respect to the 
experimental transitions.  
38 The photo-release of bq from 72 is not attributable to the longer irradiation times: 
it occurs (in low amounts) also for short irradiation times and increases with the 
irradiation time, i.e. it is not a photo-bleaching of the complex. 
39 P. Hovstadius, R. Larsson, E. Jonsson, T. Skov, A.-M. Kissmeyer, K. Krasilnikoff, 
J. Bergh, M. O. Karlsson, A. Lönnebo, J. Ahlgren, Clin. Cancer Res., 2002, 8, 2843 
- 2850. 
 
  
  
 
 
 
 
CHAPTER 9 
  
  
 
  
 233 
 
Experimental Section 
9.1 Materials  
All chemicals were purchased from Sigma-Aldrich and used as received. Solvents 
were of reagent grade. The precursors trans-RuCl2(PTA)4 (1)
1 cis-RuCl2(dmso)4 (8)
2 
trans-RuCl2(dmso-S)4 (9),
2 cis,fac-[RuCl(dmso-O)2(dmso-S)3](PF6) (20),
3 fac-
[Ru(dmso-O)3(dmso-S)3](CF3SO3)2 (21),
4 cis,cis,cis-RuCl2(CO)2(dmso-O)2 (28),
5 
trans,cis,cis-RuCl2(CO)2(dmso-O)2 (29),
5 Ru([9]aneS3)Cl2(dmso) (58),
6 
[Ru([9]aneS3)Cl(PTA)]Cl (59),
7 [(dmso)2H]trans-[RuCl4(dmso-S)2]
8
 and the ligands 
bpyAc,9 mpp10 and cppH10 were synthesized as described in the literature. 
 
9.2 Instrumental methods 
Mono- (1H (400 or 500 MHz), 13C (125.7 MHz), 31P (161 or 202 MHz)) and bi-
dimensional (1H-1H COSY, 1H-13C HSQC, 31P-31P COSY and 1H-31P HMBC, 1H-1H 
NOESY) NMR spectra were recorded at room temperature on a JEOL Eclipse 
400FT, on a Varian 400 or on a Varian 500 spectrometer. 1H and 13C chemical shifts 
were referenced to the peak of residual non-deuterated solvent (δ = 7.26 and 77.16 
for CDCl3, 2.50 and for 39.52 DMSO-d6) or were measured relative to the internal 
standard DSS (δ = 0.00) for D2O. 31P chemical shifts were measured relative to 
external 85% H3PO4 at 0.00 ppm. 
1H-31P HMBC were recorded using the standard 
sequence HMBCAD on the Varian 500 spectrometer with a coupling constant (2J) 
of 5-10 Hz.  
The 15N NMR spectra (50.65 MHx) were recorded using the standard 1H-15N 
gHMBC sequence of the 500 MHz Varian spectrometer. Multiple bond-correlation 
experiments were optimized with the following coupling constants: 3J(15N, 1H) = 1.8 
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Hz and 2J(15N, 1H) = 11 Hz. A relaxation delay of 1s was used in all experiments on 
the free ligands and in the experiments with 2J(15N, 1H) = 11 Hz on the complexes, 
whereas a delay of 2s was used in the long range coupling experiments performed 
on the complexes. The number of transients per increment was either 32 or 64 with 
a total acquisition time ranging from 3 to 11 h. 
ESI mass spectra were collected in the positive mode (when not specified) and 
negative mode on a Perkin-Elmer APII spectrometer at 5600 eV.  
UV-vis spectra were obtained on an Agilent Cary 60 spectrophotometer, using 1.0 
cm path-length quartz cuvettes (3.0 mL).  
Solid state infrared spectra were obtained as Nujol mulls between NaCl plates and 
recorded on a Perkin-Elmer Fourier transform infrared/Raman 2000 instrument in 
the transmission mode. Solution spectra (CHCl3, MeOH and EtOH) in the CO 
stretching region were recorded between CaF2 plates (0.5 mm spacer).  
A pressurized vessel (autoclave) connected to a thermostat was used for the reaction 
with CO at different pressure (30, 40 or 50 atm). 
A CEM Discover microwave reactor was used for the microwave assisted reactions 
using a 10 mL vessel. 
Elemental analyses were performed in the Department of Chemistry of the 
University of Bologna (Italy). 
Elemental analyses were performed in the Department of Chemistry of the 
University of Bologna (Italy).  
A home-made LED apparatus was used for performing the photochemical reactions. 
Briefly, it consists of a plastic-coated cylindric well capable of hosting an NMR tube 
or a test-tube (Ø = 20 mm, h = 110 mm). The inside of the apparatus is lined with 
four pairs of LED stripes, each containing five LEDs of the same color that emit in 
a narrow spectral range (ca. 10 nm). LED stripes of the same color are located 
opposite to each other. One or more colors can be activated at the same time, and the 
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LED emission power can be regulated from 1 to 40 mW. The blue (λ = 470 nm) and 
green (λ= 530 nm) LEDs were used in this case.  
HPLC analysis and purification: Analytical HPLC was performed on a Smartline 
instrument (Knauer, Berlin, Germany) with a Reprosil-Pur C-18 reversed-phase 
column at a flow rate of 1.0 mL/min. Preparative HPLC was performed on a Varian 
Prostar with a HIBAR Lichrospher 100 RP-18e reversed-phase column at a flow rate 
of 20 mL/min. Analytical and preparative runs were performed with a linear gradient 
of 5% buffer B per min starting at 5 min of buffer A (buffer A = H2O/MeCN/TFA 
95:5:0.1, v/v/v, buffer B = MeCN/H2O/TFA 95:5:0.1, v/v/v) was used.  
Lyophilization was performed on an ALPHA 1-4 LDplus lyophilizator (Martin 
Christ, Osterode am Harz, Germany). 
9.3 X-ray diffraction measurements 
Data collections were performed by Dr. Gabriele Balducci (University of Trieste) at 
the X-ray diffraction beamline (XRD1) of the Elettra Synchrotron of Trieste (Italy) 
equipped with a Pilatus 2M image plate detector. 
Collection temperature was 100K (nitrogen stream supplied through an Oxford 
Cryostream 700); the wavelength of the monochromatic X-ray beam was 0.700°A 
and the diffractograms were obtained with the rotating crystal method. The crystals 
were dipped in N-paratone and mounted on the goniometer head with a nylon loop. 
The diffraction data were indexed, integrated and scaled using the XDS code.11 The 
structures were solved by the dual space algorithm implemented in the SHELXT 
code.12 Fourier analysis and refinement were performed by the full-matrix least-
squares methods based on F2 implemented in SHELXL.13 The Coot program was 
used for modeling.14 Anisotropic thermal motion was allowed for all non-hydrogen 
atoms. Hydrogen atoms were placed at calculated positions with isotropic factors U 
= 1.2×Ueq, Ueq being the equivalent isotropic thermal factor of the bonded non 
hydrogen atom. 
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9.4 Spectrophotometric studies 
To assess the stability of the compounds in physiological like conditions, 
spectrophotometric studies were performed by a Varian Cary 50 Bio UV–vis 
spectrophotometer. Freshly prepared concentrated solutions (10–2 M for compounds 
1, 2, 11 and 12, 10–4 M for compound 3) of each compound dissolved in milliQ water 
were diluted in phosphate buffer (PB, 10 mM phosphate, pH 7.4). The concentration 
of each compound in the final sample was 3×10−5 M. The resulting solutions were 
monitored by collection of the electronic spectra for 24 h at room temperature. 
9.5 Interactions with biomolecules 
Ruthenium complex–protein/oligonucleotide adducts were prepared starting from a 
solution of each model protein at a concentration of 10–4 M in 20 mM ammonium 
acetate buffer, pH 7.4, or from a 10–4 M solution of ODN4 in milliQ water. Then, 
the ruthenium complex was added (3:1 metal-to-protein/oligonucleotide ratio) to the 
solution and the mixture was incubated at 37 °C for 24 h, using Thermoblock (Falc, 
TD15093). Protein samples were analyzed after a 20-fold dilution with milliQ water 
(the final concentration of the protein was 5 µM), while ODN4 samples were diluted 
with a mixture of 50% milliQ water and 50% MeOH to a final concentration of 10 
µM. ESI-MS spectra were recorded by direct introduction of the sample at a flow 
rate of 5 μL/min into an Orbitrap high-resolution mass spectrometer (Thermo 
Scientific, San Jose, CA, USA) equipped with a conventional ESI source. The 
working conditions for ruthenium complex-protein adducts were as follows: spray 
voltage 3.1 kV, capillary voltage 45 V and capillary temperature 220 °C. The sheath 
and the auxiliary gasses were set at 17 (arbitrary units) and 1 (arbitrary unit), 
respectively. For acquisition, Xcalibur 2.0 (Thermo Scientific) was used and 
monoisotopic and average deconvoluted masses were obtained by using the 
integrated Xtract tool. For spectrum acquisition, a nominal resolution (at m/z 400) 
Chapter 9: Experimental Section  
 
 
237 
 
of 100,000 was used. ESI-MS spectra of the ruthenium complex-ODN adducts were 
recorded in negative ion mode. The working conditions were as follows: spray 
voltage 4.5 kV, capillary voltage –10 V and capillary temperature 270 °C. The sheath 
gas was set at 10 (arbitrary units) whereas auxiliary gas was kept at 5 (arbitrary 
units). 
9.6 Cellular studies 
Cell cultures. HCT-116 (human colon cancer) and FLG 29.1 (human myeloid 
leukemia) cell lines were maintained in RPMI 1640 medium supplemented with 2 
mM L-glutamine, 10% bovine calf serum (HyClone) and maintained at 37°C in a 
humidified atmosphere in 5% CO2 in air.  
Pharmacology experiments. Cells were seeded in a 96-well flat-bottomed plate 
(Corning-Costar, Corning, NY, USA) at a cell density of 104 cells per well in RPMI 
complete medium. Each ruthenium compound (1, 2, 3, 11 and 12) was added at final 
concentrations of 200 µM, 100 µM, 50 µM, 10 µM, and 2 µM. After 24 h, viable 
cells (determined by Trypan blue exclusion) were counted in triplicate using a 
haemocytometer. Each experimental point represents the mean of four samples 
carried out in three separate experiments.  
Trypan blue assay. Cells viability was assessed by the Trypan blue exclusion assay. 
In brief, 10 µl of 0.4% trypan blue solution was added to 10 µl cell suspension in 
culture medium. The suspension was gently mixed and transferred to a 
haemocytometer. Viable and dead cells were identified and counted under a light 
microscope. Blue cells failing to exclude dyes were considered nonviable, and 
transparent cells were considered viable. The percentage of viable cells was 
calculated on the basis of the total number of cells (viable plus nonviable). The IC50 
value (i.e. the dose that caused apoptosis of 50% of cells) was calculated by fitting 
the data points (after 24 h of incubation) with a sigmoidal curve using Calcusyn 
software (Biosoft). 
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MTT assay. Dulbecco’s Modified Eagle’s Medium (DMEM), containing 10% fetal 
calf serum, 1% penicillin and streptomycin, was used as growth medium. MCF-7, 
HT-29 and PT-45 cells were detached from the wells with trypsin and EDTA, 
harvested by centrifugation and resuspended again in cell culture medium. The 
assays have been carried out on 96 well plates with 6000 cells per well for all the cell 
lines. After 24 h of incubation at 37° C and 10% CO2, the cells were treated with the 
compounds 29, 51, 52, 57 - 59, 61, 62 at 1, 10, 20, 40, 80, 100, 200 µM concentration 
(with DMSO concentrations of 0.5%) with a final volume of 200 µL per well. For a 
negative control, one series of cells was left untreated. The cells were incubated for 
48 h followed by adding 50 µL MTT (2.5 mg/mL). After an incubation time of 2 h, 
the medium was removed and 200 µL DMSO were added. The formazan crystals 
were dissolved and the absorption was measured at 550 nm, using a reference 
wavelength of 620 nm. 
9.7 Computational methods 
Calculations were done by Dr. Gabriele Balducci. It was performed periodic first 
principle calculations in the frame of density functional theory (DFT) with the Kohn–
Sham orbitals expanded in a basis of plane waves and the effects of atomic core 
regions accounted for by pseudopotentials. The QUANTUM ESPRESSO suite of 
codes was used for all the computations.15 To model an isolated molecule using a 
periodic code like QUANTUM ESPRESSO, a “molecule in the box” approach can 
be used: a single molecule is simulated in a unit cell large enough to minimize any 
interaction between the molecule itself and any of its periodic images. A cubic unit 
cell with edge length of 19.0 Å for complex 68 and 20.0 Å for complex 72 was found 
to give a minimum separation of 10 Å between nearest atoms of any two contiguous 
images. Both total energy and scf potential were corrected for the effect of the 
fictitious periodicity with the Martyna-Tuckerman method.16 Ultrasoft 
pseudopotentials were used throughout the calculations.17 The exchange–correlation 
Chapter 9: Experimental Section  
 
 
239 
 
part of the energy functional was modeled with the (spin-unpolarized) generalized 
gradient approximation (GGA), in the PBE parameterization.18 The plane wave 
expansion of the crystalline orbitals was truncated at a cutoff energy of 340 eV and 
a corresponding tenfold cutoff was used for the expansion of the augmentation 
charge needed by the ultrasoft pseudopotential method. Integrals over the first 
Brillouin zone in reciprocal space were approximated by evaluations of the integrand 
functions at the gamma point. Convergence thresholds for geometry optimization 
were 1.4 × 10−4 eV for total energy and 2.6 × 10−2 eV/Å for the maximum force 
component acting on atoms; a threshold of 1.4 × 10−8 eV was imposed for self-
consistency. Excited state calculations and UV–vis spectra simulation were 
performed with time dependent DFT (TDDFT). The QUANTUM ESPRESSO suite 
offers two codes for this purpose. The “turbo_davidson” code implements an 
improved Davidson-like algorithm for the computation of individual excitations 
clustered around a target energy value, which, differently from the “conventional” 
Davidson algorithm, can be located anywhere in the spectrum. The “turbo_lanczos” 
program uses a so-called “pseudo-Hermitian” variant of the recursive Lanczos 
scheme to evaluate the whole absorption spectrum in a given energy range using only 
the occupied states obtained in a previous self-consistent field calculation. Both 
codes rely upon the formulation of the TDDFT problem in terms of the linearized 
quantum Liouville equation and the details about the algorithms can be found in the 
original papers.19,20 60 trial vectors, a maximum of 200 basis vectors in the Davidson 
subspace and a convergence threshold of 1.0×10−4 for the squared modulus of the 
residue were used for the “turbo_davidson” runs; 5000 Lanczos iterations for each 
of the three directions of the full dynamical polarizability tensor were used in the 
UV–vis spectrum simulation with the “turbo_lanczos” code. 
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9.8 Synthesis of the complexes 
cis-RuCl2(PTA)4 (2). 
 
A procedure similar to that reported by Romerosa and co-workers,21 i.e. photo-
isomerization of 1 in aqueous solution, was followed. trans-RuCl2(PTA)4 (1, 50.0 
mg, 0.062 mmol) was dissolved in 5 mL of water and irradiated with blue light (λ = 
470 nm, 40 mW) for 1 h, during which time the orange solution turned to yellow. 
Complete removal of the solvent by rotary evaporation afforded pure 1, according to 
1H and 31P NMR spectra, as a yellow solid (Yield: 48.0 mg, 96%). Elemental analysis 
calcd for [C24H48N12Cl2P4Ru] (MW: 800.57): C 36.01; H 6.04; N 20.99. Found: C 
36.12; H 6.19; N 21.12. 1H NMR (D2O + NaCl), δ (ppm): 4.65 (m, 24H, NCH2N), 
4.47 (br s, 12H, NCH2P, mutually trans PTAs), 4.14 (br s, 12H, NCH2P, PTA trans 
to Cl). 31P NMR (D2O+ NaCl), δ (ppm): –21.6 (t, 2P, 2JP-P = 28.5 Hz, PTA trans to 
Cl), –57.6 (t, 2P, mutually trans PTAs).1H NMR (CDCl3), δ (ppm): 4.48 (m, 24H, 
NCH2N), 4.47 (br s, 12H, NCH2P, mutually trans PTAs), 4.04 (br s, 12H, NCH2P, 
PTA trans to Cl). 13C NMR from the HSQC spectrum (CDCl3), δ (ppm): 73.1 
(NCH2P), 58.7 (NCH2N mutually trans PTAs), 54.8 (NCH2P PTAs trans to Cl) 
31P 
NMR (CDCl3), δ (ppm): –24.1 (t, 2P, 2JP-P = 28.6 Hz, PTAs trans to Cl), –59.4 (t, 
2P, mutually trans PTAs). ESI mass spectrum: 765.1 m/z (calcd 765.1) (M – Cl)+, 
608.2 m/z (calcd 608.0) (M – Cl – PTA)+. UV-vis (CHCl3): λmax (ε, L mol–1 cm–1) = 
344 (1022) nm. 
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cis-[RuCl(OH2)(PTA)4](PF6)·CH3OH (2aq). 
 
[RuCl(dmso)5](PF6) (38.3 mg, 0.057 mmol) was dissolved in 10 mL of methanol. 
Five eq. of PTA (44.8 mg, 0.29 mmol) were added and the solution was left standing 
overnight in the dark. Yellow crystals formed slowly from the concentrated solution 
(5 mL). Some crystals were fished out for X-ray diffraction, the others were filtered, 
washed with diethyl ether and dried in vacuo (Yield: 22.8 mg, 42%). 
[C24H50N12ClP5F6ORu∙CH3OH] (MW: 960.15): C 31.27; H 5.67; N 17.51. Found: C 
31.47; H 5.83; N 17.70. 1H-NMR (D2O), δ (ppm): 4.59 (m, 24H, NCH2N), 4.26 (d, 
12H, NCH2P), 4.11 (s, 6H, NCH2P), 3.97 (s, 6H, NCH2P), 3.34 ppm (s, 3H, MeOH 
free). 31P-NMR (D2O), δ (ppm): –12.7 (dt, 1P, 2JAM = 30.3 Hz, 2JAX = 34.8 Hz, PTA 
trans to OH2), –22.7 (dt, 1P, 2JXM = 26.1 Hz, 2JXA = 34.8Hz, PTA trans to Cl), –52.6 
(dd, 2P, 2JMX = 26.1 Hz, 
2JMA = 30.3 Hz, mutually trans PTAs), –143.2 (septet, 1P, 
PF6). ESI mass spectrum: 765.1 m/z (calcd 765.1) (M – H2O)+. 
trans-[RuCl4(PTAH)2]Cl (3). 
 
[(dmso)2H]trans-[RuCl4(dmso-S)2] (150.0 mg, 0.27 mmol) was dissolved in 15 mL 
of methanol, obtaining an orange solution. 0.500 µL of 37% aqueous HCl and two 
equivalents of PTA (84.8 mg, 0.54 mmol) were added; a brown solid began to 
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precipitate immediately. The mixture was stirred for 1 h and then the solid was 
collected by filtration, washed with methanol and diethyl ether and dried in vacuo. 
The solid was dissolved in 4.5 mL of water at reflux. Abundant small crystals of 3, 
suitable for X-ray diffraction, were obtained upon allowing the solution to cool down 
to room temperature. The crystals were filtered, washed with a small amount of water 
and dried in vacuo (yield: 115.8 mg, 72%). Elemental analysis calcd for 
[C12H26N6Cl5P2Ru∙2H2O] (MW: 630.67): C 22.85; H 4.79; N 13.33. Found: C 23.36; 
H 4.51; N 13.05. 1H NMR (D2O), δ (ppm): 0.37 (br s, 12H), –1.17 (br s, 12H). ESI 
mass spectrum: 400.7 m/z (M – PTA)–, calcd 400.0. 
cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10).  
 
A different procedure compared to that reported by Kathó and coworkers was 
followed.22 cis-RuCl2(dmso-S)4 (8) (340 mg, 0.70 mml) was partially dissolved in 5 
mL of methanol. A solution of PTA (220 mg, 1.4 mmol, 10 ml of methanol) was 
added dropwise in 15 minutes. A pale yellow solid began to form after few minutes. 
The product was filtered after standing overnight, washed with methanol and diethyl 
ether and dried in vacuo (Yield: 357 mg, 80%). According to the 1H and 31P NMR 
spectra the product was pure 10. X-ray quality crystals of 10 were obtained by slow 
diffusion of diethyl ether into a methanol solution of the complex. Elemental analysis 
calcd for [C16H36N6Cl2P2S2OsRu] (MW: 642.55): C 29.91; H 5.65; N 13.08. Found: 
C 29.99; H 5.60; N 13.15. 1H NMR (D2O), δ (ppm): 4.51 (br s, 12H, NCH2N), 4.32 
(br s, 12H, NCH2P), 3.38 (s, 12H, dmso-S). 
31P NMR (D2O), δ (ppm): –57.9 (s). 1H 
NMR (CDCl3), δ (ppm): 4.52, 4.47 (ABq, 12H, JAB = 13.0 Hz, NCH2N), 4.41 (br s, 
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12H, NCH2P), 3.32 (s, 12H, dmso-S). 
13C NMR (CDCl3), δ (ppm): 73.1 (NCH2N), 
51.3 (NCH2P), 51.1 (dmso-S). 
31P NMR (CDCl3), δ (ppm): –63.5 (s). ESI mass 
spectrum: 643.0 m/z (calcd 643.3) (M+). 
trans-RuBr2(PTA)4 (11). 
 
RuBr3∙3H2O (60.0 mg, 0.15 mmol) was partially dissolved in 7 mL of ethanol. A 
slight excess of PTA (96.55 mg, 0.615 mmol) was added and the mixture was 
refluxed for 3 h. A clear solution was obtained within 1 h from which a dark red solid 
began to form. It was eventually removed by filtration and washed with ethanol. The 
solid was treated on the filter with chloroform (ca. 10 mL) to obtain an orange 
solution. A small amount of grey solid that remained undissolved on the filter was 
discarded. The solvent was completely removed by rotary evaporation, affording 
pure 11, according to 1H and 31P NMR spectra (Yield: 93.9 mg, 68%). X-ray quality 
crystals of 11 were obtained by slow diffusion of diethyl ether into a chloroform 
solution of the complex. Elemental analysis for the raw material: calcd for 
[C24H48N12Br2P4Ru·5H2O] (MW: 979.48): C, 29.43; H, 5.97; N, 17.16. Found: C, 
29.57; H, 6.10; N, 17.09. 1H NMR (D2O), δ (ppm): 4.61 (br s, 24H, NCH2N), 4.40 
(br s, 24H, NCH2P). 
13C NMR from the HSQC spectrum (D2O), δ (ppm): 70.5 
(NCH2N), 51.9 (NCH2P). 
31P-NMR (D2O), δ (ppm): –54.5 (s). 1H NMR (CDCl3), δ 
(ppm): 4.60, 4.55 (ABq 24H, NCH2N, JAB 13.2 Hz), 4.46 (br s, 24H, NCH2P). 
13C 
NMR from the HSQC spectrum (CDCl3), δ (ppm): 73.5 (NCH2N), 54.0 (NCH2P). 
31P NMR (CDCl3), δ (ppm): –56.5 (s). ESI mass spectrum (m/z): 811.12 (M – Br)+, 
calcd 811.59; 733.97 (M – PTA + H+)+, calcd 733.32. 
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cis-RuBr2(PTA)4 (12). 
 
trans-RuBr2(PTA)4 (11) (50.0 mg, 0.056 mmol) was dissolved in 5 mL of water and 
irradiated with blue light (λ = 470 nm, 40 mW) for 2.30 h. The orange solution turned 
to yellow within 1 h. Complete removal of the solvent by rotary evaporation afforded 
pure 12, according to 1H and 31P NMR spectra, as a yellow solid (Yield: 48.0 mg, 
96%). X-ray quality crystals of 12 were obtained by slow diffusion of acetone into a 
water solution of the complex. Elemental analysis calcd for 
[C24H48N12Br2P4Ru·5H2O] (MW: 979.48): C, 29.43; H, 5.97; N, 17.16. Found: C, 
29.55; H, 6.109; N, 17.07.1H NMR (D2O + exc. NaBr, see Chapter 1), δ (ppm): 4.70 
(m, 24H, NCH2N), 4.56 (br s, 12H, NCH2P), 4.23 (br s, 12H, NCH2P). 
31P NMR 
(D2O + exc. NaBr, see Chapter 1), δ (ppm): –24.1 (t, 2P, 2JP-P = 28.2 Hz, PTA trans 
to Br), –64.7 (t, 2P, 2JP-P = 28.2 Hz, mutually trans PTAs). 1H NMR (CDCl3), δ 
(ppm): 4.54 (br s, 12H, NCH2P), 4.50 (m, 24H, NCH2N), 4.12 (br s, 12H, NCH2P). 
13C NMR from the HSQC spectrum (CDCl3), δ (ppm): 73.0 (NCH2N), 59.2 
(NCH2P), 55.4 (NCH2P). 
31P NMR (CDCl3), δ (ppm): –27.0 (t, 2P, 2JP-P = 27.4 Hz , 
PTA trans to Br), –67.3 (t, 2P, 2JP-P = 27.4 Hz, mutually trans PTAs). ESI mass 
spectrum (m/z): 811.12 (M – Br)+, calcd 811.59. 
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cis,mer-RuCl2(dmso-S)(PTA)3 (13). 
 
trans-RuCl2(PTA)4 (1) (30.0 mg, 0.038 mmol) was partially dissolved in 1 mL of 
DMSO and the mixture was warmed to 70°C under stirring. After 2h of reaction, the 
residual unreacted 1 was filtered off. Dropwise addition of acetone to the mother 
liquor induced the formation of a pale yellow precipitate within 24h. It was removed 
by filtration, washed with diethyl ether and dried in vacuo. According to the 1H and 
31P NMR spectra it was a mixture of 13 and 2 in ca. 40:60 ratio (Yield: 9 mg, 33%). 
1H NMR (CDCl3), δ (ppm) (in the PTA region, the resonances of 2 and 13 overlap 
to such an extent that those of 13 could not be distinguished): 3.20 (s, 6H, dmso-S). 
31P NMR (CDCl3), δ (ppm): –25.6 (t, 1P, 2JP-P = 27.9 Hz, PTA trans to Cl), –61.0 (d, 
2P, mutually trans PTAs). 
 
trans,mer-RuCl2(CH3CN)(PTA)3 (14) and cis,mer-RuCl2(CH3CN)(PTA)3 (15).  
 
trans-RuCl2(PTA)4 (1) (60.0 mg, 0.075 mmol) was partially dissolved in 8 mL of 
acetonitrile and refluxed for 2 h. Upon heating complex 1 dissolved completely. The 
originally yellow solution became progressively paler and a pale yellow solid began 
to form after ca. 1 h. After cooling to room temperature, the product was filtered, 
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washed with acetonitrile and diethyl ether and dried in vacuo. According to 1H and 
31P NMR spectra it was a mixture of 14, 15 and 1 in ca. 68:17:15 % ratio (Yield: 15 
mg, 29%). 1H NMR (CDCl3), δ (ppm) of 14 and 15: 4.45 (m, NCH2N), 4.04 (br s, 
NCH2P) (it was not possible to distinguish the PTA resonances of 14 and 15), 2.46 
(s, 3H, CH3CN of 15), 2.30 (s, 3H, CH3CN of 14). 
31P NMR (CDCl3), δ (ppm) of 7: 
–16.1 (t, 1P, 2JP-P = 28.5 Hz, PTA trans to CH3CN), –53.3 (d, 2P, mutually trans 
PTAs). 31P NMR (CDCl3), δ (ppm) of 15: –24.0 (t, 1P, 2JP-P = 37.2 Hz, PTA trans to 
Cl), –54.3 (d, 2P, mutually trans PTAs). 
mer-[Ru(bpy)Cl(PTA)3]Cl (17). 
 
trans-RuCl2(PTA)4 (1) (40.0 mg, 0.050 mmol) was dissolved in 5 mL of water. One 
eq. of 2,2'-bipyridine (8.2 mg, 0.050 mmol) was added and the light-protected 
mixture was refluxed for 1 h. The yellow solution turned rapidly orange. The solvent 
was rotary evaporated affording a yellow solid that, according to the 1H and 31P NMR 
spectra, was a ca. equimolar mixture of free PTA and 17 with PTAO as impurity 
(less than 5% of PTA). X-ray quality crystals of 17 were obtained by slow diffusion 
of acetone into a water solution of the complex. Elemental analysis calcd for 
[C28H44N11Cl2P3Ru∙6H2O] (MW: 907.70): C 37.05; H 6.22; N 16.97. Found: C 36.87; 
H 6.03; N 16.87. Larger amounts of pure complex for the NMR characterization 
were obtained as PF6 salt (17PF6): the raw material (48.1 mg) was dissolved in 1 mL 
of water and 1 mL of a solution of NaPF6 (12.5 mg, 0.075 mmol) was added. The 
yellow crystals that formed in few hours were removed by filtration and dried in 
vacuo (Yield: 28.1 mg, 62%). The product was pure 17PF6 according to the 1H and 
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31P NMR spectra. 1H NMR (D2O) δ (ppm): 9.45 (d, 1H, H6), 8.65 (d, 1H, H3), 8.55 
(d, 1H, H3'), 8.41 (m, 2H, H4 + H6'), 8.18 (t, 1H, H4'), 7.94 (t, 1H, H5), 7.58 (t, 1H, 
H5'), 4.93, 4.85 (ABq, 6H, NCH2N, JAB = 13.1 Hz, PTA trans to N), 4.52 (br s, 6H, 
NCH2P, PTA trans to N), 4.54, 4.45 (ABq, 12H, JAB = 13.9 Hz, NCH2N, mutually 
trans PTAs), 3.72 (br s, 12H, NCH2P, mutually trans PTAs). 
13C NMR (partial) from 
the HSQC spectrum (D2O), δ (ppm): 156.2 (C6'), 150.7 (C6), 146.8 (C4), 138.9 
(C4'), 128.2 (C5'), 127.3 (C5), 125.6 (C3'), 124.9 (C3), 70.7 (NCH2N, PTA trans to 
N), 70.5 (NCH2N, mutually trans PTAs), 52.2 (NCH2P, PTA trans to N), 46.6 
(NCH2P, mutually trans PTAs). 
31P NMR (D2O), δ (ppm) –30.2 (t, 1P, 2JP-P = 32.8 
Hz, PTA trans to N), –47.6 (d, 2P, mutually trans PTAs). –144.4 (septet, PF6). ESI 
mass spectrum: 764.2 m/z (calcd 764.2) (M+), 607.2 m/z (calcd. 607.1) (M – PTA)+. 
UV-vis (H2O): λmax (ε, L mol–1 cm–1) = 390 (1310) nm. 
fac-[Ru(bpy)Cl(PTA)3]Cl (18).  
 
cis-RuCl2(PTA)4 (2) (45.0 mg, 0.056 mmol) was dissolved in 8 mL of water. Five 
eq. of 2,2'-bipyridine (43.9 mg, 0.280 mmol) and one eq. of AgNO3 (9.6 mg, 0.056 
mmol) were added and the light-protected mixture was refluxed for 1 h. The yellow 
solution turned rapidly orange and a grey precipitate of AgCl formed. The mixture 
was filtered over a pad of Celite and the clear solution was rotary evaporated to 
dryness affording a yellow solid that, according to the 1H and 31P NMR spectra, was 
a mixture of 17 and 18 in 1/7 ratio. No residual 2 was present. The pure facial isomer 
for full characterization was obtained as PF6 salt (18PF6): the raw mixture (87.3 mg) 
was dissolved in 1 mL of water and 1 mL of a solution of NaPF6 (18.6 mg, 0.11 
mmol) was added. The yellow microcrystalline solid that formed within few hours 
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at room temperature was removed by filtration, washed with cold water and dried in 
vacuo (Yield: 14.1 mg, 31%). The product was pure 18PF6 according to the 1H and 
31P NMR spectra. Low quality single crystals of fully protonated 18, as fac-
[Ru(bpy)Cl(PTAH)3][0.5Cl][3.5ClO4], used for X-ray diffraction analysis, were 
obtained by adding a 0.5 M solution of HClO4 into a water solution of the complex. 
Elemental analysis calcd for 18PF6 [C28H44N11ClP4F6Ru] (MW: 909.13): C 36.99; H 
4.88; N 16.95. Found: C 37.18; H 4.90; N 17.03. 1H NMR (D2O + NaCl) δ (ppm): 
8.99 (br s, 2H, H6,6’), 8.54 (d, 2H, H3,3’), 8.29 (t, 2H, H4,4’), 7.80 (t, 2H, H5,5’), 
4.65 (m, partially overlapped by the water signal, 12H, NCH2N, PTA trans to N), 
4.49 (m, partially overlapped by the singlet at 4.44, 6H, NCH2N, PTA trans to Cl), 
4.44 (s, 12H, NCH2P, PTA trans to N), 3.88 (s, 6H, NCH2P, PTA trans to Cl). 
13C 
NMR (partial) from the HSQC spectrum (D2O), δ (ppm): 154.5 (C6,6’), 140.3 
(C4,4’), 126.5 (C5,5’), 124.7 (C3,3’), 70.7 (NCH2N, PTA trans to Cl), 70.5 (NCH2N, 
PTA trans to N), 52.2 (NCH2P, PTA trans to Cl), 46.6 (NCH2P, PTA trans to N). 
31P NMR (D2O), δ (ppm): –24.3 (t, 1P, 2JP-P = 29.2 Hz, PTA trans to Cl), –43.1 (d, 
2P, PTA trans to N). –144.4 (septet, 1P, PF6). 1H NMR (D2O) δ (ppm) of 18aq: 8.95 
(br s, 2H, H6,6’), 8.58 (d, 2H, H3,3’), 8.33 (t, 2H, H4,4’), 7.83 (t, 2H, H5,5’), 4.65 
(m, 12H, NCH2N,), 4.46 (s, 12H, NCH2P,) (it was not possible to distinguish the 
PTA resonances of 18 and 18aq), 4.43 (m, 6H, NCH2N, PTA trans to OH2), 3.84 (s, 
6H, NCH2P, PTA trans to OH2). 
31P NMR (D2O), δ (ppm) of 18aq: –17.7 (t, 1P, 2JP-
P = 30.2 Hz, PTA trans to OH2), –43.5 (d, 2P, PTA trans to N). –144.4 (septet, 1P, 
PF6). ESI mass spectrum: 764.2 m/z (calcd 764.2) (M
+), 607.2 m/z (calcd. 607.1) (M 
– PTA)+. UV-vis (H2O): λmax (ε, L mol–1 cm–1) = 385 (2385) nm. 
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cis,cis-Ru(bpy)Cl2(PTA)2 (22). 
 
cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10) (70.0 mg, 0.109 mmol) was partially 
dissolved in 10 mL of ethanol. Two eq. of 2,2'-bipyridine (34.0 mg, 0.218 mmol) 
were added and the mixture was refluxed for 6h. The clear solution obtained upon 
warming gradually become ruby-red and a precipitate of the same color began to 
form after 4 h. The mixture was concentrated to ca. 3 mL and the precipitate was 
filtered after overnight standing at room temperature, washed with diethyl ether and 
dried in vacuo (Yield: 42.0 mg, 54%). According to the 1H and 31P NMR spectra the 
product was pure 22. X-ray quality crystals of 22 were obtained by slow diffusion of 
diethyl ether into a methanol solution of the complex. Elemental analysis calcd for 
[C22H32N8Cl2P2Ru] (MW: 642.46): C 41.13; H 5.02; N 17.44. Found: C 41.16; H 
5.00; N 17.45. 1H NMR (CDCl3) δ (ppm): 9.88 (d, 1H, H6 bpy), 8.55 (d, 1H, H6' 
bpy), 8.10 (d, 1H, H3 bpy), 8.04 (d, 1H, H3' bpy), 7.95 (t, 1H, H4 bpy), 7.78 (t, 1H, 
H4' bpy), 7.58 (t, 1H, H5 bpy), 7.20 (t, 1H, H5' bpy), 4.64 (s, 6H, NCH2N,  PTA 
trans to N), 4.60, 4.53 (ABq, 6H, JAB = 15.0 Hz, NCH2P, PTA trans to N), 4.39, 4.19 
(ABq, 6H, JAB = 13.0 Hz, NCH2N,  PTA trans to Cl), 3.70, 3.59 (ABq, 6H, JAB = 
15.1 Hz, NCH2P, PTA trans to Cl). 
13C NMR (partial) from the HSQC spectrum 
(CDCl3) δ (ppm): 156.7 (C6'), 151.1 (C6), 136.9 (C4), 135.2 (C4'), 125.8 (C5), 125.2 
(C5'), 122.9 (C3'), 121.7 (C3), 73.31 (NCH2N, PTA trans to N), 72.0 (NCH2N, PTA 
trans to Cl), 54.0 (NCH2P, PTA trans to N), 53.2 (NCH2P, PTA trans to Cl). 
31P 
NMR (CDCl3) (ppm): δ –21.6 (d, 1P, 2JP-P = 34.4 Hz, PTA trans to Cl), –36.2 (d, 1P, 
trans to N). 1H NMR of 22aq (D2O) δ (ppm): 9.51 (d, 1H, H6 bpy), 8.53 (d, 1H, H6' 
bpy), 8.49 (d, 1H, H3 bpy), 8.42 (d, 1H, H3' bpy), 8.27 (t, 1H, H4 bpy), 8.09 (t, 1H, 
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H4' bpy), 7.80 (t, 1H, H5 bpy), 7.50 (t, 1H, H5' bpy), 4.66 (s, 6H, NCH2N, PTA trans 
to N), 4.45 (s, 6H, NCH2P, PTA trans to N), 4.38, 4.27 (ABq, 6H, JAB = 13.3 Hz, 
NCH2N, PTA trans to OH2), 3.66 (m, 6H, NCH2P, PTA trans to OH2). 
31P NMR 
(D2O) δ (ppm): –7.0 (d, 2JP-P = 37.7 Hz, PTA trans to OH2), –31.9 (d, PTA trans to 
N). 1H NMR of 22 (D2O + NaCl) δ (ppm): 9.45 (d, 1H, H6 bpy), 8.55 (m, 1H, H6' 
bpy), 8.44 (d, 2H, H3 e H3'), 8.22 (t, 1H, H4 bpy), 8.02 (t, 1H, H4' bpy), 7.75 (t, 1H, 
H5 bpy), 7.45 (t, 1H, H5' bpy), 4.38 (m, 12H, NCH2N), 3.65 (m, 12H, NCH2P) (it 
was not possible to distinguish the PTA resonances of 22 and 22aq). 31P NMR (D2O 
+ NaCl) δ (ppm): –12.7 (d, 2JP-P = 37.1 Hz, PTA trans to Cl), –33.8 (d, PTA trans to 
N). ESI mass spectrum: 607.0 m/z (calcd. 607.1) (M – Cl)+. UV-vis (H2O): λmax (ε, 
L mol–1 cm–1) = 412 (2839) nm. 
cis,cis-Ru(bpyAc)Cl2(PTA)2 (23).  
 
cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10) (50.0 mg, 0.078 mmol) was partially 
dissolved in 15 mL of ethanol. Two eq. of 4′-methyl-2,2′-bipyridine-4-carboxylic 
acid (bpyAc, 33.4 mg, 0.156 mmol) were added and the mixture was refluxed for 6h. 
The clear solution obtained upon warming became gradually deep red. Upon cooling 
to room temperature, a red powder precipitated and was filtered, washed with ethanol 
and diethyl ether and dried in vacuo. (Yield: 20.0 mg, 37%). According to the 1H and 
31P NMR spectra the product was pure 23, as a nearly equimolar mixture of the two 
stereoisomers 23a and 23b Elemental analysis calcd for [C24H34N8Cl2P2O2Ru] (MW: 
700.5): C 41.15; H 4.39; N 16.00. Found: C 41.05; H 4.33; N 15.95. 1H NMR (D2O) 
of 23aq δ (ppm): 9.58 (d, 1H, H6 23aaq), 9.31 (d, 1H, H6' 23baq), 8.74 (s, 1H, H3 
23aaq), 8.67 (s, 1H, H3 23baq), 8.57 (d, 1H, H6 23baq), 8.42 (s, 1H, H3' 23baq), 8.36 
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(s, 1H, H3' 23aaq), 8.32 (d, 1H, H6' 23aaq), 8.06 (d, 1H, H5 23aaq), 7.76 (d, 1H, H5 
23baq), 7.68 (d, 1H, H5' 23baq), 7.39 (d, 1H, H5' 23aaq), (the PTA resonances of 
23aaq and 23baq overlapped and could not be distinguished) 4.84 (br s, 12H, NCH2N, 
PTA trans to N), 4.54 (br s, 12H, NCH2P, PTA trans to N), 4.43 (m, 12H, NCH2N, 
PTA trans to OH2), 3.77, 3.72 (ABq, 12H, NCH2P, JAB = 14.7 Hz, PTA trans to 
OH2),  2.64 (s, 3H, CH3 23baq), 2.56 (s, 3H, CH3 23aaq). 
13C NMR of 23aq (partial) 
from the HSQC spectrum (D2O), δ (ppm): 157.7 (C6 23baq), 156.4 (C6' 23aaq), 150.7 
(C6 23aaq), 149.2 (C6' 23baq), 128.3 (C5' 23aaq), 127.8 (C5' 23baq), 125.5 (C5 
23baq), 125.1 (C5 23aaq), 124.7 (C3' 23baq), 123.1 (C3 23baq), 122.5 (C3 23aaq), 
125.7 (C3' 23aaq), (the PTA resonances of 23aaq and 23baq overlapped and could not 
be distinguished) 70.5 (NCH2N, PTA trans to N), 70.5 (NCH2N PTA trans to OH2), 
49.9 (NCH2P, PTA trans to OH2), 49.5 (NCH2P, PTA trans to N), 21.0 (CH3 23baq), 
20.0 (CH3 23aaq).
 31P NMR of 23aq (D2O) δ (ppm): –4.0 (m, 4P, PTA trans to OH2), 
–26.0 (m, 4P, PTA trans to N). 31P NMR of 23 (D2O + NaCl) δ (ppm): –9.5 (m, 4P, 
PTA trans to Cl), –25.4 (m, 4P, PTA trans to N). ESI mass spectrum: 665.2 m/z 
(calcd. 665.1) (M – Cl)+. UV-vis (H2O): λmax (ε, L mol–1 cm–1) = 412 (1615) nm. 
trans,cis,cis-RuCl2(PTA)2(py)2 (24). 
 
cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (20 mg, 0.031 mmol) was partially dissolved in 
2 mL of EtOH. Four equivalents of pyridine (10 µL, 0.124 mmol) were added and 
the mixture was refluxed for 6h. The clear solution obtained upon warming became 
gradually orange. Upon cooling to room temperature, an orange powder precipitated 
and was filtered, washed with ethanol and diethyl ether and dried in vacuo. (Yield: 
10.9 mg, 55%). According to the 1H and 31P NMR spectra the product was pure 24. 
Elemental analysis calcd for [C22H34Cl2N8P2Ru] (MW: 644.1): C 41.00; H 5.32; N 
Chapter 9: Experimental Section  
 
 
252 
 
11.00. Found: C 40.95; H 5.23; N 11.05. 1H NMR (D2O) δ (ppm): 9.08 (d, 4H, H2,6), 
8.11 (t, 2H, H4), 7.66 (t, 4H, H3,5), 4.49, 4.44 (ABq, 12H, NCH2N), 4.02 (br s, 12H, 
NCH2P). 
13C NMR from the HSQC spectrum (D2O), δ (ppm): 151.0 (C2,6), 139.6 
(C4), 125.9 (C3,5), 70.4 (NCH2N), 47.0 (NCH2P). 
31P NMR (D2O) δ (ppm): –50.0 
(s, 2P). 
trans,mer-RuCl2(py)(PTA)3 (25). 
 
cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (20 mg, 0.031 mmol) was partially dissolved in 
2 mL of CHCl3 or in a 4/5 mixture of CHCl3/EtOH. Four equivalents of pyridine (10 
µL, 0.124 mmol) were added and the mixture was refluxed for 6h. The clear solution 
obtained upon warming became gradually orange. After cooling down the solution, 
the addition of few drops of diethyl ether led the formation of X-ray quality crystals 
that were filtered, washed with EtOH and diethyl ether and dried in vacuo (Yield: 
7.8 mg, 35%). According to the 1H and 31P NMR spectra the product was pure 24. 
Elemental analysis calcd for [C23H41Cl2N10P3Ru] (MW: 722.1): C 38.23; H 5.72; N 
19.39. Found: C 38.15; H 5.73; N 19.35. 1H NMR (CDCl3) δ (ppm): 9.49 (d, 2H, 
H2,6), 7.86 (t, 1H, H4), 7.43 (t, 2H, H3,5), 4.62, 4.56 (ABq, 6H, NCH2N, PTA trans 
to py), 4.47, 4.36 (ABq, 12H, NCH2N, mutually trans PTAs), 4.27 (br s, 6H, NCH2P, 
PTA trans py), 3.92 (br s, 12H, NCH2P, mutually trans PTAs). 
13C NMR from the 
HSQC spectrum (CDCl3), δ (ppm): 152.2 (C2,6), 137.7 (C4), 124.7 (C3,5), 73.3 
(NCH2N, PTA trans to py), 73.1 (NCH2N, mutually trans PTAs), 55.6 (NCH2P, PTA 
trans to py), 53.4 (NCH2P, mutually trans PTAs). 
31P NMR (CDCl3) δ (ppm): –22.5 
(t, 1P, 2JP-P = 34.5 Hz, PTA trans to py), –54.2 (d, 2P, mutually trans PTAs). 
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fac-RuCl2(CO)(dmso)3 (26). 
 
1 g amount of cis-RuCl2(dmso)4 (8) (2 mmol) was partially dissolved in 60 mL of 
methanol in a flask closed with a stopcock. The flask was first connected to a vacuum 
line and then to a reservoir of CO. Within 1.5 h the starting material dissolved 
completely and a clear pale yellow solution was obtained. After an additional hour 
of reaction, the solution was concentrated to 5 mL. Yellow crystals of the product 
formed in a few hours from the solution. They were filtered off, washed with cold 
methanol and diethyl ether, and vacuum dried. (Yield: 0.54 g, 60%). Selected IR 
absorption (cm-1): 1995 (νCO), 1H-NMR (CDCl3) δ (ppm): 3.43 (s, 6H, dmso-S), 3.26 
(s, 6H, dmso-S), 2.85 ppm (s, 6H, DMSO-O).  
cis,cis,trans-RuCl2(CO)2(dmso-S)2 (27). 
 
A 0.5 g amount of cis-RuCl2(DMSO)4 (8) (1 mmol) was heated to reflux in 100 mL 
of toluene under a stream of CO for 3 h. The resulting colorless solution was 
concentrated to 90mL and stored at room temperature. Needle-shaped crystals of the 
product formed within 1 days and were then filtered, washed with diethyl ether, and 
vacuum dried. Other fractions were collected from the mother liquor upon 
concentration to 70 mL. (Yield: 0.100 g, 25%). Selected IR absorption (cm-1): 2089 
(νCO), 2035 (νCO). 1H NMR spectrum (CDCl3) δ (ppm): 3.44 ppm (s, 12H, dmso-S).  
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fac-RuCl2(CO)3(dmso-O) (30). 
 
A 0.5 g amount of cis-RuCl2(DMSO)4 (8) (2 mmol) was partially dissolved in 40 mL 
of absolute ethanol and put in autoclave with 30 atm of CO at 80°C for 4 h. The 
resulting pale yellow solution was rotary evaporated to an oil that was threated with 
diethyl ether (10 mL x 3 times). The resulting pale yellow precipitate was filtered, 
washed with cold ethanol and diethyl ether, and vacuum 
dried. Sometimes it could be necessary put again the precipitate in autoclave for other 
4 h with 30 atm of CO at 80°C. (Yield: 0.23 g, 70%). Selected IR absorption (cm-1): 
2129 (νCO), 2060 (νCO). 1H NMR spectrum (CDCl3) δ (ppm): 2.83 ppm (s, 6H, dmso-
O). 
cis,cis,trans-RuCl2CO(dmso-S)(PTA)2 (31). 
 
We found two different ways to prepare 31 using different precursors: fac-
RuCl2(CO)(dmso)3 (26, 60 mg, 0.14 mmol) was partially dissolved in 3 mL of 
methanol. Two equivalent of PTA (44 mg, 0.28 mmol) were added and the mixture 
was stirred in the dark for one day. During the time the mixture became a yellow 
solution and after 8h a white precipitate became to form. The precipitate was filtered 
and washed with MeOH and diethyl ether and dried in vacuo (Yield: 60.9 mg, 73%). 
The solid was pure 31, according to 1H and 31P NMR.  
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X-ray quality crystals of 31 were obtained by slow diffusion of diethyl ether into a 
chloroform solution of the complex. Elemental analysis calcd for 
[C15H30Cl2N6O2P2SRu] (MW: 592.0): C 30.41; H 5.10; N 11.97. Found: C 30.45; H 
5.19; N 11.88. 1H-NMR (D2O) δ (ppm): 4.55 (br. s, 12H, NCH2N), 4.40 (br s, 12H, 
NCH2P), 3.34 (s, 6H, dmso). 
13C NMR from the HSQC spectrum (D2O), δ (ppm): 
70.2 (NCH2N), 50.42 (dmso), 48.6 (NCH2P). 
31P NMR (D2O), δ (ppm): –52.8 (s, 
2P). 1H-NMR (CDCl3) δ (ppm): 4.53 (br. S, 12H, NCH2N), 4.48,4.39 (ABq, 12H, 
NCH2P), 3.26 (s, 6H, dmso). 
13C NMR from the HSQC spectrum (CDCl3), δ (ppm): 
73.6 (NCH2N), 50.9 (NCH2P), 50.9 (NCH2P). 
31P NMR (CDCl3), δ (ppm): –54.8 (s, 
2P). Selected IR absorption (cm-1): 1950 (νCO). ESI mass spectrum: 593.0 m/z (calcd 
593.0) (M+H)+.  
Compound 31 was obtained also in the same conditions (MeOH and two equivalents 
of PTA) using cis,cis,trans-RuCl2(CO)2(dmso)2 (27, 50 mg, filtered after 1h – Yield: 
58.6 mg,  63%), cis,cis,cis-RuCl2(CO)2(dmso)2 (28, 50 mg, filtered after 3.5h, Yield: 
53.9 mg, 70%) and a mixture of 27 and 28 (filtered after 1.5h – Yield:  50%). 
trans,mer-RuCl2CO(PTA)3 (32). 
 
Microwave: fac-RuCl2(CO)(dmso)3 (26, 60 mg, 0.14 mmol) was partially dissolved 
in 2 mL of ethanol. Six equivalent of PTA (131.9 mg, 0.84 mmol) were added and 
the mixture was put in the microwave at 130°C for 30’. After the reaction a yellow 
precipitated was formed that was filtered and washed with ethanol and diethyl ether 
and dried in vacuo (Yield: 78.9 mg, 84%). The solid was pure 32, according to 1H 
and 31P NMR.  
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Refluxing ethanol: fac-RuCl2(CO)(dmso)3 (26, 60 mg, 0.14 mmol) was partially 
dissolved in 7 mL of ethanol. Six equivalent of PTA (131.9 mg, 0.84 mmol) were 
added and the mixture was refluxed for 15h within the formation of a yellow 
precipitate. After the reaction, the solid was filtered and washed with ethanol and 
diethyl ether and dried in vacuo (Yield: 80.7 mg, 86%). The solid was pure 32, 
according to 1H and 31P NMR.  
X-ray quality crystals of 32 were obtained by slow diffusion of diethyl ether into a 
chloroform solution of the complex. Elemental analysis calcd for 
[C19H36Cl2N5OP3Ru] (MW: 671.07): C 33.99; H 5.40; N 18.77. Found: C 33.95; H 
5.49; N 18.84. 1H-NMR (CDCl3) δ (ppm): 4.58 (m, 18H, NCH2N), 4.37 (br s, 12H, 
NCH2P, mutually trans PTAs), 4.32 (br s, 6H, NCH2P, PTA trans CO). 
13C NMR 
from the HSQC spectrum (CDCl3), δ (ppm):  73.2 (NCH2N), 52.4 (NCH2P, mutually 
trans PTAs), 52.2 (NCH2P, PTA trans CO). 
31P NMR (CDCl3), δ (ppm): –56.0 (d, J 
= 40.4 Hz, 2P, mutually trans PTAs), –63.6 (t, 1P, PTA trans CO). 1H-NMR (D2O) 
δ (ppm): 4.60 (m, 18H, NCH2N), 4.37 (br s, 12H, NCH2P, mutually trans PTAs), 
4.32 (br s, 6H, NCH2P, PTA trans CO). 
13C NMR from the HSQC spectrum (D2O), 
δ (ppm):  70.6 (NCH2N), 49.7 (NCH2P, mutually trans PTAs), 49.6 (NCH2P, PTA 
trans CO). 31P NMR (CDCl3), δ (ppm): –54.3 (d, J = 39.6 Hz, 2P, mutually trans 
PTAs), –60.7 (t, 1P, PTA trans CO). Selected IR absorption (cm-1): 1986 (νCO). ESI 
mass spectrum: 672.1 m/z (calcd 672.1) (M+H)+, 636.1 m/z (calcd 636.1) (M–Cl)+, 
608.1 m/z (calcd 608.1) (M–Cl–CO)+,  479.1 m/z (calcd 479.0) (M–Cl–PTA)+. 
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cis,mer-RuCl2CO(PTA)3 (33). 
 
fac-RuCl2(CO)(dmso)3 (26, 60 mg, 0.14 mmol) was dissolved in 4 mL of water. 
Three equivalents of PTA (0.065 mg, 0.41 mmol) were added and the solution was 
refluxed for 4h. During the time the color of the solution changed from pale yellow 
to yellow. After the reaction, the solvent was removed by rotary evaporation 
obtaining a yellow oil from which X-ray quality crystals formed after 10 days. 
Crystals were filtered and washed with acetone and diethyl ether and dried in vacuo 
(Yield: 75.1 mg, 80%). The solid was pure 33, according to 1H and 31P NMR. 
Elemental analysis calcd for [C19H36Cl2N5OP3Ru] (MW: 671.07): C 33.99; H 5.40; 
N 18.77. Found: C 33.90; H 5.35; N 18.74. 1H-NMR (D2O + NaCl) δ (ppm): 4.49 
(m, 18H, NCH2N), 4.33 (br s, 12H, NCH2P, mutually trans PTAs), 4.12 (br s, 6H, 
NCH2P, PTA trans Cl). 
13C NMR from the HSQC spectrum (D2O + NaCl), δ (ppm):  
70.9 (NCH2N), 70.5 (NCH2N), 52.2 (NCH2P), 46.6 (NCH2P). 
31P NMR (D2O + 
NaCl), δ (ppm): –20.7 (t, J = 25.5 Hz, 1P, PTA trans Cl), –51.9 (d, 2P, mutually 
trans PTAs). Selected IR absorption (cm-1): 1942 (νCO).  ESI mass spectrum: 636.1 
m/z (calcd 636.1) (M–Cl)+. 
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[RuCl2(CO)(PTA)2]2·8H2O (35). 
 
trans,cis,cis-RuCl2(CO)2(dmso-O)2 (29, 100 mg, 0.26 mmol) was dissolved in 3 mL 
of water obtaining a yellow solution. Two equivalents of PTA (81.8 mg, 0.52 mmol) 
were added obtaining a yellow solution. After the reaction, the water was removed 
by rotary evaporation obtaining a yellow oil. Treatment of the oil with acetone (5 
mL, 4 times) afforded to a yellow precipitate that was filtered, washed with acetone 
and diethyl ether and dried in vacuo. (Yield: 136.6 mg, 98%). The solid was pure 35, 
according to 1H and 31P NMR. Elemental analysis calcd for [C26H64Cl4N12O10P4Ru2] 
(MW: 1172.07): C 26.63; H 5.50; N 14.33. Found: C 26.84; H 5.50; N 14.50. 
1H-
NMR (D2O) δ (ppm): 4.57 (br s, 24H, NCH2N), 4.27 (br s, 24H, NCH2P). 13C NMR 
from the HSQC spectrum (D2O), δ (ppm): 70.6 (NCH2N), 46.9 (NCH2P). 31P NMR 
(D2O), δ (ppm): –47.2 (2P, mutually trans PTAs). 1H-NMR (DMSO-d6) δ (ppm): 
4.45 (br s, 24H, NCH2N), 4.12 (br s, 24H, NCH2P). 
13C NMR from the HSQC 
spectrum (DMSO-d6), δ (ppm): 72.6 (NCH2N), 49.7 (NCH2P). 31P NMR (DMSO-
d6), δ (ppm): –51.2 (2P, mutually trans PTAs). Selected IR absorption (cm-1): 1941 
(νCO). ESI mass spectrum (positive mode): 479.1 m/z (calcd 479.1) 
([RuCl(CO)(PTA)2]
+). ESI mass spectrum (negative mode): 548.1 m/z (calcd 548.1) 
([RuCl3(CO)(PTA)2]
–). 
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trans,trans,trans-RuCl2(CO)(py)(PTA)2 (36). 
 
[RuCl2(CO)(PTA)2]2·8H2O (35, 30 mg, 0.026 mmol) was dissolved in 3 mL of water 
obtaining a yellow solution; 1.2 equivalents of pyridine (5.6 µL, 0.030 mmol) were 
added and the solution was stirred at room temperature for three days. After the 
reaction, the water was removed by rotary evaporation and the precipitate was treated 
with acetone and filtered, washed with acetone and diethyl ether obtaining a yellow 
powder that was dried in vacuo. (Yield: 9.2 mg, 60%). The solid was pure 36 
according to 1H and 31P NMR. Elemental analysis calcd for [C18H29Cl2N7OP2Ru] 
(MW: 593.03): C 36.43; H 4.93; N 16.52. Found: C 36.48; H 4.89; N 16.54. 
1H-NMR 
(D2O) δ (ppm): 9.08 (d, 2H, H2,6), 8.11 (t, 1H, H4), 7.66 (t, 2H, H3,5), 4.35 (m, 
12H, NCH2N), 3.90 (br s, 12H, NCH2P). 
13C NMR from the HSQC spectrum (D2O), 
δ (ppm): 151.0 (C2,6), 139.6 (C4), 125.9 (C3,5), 70.6 (NCH2N), 47.0 (NCH2P). 31P 
NMR (D2O), δ (ppm): –50.0 (2P, mutually trans PTAs). Selected IR absorption (cm-
1): 2010 (νCO). ESI mass spectrum: 594.0 m/z (594.3 calcd) (M+H)+. 
 [RuCl2(CO)2(PTA)]2·H2O (37). 
 
cis,fac-RuCl2(CO)3(dmso-O) (30, 60 mg, 0.14 mmol) was dissolved in 3 mL of 
methanol. After the addition of one equivalent of PTA (44 mg, 0.28 mmol), a white 
solid starts to precipitate. The mixture was filtered and washed with MeOH and 
diethyl ether and dried in vacuo (Yield: 80.5 mg, 73%). The solid was pure 37, 
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according to 1H and 31P NMR. Elemental analysis calcd for [C16H26Cl4N6O5P2Ru2] 
(MW: 787.83): C 24.38; H 3.32; N 10.66. Found: C 24.28; H 3.43; N 10.66. (MW: 
787.8). 1H-NMR (DMSO-d6) δ (ppm): 4.43 (m, 24H, NCH2N + NCH2P). 31P NMR 
(DMSO-d6), δ (ppm): –28.8 (2P, PTA trans to Cl).  Selected IR absorption (cm-1): 
2060 (νCO), 1989 (νCO). ESI mass spectrum (positive mode): 409.3 m/z (calcd 409.1) 
([RuCl2(CO)2(PTA)Na]
+). ESI mass spectrum (negative mode): 421.2 m/z (calcd 
421.3) ([RuCl3(CO)2(PTA)]
–), 393.2 m/z (calcd 393.3) ([RuCl3(CO)(PTA)]
–).  
cis,cis,trans-RuCl2(CO)2(py)(PTA) (38). 
 
[RuCl2(CO)2(PTA)]2·H2O (37, 30 mg, 0.038 mmol) was partially dissolved in 3 mL 
of water obtaining a colorless solution; 1.2 equivalents of pyridine (8.0 µL, 0.046 
mmol) were added and the solution was stirred at room temperature for three days. 
After the reaction, the water was removed by rotary evaporation and the precipitate 
was extracted with chloroform and rotary evaporated to dryness (Yield: 7.3 mg, 
55%). The solid was pure 38 according to 1H and 31P NMR. Elemental analysis calcd 
for [C13H17Cl2N4O2PRu] (MW: 463.95): C 32.63; H 3.69; N 15.27. Found: C 32.58; 
H 2.59; N 12.04. 1H-NMR (CDCl3) δ (ppm): 8.91 (d, 2H, H2,6), 7.87 (t, 1H, H4), 
7.45 (t, 2H, H3,5), 4.60 (br s, 6H, NCH2N), 4.53 (br s, 6H, NCH2P). 
31P NMR 
(CDCl3), δ (ppm): –28.8 (1P, PTA trans to py). Selected IR absorption (cm-1): 2058 
(νCO), 1994 (νCO). ESI mass spectrum: 464.9 m/z (464.5 calcd) (M+H)+. 
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cis,cis,trans-RuCl2(CO)2(PTA)2 (39). 
 
cis,fac-RuCl2(CO)3(dmso-O) (30, 60 mg, 0.14 mmol) was dissolved in 3 mL of 
methanol. After the addition of two equivalents of PTA (44 mg, 0.28 mmol), a white 
solid starts to precipitate. The mixture was filtered and washed with MeOH and 
diethyl ether and dried in vacuo (Yield: 60.9 mg, 73%). The solid was pure 39, 
according to 1H and 31P NMR. X-ray quality crystals were obtained upon slowly 
evaporation of the solvent in a MeOH solution of 3. Elemental analysis calcd for 
[C14H24Cl2N6O2P2Ru] (MW: 541.99): C 31.01; H 4.46; N 15.50. Found: C 31.08; H 
4.49; N 15.54. 1H-NMR (D2O) δ (ppm): 4.61 (br s, 12H, NCH2N), 4.44 (br s, 12H, 
NCH2P). 
13C NMR from the HSQC spectrum (D2O), δ (ppm): 70.6 (NCH2N), 48.2 
(NCH2P). 
31P NMR (D2O), δ (ppm): –48.6 (2P, mutually trans PTAs). 1H-NMR 
(DMSO-d6) δ (ppm): 4.47 (m, 12H, NCH2N), 4.31 (br s, 12H, NCH2P). 13C NMR 
from the HSQC spectrum (DMSO-d6), δ (ppm): 72.1 (NCH2N), 50.0 (NCH2P). 31P 
NMR (DMSO-d6), δ (ppm): –50.3 (2P, mutually trans PTAs). 1H-NMR (CDCl3) δ 
(ppm): 4.58 (br s, 12H, NCH2N), 4.41 (br s, 12H, NCH2P). 
31P NMR (CDCl3), δ 
(ppm): –51.0 (2P, mutually trans PTAs). Selected IR absorption (cm-1): 2053 (νCO), 
1988 (νCO). ESI mass spectrum: 479.9 m/z (479.5 calcd) (M–Cl–CO)+. 
Compound 30 was obtained also using cis,cis,trans-RuCl2(dmso)2(PTA)2 (10, 10 
mg, 0.016 mmol) dissolved in 5 mL of CHCl3, put in autoclave with CO (30 atm) 
and heated at 60°C for 24h. The resulting colorless solution was rotary evaporated 
to a white powder that is pure 30 according 1H and 31P NMR spectra. (Yield: 8.2 mg, 
93%). 
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cis-[RuCl(CO)(PTA)4](NO3) (42NO3). 
 
cis-RuCl2(PTA)4 (2, 50 mg, 0.062 mmol) was partially dissolved in 9 mL of CHCl3; 
1.2 equivalents of AgNO3 (12.8 mg, 0.075 mmol) were added and the flask was first 
connected to a vacuum line and then to a reservoir of CO. After few minutes it was 
observed the formation of a white precipitate. After 1 day of reaction, the solid was 
filtered and extracted with water and then rotary evaporated to dryness. The solid 
was pure 42NO3, according to 1H and 31P NMR. (Yield 30.0 mg, 57%). Elemental 
analysis calcd for [C25H48ClN12O4P4Ru] (MW: 855.16): C 35.11; H 5.66; N 21.29. 
Found: C 35.18; H 5.69; N 21.24. 1H-NMR (D2O) δ (ppm): 4.65 (m, 32H, NCH2N 
+ NCH2P), 4.32 (br s, 6H, NCH2P). 4.19 (br s, 6H, NCH2P). 
13C NMR from the 
HSQC spectrum (D2O), δ (ppm): 70.52 (NCH2N), 55.5 (NCH2P), 52.1. 31P NMR 
(D2O), δ (ppm): –31.4 (1P, 2JA-M = 20.5 Hz, 2JA-X = 32.8 Hz, PTA trans to Cl), –59.8 
ppm (2P, mutually trans PTAs), –61.9 ppm (1P, 2JX-M = 35.8 Hz, PTA trans to CO). 
Selected IR absorption (cm-1): 2020 (νCO). ESI mass spectrum: 793.1 m/z (793.5 
calcd) (M+). 
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cis,trans-[Ru(bpy)Cl(CO)(PTA)2]Cl (43). 
 
cis,cis,trans-RuCl2CO(dmso-S)(PTA)2 (31) (40.0 mg, 0.067 mmol) was dissolved in 
5 mL of water. One eq. of 2,2'-bipyridine (10.5 mg, 0.067 mmol) was added and the 
light-protected mixture was refluxed for 16 h or put in a microwave reactor at 150°C 
for 30’. The yellow solution turned rapidly orange. The solvent was rotary 
evaporated affording a yellow solid that was washed with acetone, filtered and dried 
in vacuo. The solid was pure 43, according to 1H and 31P NMR. (Yield 30.0 mg, 
57%). 43 was also obtained also by treatment of [RuCl2(CO)(PTA)2]2·8H2O (35, 20 
mg, 0.034 mmol) with bpy (5.3 mg, 0.034 mmol) after 2h at reflux. Elemental 
analysis calcd for [C23H32Cl2N8OP2Ru] (MW: 670.06): C 41.20; H 4.81; N 16.71. 
Found: C 41.27; H 4.83; N 16.77. 1H-NMR (D2O) δ (ppm): 9.27 (d, 1H, H6), 8.93 
(d, 1H, H6’), 8.66 (d, 1H, H3), 8.55 (d, 1H, H3’), 8.42 (t, 1H, H4), 8.23 (t, 1H, H4’), 
7.96 (t, 1H, H5), 7.60 (d, 1H, H5’), 4.41, 4.31 (ABq, 12H, NCH2N), 3.82, 3.76 (ABq, 
12H, NCH2P). 
13C NMR from the HSQC spectrum (D2O), δ (ppm): 155.7 (C6’), 
149.0 (C6), 141.0 (C4), 139.4 (C4’), 128.1 (C5’), 127.9 (C5), 125.0 (C3’), 124.8 
(C3), 70.3 (NCH2N), 46.3 (NCH2P). 
31P NMR (D2O), δ (ppm): –50.6 (2P, mutually 
trans PTAs). Selected IR absorption (cm-1): 1984 (νCO). ESI mass spectrum: 635.6 
m/z (635.9 calcd) (M+). 
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mer-[Ru(bpy)(CO)(PTA)3](Cl)2 (45). 
 
cis,mer-RuCl2CO(PTA)3 (33) (40.0 mg, 0.060 mmol) was dissolved in 5 mL of 
water. One eq. of 2,2'-bipyridine (9.4 mg, 0.060 mmol) was added and the light-
protected mixture was refluxed for 1 h. The yellow solution turned rapidly to orange. 
The solvent was rotary evaporated affording a yellow solid that was washed with 
acetone, filtered and dried in vacuo. The solid was pure 44, according to 1H and 31P 
NMR. (Yield 30.0 mg, 60%). X-ray quality crystals of 33 were obtained by slow 
diffusion of acetone into a water solution of the complex. Elemental analysis calcd 
for [C30H47Cl2N11OP3Ru] (MW: 842.67): C 42.76; H 5.62; N 18.28. Found: C 42.70; 
H 5.69; N 18.24. 1H-NMR (D2O) δ (ppm): 9.07 (d, 1H, H6), 8.92 (m, 2H, H3 + H3’), 
8.53 (m, 3H, H6’ + H4 + H4’), 7.99 (m, 2H, H5 + H5’), 4.85, 4.73 (ABq, 6H, NCH2N 
PTA trans to N), 4.66 (br s, 6H, NCH2P, PTA trans to N) 4.40 (m, 12H, NCH2N 
mutually trans PTAs), 3.86, 3.80 (ABq, 12H, NCH2P). 
13C NMR from the HSQC 
spectrum (D2O), δ (ppm): 154.9 (C6), 153.8 (C6’), 142.4 (C4 + C4’), 129.9 (C5 + 
C5’), 126.9 (C3 + C3’). 31P NMR (D2O), δ (ppm): –49.6 (1P, 2JP-P = 25.2 Hz, PTA 
trans to N), –55.4 (2P, mutually trans PTAs). Selected IR absorption (cm-1): 2010 
(νCO). ESI mass spectrum: 631.6 m/z (631.7 calcd) (M–PTA+OH)+. 
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cis,trans-[Ru(bpy)(CO)2Cl(PTA)]Cl (46). 
 
[RuCl2(CO)2(PTA)]2·H2O (37, 30 mg, 0.038 mmol) was dissolved in 5 mL of water. 
One eq. of 2,2'-bipyridine (5.9 mg, 0.038 mmol) was added and the light-protected 
mixture was refluxed for 1 h. The colorless solution turned rapidly to orange-red. 
The solvent was rotary evaporated affording an orange solid that was washed with 
acetone, filtered and dried in vacuo. The solid was pure 46, according to 1H and 31P 
NMR. (Yield 13.4 mg, 65%). Elemental analysis calcd for [C18H20Cl2N5O2PRu] 
(MW: 541.34): C 39.94; H 3.72; N 12.94. Found: C 39.94; H 3.72; N 12.94. 
1H-NMR 
(D2O) δ (ppm): 9.08 (d, 2H, H6,6’), 8.67 (d, 2H, H3,3’) 8.44 (t, 2H, H4,4’), 7.91 (t, 
2H, H5,5’), 4.46 (m, 6H, NCH2N), 4.09 (br s, 6H, NCH2P). 13C NMR from the 
HSQC spectrum (D2O), δ (ppm): 153.5 (C6,6’), 142.0 (C4,4’), 129.0 (C5,5’), 125.5 
(C3,3’), 70.3 (NCH2N), 50.6 (NCH2P). 31P NMR (D2O), δ (ppm): –25.5 (1P, PTA 
trans to N). Selected IR absorption (cm-1): 2085 (νCO), 2034 (νCO). 
cis,trans-[Ru(bpy)(CO)2(PTA)2](NO3)2 (47). 
 
cis,cis,trans-RuCl2CO2(PTA)2 (39) (40.0 mg, 0.074 mmol) was dissolved in 8 mL 
of water. 2.1 eq of AgNO3 (26.4 mg, 0.155mmol) were added to the solution; one 
eq. of 2,2'-bipyridine (11.6 mg, 0.074 mmol) was added and the light-protected 
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mixture was refluxed for 1 h. After few minutes it was observed the formation of a 
grey precipitate; the colorless solution turned rapidly to orange-red. At the end of 
reaction, the grey precipitate was filtered. The solvent was rotary evaporated 
affording a red solid that was washed with acetone, filtered and dried in vacuo. The 
solid was pure 47, according to 1H and 31P NMR. (Yield 30.0 mg, 57%). Elemental 
analysis calcd for [C24H32N10O8P2Ru] (MW: 751.60): C 38.35; H 4.29; N 17.03. 
Found: C 38.30; H 4.22; N 17.09. 1H-NMR (D2O), δ (ppm): 9.02 (d, 2H, H6,6’), 
8.82 (d, 2H, H3,3’) 8.57 (t, 2H, H4,4’), 8.02 (t, 2H, H5,5’), 4.47, 4.43 (ABq, 12H, 
NCH2N), 4.04 (br s, 6H, NCH2P). 
13C NMR from the HSQC spectrum (D2O), δ 
(ppm): 153.9 (C6,6’), 142.7 (C4,4’), 129.1 (C5,5’), 126.7 (C3,3’), 70.4 (NCH2N), 
47.8 (NCH2P). 
31P NMR (D2O), δ (ppm): –50.9 (1P, mutually trans PTAs). Selected 
IR absorption (cm-1): 2086 (νCO), 2038 (νCO). 
cis,cis-[Ru(bpy)Cl(CO)(PTA)2]Cl (48). 
 
cis,trans-[Ru(bpy)Cl(CO)(PTA)2]Cl (43, 10.0 mg, 0.015 mmol) was dissolved in 2 
mL of water and irradiated with blue light (λ = 470 nm, 40 mW) for 24 h. Complete 
removal of the solvent by rotary evaporation afforded pure 48, according to 1H and 
31P NMR spectra, as a yellow solid (Yield: 9.5 mg, 95%). Elemental analysis calcd 
for [C23H32Cl2N8OP2Ru] (MW: 670.06): C 41.20; H 4.81; N 16.71. Found: C 41.15; 
H 4.89; N 16.74. 1H-NMR (D2O) δ (ppm): 9.09 (d, 1H, H6), 8.75 (d, 1H, H6’), 8.65 
(d, 1H, H3), 8.58 (d, 1H, H3’), 8.41 (t, 1H, H4), 8.32 (t, 1H, H4’), 7.87 (t, 1H, H5), 
7.81 (d, 1H, H5’), 4.61 (m, 6H, NCH2N), 4.45 (m, 6H NCH2P) 4.31, 4.16 (ABq, 6H, 
NCH2N), 3.80 (br s, 12H, NCH2P). 
13C NMR from the HSQC spectrum (D2O), δ 
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(ppm): 153.4 (C6), 153.3 (C6’), 141.5 (C4), 140.7 (C4’), 128.4 (C5), 128.1 (C5’), 
125.5 (C3), 125.0 (C3), 70.6 (NCH2N), 70.3 (NCH2N), 80.8 (NCH2P), 49.0 
(NCH2P). 
31P NMR (D2O), δ (ppm): –25.0 (1P, 2JP-P = 24.8 Hz, PTA trans to Cl), –
42.4 (1P, PTA trans to N). Selected IR absorption (cm-1): 1992 (νCO). ESI mass 
spectrum: 635.4 m/z (635.9 calcd) (M+). 
trans,cis-RuCl2(CO)2(cppH-κNp) (51) and trans,cis-RuCl2(CO)2(cppH-κNo) 
(52). 
 
A 30.0 mg amount of trans,cis,cis-RuCl2(CO)2(dmso-O)2 (29, 0.078 mmol) was 
partially dissolved in 1.5 mL of water. One eq. of cppH∙HNO3 (20.0 mg, 0.078 
mmol) was added and the mixture was refluxed for 1 h in the dark. A clear solution 
was rapidly obtained upon warming, from which a very pale yellow precipitate began 
to form after ca. 15 min of reflux. It was eventually removed by filtration, rapidly 
washed with water and dried in vacuo (Yield 15.0 mg, 45%). The product was pure 
51 according to the 1H NMR spectrum. trans,cis-RuCl2(CO)2(cppH-κNp) (51): 
Elemental analysis calcd for [C12H7N3Cl2O4Ru∙H2O] (MW: 447.19): C 32.23; H 2.03; 
N 9.39. Found: C 32.50; H 1.96; N 9.28. 1H NMR (DMSO-d6) δ (ppm): 9.82 (d, J = 
5.7 Hz, 1H, H6), 9.31 (d, J = 5.2 Hz, 1H, H6'), 8.86 (d, J = 7.9, 1.3 Hz, 1H, H3'), 
8.48 (t, J = 7.9, 1.5 Hz, 1H, H4'), 8.29 (d, J = 5.7 Hz, 1H, H5), 8.03 (t, J = 5.2 Hz 
1H, H5'). 13C NMR (DMSO-d6), δ (ppm): 195.66 (CO), 195.42 (CO), 162.72 (C6), 
153.79 (C6'), 141.35 (C4'), 130.29 (C5'), 126.57 (C3'), 122.69 (C5); unassigned 
resonances of the four quaternary carbon atoms: 163.41, 162.46, 158.06, 151.79.15N 
NMR (DMSO-d6), δ (ppm): –108.9 (No), –126.5 (Npy), –130.2 (Np). Selected IR 
absorption (cm-1): 2069 (νCO, s) 2013 (νCO, s). ESI mass spectrum: m/z 428.0 (M – 
H+). 
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When the reaction was performed at room temperature in the absence of stirring 
(30.0 mg of 29, 20.0 mg of cppH∙HNO3, 2 mL of water) a small amount of almost 
colorless crystals of 51 grew spontaneously from the pale-orange solution within 4 
h. The crystals, that were removed by filtration, washed with a minimum amount of 
water and dried in vacuo, were used for the X-ray structural analysis (Yield: 2.5 mg, 
7.5%). The mother liquor was rotary-evaporated to an oil, that was treated with 
diethyl ether to give a pale yellow solid. It was filtered, washed with diethyl ether 
and dried in vacuo (Yield 22.2 mg, 66%). The product was almost pure 52 according 
to the 1H NMR spectrum. trans,cis-RuCl2(CO)2(cppH-κNo) (52): Elemental analysis 
calcd for [C12H7N3Cl2O4Ru] (MW: 429.18): C 33.58; H 1.64; N 9.79. Found: C 33.39; 
H 1.54; N 9.61. 1H NMR (DMSO-d6) δ (ppm):  9.46 (d, J = 4.9 Hz, 1H, H6), 9.27 
(d, J = 5.4 Hz, 1H, H6'), 8.85 (d, J = 8.1 Hz, 1H, H3'), 8.46 (t, J = 7.9, 1H, H4'), 8.20 
(d, J = 4.9 Hz, 1H, H5), 8.02 (t, J = 5.4 Hz, 1H, H5'). 13C NMR (DMSO-d6) δ (ppm): 
196.31 (CO), 194.17 (CO), 162.72 (C6), 153.34 (C6'), 141.17 (C4'), 130.09 (C5'), 
127.10 (C3'), 120.83 (C5); unassigned resonances of the four quaternary carbon 
atoms: 165.21, 161.82, 161.09, 152.39. 15N NMR (DMSO-d6) δ (ppm): –86.2 (No), 
–126.5 (Npy), –143.6 (Np). Selected IR absorption (cm-1): 2059 (νCO), 2013 (νCO). 
ESI mass spectrum: m/z 428.0 (M – H+). 
Mixtures of cis,trans-RuCl2(dmso-S)2(mpp-κNp) (53), cis,cis-RuCl2(dmso-
S)2(mpp-κNp) (54), and cis,cis-RuCl2(dmso-S)2(mpp-κNp) (55).  
 
Refluxing toluene: A 50.0 mg amount of cis-RuCl2(dmso-S)4 (8, 0.10 mmol) was 
dissolved in 10 mL of toluene. A slight excess of mpp (21.0 mg, 0.12 mmol) was 
added and the mixture was refluxed for 1.5 h. The yellow solution turned rapidly 
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dark brown upon warming, and a precipitate began to form after ca. 1 h of reflux. It 
was eventually removed by filtration, washed with diethyl ether and dried in vacuo 
(Yield 32.0 mg, 64%). According to the 1H NMR spectrum, the product was a ca. 
1:2:1 mixture of 53-55. Elemental analysis calcd for [C14H21N3Cl2O2RuS2] (MW: 
499.45): C 33.67; H 4.24; N 8.41. Found: C 33.52; H 4.32; N 8.50. A second fraction 
of solid was obtained from the mother liquor: after complete rotary evaporation of 
the solvent, the oil obtained was treated with diethyl ether to obtain a solid that was 
filtered, washed with diethyl ether and dried in vacuo (Yield 15.0 mg, 30%). 
According to the 1H NMR spectrum this fraction was a ca. 1:1:1 mixture of 53-55. 
Refluxing ethanol: A 50.0 mg amount of cis-RuCl2(dmso)4 (8, 0.10 mmol) was 
dissolved in 10 mL of ethanol. A slight excess of mpp (21.0 mg, 0.12 mmol) was 
added and the mixture was refluxed for 2h. After cooling, the solution was rotary-
evaporated to ca. 3 mL and diethyl ether was added dropwise to the point of 
cloudiness. Red-orange crystals formed within 4h and a few of them were fished out 
the solution: According to the 1H NMR spectrum, they were a ca. 3:1 mixture of 53 
and 54 with a small amount of 5. Some crystals were selected for X-ray analysis and 
turned out to be of compound 53. A second fraction of precipitate, obtained from the 
mother liquor upon further concentration and addition of diethyl ether, was a ca. 
equimolar mixture of 53-55. 
Methanol at ambient temperature: A 50.0 amount of trans-RuCl2(dmso-S)4 (9, 0.10 
mmol) was dissolved in 10 mL of methanol and a slight excess of mpp (21.0 mg, 
0.12 mmol) was added. The yellow solution turned rapidly deep red. After 90 min it 
was rotary evaporated to ca. 5 mL and diethyl ether was slowly added dropwise. Red 
crystals formed within 24h and were removed by filtration, washed with diethyl ether 
and dried in vacuo (Yield: 18 mg, 36%). According to the 1H NMR spectrum the 
crystalline product was a ca. 2:3 mixture of 54 and 55. Some crystals were selected 
for X-ray analysis and turned out to be of compound 54. To be noted that when the 
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solution was concentrated to a smaller volume, precipitation of the kinetic 
intermediate 56 occurred (see below). 
cis,trans-RuCl2(dmso-S)2(mpp-κNp) (53): 1H NMR (CDCl3) δ (ppm): 9.58 (m, 2H, 
H6' overlapped with H6), 8.54 (d, J = 7.9 Hz, 1H, H3'), 7.97 (m, 1H, H4' overlapped 
with H4' of 55), 7.60 (t, J = 6.7 Hz, 1H, H5'), 7.29 (d, 1H, H5), 3.18 (s, 6H), 2.98 (s, 
6H), 2.68 (s, 3H). Selected 13C NMR from the HSQC spectrum (CDCl3) δ (ppm): 
159.4 (C6), 153.7 (C6'), 136.4 (C4'), 127.4 (C5'), 125.3 (C3'), 121.0 (C5), 41.5 and 
41.3 (dmso-S), 24.1 (CH3 mpp). 
15N NMR (CDCl3) δ (ppm): –90.2 (No), –145.0 
(Npy), –160.4 (Np). 
cis,cis-RuCl2(dmso-S)2(mpp-κNp) (54, py of mpp trans to dmso-S): 1H NMR 
(CDCl3) δ (ppm): 9.79 (m, 1H, H6' overlapped with H6 of 55), 9.62 (d, J = 6.2 Hz, 
1H, H6), 8.69 (m, 1H, H3' overlapped with H3' of 55), 8.08 (t, J = 7.6 Hz, 1H, H4'), 
7.70 (t, J = 6.6 Hz, 1H, H5'), 7.32 (d, 1H, H5), 3.53 (s, 3H), 3.51 (s, 3H) 3.30 (s, 3H), 
2.71 (s, 3H), 2.59 (s, 3H). Selected 13C NMR from the HSQC spectrum (CDCl3), δ 
(ppm): 161.6 (C6), 152.3 (C6'), 138.2 (C4'), 127.3 (C5'), 125.9 (C3'), 120.8 (C5), 
46.6 and 46.4 (dmso-S trans to N), 45.5 and 44.0 (dmso-S trans to Cl), 23.9 (CH3 
mpp). 15N NMR (CDCl3), δ (ppm): –87.7 (No), –130.7 (Npy), –153.4 (Np). 
cis,cis-RuCl2(dmso-S)2(mpp-κNp) (55, py of mpp trans to Cl): 1H NMR (CDCl3), δ 
(ppm): 9.79 (m, 1H, H6 overlapped with H6' 54), 9.51 (d, J = 6.2 Hz, 1H, H6'), 8.69 
(m, 1H, H3' overlapped with H3' of 54), 7.97 (m, 1H, H4' overlapped with H4' of 
54), 7.54 (t, J = 6.6 Hz, 1H, H5'), 7.42 (d, 1H, H5), 3.49 (m, J = 9.5 Hz, 6H), 3.09 
(s, 3H), 2.93 (s, 3H), 2.76 (s, 3H). Selected 13C NMR from the HSQC spectrum 
(CDCl3), δ (ppm): 158.5 (C6), 155.7 (C6'), 136.8 (C4'), 127.5 (C5'), 125.9 (C3'), 
121.2 (C5), 46.6 and 46.5 (dmso-S trans to N), 45.0 and 44.5 (dmso-S trans to Cl), 
24.2 (CH3 mpp).
15N NMR (CDCl3), δ (ppm): –88.7 (No), –135.9 (Npy), –147.6 
(Np). 
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trans,cis-RuCl2(dmso-S)2(mpp-κNp) (56). 
 
A 50.0 amount of trans-RuCl2(dmso-S)4 (9, 0.10 mmol) was dissolved in 10 mL of 
methanol and a slight excess of mpp (21.0 mg, 0.12 mmol) was added. The initial 
yellow solution turned rapidly deep red. After 90 min it was rotary evaporated to ca. 
2 mL, rapidly affording red crystals of 56 suitable for X-ray diffraction (Yield 14 
mg, 28%). Similar results were obtained when the reaction was performed in 
chloroform at room temperature. In this case, after 90 min the solution was rotary 
evaporated to an oil that, treated with diethyl ether, afforded a red-orange solid that 
was filtered, washed with diethyl ether and dried in vacuo. (Yield: 80.1 mg, 76%). 
The product was (almost) pure 56 according to 1H NMR spectrum. Elemental 
analysis calcd for [C14H21N3Cl2O2RuS2] (MW: 499.45): C 33.67; H 4.24; N 8.41. 
Found: C 33.76; H 4.16; N 8.38. 1H NMR (CDCl3), δ (ppm): 10.30 (br s, 1H, H6), 
8.96 (br s, 1H, H6'), 8.78 (d, J = 7.9 Hz, 1H, H3'), 8.02 (t, J = 7.7 Hz, 1H, H4'), 7.57 
(t, J = 6.6 Hz, 1H, H5'), 7.33 (d, J = 6.0 Hz, 1H, H5), 3.56 (d, J = 1.2 Hz, 12H), 2.71 
(s, 3H). Selected 13C NMR from the HSQC spectrum (CDCl3), δ (ppm): 160.7 (C6), 
152.6 (C6'), 138.3 (C4'), 126.7 (C5'), 126.3 (C3'), 120.8 (C5), 45.4 (dmso-S), 23.8 
(CH3 mpp). 
15N NMR (CDCl3), δ (ppm): –89.5 (No), –124.6 (Npy), –143.3 (Np). 
Solid-phase peptide synthesis. Peptides were synthesized manually at room 
temperature by using a Fmoc-protecting strategy and a Rink amide resin. Reactions 
were carried out in polypropylene syringes on a mechanical shaker. The resin was 
swollen in DMF before use. 
Fmoc-deprotection: 20% piperidine in DMF was added to the resin for 2 x 10 min. 
Washing: After each coupling and deprotection step, the resin was thoroughly 
washed with DMF, DCM and DMF. 
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Coupling: Fmoc-protected amino acids (4 eq.) were preactivated with TBTU (4 eq.), 
HOBT (4 eq.) and DIPEA (8 eq.) in DMF for 1 min, mixed with the resin and shaken 
for 1 hour. 
Final cleavage: Final cleavage from the resin and side chain deprotection of the 
peptides was accomplished by using a mixture of 90% TFA, 5% TIS and 5% H2O 
for 4 hours at room 
temperature. Cleaved peptides were precipitated with ice-cold dietyl ether, 
centrifuged and washed two times with dietyl ether. The peptides were lyophilized 
and purified by preparative HPLC. 
NT-cppH.  
 
The peptide was synthesized by solid phase peptide synthesis as described in the 
general experimental procedure. The coupling with cppH∙HNO3 was performed with 
TBTU/HOBT/DIPEA 4/4/5 for two hours. 
calcd for C48H69N15O9: 999.54; MS (ESI, +ve mode): m/z 999.68 [M+H]
+, tR=16.4 
min. 
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trans,cis-RuCl2(CO)2(cppH-NT-κNo) (57).  
 
This bioconjugate was prepared using two different approaches: SPPS between 
trans,cis-RuCl2(CO)2(cppH-κNo) (52) and NT(8-13) and the reaction in solution 
between trans,cis,cis-RuCl2(CO)2(dmso)2 (29) and cppH-NT (see Chapter 7 for 
details). 
SPPS: The peptide NT(8-13) was synthesized by solid phase peptide synthesis as 
described in the general experimental procedure. The coupling between NT(8-13) 
and trans,cis-RuCl2(CO)2(cppH-κNo) (52) was performed using 
PyBOP/DIPEA/Ru(II) 5/10/5 for two days, light protected; the cleavage and 
deprotection were done using TFA/phenol/TIS in 85/10/5 ratio for 2 h. The solution 
was lyophilized and purified using semi preparative HPLC. Purified: 10.9 mg (0.02 
mmol, 62%).  
Solution: A 15 mg amount of trans,cis,cis-RuCl2(CO)2(dmso)2 (29) (0.039 mmol) 
was partially dissolved in 2.5 mL of water. One equivalent of cppH-NT (39 mg, 
0.039 mmol) was added and the mixture was stirred for two days at room 
temperature, light protected. A clear yellow solution was obtained in one hour. After 
24h hours the solution turned in orange. The solution was lyophilized and purified 
using semi preparative HPLC.  Purified: 28.8 mg (0.023 mmol, 6%). 
C50H69Cl2N15O11Ru: 1227.37; MS (ESI, +ve mode): m/z 1227.25 [M+H]
+, tR=18.2 
min. Selected 
1H NMR resonances (DMSO-d6), δ (ppm):  9.81 (d, 1H, H6), 9.40 (d, 
1H, NH), 9.31 (d, 1H, H6'), 9.15 (d, 1H, H3'), 9.17 (br s, 1H, OH Tyr), 8.53 (t, 1H, 
H4'), 8.40 (d, 1H, NH), 8.29 (d, 1H, H5), 8.06 (t, 1H, H5'), 7.88-7.82 (m, 4H, NH), 
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6.99, 6.62 (d, 4H, H2,6 and 5,3 Tyr) 4.65-4.10 (m, 6H, Hα peptide). Selected 13C 
NMR from the HSQC spectrum (DMSO-d6), δ (ppm): 163.3 (C6), 154.2 (C6’), 141.4 
(C4’), 130.9 (C5’), 130.2 (C Tyr), 127.6 (C3’), 121.0 (C5), 115.5 (C Tyr), 59.5-50.6 
(Cα peptide). 
[Ru([9]aneS3)Cl(cppH-κNp)]Cl (60). 
 
A 30 mg amount of Ru([9]aneS3)Cl2(dmso) (58) (0.068 mmol) was dissolved in 2 
mL of water. One equivalent of cppH (18.6 mg, 0.068 mmol) was added and the 
mixture was refluxed for 5 h. A clear orange solution was obtained within few 
minutes that turned rapidly in red. After the reaction the solvent was concentrated 
and X-ray quality crystals became to form after 2 days. The crystals were filtered, 
washed with cold water and acetone and dried in vacuo. (Yield: 30.1 mg, 80%). 
Elemental analysis calcd for [C16H19N2Cl2O2S3Ru] (MW: 552.91): C 34.72; H 3.46; 
N 7.59. Found: C 34.76; H 3.40; N 7.52. 1H NMR (D2O + NaCl), δ (ppm): 9.47 (d, 
1H, H6), 9.04 (d, 1H, H6’), 8.89 (d, 1H, H3’), 8.22 (t, 1H, H4’), 8.13 (d, 1H, H5), 
7.78 (t, 1H, H5’), 2.85 (m, 12H, [9]aneS3). 13C NMR (D2O + NaCl), δ (ppm): δ = 
162.0 (C6), 152.9 (C6’), 138.8 (C4’), 129.03 (C5’), 126.4 (C3’), 121.4 (C5), 31.2 
([9]aneS3). 
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[Ru([9]aneS3)Cl(cppH-NT)]Cl (61). 
 
A 15 mg amount of Ru([9]aneS3)Cl2(dmso) (58) (0.034 mmol) was dissolved in 1 
mL of water. One equivalent of cppH-NT (17 mg, 0.034 mmol) was added and the 
mixture was heated at 80°C for 5 h. A clear yellow solution was obtained within few 
minutes that turned rapidly in red. The solution was lyophilized and purified using 
semi preparative HPLC. Purified: 30.8 mg (0.02 mmol, 65%). C56H87ClN15O10S4Ru: 
1394.43; MS (ESI, +ve mode): m/z 1394.81 [M+H]+, tR=17.5 min. Selected 
1H NMR 
resonances (DMSO-d6), δ (ppm):  9.51 (d, 1H, H6), 9.29 (m, 1H, NH), 9.18 (br s, 
1H, OH Tyr), 9.11 (d, 1H, H3'), 9.04 (d, 1H, H6'),  8.65 (d, 1H, NH), 8.38 (m, 1H, 
NH), 8.31 (t, 1H, H4'), 8.11 (d, 1H, H5), 7.89 (m, 1H, NH), 7.82 (m, 2H, H5’ + NH), 
6.99, 6.60 (d, 4H, H2,6 and 5,3 Tyr), 4.70-4.10 (m, 6H, Hα peptide). Selected 13C 
NMR from the HSQC spectrum (DMSO-d6), δ (ppm): 163.2 (C6), 153.8 (C6’), 138.6 
(C4’), 130.5 (C Tyr), 129.6 (C5’), 126. 9 (C3’), 120.0 (C5), 115.2 (C Tyr), 59.5-50.7 
(Cα peptide). 
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[Ru([9]aneS3)(cppH-NT)(PTA)]Cl2 (62). 
 
A 25 mg amount of [Ru([9]aneS3)Cl(PTA)]Cl (59) (0.050 mmol) was dissolved in 1 
mL of water. One equivalent of cppH-NT (50 mg, 0.050 mmol) was added and the 
mixture was heated at 80°C for 8 h. A clear yellow solution was obtained within few 
minutes that turned slowly in orange. The solution was lyophilized and purified using 
semi preparative HPLC. Purified: 43.2 mg (0.03 mmol, 60%). C60H95N19O8PS3Ru: 
1438.56; MS (ESI, +ve mode): m/z 1438.93 [M+H]+, tR=16.6 min. Selected 
1H NMR 
resonances (DMSO-d6), δ (ppm):  9.27 (m, 4H, H6 + H3’ + NH + OH Tyr), 8.82 (d, 
1H, H6'),  8.43 (m, 2H, H4’ + NH), 8.12 (d, 1H, H5), 7.89 (m, 2H, H5' + NH), 7.83, 
7.74 (d, 2H, NH), 7.01, 6.62 (d, 4H, H2,6 and 5,3 Tyr) 4.70-4.10 (m, 6H, Hα peptide). 
Selected 13C NMR from the HSQC spectrum (DMSO-d6), δ (ppm): 163.4 (C6), 154.8 
(C6’), 140.0 (C4’), 130.9 (C5’), 130.5 (C Tyr), 127. 9 (C3’), 121.4 (C5), 115.2 (C 
Tyr), 59.5-51.1 (Cα peptide). 31P NMR resonance (DMSO-d6), δ (ppm): –39.1 (br s, 
1P, PTA trans to S). 
[Ru([9]aneS3)(chel)Cl]Cl (chel = bpy (63), phen (64), 4,7-Ph2phen (65), dppz 
(66)). 
These complexes were prepared according to a modified literature procedure.23 A 
100 mg amount of Ru([9]aneS3)Cl2(dmso-S) (58) (0.23 mmol) was partially 
dissolved in 15 mL of EtOH. Two equivalents (0.46 mmol) of chel (72 mg of bpy 
(63), 83.5 mg of phen (64), 153.2 mg of 4,7-Ph2phen (65), 129.1 of dppz (66)) were 
added and the mixture was refluxed for 3 h. After 10 minutes of refluxing the solution 
changed from yellow to orange (for 63 and 64) or orange-brown (for 65) or red (for 
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66). Precipitation of the product in pure form (according to 1H NMR spectra) from 
the concentrated solution (ca. 8 mL) occurred upon standing at r.t.. It was removed 
by filtration, washed with few mL of EtOH and diethyl ether and dried in vacuo. 
Yields from 65 to 85%. 
[Ru([9]aneS3)(bpy)Cl]Cl (63).  
 
Elemental analysis calcd for [C16H20N2Cl2RuS3] (MW = 509,2): C 37.79; H 3.96; N 
5.51. Found: C 37.68; H 4.05; N 5.60. 1H NMR (D2O), δ (ppm): 9.05 (d, 2H, H6,6′), 
8.47 (d, 2H, H3,3′), 8.13 (t, 2H, H4,4′), 7.62 (t, 2H, H5,5′), 2.77 (m, 12H, [9]aneS3, 
partially overlapped with the corresponding resonances of  63aq). ESI mass spectrum: 
473.0 m/z (calcd 473.1) [M]+. UV-vis (H2O): λmax (ε, L mol–1 cm–1) = 361 (2359), 
417 (4296) nm.  
[Ru([9]aneS3)(phen)Cl]Cl (64). 
 
Elemental analysis calcd for [C18H20N2Cl2RuS3] (MW = 533.3): C 40.60; H 3.79; N 
5.26. Found: C 40.52; H 3.68; N 5.18.  1H NMR (D2O), δ (ppm): 9.48 (d, 2H, H2,9), 
8.78 (t, 2H, H4,7), 8. 22 (s, 2H, H5,6), 8.02 (d, 2H, H3,8), 2.73 (m, 12H, [9]aneS3, 
partially overlapped with the corresponding resonances of 64aq). 1H NMR (CDCl3), 
δ (ppm): 9.36 (d, 2H, H2,9), 8.49 (d, 2H, H4,7), 8.05 (s, 2H, H5,6), 7.87 (d, 2H, 
H3,8), 2.97 (m, 12H, [9]aneS3).
13C NMR from HSQC (CDCl3), δ: 152.2 (C2,9), 
136.3 (C4,7), 127.8 (C5,6), 126.0 (C3,8), 34.1 ([9]aneS3). ESI mass spectrum: 497.0 
m/z (calcd 497.1) [M]+. UV-vis (H2O): λmax (ε, L mol–1 cm–1) = 369 (4711), 415 
(4423) nm. 
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[Ru([9]aneS3)(4,7-Ph2phen)Cl]Cl (65).  
 
Elemental analysis calcd for [C30H28N2Cl2RuS3] (MW = 685.4): C 52.62; H 4.12; N 
4.09. Found: C 52.73; H 4.20; N 4.17.  1H NMR (D2O), δ (ppm): 9.52 (d, 2H, H2,9), 
8.15 (s, 2H, H5,6), 7.98 (d, 2H, H3,8), 7.69 (br s, 10H, Ph), 2.92 (m, 12H, [9]aneS3, 
partially overlapped with the corresponding resonances of 65aq). 1H NMR (CDCl3), 
δ (ppm): 9.40 (d, 2H, H2,9), 8,07 (s, 2H, H5,6), 7.78 (d, 2H, H3,8), 7.57 (m, 10H, 
Ph), 3.03 (m, 12H, [9]aneS3). 
13C NMR from HSQC (CDCl3), δ (ppm): 151.9 (C2,9), 
129.2 (Ph), 124.0 (C5,6), 122.4 (C3,8), 35.0 ([9]aneS3). ESI mass spectrum: 649.1 
m/z (calcd 649.3) [M]+.  UV-vis (H2O): λmax (ε, L mol–1 cm–1) = 370 (6598), 408 
(5786) nm. 
[Ru([9]aneS3)(dppz)Cl]Cl (66).  
 
Elemental analysis calcd for [C24H22N4Cl2RuS3] (MW = 635.5): C 45.42; H 3.49; N 
8.83. Found: C 45.50; H 3.58; N 8.91. 1H NMR (CDCl3), δ (ppm): 9.77 (d, 2H, 
H2,2′), 9.42 (d, 2H, H4,4′), 8.46 (d, 2H, H5,5′), 8.08 (d, 2H, H6,6′), 8.00 (t, 2H, 
H3,3′), 3.01 (m, 12H, [9]aneS3). 13C NMR from HSQC (CDCl3), δ (ppm): 153.6 
(C4,4′), 134.3 (C2,2′), 131.3 (C6,6′), 130.6 (C5,5′), 126.3 (C3,3′), 33.2 ([9]aneS3). 
ESI mass spectrum: 599.0 m/z (calcd 599.1) [M]+.  UV-vis (H2O): λmax (ε, L mol–1 
cm–1) = 357 (6875), 423 (4750) nm. 
 
 
Chapter 9: Experimental Section  
 
 
279 
 
[Ru([9]aneS3)(bq)Cl]Cl (67). 
 
A 50 mg amount of Ru([9]aneS3)Cl2(dmso-S) (58) (0.12 mmol) was partially 
dissolved in 2 mL of EtOH  and two equivalents (0.24 mmol) of 2,2′-biquinoline (60 
mg) were added. The mixture was microwave-heated at 140°C for 90 min. The white 
powder (unreacted bq) was removed by filtration. Evaporation of the solvent 
afforded a purple solid that was dissolved in water and filtered to remove the 
remaining traces of unreacted bq. The solution was rotary evaporated to dryness and 
the solid (pure 67, according to the 1H NMR spectrum) was dried in vacuo. (Yield 
51.1 mg, 66%). Elemental analysis calcd for [C24H24N2Cl2RuS3] (MW = 607.9): C 
47.36; H 3.97; N 4.60. Found: C 47.28; H 3.88; N 4.51. 1H NMR (D2O), δ (ppm): 
9.10 (d, 2H, H8,8′), 7.95 (t, 2H, H7,7′), 7,65 (d, 2H, H4,4′), 7,73 (m, 4H, H5,5′ + 
H6,6′), 7.49 (d, 2H, H3,3′), 2.43 (m, 12H, [9]aneS3). 13C NMR from HSQC (D2O), 
δ (ppm): 139.0 (C4,4′), 132.8 (C7,7′), 129.6 (C5,5′), 129.1 (C3,3′), 128.6 (C8,8′), 
119.4 (C6,6′), 33.1 ([9]aneS3). ESI mass spectrum: 573.1 m/z (calcd 573.2) [M]+.  
UV-vis (H2O): λmax (ε, L mol–1 cm–1) = 356 (20106), 373 (19574), 515 (4787) nm. 
[Ru([9]aneS3)(chel)(py)](Cl)2 (chel = bpy (68), phen (69), 4,7-Ph2phen (70), dppz 
(71), bq (72)). 
The preparations were performed in light-protected glassware. The precursor 
complex (0.13 mmol, i.e. 60 mg of 63, 69 mg of 64, 89 mg of 65, 82 mg of 66, 83 
mg of 67) was dissolved in 5 mL of H2O and a 50 µL amount of pyridine (0.6 mmol) 
was added. The solution was refluxed for 3h, then the solution was rotary evaporated 
to dryness. The obtained solid was sonicated with 2 mL of acetone, then removed by 
filtration, washed with acetone and diethyl ether, and dried in vacuo. According to 
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the 1H NMR spectra, in each case the product (i.e. 68, 69, 70, 71 and 72, respectively) 
was obtained in pure form. Yields from 65 to 85%. X-ray quality crystals of 69 and 
72 were obtained by slow diffusion of diethyl ether into an EtOH solution of the 
complex. 
[Ru([9]aneS3)(bpy)(py)](Cl)2 (68). 
 
Elemental analysis calcd for [C21H25N3Cl2RuS3] (MW = 588.2): C 42.93; H 4.29; N 
7.15. Found: C 42.65; H 4.25; N 7.08. 1H NMR (D2O), δ (ppm): 9.23 (d, 2H, H6,6′), 
8.66 (d, 2H, o-py), 8.38 (d, 2H, H3,3′), 8.16 (t, 2H, H4,4′), 7.77 (d, 3H, p-py + H5,5′), 
7.26 (t, 2H, m-py), 2,90 (m, 12H, [9]aneS3). ESI mass spectrum: 473.0 m/z (calcd 
473.1) [M – py + Cl]+.  UV-vis (H2O): λmax (ε, L mol–1 cm–1) = 401 (4666) nm. 
[Ru([9]aneS3)(phen)(py)](Cl)2 (69). 
 
Elemental analysis calcd for [C23H25N3Cl2RuS3] (MW = 612.4): C 45.17; H 4.12; N 
6.87. Found: C 45.25; H 4.20; N 6.98. 1H NMR (D2O), δ (ppm): 9.63 (d, 2H, H2,9), 
8.76 (d, 2H, o-py), 8.72 (m, 2H, H4,7), 8.15 (s, 2H, H5,6), 8.11 (t, 2H, H3,8), 7.71 
(d, 1H, p-py), 7.20 (t, 2H, m-py), 3.01 (m, 12H, [9]aneS3). 
13C NMR from HSQC 
(D2O), δ (ppm): 153.3 (C2,9), 152.9 (o-py), 138.2 (C4,7), 138.5 (C3,8 + C5,6), 129.0 
(p-py), 126.8 (m-py), 32.2 ([9]aneS3). ESI mass spectrum: 497.0 m/z (calcd 497.1) 
[M – py + Cl]+. UV-vis (H2O): λmax (ε, L mol–1 cm–1) =353 (5153), 405 (4384) nm. 
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[Ru([9]aneS3)(4,7-Ph2phen)(py)](Cl)2 (70).  
 
Elemental analysis calcd for [C35H33N3Cl2RuS3] (MW = 764.2): C 55.04; H 4.35; N 
5.50. Found: C 55.11; H 4.44; N 5.61.  1H NMR (D2O), δ (ppm): 9.73 (d, 2H, H2,9), 
8.87 (d, 2H, o-py), 8.09 (d, 2H, H3,8), 7.81 (m, 3H, H5,6 + p-py), 7.60 (m, 10H, Ph), 
7.34 (t, 2H, m-py), 3.11 (m, 12H, [9]aneS3). 
13C NMR from HSQC (D2O), δ (ppm): 
152.9 (C2,9), 151.9 (o-py), 125.1 (C5,6) 130.5 (C3,8 + p-py), 126.9 (Ph), 126.7 (m-
py), 33.4 ([9]aneS3). ESI mass spectrum: 649.1 m/z (calcd 649.3) [M – py + Cl]+. 
UV-vis (H2O): λmax (ε, L mol–1 cm–1) = 467 (7800), 413 (6600) nm. 
[Ru([9]aneS3)(dppz)(py)](Cl)2 (71).  
 
Elemental analysis calcd for [C29H27N5Cl2RuS3] (MW = 714.1): C 48.80; H 3.81; N 
9.81. Found: C 48.72; H 3.71; N 9.73.  1H NMR (D2O), δ (ppm): 9.76 (d, 2H, H2,2′), 
9.03 (d, 2H, o-py), 8.85 (s, 2H, H4,4′), 8.11 (t, 2H, H3,3′), 8.00 (t, 2H, p-py), 7.59 
(m, 6H, H5,5′ + H6,6′ + m-py), 3.05 (m, 12H, [9]aneS3). 13C NMR from HSQC 
(D2O), δ (ppm): 155.3 (C2,2′), 152.2 (o-py), 139.6 (C4), 133.3 (C3,3′), 133.2 (p-py), 
128.1 (C5,5′ + (C6,6′), 126.8 (m-py), 31.8 ([9]aneS3). ESI mass spectrum: 599.0 m/z 
(calcd 599.1) [M – py + Cl]+. UV-vis (H2O): λmax (ε, L mol–1 cm–1) = 355 (11882), 
423 (4117) nm. 
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[Ru([9]aneS3)(bq)(py)](Cl)2 (72).  
 
Elemental analysis calcd for [C29H27N3Cl2RuS3] (MW = 688.87): C 50.65; H 4.25; N 
6.11 Found: C 50.73; H 4.32; N 6.21. 1H NMR (D2O), δ (ppm): 8.79 (s, 4H, H3,3′ + 
H4,4′), 8.32 (m, 4H, H8,8′ + o-py), 8.17 (m, 2H, H5,5′), 7.88 (m, 1H, p-py), 7.80 (m, 
4H, H7,7′ + H6,6′), 7.28 (t, 2H, m-py), 2.52 (m, 12H, [9]aneS3). 13C NMR from 
HSQC (D2O), δ (ppm): 154.9 (o-py), 141.0 (C3,3′), 139.5 (p-py), 133.3 (C4,4′), 
129.7 (C7,7′), 128.8 (C5,5′), 127.0 (m-py), 126.9 (C8,8′), 120.3 (C6,6′), 35.8 
([9]aneS3). ESI mass spectrum: 573.1 m/z (calcd 573.2) [M – py + Cl]+. UV-vis 
(H2O): λmax (ε, L mol–1 cm–1) = 359 (14161), 378 (16207), 466 (2854), 493 (3771) 
nm. 
trans,cis-Ru(bq)Cl2(CO)2 (73).  
 
To a 60 mg amount of trans,cis,cis-RuCl2(CO)2(dmso-O)2 (29) (0.16 mmol) 
dissolved in 3 mL of CHCl3, 1 eq of 2,2′-biquinoline (43.2 mg) was added and the 
mixture was sonicated for a few minutes until complete dissolution of the ligand 
(yellow solution). After 4h small red crystals began to form. Crystals were filtered 
after one day and washed with CHCl3 and diethyl ether and dried in vacuo (Yield 
57.1 mg, 75%).  
Elemental analysis calcd for [C20H12N2 Cl2O2Ru] (MW = 484.83): C 49.60; H 2.50; 
N 5.78 Found: C 49.72; H 2.61; N 5.89. 1H NMR (CDCl3), δ (ppm): 9.25 (d, 1H, 
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H8,8′), 8.56 (d, 1H, H3,3′), 8.35 (d, 1H, H4,4′), 8.04 (t, 1H, H7,7′), 7.98 (d, 1H, 
H5,5′), 7.79 (t, 1H, H6,6′). 13C NMR (CDCl3) δ (ppm): 195.61 (CO), 141.24 (C3,3′), 
133.29 (C7,7′), 129.65 (C8,8′), 129.51 (C6,6′), 129.35 (C5,5′), 119.37 (C4,4′). ESI 
mass spectrum: 448.6 m/z (calcd 448.8) [M – Cl]+. Selected IR absorption (cm-1): 
Nujol, 2051 (νCO, s), 1981 (νCO, s).  
[Ru([9]aneS3)(bq)(NH3)](Cl)2 (74). 
 
A 20 mg amount of [Ru([9]aneS3)(bq)Cl][Cl] (67) (0.033 mmol) was dissolved in 1 
mL of H2O; a 45 µL volume of a 25% ammonia solution in water (0.42 mmol) was 
added and the mixture was heated in the microwave at 110°C for 150 min. Then the 
solvent was rotary evaporated completely and the resulting oil was crushed with 
CHCl3 obtaining a dark red solid that was filtered, washed with CHCl3 and diethyl 
ether and dried in vacuo. According to the 1H NMR spectrum the product was pure 
74. X-ray quality crystals of 74 were obtained by slow diffusion of diethyl ether into 
a methanol solution of the complex. (Yield 14.4 mg, 70%). Elemental analysis calcd 
for [C24H27N3Cl2RuS3] (MW = 624.48): C 46.07; H 4.35; N 6.72 Found: C 45.99; H 
4.28; N 6.63. 1H NMR (D2O), δ (ppm): 8.91 (d, 2H, H8,8′), 8.65 (m, 4H, 
H3,3′+H4,4′), 8.14 (s, 2H, H5,5′), 8.06 (t, 2H, H7,7′), 7.86 (t, 2H, H6,6′), 3.53 (br s, 
3H, NH3), 2.63 (m, 12H, [9]aneS3). 
13C NMR from HSQC (D2O), δ (ppm): 134.6 
(C3,3′), 131.2 (C7,7′), 129.3 (C5,5′), 129.2 (C6,6′), 126.8 (C8,8′), 120.11 (C4,4′), 
33.2 ([9]aneS3). ESI mass spectrum: 573.0 m/z (calcd 573.2) [M – NH3 + Cl]+. 
 
 
 
 
Chapter 9: Experimental Section  
 
 
284 
 
[Ru([9]aneS3)(py)2Cl]Cl (75). 
 
A 50 mg amount of Ru([9]aneS3)Cl2(dmso-S) (58) (0.13 mmol) was partially 
dissolved in 10 mL of EtOH; a 36 µL volume of  pyridine (0.52 mmol) was added 
and the mixture was refluxed for 5 h. During the heating a clear yellow-orange 
solution was obtained, from which a yellow precipitate started to form. After cooling 
the mixture to r.t., the product was removed by filtration, washed with EtOH and 
diethyl ether and dried in vacuo. (Yield 49.7 mg, 75%). The product was pure 75 
according to the 1H NMR spectrum. Elemental analysis calcd for [C16H22N2Cl2RuS3] 
(MW = 509.94): C 37.64; H 4.34; N 5.49 Found: C 37.78; H 4.44; N 5.58. 
1H NMR 
(D2O), δ (ppm): 8.70 (d, 4H, o-py), 7.87 (t, 2H, p-py), 7.43 (t, 4H, m-py), 2.41 (m, 
12H, [9]aneS3 partially overlapped with the corresponding resonances of 75aq). ESI 
mass spectrum: 475.0 m/z (calcd 475.1) [M]+.  
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Appendix of Chapter 2 
 
Figures A2.1-A2.3. NMR characterization in CDCl3 and D2O of trans-RuCl2(PTA)4 
(1). 
Figures A2.4-A2.6. NMR characterization in CDCl3 and D2O of cis-RuCl2(PTA)4 
(2). 
Figures A2.7-A2.8. NMR characterization in CDCl3 of trans-RuCl2(PTA)4 (11). 
Figures A2.9-A2.10. NMR characterization in CDCl3 and D2O of cis-RuCl2(PTA)4 
(12). 
Figure A2.11. 31P NMR spectrum in CDCl3 of cis,mer-RuCl2(dmso-S)(PTA)3 (13). 
Figures A2.12-A2.13. 31P NMR spectra in CDCl3 of trans,mer-
RuCl2(CH3CN)(PTA)3 (14) and cis,mer-RuCl2(CH3CN)(PTA)3 (15). 
Figure A2.14. Inversion recovery 1H NMR spectrum in D2O of trans-
[RuCl4(PTAH)2]Cl (3). 
Figures A2.15-A2.19. NMR characterization in D2O of mer-
[Ru(bpy)Cl(PTA)3](PF6) (17). 
Figures A2.20-A2.22. NMR characterization in D2O of fac-
[Ru(bpy)Cl(PTA)3](PF6) (18). 
Figure A2.23. 1H and 31P NMR spectra in D2O of mer-[RuCl(cppH)(PTA)3]Cl 
(19). 
Figures A2.24-A2.26. NMR characterization in CHCl3 and D2O of cis,cis,trans-
RuCl(dmso-S)2(PTA)2 (10). 
Figures A2.27-A2.32. NMR characterization in CHCl3 and D2O of cis,cis-
Ru(bpy)Cl2(PTA)2 (22). 
Figures A2.33-A2.37. NMR characterization in D2O of cis,cis-
Ru(bpyAc)Cl2(PTA)2 (23).
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Figures A2.38-A2.40. NMR characterization in CDCl3 of trans,mer-
[RuCl2(PTA)3(py)] (25). 
Figure A2.41. 1H NMR spectrum in CDCl3 of of the reaction between cis,cis,trans-
RuCl2(dmso-S)2(PTA)2 (10) and 4’MPyP. 
Figures A2.42-A2.46. UV spectra of cis-RuCl2(PTA)4 (2), mer-
[Ru(bpy)Cl(PTA)3](PF6) (17), fac-[Ru(bpy)Cl(PTA)3](PF6) (18), cis,cis-
Ru(bpy)Cl2(PTA)2 (22), cis,cis-[Ru(bpy)Cl(OH2)(PTA)2]
+ (22aq) and cis,cis-
[Ru(bpyAc)Cl(OH2)(PTA)2]
+ (23aq). 
Figure A2.47. 31P NMR pH titration of complex cis,cis,trans-RuCl2(dmso-
S)2(PTA)2 (10) in D2O. 
Figure A2.48. Molecular structure (50% probability ellipsoids) of fac-
[Ru(bpy)Cl(PTAH)2.5(PTA)0.5](ClO4)3.5·2.5H2O (18).  
Figure A2.49. Molecular structure (50% probability ellipsoids) of the two 
crystallographically independent molecules of cis-
[RuCl(OH2)(PTA)4](PF6)·CH3OH (2aq). 
  
Appendix of Chapter 2  
 
 
289 
 
 
 
Figure A2.1. 1H (left) and 31P (right) NMR spectra in CDCl3 of trans-RuCl2(PTA)4 
(1). 
 
 
Figure A2.2. 1H-13C HSQC NMR spectrum in CDCl3 of trans-RuCl2(PTA)4 (1). 
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Figure A2.3. 31P NMR spectra of trans-RuCl2(PTA)4 (1) in D2O registered: 
immediately after dissolution (a), after 8 days in the dark (b), after exposure to 
diffused indoor light for 8 days (c). 
 
 
Figure A2.4. 1H (insert) and 31P NMR spectra in CDCl3 of cis-RuCl2(PTA)4 (2). 
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Figure A2.5. 1H-13C HSQC NMR spectrum in CDCl3 of cis-RuCl2(PTA)4 (2). The 
peak marked with an asterisk belongs to a minor unidentified impurity. 
 
 
Figure A2.6. 31P-31P COSY NMR spectrum of cis-RuCl2(PTA)4 (2) in D2O. 
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Figure A2.7. 1H (left) and 31P (right) NMR spectra in CDCl3 of trans-[RuBr2(PTA)4] 
(11). 
 
Figure A2.8. 1H-13C HSQC NMR spectrum in CDCl3 of trans-[RuBr2(PTA)4] (11). 
 
NCH
2
N 
NCH
2
P 
NCH
2
N 
NCH
2
P 
Appendix of Chapter 2  
 
 
293 
 
 
Figure A2.9. 1H (insert) and 31P NMR spectra in CDCl3 of cis-[RuBr2(PTA)4] (12). 
Figure A2.10. 1H-13C HSQC NMR spectrum in CDCl3 of cis-[RuBr2(PTA)4] (12). 
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Figure A2.11. 31P NMR spectrum in CDCl3 of the precipitate obtained by heating 
trans-[RuCl2(PTA)4] (1) in DMSO at 70°C. 13 is cis,mer-RuCl2(dmso-S)(PTA)3. 
 
 
Figure A2.12. 31P NMR spectrum in CDCl3 of the precipitate obtained by refluxing 
trans-RuCl2(PTA)4 (1) in CH3CN for 3.5h. 14 is trans,mer-RuCl2(CH3CN)(PTA)3 
and 15 is cis,mer-RuCl2(CH3CN)(PTA)3. 
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Figure A2.13. 31P NMR spectrum in CDCl3 of the precipitate obtained by refluxing 
trans-RuCl2(PTA)4 (1) in CH3CN for 2h.  
Figure A2.14. Inversion recovery 1H NMR spectrum in D2O of trans-
[RuCl4(PTAH)2]Cl (3). Upward: diamagnetic signal of DSS (internal standard for 
D2O); downward: paramagnetic signals of PTA. 
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Figure A2.15. 1H-1H COSY NMR spectrum (bpy region) in D2O of mer-
[Ru(bpy)Cl(PTA)3](PF6) (17PF6). 
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 Figure A2.16. 1H-1H COSY NMR spectrum (PTA region) in D2O of mer-
[Ru(bpy)Cl(PTA)3](PF6) (17PF6). 
 
Figure A2.17. 1H-13C HSQC NMR spectrum (bpy region) in D2O of mer-
[Ru(bpy)Cl(PTA)3](PF6) (17PF6). 
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Figure A2.18. 1H-13C HSQC NMR spectrum (PTA region) in D2O of mer-
[Ru(bpy)Cl(PTA)3](PF6) (17PF6). 
 
Figure A2.19. 31P NMR spectrum in D2O of mer-[Ru(bpy)Cl(PTA)3](PF6) (17PF6). 
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Figure A2.20. 31P NMR spectrum of fac-[Ru(bpy)Cl(PTA)3](PF6) (18PF6) in D2O 
after addition of an aliquot of NaCl. 
 
 
Figure A2.21. 1H-1H COSY NMR spectrum (bpy region) in D2O of fac-
[Ru(bpy)Cl(PTA)3](PF6) (18PF6, black labels) that equilibrates with fac-
[Ru(bpy)(OH2)(PTA)3]Cl(PF6) (18aq, blue labels). 
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Figure A2.22. 1H-13C HSQC NMR spectrum (bpy region) in D2O of fac-
[Ru(bpy)Cl(PTA)3](PF6) (18PF6, black labels) that equilibrates with fac-
[Ru(bpy)(OH2)(PTA)3]Cl(PF6) (18aq, blue labels). 
 
Figure A2.23. 1H (left) and 31P (right) NMR spectra in D2O of mer-
[RuCl(cppH)(PTA)3]Cl (19). 
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Figure A2.24. 1H NMR spectra of cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10) in D2O 
(top) and in CDCl3 (bottom). 
 
Figure A2.25. 1H NMR spectra of cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10) in D2O 
registered immediately after dissolution (a); after 20 hours in the dark (b); after 120 
hours in the dark (c). 
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Figure A2.26. 31P NMR spectra of cis,cis,trans-RuCl2(dmso-S)2(PTA)2 (10) in D2O 
registered immediately after dissolution (a); after 20 hours in the dark (b); after 120 
hours in the dark (c). 
 
 
Figure A2.27. 1H-1H COSY NMR spectrum (bpy region) in CDCl3 of cis,cis-
Ru(bpy)Cl2(PTA)2 (22). 
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Figure A2.28. 1H-1H COSY NMR spectrum (PTA region) in CDCl3 of cis,cis-
Ru(bpy)Cl2(PTA)2 (22). 
 
Figure A2.29. 1H-13C HSQC NMR spectrum (bpy region) in CDCl3 of cis,cis-
Ru(bpy)Cl2(PTA)2 (22). 
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Figure A2.30. 1H-13C HSQC NMR spectrum (PTA region) in CDCl3 of cis,cis-
Ru(bpy)Cl2(PTA)2 (22). 
 
 
Figure A2.31. 31P NMR spectrum in CDCl3 of cis,cis-Ru(bpy)Cl2(PTA)2 (22). 
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Figure A2.32. 1H NMR spectrum (bpy region) in D2O of cis,cis-
[Ru(bpy)Cl(OH2)(PTA)2]
+ (22aq) after addition of an aliquot of NaCl. 
 
 
Figure A2.33. 1H-1H COSY NMR spectrum (bpyAc region) in D2O of the mixture 
of the two isomers of cis,cis-Ru(bpyAc)Cl(OH2)(PTA)2: 23aaq (red) and 23baq 
(blue).   
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Figure A2.34. 1H-1H NOESY NMR spectrum (aromatic region) in D2O of the 
mixture of the two isomers of cis,cis-Ru(bpyAc)Cl(OH2)(PTA)2: 23aaq (red) and 
23baq (blue).   
 
Figure A2.35. 1H-13C HSQC NMR spectrum (bpyAc region) in D2O of the mixture 
of the two isomers of cis,cis-Ru(bpyAc)Cl(OH2)(PTA)2: 23aaq (red) and 23baq 
(blue).   
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Figure A2.36. 1H-13C HSQC NMR spectrum (PTA region) in D2O of the mixture of 
the two isomers of cis,cis-Ru(bpyAc)Cl(OH2)(PTA)2: 23aaq (red) and 23baq (blue).   
 
 
Figure A2.37. 31P NMR spectra in D2O of the mixture of the two isomers of cis,cis-
Ru(bpyAc)Cl(OH2)(PTA)2 (23aq) (top) and after addition of an aliquot of NaCl, 
affording a mixture of 23 and 23aq (bottom). 
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Figure A2.38. 1H-1H COSY spectrum in CDCl3 of trans,mer-[RuCl2(PTA)3(py)] 
(25). See the inset drawing for the peak labels. 
 
Figure A2.39. 1H-13C HSQC spectrum in CDCl3 of trans,mer-[RuCl2(PTA)3(py)] 
(25). See the inset drawing for the peak labels. 
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Figure A2.40. 31P NMR spectrum in CDCl3 of trans,mer-[RuCl2(PTA)3(py)] (25). 
 
 
Figure A.41. 1H NMR spectrum in CDCl3 of the reaction between cis,cis,trans-
RuCl2(dmso-S)2(PTA)2 (10) and 4’MPyP. With the * are indicated the signals of the 
products. 
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Figure A2.42. UV spectrum of cis-RuCl2(PTA)4 (2) in CDCl3. 
 
Figure A2.43. UV spectrum of mer-[Ru(bpy)Cl(PTA)3](PF6) (17PF6) in H2O. 
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Figure A2.44. UV spectrum of fac-[Ru(bpy)Cl(PTA)3](PF6) (18PF6) in H2O. 
 
 
Figure A2.45. UV spectrum of cis,cis-[Ru(bpy)Cl(OH2)(PTA)2]
+ (22aq) (blue) in 
H2O and after addition of aliquots of NaCl (22, red). 
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Figure A2.46. UV spectrum of cis,cis-[Ru(bpyAc)Cl(OH2)(PTA)2]
+ (23aq) in H2O. 
 
 
Figure A2.47. 31P NMR pH titration of complex cis,cis,trans-RuCl2(dmso)2(PTA)2 
(10) in D2O. 
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Figure A2.48. Molecular structure (50% probability ellipsoids) of fac-
[Ru(bpy)Cl(PTAH)2.5(PTA)0.5](ClO4)3.5·2.5H2O (18). All three PTA ligands are 
protonated in molecule Ru1, whereas only two PTA ligands are protonated in 
molecule Ru2. Disordered ClO4
- anions and water molecules have been omitted for 
clarity. 
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Figure A2.49. Molecular structure (50% probability ellipsoids) of the two 
crystallographically independent molecules of cis-
[RuCl(OH2)(PTA)4](PF6)·CH3OH (2aq), after structure solution and one least 
squares (isotropic) refinement cycle with hydrogen atoms added at calculated 
positions (but not for the coordinated water molecule). Two PF6
- anions and two 
methanol solvent molecules have been omitted for clarity. 
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Figures A3.1-A3.5. NMR characterization in CDCl3 and D2O of cis,cis,trans-
[RuCl2(CO)(dmso-S)(PTA)2] (31). 
Figures A3.6-A3.9. NMR characterization in CDCl3 and D2O of trans,mer-
[RuCl2(CO)(PTA)3] (32). 
Figures A3.10-A3.12. NMR characterization in D2O of cis,mer-[RuCl2(CO)(PTA)3] 
(33). 
Figures A3.13-A3.15. NMR characterization in D2O of the dimer 
[RuCl2(CO)(PTA)2]2·8H2O (35). 
Figures A3.16-A.18. NMR characterization in D2O of trans,trans,trans-
RuCl2(CO)(py)(PTA)2 (36). 
Figure A3.19. 31P NMR spectrum in DMSO-d6 of dimer [RuCl2(CO)2(PTA)]2·H2O 
(37). 
Figures A3.20-A.21. NMR characterization in CDCl3 of cis,cis,trans-
RuCl2(CO)2(py)(PTA) (38). 
Figures A3.22-A3.25. NMR characterization in CDCl3 and D2O of cis,cis,trans-
[RuCl2(CO)2(PTA)2] (39). 
Figure A3.26. 31P NMR spectrum of the mixture fac-[RuCl2(CO)(PTA)3] (34) and 
cis-[RuCl(CO)(PTA)4](Cl) (42Cl) in D2O. 
Figures A3.27. 1H and 31P NMR spectrum of cis-[RuCl(CO)(PTA)4]NO3 (42NO3). 
Figure A3.28. X-ray molecular structure of cis,cis,trans-RuCl2(CO)2(py)(PTA) 
(38).  
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Figure A3.1. 1H (left) and 31P (right) NMR spectra of cis,cis,trans-
[RuCl2(CO)(dmso-S)(PTA)2] (31) in CDCl3. 
 
 
Figure A3.2. 1H-1H COSY NMR spectrum of cis,cis,trans-[RuCl2(CO)(dmso-
S)(PTA)2] (31) in CDCl3. 
 
 Appendix of Chapter 3  
 
 
317 
 
 
Figure A3.3. 1H-13C HSQC NMR spectrum of cis,cis,trans-[RuCl2(CO)(dmso-
S)(PTA)2] (31) in CDCl3. 
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Figure A3.4. 1H (left) and 31P (right) NMR spectra of cis,cis,trans-
[RuCl2(CO)(dmso-S)(PTA)2] (31) in D2O. 
 
 
Figure A3.5. 1H NMR spectra of cis,cis,trans-[RuCl2(CO)(dmso-S)(PTA)2] (31) in 
D2O immediately after dissolution (top), after 3 days (middle) and after an excess of 
NaCl. 
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Figure A3.6. 1H (left) and 31P (right) NMR spectra of trans,mer-[RuCl2(CO)(PTA)3] 
(32) in CDCl3. 
 
Figure A3.7. 1H (left) and 31P (right) NMR spectra of trans,mer-[RuCl2(CO)(PTA)3] 
(32) in D2O. 
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Figure A3.8. 1H-1H COSY NMR spectrum of trans,mer-[RuCl2(CO)(PTA)3] (32) in 
CDCl3. 
 
Figure A3.9. 1H-13C HSQC NMR spectrum of trans,mer-[RuCl2(CO)(PTA)3] (32) 
in CDCl3. 
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Figure A3.10. 1H (insert) and 31P NMR spectra of cis,mer-[RuCl2(CO)(PTA)3] 
(33) in D2O + NaCl. 
 
Figure A3.11. 1H-1H COSY NMR spectrum of cis,mer-[RuCl2(CO)(PTA)3] (33) in 
D2O + NaCl. 
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Figure A3.12. 1H-13C HSQC NMR spectrum of cis,mer-[RuCl2(CO)(PTA)3] (33) in 
D2O + NaCl. 
 
 
Figure 3.13. 1H (left) and 31P NMR (right) spectra of [RuCl2(CO)(PTA)2]2·8H2O 
(35) in D2O. 
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Figure 3.14. 1H-1H COSY NMR spectrum of [RuCl2(CO)(PTA)2]2·8H2O (35) in 
D2O. 
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Figure 3.15. 1H-13C HSQC NMR spectrum of [RuCl2(CO)(PTA)2]2·8H2O (35) in 
D2O.  
 
 
Figure A3.16. 1H (left) and 31P (right) NMR spectra of trans,trans,trans-
[RuCl2(CO)(py)(PTA)2] (36) in D2O. 
 
 
Figure 3.17. 1H-1H COSY NMR spectrum of trans,trans,trans-
RuCl2(CO)(py)(PTA)2 (36) in D2O. 
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Figure 3.18. 1H-13C HSQC NMR spectrum of trans,trans,trans-
RuCl2(CO)(py)(PTA)2 (36) in D2O. 
 
 
 
Figure A3.19. 31P NMR spectra of the dimer [RuCl2(CO)2(PTA)]2·H2O (37) in 
DMSO-d6. 
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Figure A3.20. 1H (left) and 31P (right) NMR spectra of cis,cis,trans-
RuCl2(CO)2(py)(PTA) (38) in CDCl3. 
 
 
 
Figure A3.21. 1H-1H COSY NMR spectrum of cis,cis,trans-RuCl2(CO)2(py)(PTA) 
(38) in CDCl3. 
 
 Appendix of Chapter 3  
 
 
327 
 
 
Figure A3.22 1H (left) and 31P (right) NMR spectra of cis,cis,trans-
[RuCl2(CO)2(PTA)2] (39) in CDCl3. 
 
 
Figure A3.23. 1H (left) and 31P (right) NMR spectra of cis,cis,trans-
[RuCl2(CO)2(PTA)2] (39) in D2O. 
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Figure A3.24. 1H-1H COSY NMR spectrum of cis,cis,trans-[RuCl2(CO)2(PTA)2] 
(39) in D2O. 
 
 
Figure A3.25. 1H-1C HSCQ NMR spectrum of cis,cis,trans-[RuCl2(CO)2(PTA)2] 
(39) in D2O. 
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Figure A3.26. 31P NMR spectrum of the mixture fac-[RuCl2(CO)(PTA)3] (34) and 
cis-[RuCl(CO)(PTA)4](Cl) (42Cl) in D2O. 
 
 
Figure A3.27. 1H (insert) and 31P NMR spectra of cis-[RuCl(CO)(PTA)4]NO3 
(42NO3) in D2O. 
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Figure A3.28. X-ray molecular structure (50% probability ellipsoids) of 
cis,cis,trans-RuCl2(CO)2(py)(PTA) (38). The crystals spontaneously form in D2O 
after one week. 
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Figures A4.1-A4.5. NMR characterization in D2O of cis,trans-
[Ru(bpy)Cl(CO)(PTA)2]Cl (43). 
Figures A4.6-A4.8. NMR characterization in DMSO-d6 of trans,cis-
Ru(bpy)Cl2(CO)PTA (44). 
Figures A4.9-A4.15. NMR characterization in D2O of mer-
[Ru(bpy)(CO)(PTA)3]Cl2 (45). 
Figures A4.16-A4.18. NMR characterization in D2O of cis,trans-
[Ru(bpy)(CO)2Cl(PTA)]Cl (46). 
Figures A4.19-A4.21. NMR characterization in D2O of cis,trans-
[Ru(bpy)(CO)2(PTA)2](NO3)2 (47). 
Figures A4.22-A4.26. 31P NMR spectrum in DMSO-d6 of cis,cis-
[Ru(bpy)Cl(CO)(PTA)2]Cl (48). 
Figures A4.20-A4.21. NMR characterization in CDCl3 of cis,cis,trans-
RuCl2(CO)2(py)(PTA) (38). 
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Figure A4.1. 1H (left) and 31P (right) NMR spectra of cis,trans-
[Ru(bpy)Cl(CO)(PTA)2]Cl (43) in D2O. 
 
 
Figure A4.2. 1H-1H COSY NMR spectrum (bpy region) of cis,trans-
[Ru(bpy)Cl(CO)(PTA)2]Cl (43) in D2O. 
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Figure A4.3. 1H-1H COSY NMR spectrum (PTA region) of cis,trans-
[Ru(bpy)Cl(CO)(PTA)2]Cl (43) in D2O. 
 
 
Figure A4.4. 1H-13C HSQC NMR spectrum (bpy region) of cis,trans-
[Ru(bpy)Cl(CO)(PTA)2]Cl (43) in D2O. 
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Figure A4.5. 1H-13C HSQC NMR spectrum (PTA region) of cis,trans-
[Ru(bpy)Cl(CO)(PTA)2]Cl (43) in D2O. 
 
 
 
Figure A4.6. 1H (left) and 31P (right) NMR spectra of trans,cis-Ru(bpy)Cl2(CO)PTA 
(44) in DMSO-d6. 
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Figure A4.8. 1H-13C HSQC NMR spectrum of trans,cis-Ru(bpy)Cl2(CO)PTA (44) 
in DMSO-d6. 
 
 
 
 
Figure A4.9 1H-1H COSY NMR spectrum (bpy region) of mer-
[Ru(bpy)(CO)(PTA)3]Cl2 (45) in D2O. 
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Figure A4.10 1H-1H COSY NMR spectrum (PTA region) of mer-
[Ru(bpy)(CO)(PTA)3]Cl2 (45) in D2O. 
 
Figure A4.11 1H-13C HSQC NMR spectrum (bpy region) of mer-
[Ru(bpy)(CO)(PTA)3]Cl2 (45) in D2O. 
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Figure A4.12 1H-13C HSQC NMR spectrum (PTA region) of mer-
[Ru(bpy)(CO)(PTA)3]Cl2 (45) in D2O. 
 
Figure A4.13 1D NOESY NMR spectrum of mer-[Ru(bpy)(CO)(PTA)3]Cl2 (45) in 
D2O. 
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Figure A4.14 1D NOESY NMR spectrum of mer-[Ru(bpy)(CO)(PTA)3]Cl2 (45) in 
D2O. 
 
Figure A4.15 31P NMR spectrum of mer-[Ru(bpy)(CO)(PTA)3]Cl2 (45) in D2O. 
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Figure 4.16. 1H (left) and 31P (right) NMR spectra of cis,trans-
[Ru(bpy)(CO)2Cl(PTA)]Cl (46) in D2O. 
 
 
Figure A4.17. 1H-1H COSY NMR spectrum of cis,trans-[Ru(bpy)(CO)2Cl(PTA)]Cl 
(46) in D2O. 
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Figure A4.18. 1H-13C HSQC NMR spectrum of cis,trans-
[Ru(bpy)(CO)2Cl(PTA)]Cl (46) in D2O. 
 
 
Figure 4.19. 1H (left) and 31P (right) NMR spectra of cis,trans-
[Ru(bpy)(CO)2(PTA)2](NO3)2 (47) in D2O. 
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Figure A4.20. 1H-1H HSQC NMR spectrum of cis,trans-
[Ru(bpy)(CO)2(PTA)2](NO3)2 (47) in D2O. 
 
 
Figure A4.21. 1H-13C HSQC NMR spectrum of cis,trans-
[Ru(bpy)(CO)2(PTA)2](NO3)2 (47) in D2O. 
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Figure A4.22. 1H (left) and 31P (right) NMR spectra of cis,cis-
[Ru(bpy)Cl(CO)(PTA)2]Cl (48) in D2O. 
 
 
Figure A4.23. 1H-1H COSY NMR spectrum (bpy region) of cis,cis-
[Ru(bpy)Cl(CO)(PTA)2]Cl (48) in D2O. 
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Figure A4.24. 1H-1H COSY NMR spectrum (PTA region) of cis,cis-
[Ru(bpy)Cl(CO)(PTA)2]Cl (48) in D2O. 
 
 
Figure A4.25. 1H-13C HSQC NMR spectrum (bpy region) of cis,cis-
[Ru(bpy)Cl(CO)(PTA)2]Cl (48) in D2O. 
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Figure A4.26. 1H-13C HSQC NMR spectrum (PTA region) of cis,cis-
[Ru(bpy)Cl(CO)(PTA)2]Cl (48) in D2O. 
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Figures A5.1-A5.2. UV-vis spectra of 1.5 mM solutions of trans-RuCl2(PTA)4 (1), 
cis-RuCl2(PTA)4 (2), trans-RuBr2(PTA)4 (8) and cis-RuBr2(PTA)4 (9) in CHCl3. 
 
Figures A5.3-5.7. UV-vis spectra of trans-RuCl2(PTA)4 (1), cis-RuCl2(PTA)4 (2), 
trans-RuBr2(PTA)4 (8), cis-RuBr2(PTA)4 (9) and trans-[RuCl4(PTAH)2]Cl (3) in 
H2O. 
 
Figure A5.8. LTQ Orbitrap ESI mass spectra of of trans-RuCl2(PTA)4 (1), cis-
RuCl2(PTA)4 (2), trans-RuBr2(PTA)4 (8), cis-RuBr2(PTA)4 (9) and trans-
[RuCl4(PTAH)2]Cl (3) dissolved in 20 mM ammonium acetate buffer, pH 7.4, in 
the presence of RNase A. 
 
Figure A5.9. LTQ Orbitrap ESI mass spectrum of trans-[RuCl4(PTAH)2]Cl (3 
dissolved in milliQ water, in the presence of ODN4. 
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Figure A5.1. UV-vis spectra of 1.5 mM solutions of trans-[RuCl2(PTA)4] (1) and 
trans-[RuBr2(PTA)4] (8) in CHCl3. 
 
 
Figure A5.2. UV-vis spectra of saturated solutions of cis-[RuCl2(PTA)4] (2, blue 
line) and cis-[RuBr2(PTA)4] (9, red line) in CHCl3. 
 
 
Figure A5.3. UV-vis spectra of cis-[RuCl2(PTA)4] (2) 1.0 mM solution in H2O and 
of cis-[RuBr2(PTA)4] (9) 1.1 mM solution in H2O, immediately after dissolution (2 
blue, 9 red) and after 15 hours at room temperature (2 green, 9 purple). 
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Figure A5.4. UV-vis spectra of a 1.0 mM solution of cis-[RuCl2(PTA) 4] (2) in H2O 
immediately after dissolution (blue line) and after addition of an excess of NaCl 
(red). 
 
 
Figure A5.5. UV-vis spectra of a 1.1 mM solution of cis-[RuBr2(PTA)4] (9) in H2O 
immediately after dissolution (blue line) and after addition of an excess of NaBr 
(red). 
 
 
Figure A5.6. UV-vis spectra of ca. equimolar aqueous solutions of cis-
[RuCl2(PTA)4] (2) after addition of an excess of NaCl (blue) and of cis-
[RuBr2(PTA)4] (9) after addition of an excess of NaBr (red). 
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Figure A5.7. UV-vis spectra of a 0.4 mM solution of trans-[RuCl4(PTAH)2]Cl (3) 
in H2O during time: immediately after dissolution (blue), 24 h (red), 48 h (green), 72 
h (purple) and after addition of an excess of NaCl (orange). 
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Figure A5.8. LTQ Orbitrap ESI mass spectra of compounds 1 (A), 2 (B), 8 (C), 9 
(D), and 3 (E) dissolved in 20 mM ammonium acetate buffer, pH 7.4, in the presence 
of RNase A after 24h incubation at 37°C. 
 
 
Figure A5.9. LTQ Orbitrap ESI mass spectrum of compound 3 dissolved in milliQ 
water, in the presence of ODN4 after 24h incubation at 37°C. 
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Figure A6.1. 1H NMR spectrum of a mixture of trans,cis-RuCl2(CO)2(cppH) (51) 
and trans,cis-RuCl2(CO)2(cppMe) (51Me) in DMSO-d6. 
 
Figure A6.2. {1H,15N}- HMBC spectra of cppH·HNO3 in DMSO-d6. 
 
Figures A6.3 {1H,15N}- HMBC spectra (cppH region) of a mixture of 
[Ru([9]aneS3)(cppH-κNp)(PTA)](Cl)2 and [Ru([9]aneS3)(cppH-κNo)(PTA)](Cl)2 
(50Np and 50No) in DMSO-d6 
 
Figures A6.4-A6.5. NMR characterization of trans,cis-RuCl2(CO)2(cppH-κNp) 
(51) in DMSO-d6. 
 
Figures A6.6-A6.7. NMR characterization of trans,cis-RuCl2(CO)2(cppH-κNo) 
(52) in DMSO-d6. 
 
Figures A6.8. {1H,15N}- HMBC spectrum of mpp in CDCl3. 
 
Figures A6.9-A6.13 NMR characterization of cis,trans-RuCl2(dmso-S)2(mpp-κNp) 
(53, with minor amounts of 54 and 55) in CDCl3. 
 
Figures A6.14-A6.16. NMR characterization of a mixture of the two cis,cis-
RuCl2(dmso-S)2(mpp-κNp) isomers (54 + 55) in CDCl3. 
 
Figures A6.17-A6.20. NMR characterization of trans,cis-RuCl2(dmso-S)2(mpp-
κNp) (56) in CDCl3. 
 
Figure A6.21. Molecular structure (50% probability ellipsoids) of trans,cis-
RuCl2(CO)2(cppH-κNp) (51), trans,cis-RuCl2(CO)2(cppCH3-κNp) (51Me), and of 
the 55/45 mixture 51/51Me. 
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Figure A6.1. 1H NMR spectrum of a mixture of trans,cis-RuCl2(CO)2(cppH) (51, 
blue labels) and trans,cis-RuCl2(CO)2(cppMe) (51Me, red labels) in DMSO-d6. 
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Figure A6.2. {1H,15N}- HMBC spectra of cppH·HNO3 in DMSO-d6 with J = 11 Hz 
(top) and with J = 1.8 Hz (bottom). 
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Figure A6.3. {1H,15N}- HMBC spectra (cppH region) of a mixture of 
[Ru([9]aneS3)(cppH-κNp)(PTA)][Cl2] and [Ru([9]aneS3)(cppH-κNo)(PTA)][Cl2] 
(50Np and 50No) in DMSO-d6 with J = 11 Hz (top) and J = 1.8 Hz (bottom). 
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Figure A6.4. 1H-1H COSY NMR spectrum of trans,cis-RuCl2(CO)2(cppH-κNp) (51) 
in DMSO-d6. 
 
 
Figure A6.5. 1H-13C HSQC NMR spectrum of trans,cis-RuCl2(CO)2(cppH-κNp) 
(51) in DMSO-d6. 
 
Appendix of Chapter 6  
 
 
356 
 
 
 
Figure A6.6. 1H-1H COSY NMR spectrum of trans,cis-RuCl2(CO)2(cppH-κNo) (52) 
in DMSO-d6. 
 
 
Figure A6.7. 1H-13C HSQC NMR spectrum of trans,cis-RuCl2(CO)2(cppH-κNo) 
(52) in DMSO-d6. 
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 Figure A6.8. {1H,15N}- HMBC spectrum of mpp with J = 11 Hz in CDCl3. 
 
Figure A6.9. 1H NMR spectra (aromatic region) of cis,trans-RuCl2(dmso-
S)2(mpp-κNp) (53, bottom, with minor amounts of 54 and 55), a mixture of the two 
cis,cis-RuCl2(dmso-S)2(mpp-κNp) isomers (54 + 55, middle), and trans,cis-
RuCl2(dmso-S)2(mpp-κNp) (56, top) in CDCl3. 
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Figure A6.10. 1H-1H COSY NMR spectrum (aromatic region) of cis,trans-
RuCl2(dmso-S)2(mpp-κNp) (53, with minor amounts of 54 and 55) in CDCl3. 
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Figure A6.11. 1H-13C HSQC NMR spectrum of cis,trans-RuCl2(dmso-S)2(mpp-κNp) 
(53, with minor amounts of 54 and 55) in CDCl3: aromatic region (top) and methyl 
region (bottom). 
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Figure A6.12.{1H,15N}- HMBC spectrum (aromatic resonances of mpp) of a 
mixture of cis,trans-RuCl2(dmso-S)2(mpp-κNp) (53), and the two cis,cis-
RuCl2(dmso-S)2(mpp-κNp) isomers (54 + 55), with J = 11 Hz in CDCl3. 
 
Figure A6.13. {1H,15N}- HMBC spectrum (region of methyl resonances) of a 
mixture of cis,trans-RuCl2(dmso-S)2(mpp-κNp) (53), and the two cis,cis-
[RuCl2(dmso-S)2(mpp-κNp)] isomers (54+ 55), with J = 1.8 Hz in CDCl3. 
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Figure A6.14. 1H-1H COSY NMR spectrum (aromatic region) of a mixture of the 
two cis,cis-RuCl2(dmso-S)2(mpp-κNp) isomers (54 + 55) in CDCl3. 
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Figure A6.15. 1H-13C HSQC NMR spectrum of a mixture of the two cis,cis-
RuCl2(dmso-S)2(mpp-κNp) isomers (54 + 55) in CDCl3: aromatic region (top) and 
methyl region (bottom). 
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Figure A6.16. {1H,15N}- HMBC spectrum (aromatic resonances of mpp) of a 
mixture of the two cis,cis-RuCl2(dmso-S)2(mpp-κNp) isomers (54 + 55) with J = 11 
Hz in CDCl3. 
 
Figure A6.17. 1H-1H COSY NMR spectrum (aromatic region) of trans,cis-
RuCl2(dmso-S)2(mpp-κNp) (56) in CDCl3. 
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Figure A6.18. 1H-13C HSQC NMR spectrum of trans,cis-RuCl2(dmso-S)2(mpp-
κNp) (56) in CDCl3: aromatic region (top) and methyl region (bottom). 
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Figure A6.19. {1H,15N}- HMBC spectrum (aromatic resonances of mpp) of 
trans,cis-RuCl2(dmso-S)2(mpp-κNp) (56) with J = 11 Hz in CDCl3. 
 
Figure A6.20. {1H,15N}- HMBC spectrum (region of methyl resonance) of 
trans,cis-RuCl2(dmso-S)2(mpp-κNp) (56) with J = 11Hz in CDCl3. 
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X-ray structure of 51/51Me  
As said in the text, when the preparation of 51 was performed in methanol part of 
the carboxylate groups of coordinated cppH are methylated and a mixture of 
trans,cis-RuCl2(CO)2(cppH-κNp) (51) and trans,cis-RuCl2(CO)2(cppCH3-κNp) 
(51Me) cocrystallyzes. The fraction of molecules with esterified cppH has been 
estimated at 45%. The X-ray structures of 51, 51Me, and of the mixture 51/51Me 
after refinement are shown in Figure A6.21. 
 
  
 
Figure A6.21. X-ray structures (50% probability ellipsoids) of trans,cis-
RuCl2(CO)2(cppH-κNp) (51, top), trans,cis-RuCl2(CO)2(cppCH3-κNp) (51Me, 
middle), and of the 55/45 mixture 51/51Me (bottom). Coordination distances (Å): 
Ru1–N11 = 2.122(3), Ru1–N12 = 2.114(3), Ru1–Cl1 = 2.388(1), Ru1–Cl2 = 
2.396(1), Ru1–C1 = 1.879(6), Ru1–C2 = 1.874(5). 
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Figures A7.1-A7.2. NMR characterization of [Ru([9]aneS3)Cl(cppH)]
+ (60) in D2O. 
 
Figures A7.3-A7.5. NMR characterization of trans,cis-RuCl2(CO)2(cppH-NT) (57) 
in DMSO-d6 and D2O. 
 
Figures A7.6-A7.9. NMR characterization of [Ru([9]aneS3)Cl(cppH-NT)]
+ (61) in 
DMSO-d6 and D2O. 
 
Figures A7.10-A7.13. NMR characterization of [Ru([9]aneS3)(cppH-NT)(PTA)]
2+ 
(62) in DMSO-d6 and D2O. 
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Figure A7.1. 1H NMR spectra in D2O of [Ru([9]aneS3)Cl(cppH)]
+ (60) after 
dissolution in D2O (top) and after addition of an excess of NaCl (bottom). 
 
 
 
Figure A7.2. 1H-1H COSY NMR spectrum in D2O of [Ru([9]aneS3)Cl(cppH)]
+ (60). 
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Figure A7.3. 1H-13C HSQC NMR spectrum in DMSO-d6 of the aromatic region of 
trans,cis-RuCl2(CO)2(cppH-NT) (57). R is the peptide sequence: Arg-Arg-Pro-Tyr-
Ile-Leu. NH indicates the amidic protons of the peptide. 
 
 
Figure A7.4. Upfield region of 1H NMR spectrum in DMSO-d6 of trans,cis-
RuCl2(CO)2(cppH-NT) (57). 
H2O
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Figure A7.5. Upfield region of 1H NMR spectrum in D2O of trans,cis-
RuCl2(CO)2(cppH-NT) (57). 
 
 
Figure A7.6. 1H-1H COSY NMR spectrum in DMSO-d6 of the aromatic region of 
[Ru([9]aneS3)Cl(cppH-NT)]
+ (61). R is the peptide sequence: Arg-Arg-Pro-Tyr-Ile-
Leu. NH indicates the amidic protons of the peptide. 
H2O
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Figure A7.7. 1H-13C HSQC NMR spectrum in DMSO-d6 of the aromatic region of 
[Ru([9]aneS3)Cl(cppH-NT)]
+ (61). R is the peptide sequence: Arg-Arg-Pro-Tyr-Ile-
Leu. NH indicates the amidic protons of the peptide. 
 
 
Figure A7.8. Upfield region of 1H NMR spectrum in DMSO-d6 of 
[Ru([9]aneS3)Cl(cppH-NT)]
+ (61). 
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Figure A7.9. Upfield region of 1H NMR spectrum in D2O of [Ru([9]aneS3)Cl(cppH-
NT)]+ (61). 
 
 
Figure A7.10. 1H-1H COSY NMR spectrum in DMSO-d6 of the aromatic region of 
[Ru([9]aneS3)(cppH-NT)(PTA)]
2+ (62). R is the peptide sequence: Arg-Arg-Pro-
Tyr-Ile-Leu. NH indicates the amidic protons of the peptide. 
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Figure A7.11. 1H-13C HSQC NMR spectrum in DMSO-d6 of the aromatic region of 
[Ru([9]aneS3)(cppH-NT)(PTA)]
2+ (62). R is the peptide sequence: Arg-Arg-Pro-
Tyr-Ile-Leu. NH indicates the amidic protons of the peptide. 
 
 
Figure A7.12. Upfield region of 1H NMR spectrum in DMSO-d6 of 
[Ru([9]aneS3)(cppH-NT)(PTA)]
2+ (62). 
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Figure A7.13. Upfield region of 1H NMR spectrum in D2O of [Ru([9]aneS3)(cppH-
NT)(PTA)]2+ (62).  
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Figure A8.1. 1H NMR spectrum (aromatic region) in D2O of 
[Ru([9]aneS3)(bpy)Cl]Cl (63), and [Ru([9]aneS3)(bpy)(OH2)](Cl)2 (63aq). 
 
Figures A8.2-A8.5. 1H NMR spectra in D2O of [Ru([9]aneS3)(bpy)(py)](Cl)2 (68), 
[Ru([9]aneS3)(phen)(py)](Cl)2 (69), [Ru([9]aneS3)(4,7-Ph2phen)(py)](Cl)2 (70), 
[Ru([9]aneS3)(dppz)(py)](Cl)2 (71). 
 
Figure A8.6. 1H NMR spectrum in DMSO-d6 of [Ru([9]aneS3)(bq)(py)](Cl)2 (72) 
after 240 min of irradiation (λ = 470 nm, 40 mW). 
 
Figure A8.7. 1H NMR spectrum in D2O of [Ru([9]aneS3)(bq)(py)](Cl)2 (72) at 
different irradiation times (λ = 470 nm, 40 mW). 
 
Figure A8.8. UV-vis spectra of compounds [Ru([9]aneS3)(bpy)Cl]Cl (63), 
[Ru([9]aneS3)(phen)Cl]Cl (64), [Ru([9]aneS3)(4,7-Ph2phen)Cl]Cl (65), 
[Ru([9]aneS3)(dppz)Cl]Cl (66), [Ru([9]aneS3)(bq)Cl]Cl (67) (ca. in 0.1 mM H2O) in 
the visible region. 
 
Figure A8.9. UV-vis spectra of [Ru([9]aneS3)(dppz)](Cl)2 (66) (ca. in 0.1 mM H2O) 
in between 450 and 600 nm. 
 
Figure A8.10. Molecular structure (50% probability ellipsoids) of 
[Ru([9]aneS3)(phen)(py)](Cl)2·EtOH (69). 
 
Figure A8.11. Experimental and calculated (with the “turbo_lanczos” program) 
absorption spectra for [Ru([9]aneS3)(bpy)(py)](Cl)2 (68). The vertical bars in the 
simulated spectrum are the calculated transitions (with the “turbo_davidson” code), 
with height equal to the oscillator strength. 
 
Figure A8.12. Selected molecular orbitals for [Ru([9]aneS3)(bpy)(py)](Cl)2 (68) and 
[Ru([9]aneS3)(bq)(py)](Cl)2 (72) in the singlet ground state. 
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Figure A8.1. 1H NMR spectrum (aromatic region) in D2O of 
[Ru([9]aneS3)(bpy)Cl]Cl (63), and [Ru([9]aneS3)(bpy)(OH2)](Cl)2 (63aq). 
 
 
Figure 8.2. 1H NMR spectrum in D2O of [Ru([9]aneS3)(bpy)(py)](Cl)2 (68). 
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Figure A8.3. 1H NMR spectrum in D2O of [Ru([9]aneS3)(phen)(py)](Cl)2 (69). 
 
 
Figure A8.4. 1H NMR spectrum in D2O of [Ru([9]aneS3)(4,7-Ph2phen)(py)](Cl)2 
(70). 
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Figure A8.5. 1H NMR spectrum in D2O of [Ru([9]aneS3)(dppz)(py)](Cl)2 (71).  
 
 
Figure A8.6. 1H NMR spectrum in DMSO-d6 of [Ru([9]aneS3)(bq)(py)](Cl)2 (72) 
after 240 min of irradiation (λ = 470 nm, 40 mW).  
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Figure A8.7. 1H NMR spectrum in D2O of [Ru([9]aneS3)(bq)(py)](Cl)2 (72) after 30 
min (top), 60 min (middle) and 120 min (bottom) of irradiation (λ = 470 nm, 40 
mW).  
 
 
Figure A8.8. UV-vis spectra of [Ru([9]aneS3)(bpy)Cl]Cl (63), 
[Ru([9]aneS3)(phen)Cl]Cl (64), [Ru([9]aneS3)(4,7-Ph2phen)Cl]Cl (65), 
[Ru([9]aneS3)(dppz)Cl]Cl (66), [Ru([9]aneS3)(bq)Cl]Cl (67)  (ca. in 0.1 mM H2O) 
in the visible region. 
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Figure A8.9. UV-vis spectrum of [Ru([9]aneS3)(dppz)(py)](Cl)2 (71) (ca. in 0.1 mM 
H2O) between 450 and 600 nm. 
 
Figure A8.10. Molecular structure (50% probability ellipsoids) of 
[Ru([9]aneS3)(phen)(py)](Cl)2·EtOH (69). 
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Figure A8.11. Experimental (top) and calculated (with the “turbo_lanczos” program, 
bottom) absorption spectra for complex [Ru([9]aneS3)(bpy)(py)](Cl)2 (68). The 
vertical bars in the simulated spectrum are the calculated transitions (with the 
“turbo_davidson” code), with height equal to the oscillator strength. 
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Figure A8.12. Selected molecular orbitals for [Ru([9]aneS3)(bpy)(py)](Cl)2 (68) 
(right) and [Ru([9]aneS3)(b7)(py)](Cl)2 (72) (left) in the singlet ground state. 
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Table A8.1. Selected TDDFT singlet transitions for [Ru([9]aneS3)(b7)(py)](Cl)2 
(72). Only contributions ≥ 2% are reported. 
Energy 
(eV) 
Wavelength 
(nm) 
Oscillator 
strength 
Major contributions 
2.2707 
 
546 0.1006 HOMO→LUMO          
84% 
HOMO–1→LUMO      
12% 
HOMO–1→LUMO+1    
2% 
2.7264 455 0.0052 HOMO–3→LUMO      
88% 
HOMO–4→LUMO        
5% 
HOMO–1→LUMO        
2% 
2.9608 419 0.0147 HOMO→LUMO+1      
63% 
HOMO–4→LUMO      
17% 
HOMO–5→LUMO        
7% 
HOMO–1→LUMO+1    
5% 
HOMO–3→LUMO        
3% 
3.0767 403 0.0537 HOMO→LUMO+2      
41% 
HOMO–1→LUMO+1  
25% 
HOMO→LUMO+1      
12% 
HOMO–4→LUMO      
11% 
HOMO–1→LUMO+2    
7% 
3.0881 401 0.0542 HOMO–1→LUMO+1  
59% 
HOMO→LUMO+2      
15% 
HOMO–1→LUMO+2    
7% 
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HOMO→LUMO+3        
6% 
HOMO–5→LUMO        
4% 
HOMO–4→LUMO        
2% 
3.1606 392 0.1629 HOMO→LUMO+2      
35% 
HOMO–4→LUMO      
20% 
HOMO→LUMO+1      
17% 
HOMO–1→LUMO+5    
7% 
HOMO–5→LUMO        
6% 
HOMO–1→LUMO+3    
5% 
HOMO–1→LUMO+2    
3% 
3.2265 384 0.0863 HOMO–1→LUMO+2  
66% 
HOMO→LUMO+4        
9% 
HOMO→LUMO+3        
8% 
HOMO–4→LUMO        
5% 
HOMO–1→LUMO+3    
3% 
HOMO→LUMO+2        
2% 
HOMO→LUMO+1        
2% 
3.2706 379 0.0298 HOMO→LUMO+3      
73% 
HOMO→LUMO+4        
9% 
HOMO–1→LUMO+3    
3% 
HOMO–5→LUMO        
2% 
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HOMO–1→LUMO+5    
2% 
HOMO–1→LUMO+4    
2% 
HOMO–1→LUMO+1    
2% 
HOMO→LUMO+2        
2% 
3.3145 374 0.0278 HOMO–1→LUMO+3  
61% 
HOMO→LUMO+4      
16% 
HOMO–1→LUMO+2    
6% 
HOMO–2→LUMO+1    
5% 
HOMO–3→LUMO+1    
3% 
HOMO→LUMO+2        
2% 
3.3646 368 0.0106 HOMO–2→LUMO+1  
63% 
HOMO→LUMO+4      
24% 
HOMO–1→LUMO+5    
6% 
HOMO→LUMO+3        
2% 
3.3961 365 0.0147 HOMO–1→LUMO+4  
42% 
HOMO–2→LUMO+1  
15% 
HOMO–3→LUMO+1  
13% 
HOMO→LUMO+4      
13% 
HOMO→LUMO+3        
4% 
HOMO–1→LUMO+3    
3% 
HOMO–1→LUMO+2    
2% 
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HOMO→LUMO+5        
2% 
3.4274 362 0.0245 HOMO→LUMO+5      
36% 
HOMO–1→LUMO+4  
16% 
HOMO→LUMO+4      
14% 
HOMO–2→LUMO+1  
10% 
HOMO–1→LUMO+3  
10% 
HOMO–5→LUMO+1    
3% 
3.4543 359 0.0336 HOMO→LUMO+5      
52% 
HOMO–1→LUMO+4  
17% 
HOMO–1→LUMO+3    
7% 
HOMO→LUMO+4        
5% 
HOMO–4→LUMO+1    
4% 
HOMO–1→LUMO+5    
3% 
HOMO–2→LUMO+2    
2% 
3.5194 352 0.1029 HOMO–1→LUMO+5  
39% 
HOMO–2→LUMO+2  
38% 
HOMO–2→LUMO+3    
5% 
HOMO–4→LUMO        
4% 
HOMO→LUMO+4        
3% 
HOMO–3→LUMO+5    
2% 
3.5475 349 0.0652 HOMO–2→LUMO+2  
41% 
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HOMO–1→LUMO+5  
27% 
HOMO–2→LUMO+3    
8% 
HOMO–3→LUMO+2    
6% 
HOMO–3→LUMO+1    
4% 
HOMO–4→LUMO        
2% 
HOMO–3→LUMO+3    
2% 
 
 
 
 
 
 
 
 
